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Summary 
Vascular smooth muscle cell (VSMC) activation leading to proliferation, migration 
and extracellular matrix (ECM) production is a major cause of neointimal 
formation after stenting and coronary artery bypass grafting. Drug-eluting stents 
have reduced clinical incidence of in-stent restenosis by inhibiting this 
proliferative response but they can also delay vessel re-endothelialisation after 
injury leading to an increased thrombotic risk. MicroRNAs (miRNAs) are short 
(~22 nt) non-protein-coding RNAs which act as regulators of gene expression 
largely through binding to the 3’ untranslated region of target genes and causing 
degradation or repression of expression. MiR-143 and miR-145 are a miRNA 
family that are enriched in VSMCs and have been previously shown to influence 
VSMC phenotype through regulation of their gene targets. Consequently, the aim 
of this study was to investigate the role that miR-143 and miR-145 play in the 
neointimal response to stenting. 
Initial experiments investigated whether modulation of miR-143 or miR-145 
expression was capable of significantly altering VSMC phenotype. It was found 
that modulation of miRNA levels in human saphenous vein (HSV) SMC or 
endothelial cells (EC) using adenoviruses was not ideal due to transduction and 
toxicity issues. Use of antimiR miRNA inhibitors and premiR miRNA mimics 
revealed that modulation of miR-143 or miR-145 levels alone was not sufficient 
to alter proliferation or migration of HSV SMCs in vitro. Knockdown of miR-143 
expression in cells resulted in de-repression of target genes kruppel-like factor 4 
(KLF4) and KLF5 but expression levels of other previously identified target genes 
were unaltered by miRNA modulation. 
Pre-clinical stenting studies are largely performed in porcine models due to 
similarities in vessel structure and neointimal formation, however large animal 
models are not ideal for early investigative studies.  In order to examine the role 
of miR-143 and miR-145 in stent-induced vascular injury we utilised a mouse 
model where a bare metal stent is deployed in the thoracic aorta of a donor 
mouse and interposition grafted into the carotid artery of a recipient. This 
model resulted in the development of a defined neointima over 28 days which 
consisted largely of VSMCs and ECM, similar to that of the human in-stent 
restenosis. 
  19 
 
 
Vessel expression of miR-143 and miR-145 has been previously shown to be 
reduced following vascular injury and furthermore overexpression of these 
miRNA can reduce neointimal formation. MiR-143 and miR-145 knockout (KO) 
mice have previously been shown to have abnormal VSMC phenotype in their 
vessel walls including perturbed stress fiber formation, increased presence 
synthetic machinery and an increased number of synthetic versus contractile 
VSMCs. MiR-143 and miR-145 KO mice were found to develop significantly less 
neointimal formation in response to stenting than WT mice indicating that these 
miRNA are essential for normal vessel response to injury. 
The reduced neointimal formation following genetic ablation of miR-143 or miR-
145 led to the investigation of whether pharmacological knockdown of these 
miRNA was able to mimic this effect. An antimiR consisting of DNA and locked 
nucleic acid bases targeted against mature miR-143 expression was used to 
knockdown miR-143 expression in mice prior to stenting. AntimiR-143-mediated 
knockdown of miR-143 expression did not significantly alter the degree of 
neointimal formation seen 28 days following stent deployment when compared 
to mice that received a control non-targeted antimiR (antimiR-ctl).  The 
neointima of both antimiR-143 and antimiR-ctl mice were comparable and 
consisted largely of VSMCs and ECM. Re-endothelialisation had occurred by day 
28 post-injury in antimiR-143 and antimiR-ctl treated mice indicating that 
knockdown of miR-143 did not significantly delay EC repopulation in this model. 
Expression of miRNA and mRNA after vascular injury can be both spatial and 
temporal. Target de-repression was not detected in the aorta or heart of miRNA 
KO or antimiR-143 treated mice. This is likely to reflect the complex nature of 
miRNA gene regulation in vivo which is governed by many different factors 
including the relative expression of the miRNA and its target, cell stress, and 
transcriptional activation or inhibition by growth and transcription factors.  
In summary, the influence of miR-143 and miR-145 on VSMC biology was 
investigated in vitro using a range of molecular biology techniques and in vivo in 
a mouse model of in-stent stenosis.  Results have extended current knowledge of 
the degree of influence these miRNA exert over VSMC phenotype and identified 
that miR-143 and miR-145 are involved in neointimal formation after stenting.
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1.1 Cardiovascular Disease  
Cardiovascular disease (CVD) is the primary cause of morbidity and mortality 
worldwide, with an estimated 17.3 million deaths from CVD in 2008 alone (World 
Health Organization, 2013). Advances in the treatment of CVD have been 
successful in pushing mortality rates into decline however CVD is still responsible 
for around 50,000 premature deaths in the UK each year (British Heart 
Foundation, 2012). With global annual mortality predicted to reach 25 million by 
2030 (World Health Organization, 2013) there is a need to develop more 
specialised treatments for CVD to improve patient survival.  
Coronary heart disease (CHD) is the most prominent form of CVD and is 
responsible for around 45% of the deaths from CVD each year in the UK (British 
Heart Foundation, 2012) . The two main consequences of CHD are angina, due to 
impaired blood flow and inadequate oxygen delivery to the heart, and 
myocardial infarction (MI) which occurs when a coronary artery becomes 
occluded by a thrombus. Angina and MI are a direct result of the presence or 
rupture of lipid rich atherosclerotic plaques within the wall of the coronary 
vessels. 
1.1.1 Pathogenesis of atherosclerosis 
1.1.1.1 Endothelial dysfunction 
The endothelium forms the tunica intima of the artery, a monolayer of 
endothelial cells (ECs) that forms the interface with the blood (Figure 1.1). 
Surrounding the tunica intima is the internal elastic lamina, which forms the 
inner surface of tunica media. The media is comprised of layers of vascular 
smooth muscle cells (VSMCs), elastin fibers and extracellular matrix (ECM) 
surrounded by the external elastic lamina.  The outermost layer of the artery is 
the tunica adventitia which consists of connective tissue comprised largely of 
collagen.  
The initiation of an atherosclerotic plaque is believed to occur due to an insult 
to the vascular endothelium lining the coronary arteries and is most likely to 
occur in areas of low shear stress, for example, near curvatures or bifurcations 
(Cunningham and Gotlieb, 2005). Risk factors include tobacco use, hypertension, 
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high circulating cholesterol, sedentary lifestyle and obesity (British Heart 
Foundation, 2012, Ross, 1999).  The endothelium plays an essential role in the 
vasculature, providing an antithrombotic, antiplatelet and anticoagulant 
interface with the blood through expression of several molecules including nitric 
oxide (NO), prostacyclin, thrombomodulin, tissue plasminogen activator and 
endothelium derived hyperpolarizing factor (Davignon and Ganz, 2004). The 
endothelium also controls vessel tone by release of a variety of vasoactive 
substances including NO, endothelin and angiotensin II (Ang II) (Davignon and 
Ganz, 2004). 
One of the key signalling molecules secreted by the endothelium is NO which is 
produced by endothelial NO synthase (eNOS) (Furchgott and Zawadzki, 1980, 
Palmer et al., 1987, Ignarro et al., 1987). NO is an essential mediator of the 
endothelium which inhibits platelet activation and aggregation as well as having 
anti-inflammatory effects via inhibition of inflammatory cell adhesion and 
migration. NO is a potent vasodilator which diffuses to underlying medial VSMCs 
and promotes VSMC relaxation and inhibition of proliferation (Deanfield et al., 
2007). Damage to the vascular endothelium results in impaired production of NO 
by eNOS and increased production of reactive oxygen species including 
superoxide, which reduces NO bioavailability in the vessel wall, resulting in a 
loss of endothelial-dependent vasorelaxation (Deanfield et al., 2007, Davignon 
and Ganz, 2004, Ludmer et al., 1986). This phenomenon of ‘endothelial 
dysfunction’ was first discovered when atherosclerotic arteries were found to 
constrict rather than dilate in the presence of acetylcholine (Ludmer et al., 
1986).   
1.1.1.2 Inflammation and plaque formation 
Endothelial dysfunction results in a shift to a pro-inflammatory state whereby 
adhesion molecule expression and vascular permeability are increased allowing 
leukocyte and platelet adhesion. These changes are accompanied by the release 
of inflammatory cytokines, macrophage recruitment and stimulation of VSMC 
proliferation and migration (Ross, 1999). Increased permeability of the vascular 
endothelium leads to uptake of low density lipoprotein (LDL) from the 
circulation into the intima of the vessel wall where it becomes trapped and 
accumulates (Steinberg, 1997). Trapped LDL becomes oxidised within the vessel 
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wall forming oxidised LDL (oxLDL) which promotes inflammation through 
monocyte recruitment from the blood and increased expression of inflammatory 
genes. This early atherosclerotic plaque is termed a ‘fatty streak’.  
Monocytes recruited from the blood differentiate into macrophages in the vessel 
wall and engulf oxLDL to form foam cells, a characteristic cell type of the 
atherosclerotic plaque (Steinberg, 1997).  A necrotic core that contains 
leukocytes, foam cells, cell debris and lipid is eventually formed. Macrophages 
and T Cells within the plaque secrete cytokines which stimulate VSMC 
proliferation and migration from the medial layer into the lesion where they 
produce ECM proteins, including collagen, that form a fibrous cap which contains 
the necrotic core (Ross, 1999).  
Vessels with developing atherosclerotic plaques can undergo outward ‘positive’ 
remodelling, where the external elastic lamina expands, or inward ‘negative’ 
remodelling where the external elastic lamina shrinks at the site of the plaque 
(Figure 1.1)(Hermiller et al., 1993, Nishioka et al., 1996). Reduction in lumen 
area is higher in negatively remodelled vessels than positively remodelled 
vessels (Nishioka et al., 1996, Pasterkamp et al., 1995). Conversely, 
atherosclerotic plaques with positive remodelling have been shown to contain 
larger lipid and macrophage content (Varnava et al., 2002).  It has been shown 
that negative remodelling is associated with stable whereas positive remodelling 
tends to be associated with unstable angina (Schoenhagen et al., 2000).  
An atherosclerotic plaque is thought to be less likely to rupture when it displays 
a thick fibrous cap which contains a high proportion of VSMCs and collagen and 
low lipid and macrophage content (van der Wal and Becker, 1999, Davies et al., 
1993). Larger lipid and inflammatory cell content is often seen in unstable 
atherosclerotic plaques which are associated with increased incidence of 
coronary thrombosis (Falk, 1989, van der Wal et al., 1996, Arbustini et al., 
1995). However, plaques from clinically stable angina can be histologically 
unstable (van der Wal et al., 1996). Several studies have reported the 
association between inflammatory cells and plaque rupture with macrophage, T 
cell and mast cell density high at the site of fibrous cap erosion and rupture (van 
der Wal et al., 1994, Lendon et al., 1991, Kovanen et al., 1995). It was later 
shown that activated matrix metalloproteinases (MMPs), which are produced by 
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both macrophages and VSMCs, are enriched in atherosclerotic plaques and are 
responsible for collagen breakdown and weakening of the fibrous cap which can 
lead to plaque rupture (Shah et al., 1995, Galis et al., 1994). VSMC apoptosis is 
also thought to contribute to plaque instability and rupture (Isner et al., 1995, 
Geng and Libby, 1995). VSMC apoptosis can be stimulated by growth factors and 
cytokines released from cells which are present in atherosclerotic plaques 
including T Cell derived interferon gamma (IFN-γ) and macrophage derived 
tumour necrosis factor alpha (TNF-α) and  interleukin-1β (IL-1β) (Geng et al., 
1996). Increased apoptosis was seen in cultured human VSMCs isolated from 
atherosclerotic plaques (Bennett et al., 1995). Furthermore, the pathology of 
lesions following VSMC apoptosis in atherosclerotic apolipoprotein E (ApoE) 
knockout (KO) mice shared many features with human unstable plaques (Clarke 
et al., 2006). This included fibrous cap thinning, loss of ECM proteins, increased 
lipid core and increased inflammation, seen by greater expression of monocyte 
chemoattractant protein 1 (MCP-1) and influx of macrophages (Clarke et al., 
2006).  
Atherosclerotic plaques can undergo cycles of rupture and repair which are 
clinically silent (Davies and Thomas, 1985). Sites of prior plaque rupture show 
increased presence of VSMCs which proliferate and migrate to the site and 
synthesize ECM components to heal the rupture (Mann and Davies, 1999). Cycles 
of plaque rupture and repair has been shown to result in greater vessel stenosis 
(Mann and Davies, 1999)  and were also shown to be associated with sudden 
cardiac death (Burke et al., 2001). Rupture of an atherosclerotic plaque leads to 
exposure of the blood to the thrombogenic plaque core, resulting in activation of 
the coagulation cascade, platelet activation and accumulation and formation of 
a thrombus (Falk, 1991, Zaman et al., 2000). Whether a thrombus remains silent 
and is repaired or progresses to fully occlude the vessel leading to clinical 
presentation seems to depend on several factors including degree of plaque 
disruption, blood flow, thrombotic versus thrombolytic activity of the blood and 
composition of the exposed plaque (Falk, 1991). Plaque rupture and thrombus 
formation is the major cause of MI and sudden cardiac death (Davies and 
Thomas, 1985). 
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Figure 1.1. The normal and the atherosclerotic artery. 
The artery is made up of 3 distinct layers (top left), the tunica intima, comprising of ECs, the VSMC-
containing tunica media and the tunica adventitia which is composed of connective tissues. Cross 
section of the atherosclerotic artery (top right) showing an atherosclerotic plaque which impinges 
on the lumen. Longitudinal view of positive remodelling, (bottom left), where the external elastic 
lamina remodels outwards, and negative remodelling (bottom right) where shrinkage of the external 
elastic lamina at the site of the atherosclerotic plaque contributes to luminal narrowing. Adapted 
from Servier Medical Art.  
1.1.2 Treatments of atherosclerosis 
The main pharmacological intervention used to treat atherosclerosis is inhibition 
of Hydroxymethylglutaryl-CoA (HMG-CoA) reductase (Go et al., 2013), a key 
enzyme involved in the production of cholesterol in the liver. HMG-CoA 
reductase inhibitors are widely known as statins. Statins significantly lower 
cholesterol content in the liver hepatocytes which results in the upregulation of 
LDL receptors that act to clear LDL from the blood, significantly lowering 
circulating levels (Vaughan et al., 2000, Maron et al., 2000). This allows statins 
to significantly reduce plaque progression and even promote regression of plaque 
size (Vaughan et al., 2000). Statins are hugely successful clinically and reduce 
the incidence of major cardiac events by approximately 30% (Maron et al., 
2000).  
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When an atherosclerotic plaque causes narrowing of the lumen to a degree in 
which blood flow through the coronary artery is significantly impaired a coronary 
artery bypass graft (CABG) or percutaneous coronary intervention (PCI) may be 
performed to re-vascularise the myocardium. PCI is the most common 
revascularisation procedure performed in the UK with around 80,000 operations 
performed per annum compared to approximately 25,000 CABG procedures 
(British Heart Foundation, 2012). CAGB is generally regarded as preferential to 
PCI for patients with triple vessel or left main coronary-artery disease as it has 
been shown in randomised trials to reduce incidence of major cardiac events in 
this patient group (Serruys et al., 2009, Mohr et al., 2013).  
The CABG procedure involves harvesting of a vein or artery from the patient 
which is then engrafted into the heart to allow blood to bypass the narrowed 
coronary artery. Arterial conduits such as the internal mammary artery have 
more successful long term patency than the saphenous vein, with 10 year 
patency rates of around 85% vs. 61% respectively (Goldman et al., 2004). 
However, the saphenous vein is still commonly used for CABG due to the need to 
bypass multiple vessels (Goldman et al., 2004). The failure of around 40% of vein 
grafts within 10 years is due to the remodelling of the vein under the high 
pressures of the arterial circulation which occurs largely via endothelial 
dysfunction, VSMC proliferation and migration and ECM production, eventually 
followed by the development of atherosclerosis within the engrafted vein (Cox 
et al., 1991).  
PCI involves a balloon angioplasty of the narrowed vessel often accompanied by 
placement of a metal scaffold known as a ‘stent’. During the balloon angioplasty 
procedure a balloon angioplasty catheter is fed through the vasculature to the 
narrowed coronary artery where it is then inflated to a certain pressure in order 
to compress the atherosclerotic plaque against the vessel wall, leading to 
revascularisation of the lumen. The balloon angioplasty procedure is initially 
very successful in restoring blood flow but is hampered by high rates of 
restenosis (Serruys et al., 1994, Fischman et al., 1994). The introduction of 
bare-metal stents (BMS) in 1994 significantly reduced restenosis rates associated 
with balloon angioplasty alone (Fischman et al., 1994, Serruys et al., 1994). 
However, target vessel revascularisation is still required in around 15%-17% of 
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vessels with BMS by 5 years due to in-stent restenosis (Kiemeneij et al., 2001, 
Rubartelli et al., 2003).  
1.1.3 In-stent restenosis 
The PCI procedure results in denudation of the endothelium lining of the vessel 
as well as mechanical stretch to the underlying medial layer of VSMCs. 
Endothelial denudation provides a surface favoured for thrombus formation, 
platelet aggregation and influx of inflammatory molecules such as macrophages 
(Libby et al., 1992). This triggers inflammatory signalling whereby growth factors 
and cytokines are released and promote cell VSMC migration, proliferation and 
ECM deposition resulting in neointimal formation and restenosis of the vessel 
(Figure 1.2) (Libby et al., 1992, Clowes and Schwartz, 1985, Clowes and Clowes, 
1985). It has been shown that degree of mechanical stretch and injury to the 
vessel wall during stent deployment directly relates to amount of neointimal 
formation that occurs (Schwartz et al., 1992). Neointimal formation is thought to 
be largely due to activation of resident VSMCs which proliferate and migrate 
from the media (Clowes and Schwartz, 1985, Clowes and Clowes, 1985, Schwartz 
et al., 1975). However, there is also evidence to suggest that a proportion of the 
neointimal VSMCs are derived from the bone marrow (Han et al., 2001, Sata et 
al., 2002).  
Inhibition of VSMC migration and proliferation is therefore a major clinical goal 
to prevent restenosis. This led to the development of drug-eluting stents (DES), 
which elute cell cycle inhibitory drugs such as Sirolimus and Paclitaxel 
(Schampaert et al., 2006, Caixeta et al., 2009, Stone et al., 2009). DES are 
coated with polymers that allow drugs to be loaded and released over a certain 
time period (usually within 4-6 weeks) to lessen the initial proliferative response 
evoked following stent deployment (Htay and Liu, 2005). DES have been highly 
successful clinically in further reducing incidence of in-stent restenosis 
confirming that inhibition of cell proliferation is a viable strategy (Schampaert et 
al., 2006, Caixeta et al., 2009, Stone et al., 2009). 
However, DES are inhibitors of cell cycle in all cells exposed to them and thus 
are non-specific and target both ECs and VSMCs. This can lead to delayed or 
incomplete re-endothelialisation following stent deployment (Joner et al., 
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2006). This delayed re-endothelialisation leads to increased risk of fatal late in-
stent thrombosis in patients with DES versus BMS (Figure 1.2) (Joner et al., 2006, 
Finn et al., 2007). Discontinuation of antiplatelet therapy is a risk factor for late 
in-stent thrombosis (Pfisterer et al., 2006, McFadden et al., 2004).  
DES have proved extremely successful in improving the patency rates of stented 
vessels. However the risks associated with delayed and incomplete re-
endothelialisation indicate that there is a substantial need for new therapies 
which specifically target the VSMCs. 
Bare metal stent Drug-eluting  stent 
Stented Artery 
In-stent restenosis In-stent thrombosis 
 
Figure 1.2. Problems associated with stenting. 
During the stent procedure a balloon catheter is inflated to compress the atherosclerotic plaque 
against the vessel wall and a metal stent is deployed to acts as a scaffold to maintain the newly 
revascularised lumen. Stenting causes endothelial denudation and mechanical injury to the vessel 
which results in activation of VSMC proliferation and migration which leads to in-stent restenosis, a 
common side-effect of BMS. DES inhibit VSMC proliferation thereby reducing incidence of in-stent 
restenosis. However DES also inhibit EC proliferation which can lead to delayed re-
endothelialisation of the vessel and increased risk of in-stent thrombosis. Adapted from Servier 
Medical Art. 
 
 
Chapter 1 - Introduction  29 
 
 
1.2 Vascular smooth muscle cells 
VSMCs are not terminally differentiated and can undergo phenotypic modulation 
from a differentiated ‘contractile’ to a dedifferentiated ‘synthetic’ state in 
response to environmental cues (Owens et al., 2004). VSMCs are a major 
structural component of the vessel wall which express a unique set of proteins 
including components of the actin cytoskeleton and contractile response e.g. 
alpha smooth muscle actin (α-SMA); smooth muscle myosin heavy chain (SM-
MHC) and calponin, termed ‘contractile proteins’ (Shanahan and Weissberg, 
1998). These contractile proteins, together with other proteins including ion 
channels and receptors, act together to maintain vascular tone (Owens et al., 
2004). In healthy adult vessels there is high expression of contractile proteins 
and very low (or no) expression of synthetic proteins, for example embryonic SM-
MHC (SMemb), which is expressed in the VSMCs of the developing embryo prior 
to them reaching full differentiation (Kuro-o et al., 1991, Shanahan and 
Weissberg, 1998). Adult VSMCs show virtually no migration and very low 
proliferation rates (Owens et al., 2004). Injury to the vessel wall as occurs in 
revascularisation procedures triggers a signalling cascade by release of cytokines 
and growth factors from cells of the vessel wall, platelets and inflammatory cells 
(Libby et al., 1992). Cytokine and growth factor signalling after vascular injury 
leads to a phenotypic modulation of VSMCs from a contractile to a synthetic 
state which results in proliferation, migration and neointimal formation (Kocher 
et al., 1991, Orlandi et al., 1994). 
Fully synthetic VSMCS display an epithelioid morphology which is easily 
distinguished from the long spindle-like shape of contractile VSMCs (Figure 1.3) 
(Walker et al., 1986). The change in cell morphology following vascular injury is 
accompanied by decreased expression of contractile marker proteins including α-
SMA and SM-MHC (Kuro-o et al., 1991, Kocher et al., 1991). Increased expression 
of dedifferentiation markers such as embryonic SMemb accompanies the 
decrease in contractile gene expression, indicating that the VSMCs are 
transitioning towards a dedifferentiated phenotype (Kuro-o et al., 1991). α-SMA 
comprises around 40% of all protein in contractile VSMCs and together with 
myosin forms highly organised contractile filaments which govern VSMC 
contraction (Fatigati and Murphy, 1984). Reduced α-SMA expression seen in 
synthetic intimal VSMCs is accompanied by a significant reduction in the number 
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of actin stress fibers within these cells and thus a major rearrangement of the 
actin cytoskeleton (Manderson et al., 1989, Kocher et al., 1991, Kocher et al., 
1984). Synthetic VSMCs also produce large amounts of ECM proteins, which 
comprise largely of collagen, elastin and proteoglycans. They also contain 
increased numbers of the protein synthesis apparatus- rough endoplasmic 
reticulum (ER), free ribosomes and golgi apparatus (Chamley-Campbell et al., 
1979). DNA synthesis and cell proliferation along with cell migration is also 
increased in synthetic VSMCs when compared with contractile VSMCs (Clowes 
and Schwartz, 1985). It should be noted that decrease in VSMC contractile 
proteins does not always result in increased proliferation and migration and vice 
versa, instead there appears to be a scale of dedifferentiation between a fully 
contractile to fully synthetic phenotype (Shanahan and Weissberg, 1998).  The 
consequence of this shift to a more synthetic state following vascular injury is 
migration and proliferation of the VSMCs from the media to the intima resulting 
in the formation of neointima and vessel stenosis (Clowes and Schwartz, 1985).  
It has been reported that a small population of SM-MHC-negative cells (~10%) 
exist in the media that are multipotent and can differentiate into neural cells 
and mesenchymal SC-like cells (Tang et al., 2012). A lineage tracing experiment, 
in which SM-MHC-positive cells were labelled with EGFP, revealed that following 
isolation of medial cells by enzymatic digestion SM-MHC-positive cells were the 
dominant cell type (>92%) in culture. However, after culture for 10 days only SM-
MHC-negative multipotent vascular SCs remained, indicating that these cells 
appear to have a greater proliferative capacity in vitro than VSMCs. Culture of 
multipotent vascular SCs resulted in differentiation into mesenchymal SC-like 
cells which further differentiated into SM-MHC-positive VSMCs following 8 weeks 
in culture, indicating that accumulation of VSMCs following vascular injury could 
be partly due to proliferation and differentiation of multipotent vascular SCs 
(Tang et al., 2012). Significantly, following carotid artery injury in mice which 
express EGFP-labelled SM-MHC, expression of the proliferation marker Ki67 was 
restricted to EGFP-negative cells which expressed the multipotent vascular SC 
marker S100β. The authors further investigated this in a rat EC denudation 
model and found that Ki67 expression in multipotent vascular SCs was decreased 
from 32% at day 15 to around 1% at day 30 post-injury. Furthermore, at day 30 
post-injury the majority of cells positive for S100β were also positive for SM-
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MHC, suggesting that multipotent vascular SCs may have started to differentiate 
into VSMCs (Tang et al., 2012). The results of this study certainly suggest that 
proliferation of multipotent vascular SCs and not de-differentiation of adult 
VSMCs may be the causative factor behind neointimal formation. 
Nemenoff and colleagues (Nemenoff et al., 2011) utilised a mouse model in 
which SM-MHC-positive cells were labelled with β-gal to show that accumulations 
of β-gal-positive VSMCs were present in the neointima 7 days post wire-injury of 
the femoral artery, indicating that migration of differentiated VSMCs to the 
intima plays a role in neointimal formation.  Furthermore the authors showed 
that 3 weeks post-injury the majority of proliferating cells in the media and 
neointima were SM-MHC expressing β-gal-positive cells, indicating the presence 
of proliferating VSMCs (Nemenoff et al., 2011). These results are in contrast to 
Tang and colleagues who found that 5 days after wire-injury the majority of 
medial cells expressed multipotent vascular SC marker S100β and lost expression 
of SM-MHC (Tang et al., 2012). It was suggested that the discrepancies between 
these two studies may be due in part to a greater degree of VSMC death in the 
media following a more severe vascular injury in the study by Tang and 
colleagues, which may have resulted in the lack of contribution to neointimal 
formation by VSMCs (Tang et al., 2012). These studies highlight that neointimal 
formation after vascular injury may have contributions from both multipotent 
vascular SCs and VSMCs. 
1.2.1 Regulation of VSMC phenotype 
1.2.1.1 Serum response factor  
The transcription factor serum response factor (SRF) is a major signalling 
molecule which governs VSMC phenotype. SRF binds to CC(A/T)6GG sequences 
known as a CArG elements/boxes which are present in the promoter and 
enhancer regions of target genes (Mack and Owens, 1999, Li et al., 1997, 
Manabe and Owens, 2001).  CArG elements have been found in the promoters 
and enhancers of virtually all contractile genes and mutation of these elements 
can abolish expression of these genes in vivo including α-SMA, SM-MHC and 
smooth muscle 22 alpha (SM22α) (Mack and Owens, 1999, Li et al., 1997, Manabe 
and Owens, 2001). SRF targets include not only contractile genes but also a 
Chapter 1 - Introduction  32 
 
 
significant number of components of the actin cytoskeleton (Miano et al., 2007).  
SRF target genes include proteins involved in actin cytoskeleton arrangement, 
cell migration, calcium handling, and contraction (Miano et al., 2007). Myocardin 
is an SRF cofactor which acts as a powerful promoter of VSMC differentiation 
when bound to SRF, increasing contractile gene expression within VSMCs and also 
activating the expression of contractile genes in pluripotent embryonic stem 
cells (ESCs) (Chen et al., 2002, Du et al., 2003, Yoshida et al., 2003).  
Furthermore, myocardin KO mice die in utero with complete absence of SMC 
differentiation (Li et al., 2003). Significantly, myocardin gene expression is 
downregulated following vascular injury (Hendrix et al., 2005), suggesting that 
this loss of myocardin may be a causative factor for the loss of contractile gene 
expression seen following vascular injury. Myocardin–related transcription 
factors (MRTF-A, MRTF-B) have also been identified which act as coactivators of 
SRF (Wang et al., 2002). The induction of contractile gene expression by MRTF-
A, MRTF-B and myocardin in ESCs was shown to be entirely dependent on SRF 
expression (Wang et al., 2002). The importance of myocardin in VSMC contractile 
gene expression was further shown when it was described how the ETS domain-
containing protein ELK-1 competes with and can displace myocardin from its 
binding site on SRF, resulting in the suppression of a contractile gene expression 
(Wang et al., 2004).  Functional studies have identified that myocardin acts an 
inhibitor of cell proliferation consistent with the promotion of a differentiated 
cell state (Tang et al., 2008, Long et al., 2008).  
1.2.1.2 Growth factor and cytokine regulation of VSMCs 
Many growth factors are major regulators of VSMCs and are released by resident 
or infiltrating cells in the vessel wall including ECs, VSMCs, macrophages and 
platelets (Raines and Ross, 1993). Increased expression levels of several 
cytokines and growth factors including platelet-derived growth factor (PDGF), 
transforming growth factor beta (TGF-β), IL-1, and basic fibroblast growth factor 
(bFGF), have been detected in atherosclerotic plaques and after vessel injury 
(Ross et al., 1990, Hughes et al., 1993, Arbustini et al., 1995, Majesky et al., 
1991). Stimulation by these agents is thought to be the driving force behind 
VSMC chemotaxis, proliferation and migration into the plaque and ECM 
deposition to form the fibrous cap which helps to increase plaque stability 
(Raines and Ross, 1993). Similarly, growth factors released after vascular injury 
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promote a synthetic VSMC phenotype which leads to formation of neointima 
(Libby et al., 1992). Some of the most influential regulators of VSMC phenotype 
are discussed below.  
1.2.1.3 Platelet-derived growth factor 
PDGF is a potent promoter of VSMC proliferation, migration, chemotaxis and ECM 
production (Amento et al., 1991, Deguchi et al., 1999). PDGF production is high 
in VSMCs in early post-natal rats but much lower in VSMCs isolated from in adults 
(Seifert et al., 1984). Similarly, synthetic VSMCs isolated from the intima of 
injured rat carotids produce more PDGF than those from the media exhibiting a 
contractile phenotype, indicating that PDGF is important synthetic VSMC 
signalling (Walker et al., 1986). In vitro, exposure of aortic VSMCs to PDGF 
results in cell proliferation and downregulation of VSMC marker genes including 
α-SMA and SM-MHC (Blank and Owens, 1990, Holycross et al., 1992). PDGF can be 
released from several cell types including ECs, VSMCs, macrophages and 
platelets and PDGF-B has been shown to be expressed with macrophages 
throughout all stages of atherosclerosis (Ross et al., 1990). Furthermore, 
expression of the PDGF receptor β subunit is also increased in atherosclerosis 
(Ross et al., 1990). This suggests that PDGF may play a role in triggering VSMC 
proliferation and migration from the intima to promote and fibrous cap 
formation in atherosclerosis.  
PDGF is elevated in the human coronary circulation after angioplasty as is the 
mitogenicity of isolated serum (Caplice et al., 1997). Inhibition of PDGF and 
bFGF significantly reduced proliferation of cultured VSMCs induced by mitogenic 
serum suggesting that they these growth factors may promote VSMC activation 
after injury (Caplice et al., 1997). PDGF and bFGF expression is upregulated in 
the atherosclerotic plaque and further upregulated in vessels with restenosis, 
indicating that these growth factors may be important activators of VSMCs after 
injury (Arbustini et al., 1995). Neutralisation of bFGF using an antibody has been 
shown to significantly reduce VSMC proliferation in the medial layer of the 
balloon-injured rat carotid but did not result in decreased neointimal formation 
(Lindner and Reidy, 1991). This result is consistent with another study which 
showed that bFGF inhibition does not affect intimal SMC proliferation or 
neointimal formation (Olson et al., 1992).  
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In vivo studies have confirmed the importance of PDGF in VSMC phenotypic 
switching. Infusion of PDGF-BB into rats following carotid artery endothelial 
denudation resulted in small increases (2-3 fold) in medial VSMC proliferation 
and larges increases (approximately 20-fold) in VSMC migration to the intima, 
resulting in increased neointimal formation (Jawien et al., 1992). Furthermore, 
inhibition of either the PDGF-A chain or PDGF-B chain significantly reduced 
neointimal formation following balloon catheter injury of the carotid artery 
(Deguchi et al., 1999, Kotani et al., 2003). This appears to occur both through 
decreased proliferation and decreased chemotaxis of VSMCs to the intima 
following PDGF inhibition (Deguchi et al., 1999, Ferns et al., 1991). 
1.2.1.4 Transforming growth factor beta 
TGF-β is released from cells including macrophages and VSMCs and expression 
has been shown to be upregulated in atherosclerotic plaques, after vascular 
injury and in vessels with restenosis (Rappolee et al., 1988, Majesky et al., 1991, 
Nikol et al., 1992). TGF-β is a potent agonist of ECM production which stimulates 
production of collagens I and II by VSMCs (Amento et al., 1991).  TGF-β control 
elements (TCE) exist in the promoter regions of contractile genes and along with 
the CArG box are essential for TGF-β mediated control of the contractile genes 
α-SMA, SM-MHC and SM22α (Adam et al., 2000, Hautmann et al., 1997). It has 
been shown that TGF-β promotes binding of kruppel-like factor (KLF) 5 to the 
TCE which enhances transcription of contractile genes through an SRF-CArG box 
dependent mechanism (Hautmann et al., 1997, Adam et al., 2000). TGF-β also 
inhibits the expression of KLF4, which competes at the TCE with KLF5 to 
decrease contractile gene expression (Adam et al., 2000). TGF-β has been shown 
to inhibit human VSMC proliferation and migration in vitro and can inhibit PDGF–
induced migration (Mii et al., 1993, Reddy and Howe, 1993). Interestingly, 
despite the inhibitory effect TGF-β exerts of PDGF induced migration TGF-β can 
promote VSMC migration in a dose dependent manner (Koyama et al., 1990). 
Others have reported that TGF-β stimulates VSMC proliferation via activation of 
PDGF-AA secretion by VSMCs in a dose dependent manner and also potentiates 
growth responses to bFGF, PDGF –BB and epidermal growth factor in vitro 
(Stouffer and Owens, 1994, Battegay et al., 1990). Conversely high doses of TGF-
β inhibit VSMC proliferation and decrease PDGF receptor alpha subunit 
expression (Battegay et al., 1990).  
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Injury to the rat carotid artery has been reported to result in significantly 
increased expression of several TGF-β isoforms with TGF-β1 showing the greatest 
upregulation of expression, whilst infusion of TGF-β1 promoted proliferation of 
the neointima (Majesky et al., 1991, Smith et al., 1999). Delivery of a TGF-β1 
expression plasmid to porcine arteries resulted in neointimal hyperplasia and 
ECM synthesis (Nabel et al., 1993). Furthermore inhibition of TGF-β1 by a 
neutralising antibody significantly reduced neointimal formation and expression 
of ECM proteins fibronectin and versican after vascular injury (Wolf et al., 1994).  
Similarly, delivery of soluble TGF-β receptor II (TGF-βRII) was shown to lead to a 
significant reduction in neointimal lesion formation (Smith et al., 1999). The 
expression of the TGF-βRII is reduced in VSMCs isolated from human 
atherosclerotic plaques and in proliferating intimal VSMCs following vascular 
injury (Smith et al., 1999, McCaffrey et al., 1995). TGF-β1 was shown to exert an 
antiproliferative response on in VSMCs derived from normal arteries but this 
effect was absent in VSMCs derived from atherosclerotic arteries where TGF-β1 
strongly promoted synthesis of ECM (McCaffrey et al., 1995). Delivery of TGF-βRII 
to atherosclerotic VSMCs resulted in an antiproliferative response to TGF-β1, 
indicating that the promotion of neointimal formation by TGF-β in vivo following 
injury may be partly due to decreased expression of TGF-βRII (McCaffrey et al., 
1995).  Taken together these studies indicate that the role of TGF-β in governing 
VSMC phenotype is largely context dependent, however, following vascular 
injury TGF-β signalling appears to promote neointimal formation by activation of 
VSMCs.   
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Figure 1.3. The contractile and synthetic VSMC. 
Serum response factor (SRF) in combination with its cofactor myocardin, myocardin related 
transcription factor A (MRTF-A) or MRTF-B promotes a contractile phenotype. Fully contractile 
VSMCs have an elongated shape with an abundance of highly organised actin stress fibers and 
contractile proteins including alpha smooth muscle actin (α-SMA), smooth muscle myosin heavy 
chain (SM-MHC), calponin and smooth muscle 22 alpha (SM22α). Contractile VSMCs are largely 
non-proliferative and non-migratory.  Synthetic VSMC phenotype is promoted by signalling of 
growth factors such as platelet-derived growth factor (PDGF) and transforming growth factor beta 
(TGF-β). Fully synthetic VSMCs have an epithelioid shape and display less contractile gene 
expression and increased expression of synthetic genes such as SMemb. Stress fiber numbers are 
decreased in synthetic VSMCs whereas there is increased expression of the protein synthesis 
machinery- golgi apparatus, rough endoplasmic reticulum and free ribosomes. Synthetic VSMCs 
produce large amounts of ECM and are proliferative and migratory. Adapted from Servier Medical 
Art. 
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1.3 MicroRNAs 
The human genome contains approximately 20,000 - 25,000 protein coding 
genes, surprisingly only around 30-fold more than that of a nematode worm 
(IHGSC, 2004). Protein coding genes make up less than 2% of the human genome 
whereas the remainder is made up of non-protein coding deoxyribonucleic acid 
(DNA) (IHGSC, 2004). Non-coding DNA was originally thought of as ‘junk’ DNA 
with no purpose but it was later shown that approximately 75% of the human 
genome is in fact transcribed indicating that non-coding ribonucleic acid (RNA) 
accounts for a large proportion of transcriptional output (Djebali et al., 2012). 
Non-coding RNAs include well described RNAs including transfer RNA and 
ribosomal RNA which have functions in protein synthesis as well as the more 
recently discovered long non-coding RNAs, small interfering RNAs (siRNAs) and 
microRNAs (miRNAs) (Mercer et al., 2009, Zeng et al., 2003). MiRNAs were first 
discovered by the Ambros lab in 1993 when a small non-protein coding RNA was 
shown to control developmental timing through gene regulation in 
Caenorhabditis elegans (C. elegans) (Lee et al., 1993). Decades on and hundreds 
of miRNAs have now been discovered and are believed to regulate a large 
proportion of the human genome (van Rooij, 2011).  
1.3.1 MiRNA Biogenesis  
MiRNAs are ~20-25 nucleotide (nt) non coding RNA molecules which regulate 
gene expression typically through binding to the 3’ untranslated region (UTR) of 
messenger RNA (mRNA) transcripts and preventing translation via RNA 
interference (Lee et al., 1993, Wightman et al., 1993, Lau et al., 2001, Lagos-
Quintana et al., 2001). MiRNAs can be encoded within the introns of coding 
genes or in intergenic regions (Ramalingam et al., 2014, Saini et al., 2007, 
Monteys et al., 2010). MiRNAs encoded within introns can share a common 
transcriptional unit with the host gene and may therefore show concordant 
expression with the host gene (Baskerville and Bartel, 2005).  However, other 
intron encoded miRNAs show differential expression patterns to the host gene 
and have been found to be transcribed from separate transcriptional units 
(Ramalingam et al., 2014, Monteys et al., 2010). A miRNA may exist alone or 
clustered alongside other miRNAs on the genome  giving rise to ‘families’ of 
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miRNA, which have been commonly found to work to within in similar pathways 
(Baskerville and Bartel, 2005, Gregory et al., 2008).  
MiRNA biogenesis begins in the nucleus with transcription by RNA polymerase II 
or RNA polymerase III to form a long transcript, often more than 1 kilobase (kb) 
in length, known as a primary miRNA (pri-miRNA) (Figure 1.4) (Lee et al., 2004, 
Borchert et al., 2006, Lee et al., 2002). For miRNAs clustered on the genome a 
single pri-miRNA may be produced which encodes several miRNAs (Lee et al., 
2002). It has also been shown that pri-miRNA transcripts containing single 
miRNAs can be produced from miRNA clusters through separate transcriptional 
unit or alternative splicing on the host gene (Ramalingam et al., 2014). Post-
transcriptional modification of pri-miRNAs by adenosine deaminases acting upon 
RNA (ADARs) has been described for several miRNAs (Luciano et al., 2004). 
ADARs act upon the pri-miRNA to change adenosine to inosine, which can lead to 
alterations in base-pairing, structure, processing and target recognition (Yang et 
al., 2006). Typically, pri-miRNAs contain a double stranded hairpin stem around 
33 base pairs  (bp) in length, with terminal loop and two single stranded flanking 
regions located at the 5’ and 3’ ends of the transcript with a 5′ 7-methyl 
guanosine cap and a 3′ poly-A tail  (Cai et al., 2004, Lee et al., 2004). It is this 
general structure, that allows the pri-miRNA to be distinguished from other 
hairpin RNAs and be recognised by the miRNA ‘microprocessor complex’ Drosha 
and DiGeorge critical region 8 (DGCR8) (Lee et al., 2003, Gregory et al., 2004, 
Han et al., 2006). Drosha is a class II ribonuclease (RNase) III enzyme, which 
contains two RNase III domains and one double-stranded RNA binding domain 
(dsRBD) (Han et al., 2004). The two RNase III domains of Drosha form an 
intramolecular dimer which cleaves the pri-miRNA at the 5’ and 3’ strand leaving 
an overhang of around 2 bp in the 3’ strand (Han et al., 2004). DGCR8 contains 
two dsRBD and has been shown to be an essential component of the 
microprocessor complex (Gregory et al., 2004, Denli et al., 2004, Landthaler et 
al., 2004). The current model predicts that DGCR8 acts as an anchor by binding 
to the pri-miRNA at the junction where the single stranded flanking regions meet 
the double stranded hairpin stem (Han et al., 2006). DGCR8 anchoring to the pri-
miRNA appears essential in aiding Drosha to identify the correct position for 
cleavage of the pri-miRNA (Han et al., 2006). This position is believed to be 
approximately 11 bp from the junction where the single stranded flanking arm 
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meets the double stranded stem of the pri-miRNA (Han et al., 2006). In intronic 
miRNAs which share a transcriptional unit with the host gene, Drosha cleavage 
has been shown to occur prior to the completion of intron splicing (Kim and Kim, 
2007).  The result of cleavage by Drosha is a double-stranded stem-loop 
precursor miRNA (pre-miRNA) around 60 - 100 nt long.  
The pre-miRNA, along with its 3’ overhang created during cleavage by Drosha, is 
recognised by Exportin 5, which in the presence of its cofactor Ran-guanosine 
triphosphate (GTP) allows for the nuclear export of the pre-miRNA to the 
cytoplasm (Figure 1.4) (Yi et al., 2003, Bohnsack et al., 2004). Once in the 
cytoplasm the pre-miRNA is acted upon by the RNA induced silencing complex 
(RISC)-loading complex comprised of Argonaute (Ago) 2, the class III RNase III 
enzyme Dicer and the cofactors TAR RNA binding protein (TRBP) and protein 
activator of PKR (PACT) (Hutvagner et al., 2001, Lee et al., 2006, MacRae et al., 
2008, Chendrimada et al., 2005). Dicer contains two RNase III domains, one 
dsRBD and a long N terminus containing a PIWI/Argonaute/Zwille (PAZ) domain 
which recognises the 2 nt 3’ overhang (Ma et al., 2004) and cleaves the pre-
miRNA via its RNase III domains around 22-25 nt from the 3’ terminus (Macrae et 
al., 2006, Zhang et al., 2002).  TRBP and PACT are double stranded RNA binding 
proteins which form a complex with Dicer that is not essential for but helps 
facilitate Dicer’s cleavage of the pre-miRNA  (Haase et al., 2005, Lee et al., 
2006, Chendrimada et al., 2005). Interestingly, biogenesis of miR-451, a miRNA 
abundantly expressed in red blood cells, has been shown to be processed by a 
Dicer-independent mechanism that requires Ago2-dependent cleavage to form 
mature miR-451 (Yang et al., 2010, Cifuentes et al., 2010). Dicer cleavage 
removes the loop region of the pre-miRNA to form an intermediate RNA duplex 
around 22 nt long with 2 nt 3’ overhangs on each strand.  Once Dicer cleavage 
has occurred the RNA duplex associates with Ago2 and is unwound, a 
phenomenon that has recently been shown to be dependent upon the N domain 
of Ago2 (Kwak and Tomari, 2012). The strand with the least stable hydrogen 
bonds in its 5’ region is usually preferentially chosen to become the ’guide 
strand’ and is loaded onto Ago2 to form the RISC, whereas the remaining 
passenger strand is predominantly degraded (Schwarz et al., 2003, Khvorova et 
al., 2003). However, it has been shown that in some tissues a miRNA may 
undergo passenger strand degradation whereas in other tissues both strands of 
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the same miRNA are retained suggesting that the passenger strand may have a 
functional role (Ro et al., 2007).  
1.3.2 Function of miRNAs 
The miRNA guides the RISC to mRNA targets which it recognises via 
complementary base pairing to the 3’ UTR of target mRNAs. Complementarity to 
the highly evolutionary conserved ‘seed sequence’, nucleotides 2 to 7 in the 5’ 
region of the miRNA and corresponding 3’ region of its target mRNA is needed 
for target recognition, although additional binding to further sites in the 3’ UTR 
is thought to aid recognition (Wightman et al., 1993, Lewis et al., 2003, Grimson 
et al., 2007). The degree of complementarity between the miRNA and its mRNA 
target in the 3’UTR appears important in determining whether mRNA 
degradation or repression occurs (Zeng et al., 2003). Full complementary of a 
miRNA within the 3’UTR can result in target mRNA cleavage as is seen in siRNAs, 
however this appears to be much more common in plants and rarer in animal 
miRNAs (Rhoades et al., 2002, Davis et al., 2005).  Ago proteins are an essential 
component of the RISC with Ago2 shown to be vital for RISC cleavage of mRNA 
(Liu et al., 2004, Meister et al., 2004). Structural studies have revealed that the 
Ago2 p element-induced wimpy testes (PIWI) domain is highly similar in structure 
to the endonuclease RNase H, which cleaves mRNA to form a 5’ phosphate and 
3’ hydroxyl groups products (Liu et al., 2004, Song et al., 2004). Site-directed 
mutagenesis studies have revealed that it is this RNase-H-like PIWI domain 
within Ago2 that is responsible for cleavage activity (Liu et al., 2004). Ago2 
proteins also contain a PAZ domain, which binds the 3’ region of the guide 
strand and a middle domain which anchors the 5’ region (Song et al., 2003, 
Frank et al., 2010).  
MiRNAs which do not have full complementarity to mRNA target 3’ UTR, but are 
complementary to the seed sequence may trigger repression rather than 
cleavage of the mRNA (Figure 1.4) (Zeng et al., 2003). This has been found to 
occur through inhibition of the initiation of translation (Humphreys et al., 2005, 
Pillai et al., 2005) and also following the initiation of translation (Olsen and 
Ambros, 1999, Petersen et al., 2006, Nottrott et al., 2006).  However, several 
studies looking into the abundance of miRNAs and their target mRNAs have 
shown that target mRNA levels largely inversely correlate with miRNA levels 
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suggesting that mRNA degradation may be the more common form of gene 
silencing than translational repression (Lim et al., 2005, Baek et al., 2008, Guo 
et al., 2010, Hendrickson et al., 2009). MiRNAs which pair imperfectly to target 
mRNA 3’UTR have been shown to regulate expression by directing targets to 
mRNA degradation pathways (Figure 1.4). This has been shown to occur through 
decapping and deadenylation of the mRNA which leads to its degradation 
(Rehwinkel et al., 2005, Wu et al., 2006, Eulalio et al., 2009, Piao et al., 2010). 
These studies indicate that a miRNA-RISC complex can regulate target expression 
through a variety of mechanisms and are likely to depend on the miRNA itself 
and its complementarity to each individual target gene 3’UTR.  
Importantly, activity of miRNA passenger strands which are not degraded by the 
cell has now been demonstrated for several miRNAs, indicating that these 
strands can be incorporated into the RISC and functionally inhibit target 
expression (Zhang et al., 2013, Yang et al., 2013). For example both miR-126 
and its passenger strand miR-126* were shown to inhibit the expression of target 
gene SDF-1α, which promotes tumour angiogenesis (Zhang et al., 2013).  This 
resulted in reduced recruitment of mesenchymal SCs and inflammatory cells to 
the primary tumour site and reduced incidence of lung metastasis in mice (Zhang 
et al., 2013).  
An overview of miRNA biogenesis is shown in figure 1.4 with miR-143 and miR-
145 used as an example for the biogenesis of clustered miRNAs.    
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Figure 1.4. Biogenesis of miR-143 and miR-145. 
MiR-143 and miR-145 are transcribed by RNA Polymerase II or III (RNA Pol II/III) from a common 
bicistronic gene in the nucleus to form a large pri-miRNA transcript which contains both miRNAs. 
The pri-miRNA is cleaved by Drosha and its cofactor DiGeorge critical region 8 (DGCR8) to form 
the individual pre-miR-143 and pre-miR-145. Pre-miR-143 and pre-miR-145 are transported to the 
cytoplasm by Exportin 5 and its cofactor ran-guanosine triphosphate (Ran-GTP) where they are 
then acted upon by Dicer and its cofactors tar binding protein (TRBP) and protein activator of PKR 
(PACT) which cleave the stem loop to form double stranded intermediates. One strand is chosen 
and loaded onto the RISC complex composed of argonaute proteins to act as a ‘guide’ where it 
directs the RISC to target mRNA recognised by complementary based pairing to the 3’ region of 
the mRNA, triggering mRNA degradation or translational repression.  
 
1.3.3 Importance of miRNAs during development 
MiRNAs are essential during development where the expression profiles of 
individual miRNAs are modulated, according to developmental stage (Wienholds 
et al., 2005, Mineno et al., 2006). By increasing miRNAs profiles the expression 
of certain genes can essentially be ‘switched off’ by miRNA repression or 
alternatively absent or decreased miRNA expression levels may permit 
translation and gene expression. Studies in vertebrates have shown that certain 
miRNAs are important in the critical maternal to zygotic transition stage of 
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embryogenesis where they act to degrade maternal mRNAs to allow development 
to continue under the control of the zygotic genome (Giraldez et al., 2006, Lund 
et al., 2009). ESCs are pluripotent cells that are isolated from the inner cell 
mass of the blastocyst (4-5 days post-fertilisation in humans), which can 
differentiate to form all cells within the 3 major germ layers: ectoderm, 
endoderm and mesoderm (Evans and Kaufman, 1981, Martin, 1981). ESCs have 
been shown to express a unique set of miRNAs, including the miR-302 family 
consisting of 5 clustered miRNAs, which appear to be ESC-specific and are not 
detectable at later stages of development or in adult tissues (Houbaviy et al., 
2003, Suh et al., 2004). It is thought that these miRNAs may play an essential 
role in maintaining pluripotency and aiding differentiation of ESCs (Houbaviy et 
al., 2003, Suh et al., 2004). Conditional KO of Dicer, an enzyme responsible for 
miRNA maturation, has been shown to reduce differentiation and proliferation of 
ESCs (Murchison et al., 2005, Kanellopoulou et al., 2005).  
The first study to show the importance of miRNAs during development came at 
their very discovery, when lin-4 was shown to negatively regulate the expression 
of lin-14 in C. elegans (Lee et al., 1993, Wightman et al., 1993). Lin-14 is a 
heterochronic gene whose protein is expressed in a temporal gradient that 
controls the timing of developmental events in larvae (Ambros and Horvitz, 
1987, Ruvkun and Giusto, 1989). By post-transcriptionally repressing lin-14 
expression, lin-4 was shown to create this temporal gradient of lin-14 
expression, thus controlling developmental timing in C.elegans (Lee et al., 
1993). The use of profiling techniques, such as miRNA arrays, has allowed the 
expression of large numbers of miRNAs to be studied during vertebrate and 
mammalian embryogenesis and development where temporal patterns of miRNA 
expression, similar to those seen in C. elegans, are observed (Wienholds et al., 
2005, Mineno et al., 2006, Cao et al., 2012, Krichevsky et al., 2003).  
Further evidence for the importance of miRNAs in development comes from KO 
mouse studies where global KO of Dicer, an essential component of the miRNA 
biogenesis pathway, was shown to be embryonically lethal (Bernstein et al., 
2003). Importantly, Dicer is also essential for the development of the 
cardiovascular system. A cre recombinase mediated cardiac-specific Dicer KO, 
which under the control of the Nkx2.5 promoter directs Dicer KO in cardiac 
progenitor cells by embryonic day (E) 8.5,  was shown to be embryonic lethal in 
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mice by E12.5 due to gross abnormalities in cardiac development (Zhao et al., 
2007). Cardiovascular specific Dicer KO has also been performed using cre 
recombinase under the control the alpha myosin heavy chain promoter, where 
miRNA level began to decrease in the heart at E14.5. The loss of Dicer 
expression at this later time point resulted in postnatal lethality within 4 days of 
birth due to dilated cardiomyopathy and heart failure (Chen et al., 2008). 
Similarly, cardiomyocyte specific KO of DGCR8, an essential cofactor of Drosha 
mediated cleavage of pri-miRNAs, was shown to result in lethality within 2 
months of birth in mice, due to dilated cardiomyopathy and heart failure (Rao et 
al., 2009).  
Individual miRNAs that are tissue specific or are enriched within a certain tissue 
type can also be particularly important for development. This has been 
demonstrated for the skeletal and cardiac muscle-specific bicistronic miRNAs 
miR-1 and miR-133a, which are essential for normal cardiac development. KO of 
miR-1-2 resulted in 50% lethality in mice occurring from E15.5 to a few days 
postnatally, which was attributed to the presence of ventricular septal defect 
and pericardial oedema (Zhao et al., 2007). Furthermore surviving miR-1-2 KO 
mice displayed abnormalities in cardiac electrical conductance including 
prolonged ventricular depolarisation (Zhao et al., 2007). Conversely, 
overexpression of miR-1 in the developing heart also led to embryonic lethality 
by E13.5 due to thin ventricular walls and heart failure (Zhao et al., 2005). 
Similar to its cotranscribed miR-1, KO of both miR-133a-1 and miR-133a-2 led to 
around 50% embryonic lethality due to ventricular septal defect, whereas 
surviving mice went on to develop dilated cardiomyopathy and heart failure (Liu 
et al., 2008).   
1.3.4 Dysregulation of miRNAs in disease 
Currently more than 1000 human microRNAs have been identified which are 
thought to regulate approximately 60% of genes (van Rooij, 2011). When 
considering the importance of miRNAs in regulating normal cellular homeostasis 
in health, it is perhaps unsurprising that aberrant expression of these regulators 
has been reported in a broad range of human diseases including heart disease 
(Sucharov et al., 2008, Naga Prasad et al., 2009) and cancer (Lu et al., 2005, 
Blenkiron et al., 2007, Zhang et al., 2007). Differential expression patterns of 
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miRNAs are also reflected in animal models of disease and alteration of miRNA 
levels can provide a therapeutic benefit (Fiedler et al., 2011, van Rooij et al., 
2006, Kumar et al., 2008). The therapeutic benefit of altering miRNA expression 
is now being investigated in humans with the first miRNA-targeted drug 
Miravirsen, currently in phase II clinical trials (Lindow and Kauppinen, 2012). 
Miravirsen is a locked nucleic acid (LNA) antisense oligonucleotide which binds to 
miR-122 inhibiting its expression. MiR-122 is an abundantly expressed liver 
miRNA which promotes the expression of hepatitis C viral RNA in infected cells 
through binding to sites in the viral 5’ terminus and protecting it from 
nucleolytic degradation (Jopling et al., 2005, Machlin et al., 2011). In non-
human primates inhibition of miR-122 provides an antiviral effect, significantly 
reducing hepatitis C viral titre (Lanford et al., 2010). Although the action of 
miR-122 on hepatitis C viral RNA is somewhat unconventional in that it increases 
RNA levels rather than degrading or repressing them, these studies provide 
strong support that drugs targeting miRNAs may be useful clinically.   
1.3.5 Importance of miRNAs in VSMCs 
The global importance miRNA expression for VSMC development was highlighted 
in a study by Albinsson and colleagues (Albinsson et al., 2010) who showed that 
KO of Dicer within the VSMCs resulted in late embryonic death between E16 to 
E17 due to haemorrhaging. VSMC-Dicer KO embryos displayed reduced SMC 
proliferation, thin aortic walls and reduced vessel contractility as well as 
reduced levels of VSMC differentiation markers SM-MHC, SM22α and calponin 
(Albinsson et al., 2010).  Albinsson and colleagues went on to generate adult 
VSMC-Dicer KO mice by a tamoxifen-dependent cre recombinase under the 
control of SM-MHC promoter (Albinsson et al., 2011). Blood pressure 
measurements performed 6-8 weeks post-tamoxifen treatment revealed that 
adult VSMC Dicer-KO mice had substantial reductions in both systolic and 
diastolic blood pressure. VSMC-Dicer KO mice also displayed significantly blunted 
contractile responses to phenylephrine and reduced expression of contractile 
proteins calponin, α-SMA and SM-MHC (Albinsson et al., 2011). Together these 
studies highlight the fundamental role of miRNAs in the development and 
maintenance of VSMCs phenotype. Some of the individual miRNAs identified as 
important regulators of VSMC phenotype are discussed in more detail below.   
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MiR-21 has been identified as a potent regulator of VSMC phenotype and its 
expression has been shown to induce proliferation and decreases apoptosis of 
cultered VSMCs (Ji et al., 2007). MiR-21 expression is upregulated in the vessel 
wall following balloon catheter injury of the rat carotid artery and knockdown of 
miR-21 using an antagomiR significantly reduces neointimal formation (Ji et al., 
2007). Furthermore knockdown of miR-21 resulted in around 50% increase in 
apoptosis and decrease in proliferation in the neointima detected 7 days post 
balloon injury (Ji et al., 2007).  
The expression of miR-221 and miR-222 is also increased in the vessel wall 
following injury and was localised to VSMCs (Liu et al., 2009). Expression of 
these miRNA is increased in VSMCs following PDGF or serum-induced 
proliferation and knockdown of miR-221 or miR-222 reduces proliferation. This 
has been shown to occur partly through repression of their targets p27(Kip1) and 
p57(Kip2) (Liu et al., 2009). Furthermore, p27(Kip1) and p57(Kip2) were 
downregulated in the vascular wall following injury and upregulated following 
miR-221 and miR-222 inhibition, suggesting that they are targeted by these 
miRNA in vivo. Inhibition of both miRNA reduced neointimal formation after 
balloon catheter injury of the carotid artery by around 40% (Liu et al., 2009).  
PDGF has been previously shown to repress VSMC contractile gene expression by 
activating the expression of stimulating protein-1 (Sp-1), which binds to sites in 
the KLF4 promoter to activate transcription and promote the inhibitory action of 
KLF4 on myocardin (Deaton et al., 2009). MiR-133 expression is decreased in 
proliferating and migrating VSMCs and PDGF has been shown to repress the 
expression of this miRNA through a mechanism involving the ERK1/2-dependent 
pathway (Torella et al., 2011). Overexpression of miR-133 inhibited both VSMC 
proliferation and PDGF induction of Sp-1 and KLF4 which prevented myocardin 
downregulation and the downregulation of VSMC markers α-SMA and SM-MHC 
(Torella et al., 2011). Adenoviral overexpression of miR-133 in the balloon-
injured rat carotid artery reduced neointimal formation by around 60% which 
was concurrent with decreased proliferation and reduced Sp-1 induction.  
Furthermore, delivery of an antimiR against miR-133 significantly increased 
neointimal formation and proliferation (Torella et al., 2011). 
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MiR-146a is a promoter of VSMC proliferation and knockdown of miR-146a in vivo 
using an antimiR significantly reduced neointimal formation and proliferation in 
the injured rat carotid artery (Sun et al., 2011).  MiR-146a represses the 
expression of its target KLF4, which in turn competes with KLF5 for a common 
binding site in the miR-146a promoter. KLF4 and KLF5 were shown to exert 
opposing effects on the miR-146a promoter activity with KLF4 decreasing miR-
146a expression in VSMCs and KLF5 increasing expression respectively (Sun et 
al., 2011). Therefore miRNAs can act in feedback loops with transcription factors 
in VSMCs. 
1.3.6 Importance of miRNAs in ECs 
ECs have high expression of many miRNAs including members of the let-7 family, 
miR-126, miR-221, miR-222 and miR-21 (Kuehbacher et al., 2007). ECs are 
usually quiescent in adult vessels but can become activated following vascular 
injury or during ischemia. Angiogenesis, the formation of new capillaries from 
existing vessels, primarily involves ECs which are stimulated to proliferate and 
migrate outwards from the vessel whilst organising into vessel like structures 
(Auerbach and Auerbach, 1994). Angiogenesis occurs following MI where it helps 
to revascularise the ischaemic tissue and also during cancer where 
vascularisation of the tumour has been shown to promote progression and 
metastasis (Auerbach and Auerbach, 1994). 
Knockdown of Dicer using siRNAs in vitro significantly reduces FGF-induced EC 
capillary sprouting, formation of capillary-like structures on matrigel and 
migration and proliferation (Kuehbacher et al., 2007, Suarez et al., 2007). 
Furthermore Dicer-deficient ECs showed significantly impaired formation of 
capillary-like structures in matrigel plugs in vivo in nude mice, indicating the 
global importance of miRNAs in angiogenesis (Kuehbacher et al., 2007).  Further 
studies identified many EC miRNAs which are regulators of angiogenesis. MiR-
126, an EC-specific miRNA, has been shown to enhance vascular endothelial 
growth factor (VEGF) and FGF activation of MAP kinase signalling by repressing 
the expression of its target Spred-1 (Wang et al., 2008b). MiR-126 promotes EC 
proliferation, migration and angiogenesis and miR-126 KO mice show impaired 
ability to form vessel-like structures in matrigel plugs in reponse to FGF-2 in vivo 
(Wang et al., 2008b). MiR-126 KO mice were associated with around 50% 
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lethality due to severe oedema and blood vessel rupture and haemorrhage (Wang 
et al., 2008b). Induction of MI resulted in death in approximately 30% of 
wildtype (WT) mice compared with 80% of miR-126 KO mice, which were found 
to have extensive fibrosis and ventricular dilatation and significantly abrogated 
vascularization of the injured myocardium compared to WT mice (Wang et al., 
2008b). Together these studies suggest that miR-126 is an important promoter of 
angiogenesis. Other pro-angiogenic miRNAs include the let-7 cluster (Kuehbacher 
et al., 2007) and miR-17-92 cluster, which contains miRNAs with both pro- and 
anti-angiogenic effects (Dews et al., 2006, Bonauer et al., 2009, Doebele et al., 
2010, Suarez et al., 2008). Overexpression of miR-221 and miR-222 has been 
shown to be anti-angiogenic by reducing the ability of stem cell factor to 
promote EC migration and formation of capillary-like structures on matrigel 
(Poliseno et al., 2006). This is thought to occur partly through inhibition of its 
receptor c-Kit (Poliseno et al., 2006). MiR-21 expression is reduced during 
angiogenesis and overexpression of this miRNA reduced EC migration and 
capillary-like tube formation in matrigel (Sabatel et al., 2011). This effect was 
mimicked by siRNA knockdown of miR-21 target RhoB, which has been shown to 
stimulate actin stress fiber formation, indicating a possible mechanism (Sabatel 
et al., 2011). The process of endothelial-to-mesenchymal transition, where ECs 
change to fibroblasts, occurs during cardiac fibrosis and has been shown to be 
mediated in part through TGF-β stimulation of miR-21 (Kumarswamy et al., 
2012).  
MiR-126 directly represses the expression of vascular cell adhesion molecule 1 
(VCAM-1) which is upregulated during vascular inflammation, indicating the miR-
126 may act to reduce leukocyte adhesion in vivo (Harris et al., 2008).  MiR-155 
represses the expression of the Ang II type 1 receptor and overexpression of this 
miRNA can reduce Ang II stimulated T cell adhesion and migration of ECs (Zhu et 
al., 2011). Together these studies indicate that miRNAs play an important role in 
the regulation of ECs including influencing proliferation, migration, angiogenesis 
and inflammation.  
1.3.7 MiR-143 and miR-145 are enriched in VSMCs 
Two miRNAs which have been identified as particularly important for normal 
VSMC development and function are the bicistronic miRNAs miR-143 and miR-145 
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(Figure 1.4). MiR-143 and miR-145 are highly conserved, 21 nt and 23 nt long 
miRNAs, which are clustered on human chromosome 5 and mouse chromosome 
18 where they are co-transcribed from the same transcriptional unit (Cordes et 
al., 2009). Studies of mouse embryonic development revealed that miR-143 and 
miR-145 are highly expressed in multipotent cardiac progenitor cells which are 
capable of differentiating into cardiomyocytes, SMCs and ECs (Cordes et al., 
2009). The expression of both miR-143 and miR-145 remains high during heart 
development but decreases during later cardiogenesis. Postnatally, expression is 
mostly observed in VSMCs and SMCs lining organs, including the lung, bladder 
and organs of the gastrointestinal tract (Cordes et al., 2009, Boettger et al., 
2009, Xin et al., 2009). In adults miR-143 and miR-145 are the most abundantly 
expressed miRNAs in the artery wall where expression is enriched and largely 
confined to VSMCs, although low expression can be detected in ECs (Ji et al., 
2007, Cheng et al., 2009, Hergenreider et al., 2012). It is generally thought that 
the differential expression of miRNAs in different lineages is reflective of the 
importance of different miRNAs in different cell types, for example the high 
expression miR-126 in ECs (Wang et al., 2008b). The enrichment of miR-143 and 
miR-145 in VSMCs suggests that miR-143 and miR-145 may predominately act to 
regulate these cells. 
1.3.8  Control of the miR-143/145 gene by serum response factor 
SRF, a major regulator of the actin cytoskeleton, regulates migration, 
contraction, and in combination with its cofactor myocardin, differentiation of 
VSMCs via the transcriptional regulation of numerous genes (see section 1.2.1.1) 
(Miano et al., 2007, Du et al., 2003). Strong evidence of the importance of miR-
143 and miR-145 in the maintenance of VSMC phenotype comes from studies 
which show that the miR-143/145 cluster is transcriptionally activated by SRF in 
combination with its cofactor myocardin or MRTF-A (Cordes et al., 2009, Xin et 
al., 2009).  SRF in combination with myocardin or MRTF-A was found to bind to 
an evolutionary conserved CArG box within cis regulatory elements in the miR-
143/145 enhancer region and activate transcription. Studies revealed that 
disruption of the CArG box binding site by mutagenesis abolished the expression 
of miR-143/145 reporter genes within the SMCs and heart of developing embryos 
(Xin et al., 2009, Cordes et al., 2009).  
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1.3.9 MiR-143 and miR-145 influence VSMC phenotype in vitro 
The evidence that miR-143 and miR-145 are both enriched within VSMCs and 
activated by SRF/myocardin signalling pathways prompted many groups to 
investigate whether these miRNAs are important in maintaining VSMC 
phenotype. In vitro studies have revealed that miR-143 and miR-145 expression 
is significantly reduced in VSMCs exposed to PDGF, which promotes SMC 
proliferation and migration (Cheng et al., 2009, Quintavalle et al., 2010). 
Furthermore, PDGF-induced VSMC proliferation and concurrent downregulation 
of markers of VSMC differentiation - calponin, SM-MHC and α-SMA - is inhibited 
by overexpression of miR-145 (Cheng et al., 2009, Cordes et al., 2009). Inhibition 
of miR-143 expression has been shown to increase the proliferation rate of 
VSMCs (Cordes et al., 2009). MiR-145 expression is necessary for myocardin 
reprogramming of fibroblasts into VSMCs (Cordes et al., 2009). In addition, 
exposure of multipotent neural crest SCs to miR-145 was found to be sufficient 
to guide 75% to VSMC fate (Cordes et al., 2009). Together these studies suggest 
that miR-143 and miR-145 may have a regulatory role in VSMC phenotype.  
1.3.10 MiR-143 and miR-145 expression after vascular injury  
In vivo studies have revealed that vessel wall expression of miR-143 and miR-145 
is reduced in vascular injury models characterised by VSMC proliferation and 
migration. Elia and colleagues demonstrated that following transverse aortic 
constriction in the rat miR-143 and miR-145 expression is decreased by around 
70% in the areas surrounding the constricted site (Elia et al., 2009). Mice 
deficient of ApoE, a glycoprotein important for cholesterol clearance, have 
elevated blood cholesterol and develop spontaneous atherosclerotic lesions 
within their vessels, a phenomenon which is exacerbated by high fat feeding 
(Piedrahita et al., 1992, Plump et al., 1992). Basal expression of miR-143 and 
miR-145 in the vessels of ApoE KO is approximately 50% less than that of WT 
mice and is further decreased upon high fat feeding (Elia et al., 2009). 
Furthermore, expression of miR-145 is significantly reduced in human carotid 
atherosclerotic plaques when compared to adjacent plaque-free sites (Lovren et 
al., 2012). A substantial loss of miR-143 and miR-145 also occurs following 
carotid artery ligation in the mouse and coincides with decreased expression of 
SMC contractile gene α-SMA (Cordes et al., 2009). Cheng and colleagues 
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demonstrated that following carotid balloon-injury in the rat miR-145 is 
downregulated by around 80% at 7 days and is concordant with decreased 
expression of α-SMA, calponin and SM-MHC and that recovery of expression of 
these genes over 28 days was closely associated with recovery of miR-145 
expression (Cheng et al., 2009). MiR-145 expression has also been reported to be 
decreased in human aortic biopsies from patients presenting with aortic 
aneurysms (Elia et al., 2009). These studies provide evidence that the adoption 
of a synthetic phenotype by VSMCs occurs in concordance with a loss of miR-143 
and miR-145 expression in vivo.  
In order to determine whether downregulation of miR-143 or miR-145 in vascular 
injury directly affects VSMC phenotype several groups used overexpression 
strategies. Local delivery of adenovirus overexpressing either miR-143 or miR-
145 was capable of reducing neointimal formation in the rat carotid balloon-
injury model (Elia et al., 2009, Cheng et al., 2009). Furthermore, lentiviral-
mediated overexpression of miR-145 in the ligated carotid artery of mice was 
sufficient to increase the expression of contractile genes α-SMA and calponin as 
well as myocardin (Cordes et al., 2009).  
Systemic delivery of a miR-145-expressing lentivirus with a SM22α promoter was 
shown to increase miR-145 expression in the VSMCs of ApoE KO mice (Lovren et 
al., 2012). Atherosclerotic lesion area following 12 weeks of western diet was 
reduced by up to 60% in lentiviral-miR-145 treated ApoE KO mice, which showed 
sustained increases (approximately 2.5 fold) in miR-145 expression over the 
course of the study (Lovren et al., 2012). Reduced plaque area was concurrent 
with increased expression of markers of plaque stability including reduced lipid 
and macrophage content, increased fibrous cap area, increased plaque collagen 
content and increased expression of VSMC differentiation markers α-SMA and 
calponin (Lovren et al., 2012).   
The evidence that miR-143 and miR-145 are downregulated following vascular 
injury and that restoring expression of these miRNAs reduces neointimal 
formation supports in vitro studies which indicate the possible role of these 
miRNAs in inhibiting VSMC proliferation and migration. 
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1.3.11 Identifying miRNA targets 
A widely used method to identify potential miRNA targets are bioinformatics 
websites (e.g. TargetScan, PicTar). This software identifies possible mRNA 
targets based on the complementarity between the 3’UTR of an mRNA and the 
miRNA of interest. They usually take into account areas of the 3’UTR which show 
strong evolutionary conservation which increases the likelihood of regulation 
occurring and reduces the incidence of false positives (Bartel, 2009). A 7 nt 
match to the seed sequence, nt 2-7, plus nt 1 or 8 in the 5’ region of the miRNA  
is effective at predicting target mRNA (Bartel, 2009). The number of predicted 
binding sites for the miRNA within a 3’UTR are also usually considered. Some 
software requires strict seed pairing whereas others allow slight mismatch in the 
seed sequence which may allow for prediction of valid targets that would 
otherwise be missed. It has been shown that pairing to further complementary 
regions outside the seed sequence in the 3’ UTR, termed ‘compensatory’ 
regions, can result in target repression even in the case of a base mismatch in 
the seed sequence (Yekta et al., 2004). Continuous ‘supplementary’ pairing to 
nucleotides 13-16 of the 3’UTR has been shown to associate with increased 
incidence of target repression (Grimson et al., 2007). Bioinformatics websites 
predict potential targets and list them in order of preference based on 
properties described above. 
Proteomic approaches such as staple isotope labelling with amino acids in cell 
culture (SILAC) are high-throughput methods which have been utilised to assess 
the expression of large numbers of proteins in response to alterations in miRNA 
levels by introduction of miRNA mimics or inhibitors (Baek et al., 2008). 
Microarrays are another high-throughput approach which can be used to identify 
mRNAs which are dysregulated in cells following overexpression or knockdown of 
the miRNA of interest (Guo et al., 2010). Several studies have reported that the 
vast majority of miRNA targets are dysregulated at both the protein and mRNA 
level indicating that identifying targets at the mRNA level is a valid method (Guo 
et al., 2010, Baek et al., 2008, Selbach et al., 2008). Microarrays are particularly 
useful when used together with bioinformatics software to help identify mRNAs 
which contain complementarity regions to the miRNA suggesting that direct 
regulation may occur. Quantitative real-time polymerase chain reaction (qRT-
PCR) can be used to confirm the dysregulation of an mRNA in response to a 
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miRNA in overexpression or knockdown studies to help remove the risk of false 
positives. 
To test direct binding of a miRNA to a target mRNA luciferase constructs are 
often used. This involves cloning of the 3’UTR of the potential mRNA target into 
a luciferase reporter which is then either transfected into cells which express 
the miRNA of interest or transfected into cells along with a miRNA mimic of the 
miRNA of interest. Decreased luciferase activity suggests that target repression 
is occurring (van Rooij, 2011). Mutations are often made in the 3’UTR as a 
control to ensure that target repression does not occur when binding sites are 
disrupted. 
1.3.12 Targets of miR-143 and miR-145  
Several target mRNA have been identified for miR-143 and miR-145, with many 
of them encoding proteins involved in cell proliferation, migration and SMC gene 
expression. For example, miR-145 negatively regulates the expression of 
calcium/calmodulin-dependent protein kinase II delta (caMKIIδ), which is 
induced in VSMCs and fibroblasts following injury and promotes proliferation, 
migration and neointimal formation (Cordes et al., 2009, House and Singer, 
2008). MiR-145 regulates the expression of angiotensin converting enzyme (ACE) 
which converts Ang I into its active form Ang II, a well-studied regulator of VSMC 
contraction and proliferation (Boettger et al., 2009, Daemen et al., 1991). MiR-
143 and miR-145 are both downregulated in glioma tumours, a phenomenon that 
is associated with poor prognosis (Lee et al., 2013). Conversely overexpression of 
miR-145 reduces glioma cell migration and invasion via downregulation of its 
target connective tissue growth factor (CTGF), suggesting that miR-145 is 
important in preventing tumour invasion into surrounding tissue (Lee et al., 
2013). MiR-145 expression is also significantly downregulated in bladder cancer 
whereas the expression of its target, actin-binding protein fascin homologue 1 
(FSCN1) is upregulated (Chiyomaru et al., 2010). Knockdown of FSCN1 is capable 
of reducing invasion and migration in bladder cancer cell lines (Chiyomaru et al., 
2010). MiR-145 has also been shown to target FSCN1 and reduce proliferation 
and invasion in oesophageal squamous cell carcinoma cell lines (Kano et al., 
2010). Together these studies indicate that miR-145 may function as a tumour 
suppressor. Disabled protein 2 (DAB2) acts as an inhibitor of wnt signalling 
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pathways and has been identified as a target of miR-145 in mesenchymal SCs and 
pulmonary SMCs (Mayorga and Penn, 2012, Caruso et al., 2012). Interestingly, 
Wnt signalling promotes cell proliferation (Mayorga and Penn, 2012) so by 
repressing the expression of DAB2 miR-145 may be predicted to induce 
proliferation, however further studies are required to determine whether this 
occurs. In human pulmonary artery SMCs the expression of Intergrin beta-like 1 
(ITGβL1) and TGF-β2 are downregulated by overexpression of miR-145 whereas 
knockdown with antimiR-145 upregulated their expression suggesting these 
mRNA may also be targets of miR-145 (Caruso et al., 2012).  
Some miR-143 and miR-145 targets that have been studied in more detail are 
discussed below.  
1.3.12.1 Kruppel-like factor 5 
MiR-143 and miR-145 have both been shown to bind to luciferase constructs 
containing the 3’ UTR of KLF5 resulting in reduced luciferase activity (Cheng et 
al., 2009, Xin et al., 2009). This phenomenon was further investigated for miR-
145 where it was shown that miR-145 downregulation of luciferase activity was 
inhibited by mutations in the predicted miR-145 binding site in the KLF5 3’UTR 
(Cheng et al., 2009). In cultured VSMCs KLF5 expression is upregulated by miR-
145 knockdown and downregulated by miR-145 overexpression. Furthermore, 
adenovirus-mediated overexpression of miR-145 is capable of preventing the 
increase in KLF5 levels that occurs following balloon injury to the rat carotid 
artery (Cheng et al., 2009). Together this evidence supports that KLF5 is a direct 
target of miR-145.  
KLF5 is a member of the KLF family of zinc-finger proteins and is associated with 
a synthetic VSMC phenotype. SM-MHC isoforms SM-1 and SM-2 are the 
predominantly expressed forms of SM-MHC in adult vessels (Kuro-o et al., 1991). 
Following vessel injury SM-2 expression is absent in the developing neointima 
and SMemb expression appears (Kuro-o et al., 1991). KLF5 is abundantly 
expressed in SMCs of the vessel walls during fetal development but is markedly 
reduced in adult vessels (Hoshino et al., 2000). However, following balloon-
injury to the rat aorta, KLF5 expression is induced in the developing neointima 
(Watanabe et al., 1999). KLF5 has been shown to bind to a cis-regulatory 
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element to promote transcription of SMemb within the neointima, a 
phenomenon associated with the de-differentiation of VSMCs (Watanabe et al., 
1999, Kuro-o et al., 1991). Interestingly, KLF5 can also promote transcriptional 
activation of contractile gene SM22α suggesting that  KLF5 may have variable 
roles depending on the context of expression (Adam et al., 2000). Homozygous 
KLF5 KO results in embryonic lethality, however mice that are heterozygous for 
KLF5 KO have thin vessel walls and display significantly less neointima formation 
following femoral cuff placement (Shindo et al., 2002). Conversely, adenoviral 
overexpression of KLF5 following vascular injury results in increased neointima 
formation and cell proliferation (Suzuki et al., 2009). This was further dissected 
in vitro where it was shown that KLF5 expression in cultured VSMCs increases the 
number of cells in the S phase whereas reduction in KLF5 expression reduces S 
phase transition (Suzuki et al., 2009). KLF5 transcriptional activation of cyclin 
D1, a key regulator of cell-cycle progression, may be responsible at least in part, 
for the increased proliferation seen with KLF5 expression (Suzuki et al., 2009). 
KLF5 has also been shown to transcriptionally activate PDGF-A and TGF-β 
expression in response to Ang II stimulation, indicating that KLF5 is involved in a 
number of signalling pathways known to influence cell proliferation and 
migration (Shindo et al., 2002). In patient coronary atherectomy samples high 
KLF5 expression is associated with restenosis (Sakamoto et al., 2003, Hoshino et 
al., 2000). Together these studies provide strong evidence for the role KLF5 in 
promoting cell proliferation, migration and neointimal formation. The negative 
regulation of KLF5 by miR-143 and miR-145 indicates that downregulation of 
these miRNA following vascular injury may influence VSMC phenotype in part via 
de-repression of KLF5.  
1.3.12.2 ELK-1 and myocardin 
Luciferase reporter assays have revealed that miR-143 binds the 3’ UTR of the 
ETS-domain transcription factor, Elk-1, in vitro and reduces luciferase 
expression (Cordes et al., 2009). Overexpression of miR-143 in VSMCs reduces 
ELK-1 protein expression but not mRNA, suggesting that miR-143 represses rather 
than degrades Elk-1 at the mRNA level (Cordes et al., 2009). Elk-1 has been 
shown to play an important role in the SRF signalling pathway by opposing the 
SRF-myocardin interaction and promoting a synthetic VSMC phenotype (Wang et 
al., 2004). SRF promotes a contractile VSMC phenotype when in association with 
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its cofactor myocardin (see section 1.2.1.1). However, upon PDGF stimulation, 
Elk-1 was shown to inhibit the myocardin-SRF interaction by binding 
competitively to the docking site myocardin utilises for SRF-binding (Wang et al., 
2004). This was demonstrated at the promoter region of the contractile genes 
SM22 and α-SMA genes which contain ternary complex factor binding sites, 
utilised by ELK-1, adjacent to SRF binding site. The Elk-1-SRF interaction 
resulted in repressed SMC contractile gene expression, thought to occur due to 
the disruption in myocardin binding (Wang et al., 2004).  
Interestingly, miR-145 was shown to directly bind to the 3’UTR and enhance the 
expression of myocardin (Cordes et al., 2009). Myocardin in combination with 
SRF is known to promote the transcription of miR-143/145 therefore suggesting 
that miR-145 and myocardin mutually promote expression of one another 
(Cordes et al., 2009). By repressing Elk-1 and promoting myocardin expression 
miR-143 and miR-145 promote the SRF-myocardin interaction which will not only 
promote the expression of contractile genes but may also promote miR-143/145 
transcription.  
1.3.12.3 Kruppel-like factor 4 
KLF4 has been shown to be a miR-143 and miR-145 target through 3’UTR 
luciferase and knockdown studies (Cordes et al., 2009, Xin et al., 2009, Davis-
Dusenbery et al., 2011). KLF4 expression has also been shown to be upregulated 
in human atherosclerotic plaques which show concurrent downregulation of miR-
145 expression (Lovren et al., 2012). KLF4, along with the transcription factors; 
Oct3/4, c-Myc and Sox2, is capable of producing induced pluripotent cells from 
adult human fibroblasts, indicating that KLF4 is important in producing a de-
differentiated phenotype (Takahashi et al., 2007). Expression of KLF4 is low in 
adult vessels but is upregulated following vascular injury (Liu et al., 2005). KLF4 
has been shown repress both expression of myocardin itself and myocardin-SRF 
activation of the α-SMA gene by binding to SRF at the same domain utilised by 
myocardin. Interaction of KLF4 with SRF prevented SRF from binding to the CArG 
box in the α-SMA promoter and thus prevented activation of α-SMA transcription 
(Liu et al., 2005). KLF4 is recruited to a TCE, located adjacent to the SRF CArG 
binding site in the promoter region of contractile genes (e.g. α-SMA, SM-MHC and 
SM22α) following vascular injury, which allows the interaction between SRF and 
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KLF4 (Adam et al., 2000, Liu et al., 2005, Yoshida et al., 2008). In ApoE KO mice 
restoration of miR-145 expression to VSMCs was shown to decrease KLF4 
expression and increase myocardin expression (Lovren et al., 2012). PDGF-BB 
activates KLF4 expression and was shown also shown to inhibit interaction of SRF 
with the CArG binding domain in α-SMA an action that could be partially blocked 
by inhibition of KLF4 expression (Liu et al., 2005).  KLF4 has also been shown to 
supress activation of SM22α via a TCE in its promoter (Adam et al., 2000). 
Conversely, others have reported that KLF4 is required for the upregulation of 
SMC contractile gene expression by all-trans-retinoic acid (Wang et al., 2008a). 
The expression of SM22α and α-SMA is reduced following vascular injury; 
however in mice with conditional KLF4 KO the downregulation of these SMC 
contractile genes is delayed suggesting that KLF4 may be crucial in the initial 
suppression of contractile gene expression (Yoshida et al., 2008). Interestingly, 
despite KLF4 expression being increased following vascular injury, KO of KLF4 
resulted in greater neointimal formation following carotid ligation. It was found 
the KLF4 directly represses SMC proliferation via a synergistic interaction with 
p53 at the cyclin-dependent kinase inhibitor p21waf1/cip1 promoter region (Yoshida 
et al., 2008). Other studies have also reported that KLF4 inhibits cell 
proliferation in vitro (Wassmann et al., 2007). The conflicting evidence suggests 
the role of KLF4 in maintaining SMC phenotype is extremely complex and it may 
have differential effects depending on the context. MiR-145 regulation of KLF4 
expression may result in different outcomes depending upon the context and the 
actions of other signalling molecules involved.  
1.3.13 Signalling pathways involving miR-143 and miR-145  
The de-regulation of miR-143 and miR-145 in migrating and proliferating VSMCs 
in vitro and in vivo has prompted many studies into what signalling pathways 
control miR-143/143 expression.  
1.3.13.1 Communication between ECs and VSMCs by miR-143/miR-145 
Despite miR-143 and miR-145 expression being relatively SMC enriched, the 
expression of these miRNAs is detectable in ECs albeit at much lower levels. 
However, although low basal expression of a miRNA within a cell type suggests 
minimal regulation may occur, miRNAs can be upregulated within a cell by stress 
Chapter 1 - Introduction  58 
 
 
and have a functional effect. The relevance of miR-143/145 expression in ECs 
was investigated in a recent study where it was shown that high shear stress 
results in a significant increase in miR-143/145 expression within ECs 
(Hergenreider et al., 2012). High shear stress is protective against the formation 
of atherosclerotic lesions, which most commonly form at areas of low sheer 
stress such as bifurcations (Cunningham and Gotlieb, 2005).  Laminar flow 
induces expression of KLF2, which was shown to directly bind to a putative KLF2 
binding site in the miR-143/145 promoter region, activating transcription in 
human umbilical vein ECs (HUVECs) (Hergenreider et al., 2012). This resulted in 
an approximately 30-fold enrichment of miR-143 and miR-145 in extracellular 
exosomes, significantly greater than the 10-fold increase observed in the 
HUVECs. The authors went on to show that co-culture of KLF2-overexpressing 
HUVECs with VSMCs resulted in exosomal transfer to VSMCs resulting in increased 
expression of miR-143 and miR-145 in VSMCs and decreased expression of targets 
mRNA ELK-1 and KLF4 (Figure 1.5) (Hergenreider et al., 2012). Furthermore, 
injection of the miR-143/145 enriched exosomes into fat fed ApoE KO mice 
significantly reduced aortic atherosclerotic lesion area, showing that this ‘miRNA 
transfer’ can function in vivo (Hergenreider et al., 2012).  
1.3.13.2 Alteration of the SRF cofactor expression by TGF-β and BMP4 
Bone morphogenetic protein 4 (BMP4) is a major signalling molecule known to 
promote a contractile VSMC phenotype and has been shown to promote miR-
143/145 transcription in pulmonary artery SMCs (Figure 1.5). This was shown to 
occur via stimulation of the nuclear translocation of SRF cofactor MRTF-A, 
thereby promoting the SRF-MRTF-A interaction with the CArG box and 
transcriptionally activating miR-143/145 (Davis-Dusenbery et al., 2011). 
Interestingly, another major regulator of VSMC phenotype, TGF-β, was shown to 
promote miR-143/145 transcription via activation of SRF cofactor myocardin in 
pulmonary and human coronary artery SMCs (Long and Miano, 2011).  
Furthermore, activation of miR-143/145 by TGF-β or BMP4 was essential for the 
downregulation of KLF4 by these signalling molecules (Long and Miano, 2011, 
Davis-Dusenbery et al., 2011).  
Induction of myocardin expression and activation of miR-143/145 expression by 
TGF-β occurs through binding of SMAD2/3 and SMAD4 to SMAD–binding elements 
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(SBEs) in the myocardin promoter and activating transcription (Davis-Dusenbery 
et al., 2011). Activation of myocardin transcription and increased miR-143/145 
expression has also been shown to occur through a p38 mitogen activated 
protein kinase (p38MAPK) dependent pathway (Long and Miano, 2011). TGF-β-
induced SMAD signalling was also shown to directly activate miR-143/145 
transcription by promoting SMAD3 and SMAD4 binding to a SBE in the miR-
143/145 promoter (Figure 1.5) (Long and Miano, 2011). Significantly, both the 
SBE and CArG sequence were essential for TGF-β activation of miR-143/145 
transcription, which promoted increased expression of contractile genes CNN1 
and ACTA2, suggesting that miR-143/145 is an essential downstream mediator of 
TGF-β signalling (Long and Miano, 2011).  
1.3.13.3 SRF-independent regulation of MiR-143/145 
MiR-143/145 expression can also be regulated by SRF-independent mechanisms. 
It has been shown that Jagged-1 activation of Notch receptors leads to nuclear 
translocation of the Notch intracellular domain (ICD) and formation of a complex 
with transcription factor CBF1 (Figure 1.5) (Boucher et al., 2011). This occurred 
in concurrence with an increased expression of contractile genes including α-SMA 
and SM22α, which could be inhibited by inhibition of miR-143 or miR-145 
expression. Upon further investigation a CBF1 binding domain was shown to exist 
in the miR-145/145 promoter which could be activated upon binding of the 
Notch ICD/CBF1 complex (Boucher et al., 2011).  
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Figure 1.5. Overview of miR-143/145 transcription. 
Jagged-1 (Jag-1) signalling promotes nuclear translocation of the Notch intracellular domain 
(NotchICD) which forms a complex with CBF1 to activates miR-143/145 transcription via a CBF1 
binding site. Transforming growth factor beta (TGF-β) promotes SMAD binding to SMAD binding 
elements  (SBE) leading to transcriptional activation of miR-143/145 via the SBE in the miR-
143/145 and myocardin promoter. TGF-β also promotes myocardin expression via the p38MAPK 
pathway. SRF in combination with its cofactor myocardin or MRTF-A promotes transcription of 
miR-143/145 via a CArG box in the miR-143/145 regulatory region. The nuclear translocation of 
MRTF-A is stimulated by bone morphogenetic protein 4 (BMP4) resulting in increased SRF/MRTF-
A binding and miR-143/145 transcription.  A kruppel-like factor 2 (KLF2) binding site in the miR-
143/145 promoter activates transcription of miR-143/145 in ECs which are transferred to VSMCs 
via exosomes. MiR-143 and miR-145 promote a contractile phenotype by negatively regulating the 
expression of targets involved in proliferation and migration including including ELK-1, KLF4 and 
KLF5. KLF4 and ELK-1 compete with myocardin at the SRF binding site to prevent myocardin/SRF 
interaction and reduce SRF mediated activation of contractile genes alpha smooth muscle actin (α-
SMA), smooth muscle myosin heavy chain (SM-MHC) and smooth muscle 22 alpha (SM22α). 
 
1.3.14 Studies in miR-143 and miR-145 KO mice  
In vitro and in vivo evidence that miR-143 and miR-145 regulate VSMC phenotype 
prompted several groups to further investigate the importance of these miRNA in 
the vasculature, by use of KO mice (Boettger et al., 2009, Elia et al., 2009, Xin 
et al., 2009, Quintavalle et al., 2010).  
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1.3.14.1 Abnormalities in the vessels of miR-143/145 KO mice 
Mice that have had the entire genomic pre-miRNA sequence of both miR-143 and 
miR-145 removed (miR-143/145 KO) are reported to have abnormal vessels when 
compared to WT mice (Elia et al., 2009, Boettger et al., 2009, Xin et al., 2009). 
The arteries of miR-143/145 KO mice are thinner than those of WT mice with the 
femoral wall approximately half the thickness of WT mice and the aortic wall 
reduced by around a third (Elia et al., 2009, Boettger et al., 2009). This was 
found to be due to a reduction in VSMC size but not number (Boettger et al., 
2009, Xin et al., 2009, Elia et al., 2009). Xin and colleagues dissected this 
further by producing individual miR-143 KO and miR-145 KO mice and showed 
that miR-145 KO but not miR-143 KO resulted in reduced vessel wall thickness 
(Xin et al., 2009). Electron microscopy studies revealed that miR-143/145 KO 
mice have reduced numbers of contractile and increased numbers of synthetic 
VSMCs within their vessel walls, with no change in proliferation or apoptosis 
rates (Boettger et al., 2009, Elia et al., 2009). It is believed that that the shift in 
the number of elongated contractile vs. epithelioid shaped synthetic VSMCs may 
be responsible for the overall reduction in VSMC size and thus vessel wall 
thickness (Boettger et al., 2009). Another study reported the presence of small 
groups of synthetic VSMCs within the intima region of the vessel walls, 
potentially from migration from the media (Elia et al., 2009). In vitro analysis of 
VSMCs isolated from miR-143/145 KO mice revealed these cells exhibit greater 
migration towards PDGF than cells isolated from WT mice (Elia et al., 2009). 
Organised actin stress fibers are essential for SMC contraction and are a feature 
of a differentiated VSMC phenotype. Interestingly, miR-143/145 KO and miR-145 
KO mice showed reduced numbers and disorganisation of actin stress fibers 
within their VSMCs both in vivo and in vitro indicating these miRNAs are 
important for the arrangement of the actin cytoskeleton (Xin et al., 2009).VSMCs 
of miR-143/145, miR-143 and miR-145 KO mice also had increased numbers of 
rough ER which were reported to be dilated, characteristics of synthetic SMCs 
(Elia et al., 2009, Xin et al., 2009, Boettger et al., 2009). It has been reported 
that a thick ECM surrounds the VSMCs in the aorta of miR-143/145 and miR-145 
KO mice however other have reported areas of ECM degradation (Xin et al., 
2009, Elia et al., 2009). The expression of VSMC marker genes including 
calponin, α-SMA and SM-MHC were decreased in the vessels of miR-143/145 KO 
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mice in some studies (Elia et al., 2009, Boettger et al., 2009) but this was not 
seen by others (Xin et al., 2009). Many miR-143 and miR-145 targets, including 
KLF4 and KLF5 are also upregulated in carotid arteries of miR-143/145 KO mice 
(Xin et al., 2009). 
1.3.14.2 Vascular tone in miR-143/145 KO mice 
MiR-143/145 KO and MiR-145 KO mice are reported to have reduced heart weight 
and left ventricular mass when compared to control mice (Xin et al., 2009, 
Boettger et al., 2009).The reduction in vessel wall thickness and actin stress 
fibers within the vessel walls of miR-143/145 KO and miR-145 KO mice prompted 
investigations into their blood pressure. MiR-143/145 KO and miR-145 KO mice 
were found to be hypotensive with significant reductions in mean arterial, 
systolic and diastolic blood pressure (Xin et al., 2009, Boettger et al., 2009). 
However, others reported no significant different in basal systolic blood pressure 
in miR-143/145 KO mice (Elia et al., 2009). This phenomenon is not only due to 
reduced vascular tone as a result of the thin arterial walls but also due to a 
reduction in receptor-mediated vasoconstriction (Xin et al., 2009, Boettger et 
al., 2009). Boettger and colleagues investigated VSMC contraction in arterial 
rings isolated from miR-143/145 KO mice and showed that they display 
significantly blunted contractile responses to pressor agents Ang II and 
phenylephrine (Boettger et al., 2009). MiR-143/145 KO mice were also shown in 
vivo to have a blunted increase in systolic blood pressure in response to Ang II 
(Elia et al., 2009). This reduction in contractile response was found to be due, in 
part, to reduced calcium sensitivity of synthetic VSMCs within the miR-143/145 
KO vessels and also reduced receptor mediated contraction by VSMCs (Boettger 
et al., 2009). This was further dissected in vivo where it was shown that miR-
143/145 KO mice have increased local Ang II signalling within their VSMCs which 
may result in VSMCs desensitisation and thus blunted contractile response to Ang 
II. ACE, the enzyme which converts Ang I to Ang II was upregulated in the VSMCs 
of miR-143/145 KO mice and is a target of miR-145 (Boettger et al., 2009). 
Inhibition of ACE or the Ang type I receptor was capable of partially rescuing the 
blunted contractile responses to Ang II, phenylephrine and calcium in miR-
143/145 KO mice (Boettger et al., 2009). This was thought to occur in part due 
to decreased Ang II signalling but also the normalisation of expression of many 
hundreds of transcripts that differed between WT and miR-143/145 KO mice, 
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many of which are known to be involved in VSMC contraction (Boettger et al., 
2009).  
1.3.14.3 Neointimal lesions in aged miR-143/145 KO mice 
Boettger and colleagues went on to investigate the long term consequence of 
miR-143/145 KO and reported the presence of neointimal lesions in the femoral 
arteries of 18 month miR-143/145 KO mice (Boettger et al., 2009). The 
composition of these lesions varied from accumulation of VSMCs in the intima at 
earlier time points, to the addition of macrophages and collagen I in more 
advanced lesions, however no  accumulation of lipids was observed  (Boettger et 
al., 2009). These results suggest that that the increase in synthetic VSMCs and 
global dysregulation of targets brought about by loss of miR-143/145 promotes a 
signalling process that over time leads to neointimal formation. 
1.3.14.4 Podosome formation in miR-143/145 KO mice  
 It has been reported that the aortas of miR-143/145 KO mice contain a 
significant presence of podosomes (Quintavalle et al., 2010). Podosomes are 
actin rich membrane structures which are found in migrating cells, including 
VSMCs, and are involved in cell adhesion and ECM degradation (Gimona et al., 
2003, Linder and Aepfelbacher, 2003). Podosome formation was shown to be 
under the control of PDGF which stimulates a Src tyrosine kinase-mediated 
decrease in miR-143/145 expression that promotes podosome formation 
(Quintavalle et al., 2010). This was further investigated and it was shown that 
Src inhibition of the p53 tumour suppressor protein was essential for miR-
143/145 inhibition and podosome formation (Quintavalle et al., 2010).  Response 
elements for p53 repressor were discovered in the miR-143/145 promoter which 
allowed p53 regulation of miR-143/145, with inhibition of p53 shown to reduce 
miR-143/145 transcription (Quintavalle et al., 2010). Protein kinase C ε (PKC-ε) 
and PDGF receptor alpha were shown to be targets of miR-143 and FSCN1 a 
target of miR-145 and these targets were upregulated in miR-143/145 KO VSMCs. 
Knockdown of PKC-ε or FSCN1 in vitro in miR-143/145 KO VSMCs reduced 
podosome formation and migration indicating that repression of these targets by 
miR-143 and miR-145 may reduce the formation of podosomes (Quintavalle et 
al., 2010).  
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1.3.14.5 Reduced neointimal formation in miR-143/145 KO mice 
Interestingly, neointimal formation in response to coronary artery ligation was 
significantly reduced by 60% in miR-143 KO mice and almost ablated in miR-145 
and miR-143/145 KO mice (Xin et al., 2009). Furthermore, carotid artery ligation 
resulted in premature death in 50% of miR-143/145 KO and miR-145 KO mice, 
which displayed severe neurological abnormalities, including loss of 
coordination, seizures and circling behaviour (Xin et al., 2009). The authors 
postulated that this may have been due to failure of the circle of willis to supply 
the left hemisphere of the brain following carotid artery ligation, resulting in 
ischemia and cell death in the left hemisphere (Xin et al., 2009). The reduced 
neointimal formation in miR-143 and miR-145 KO mice is in contrast to several 
studies that have reported that restoration of miR-145 levels in WT models of 
neointimal formation resulted in reduced neointimal formation (Elia et al., 2009, 
Cheng et al., 2009). Furthermore overexpression studies revealed increased 
expression of contractile VSMC marker genes including α-SMA and SM-MHC 
(Cordes et al., 2009). The differential effects seen following overexpression and 
genetic KO may be due to developmental differences or differences in the ability 
for VSMCs to change phenotype. Both overexpression and KO studies indicate 
that miR-143 and miR-145 are important for VSMC fate. 
1.3.15 Potential role of miR-143 and miR-145 in stenting 
The results of the studies discussed above have suggested that miR-143 and miR-
145 are important for the development and maintenance of a contractile VSMC 
phenotype.  The expression of these miRNA promotes contractile and reduces 
synthetic gene expression and is capable of reducing neointimal formation in 
animal models. However, genetic loss of these miRNA reduces neointimal 
formation which raises uncertainties about the exact role of these miRNA in 
VSMC phenotype.  MiR-143/145 transcription is under the control of several 
important regulators of VSMC phenotype including TGF-β, BMP4 and SRF-
myocardin/MRTF which utilise these miRNA as downstream effectors of gene 
expression. MiR-143 and miR-145 are the most abundantly expressed miRNA in 
VSMCs. The low expression of these miRNA in ECs and preferential transfer of 
these miRNAs from ECs to VSMCs following shear stress suggests that these 
miRNA may act as relatively specific regulators of VSMCs. Therefore, we propose 
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that miR-143 and miR-145 are promising candidate miRNA that could have 
therapeutic benefit in preventing in-stent restenosis. 
1.4 Aims  
In-stent restenosis is a major clinical problem that is characterised by VSMC 
proliferation and migration from the media to the intima resulting in neointimal 
formation.  MiR-143 and miR-145 are important regulators of VSMC contractile 
phenotype which can reduce neointimal formation in animal models. Therefore 
it is the aim of this thesis to investigate the role of miR-143 and miR-145 in 
stent-induced vascular injury.  
The specific aims of the study are:  
1. To investigate the role that miR-143/145 play in human VSMC and EC 
biology. 
2. To reproduce a relevant small animal model of stenting. 
3. To compare the response of miR-143 and miR-145 KO and WT mice to a 
model of in-stent stenosis. 
4. To determine the effect of pharmacologically modulating miR-143/145 
levels on stenosis in WT mice. 
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2 Materials and Methods 
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2.1 Materials 
All chemicals unless otherwise stated were purchased from Sigma-Aldrich (Poole, 
UK). All cell culture reagents were purchased from Gibco (Paisley, UK) unless 
otherwise stated. Magnesium- and calcium-free Dulbecco’s phosphate-buffered 
saline (PBS) was used for all cell culture experiments.  
2.2 General cell culture techniques 
Cell culture was performed in class II biological safety vertical laminar flow 
cabinets under sterile conditions. All cells were cultured as a monolayer in 25 
cm2, 75 cm2 or 150 cm2 vented-cap cell culture flasks (Corning, Poole, UK) and 
maintained in incubators at 37ºC in 5% CO2. Cell culture medium was replenished 
on cells every 2-3 days and cells were passaged when approximately 80% 
confluent to prevent overgrowth.  
To passage cells media was removed and cells were washed twice with PBS 
before incubation with 0.05% trypsin 0.02% (w/v) ethylenediamine tetra-acetic 
acid (trypsin-EDTA) solution at 37ºC for 5 minutes (min). When the majority of 
cells had detached from the bottom of the flask, an equal volume of the 
appropriate complete cell culture medium was added to neutralise the reaction. 
Cells were pelleted by centrifugation at 1500 x g for 5 min before being 
resuspended in medium and passaged. Cells were counted using a 
haemocytometer prior to plating for experiments where a known seeding density 
was required. 
2.3 Production of miRNA expressing adenovirus 
2.3.1 Cloning of pre-miRNA sequences into pAdEasy-1 
Prior to the commencement of this PhD, the full human pre-miR-143 and pre-
miR-145 sequences were cloned in house into the adenovirus serotype 5 (Ad5) 
based vector pAdEasy-1 (Agilent Technologies Ltd, Cambridge, UK). Double 
stranded DNA constructs of hsa-pre-miR-143 and hsa-pre-miR-145 were designed 
in house and produced by GeneArt® (Invitrogen, Paisley, UK). To ensure 
expression of the pre-miRNA a Kozak sequence (ACCATGG) was included at the 
5’ end immediately prior to the start of each pre-miRNA. A stop codon (TAG) and 
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poly(A) tail sequence (TTTTTT) were included at the 3’ end of the constructs to 
ensure miRNA production and nuclear export following transcription. The full 
cloned sequence of hsa-pre-miR-143 and hsa-pre-miR-145 including start/stop 
codons and poly(A) tail are shown below for the 5’ strand, the mature miRNA 
sequence is underlined.  
hsa-pre-miR-143 
5’ACCATGGGCGCAGCGCCCTGTCTCCCAGCCTGAGGTGCAGTGCTGCATCTCTGGTCA
GTTGGGAGTCTGAGATGAAGCACTGTAGCTCAGGAAGAGAGAAGTTGTTCTGCAGCTAG
TTTTTT 3’ 
hsa-pre-miR-145 
5’ACCATGGCACCTTGTCCTCACGGTCCAGTTTTCCCAGGAATCCCTTAGATGCTAAGAT
GGGGATTCCTGGAAATACTGTTCTTGAGGTCATGGTTTAGTTTTTT 3’ 
Pre-miRNAs were initially cloned into the shuttle vector pShuttle-CMV, which 
contains right and left arms which are homologous to the pAdEasy-1. The 
pShuttle-CMV vector containing pre-miRNA was then cloned into the pAd-Easy-1 
vector by homologous recombination in accordance with the AdEasy™ Adenoviral 
Vector System (Agilent Technologies Ltd). The pAdEasy-1 vector is deleted of the 
E1 and E3 regions of the Ad5 genome, which render it replication incompetent. 
Transcription of the pre-miRNA was driven by the cytomegalovirus (CMV) 
promoter.  An overview of the cloning system is shown below in Figure 2.1. 
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Figure 2.1. Overview of pre-miRNA cloning procedure. 
The miRNA constructs were first cloned into the pShuttle-CMV vector which contains right and left 
arms which are homologous to the right and left arms of the larger pAdEasy-1 plasmid. pShuttle-
CMV was linearized by restriction digest with Pme I and transformed into BJ5183-AD-1 bacteria 
cells, which are pre-transformed with pAdEasy-1. This allows recombination to occur between the 
arms of homology. Recombinant plasmids were identified by kanamycin resistance followed by 
restriction digest with Pac I. Linearized recombinants were transfected into Ad-293 or HEK-293 
cells to prepare a primary viral stock. Adapted from the ‘AdEasy™ Adenoviral Vector System’ 
instruction manual (Agilent technologies Ltd). 
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2.3.2 Production of adenovirus stocks 
All Ad production from this stage forward was carried out by me. From here on 
in the cloned viruses will be referred to as AdmiR-143 and AdmiR-145, 
representing the pAdEasy-1 vector expressing hsa-pre-miR-143 and hsa-pre-miR-
145, respectively.  
Human Embryonic Kidney (HEK) 293 cells express the E1 region of the Ad5 
genome that is absent in pAdEasy-1. Transduction of HEK 293 cells with E1 
deficient Ads allows viral replication to occur resulting in propagation of the 
virus.  Briefly, 50 µl of crude AdmiR-143 or AdmiR-145 was added to one bottle 
of normal growth medium [minimum essential medium (MEM) supplemented with 
10% (v/v) foetal calf serum (FCS), 100 IU/ml penicillin, 100 µg/ml streptomycin, 
2 mM L-glutamine and 111 µg/ml sodium pyruvate].  Ad-containing medium (22-
25 ml) was added to 70-80% confluent HEK 293 cells cultured in 150 cm2 vented 
cap cell culture flasks and maintained at 37ºC in 5% (v/v) CO2. Media was 
refreshed every 3 days and cells were left until a cytopathic effect became 
apparent (cells round up and begin to detach from bottom of flask). Media was 
collected and centrifuged at 2000 x g for 10 min. Cell pellets were resuspended 
in 5 ml of PBS. An equal volume of Arklone P (trichlorofluoroethane) was added 
to cells to extract the virus and mixed thoroughly by inverting the several times 
prior to centrifugation at 3000 x g for 10 min. The aqueous top layer containing 
crude Ad was removed and stored at -80ºC until purification.   
2.3.3 Adenovirus purification 
Ad purification was performed using caesium chloride (CsCl) gradients. Briefly, 
2.5 ml of both 1.40 g/ml and 1.25 g/ml CsCl were layered in a sterilised ultra-
clear centrifuge tube (Beckman Coulter Ltd, Buckinghamshire, UK). The crude 
Ad was gently dripped on top of the gradient and the tube filled with PBS. Tubes 
were centrifuged using the Beckman Optima L-80 ultracentrifuge and Beckman 
SW40Ti swing out bucket rotor at 25,000 rpm for 1.5 hour (h) at 4°C. A white 
band containing the Ad was visualised between the two CsCl layers.  A 21 gauge 
needle was used to pierce the ultra-centrifuge tube directly below the band and 
the Ad was isolated by gently pulling back on the syringe. A second CsCl gradient 
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was created by adding the Ad on top of 5 ml of 1.34 g/ml CsCl and centrifuging 
at 25,000 rpm for 18 h at 4°C. The Ad band was removed as described above.  
Dialysis of Ads was performed using Pierce Slide-A-Lyzer Dialysis Cassettes with a 
molecular weight cut off of 10,000 Da (Thermo Scientific, Leicestershire, UK). 
Briefly, Ads were added to hydrated dialysis cassettes using a 21 gauge needle 
and incubated in 1 X Tris-EDTA dialysis buffer [10X stock contains: 10 mM Tris-
HCL and 1 mM EDTA, pH 8] for 2 h. Dialysis buffer was then replaced and 
supplemented with 10% (v/v) glycerol and dialysis was continued overnight. 
Purified Ad was removed from dialysis cassettes, aliquoted and stored -80°C. 
2.3.4 Virus titration by end-point dilution assay 
The plaque forming unit (PFU) titre of AdmiR-143 and AdmiR-145 was 
determined by end-point dilution assay. Briefly, HEK 293 cells were seeded in 96 
well cell culture plates and grown to 50-60% confluence. Purified Ad stocks were 
serially diluted in normal growth medium to the following dilutions: 1X10-4, 
1X10-6, 1X10-7, 1X10-8, 1X10-9, 1X10-10 and 1X10-11. Media was refreshed on the 
bottom row of cells with 100 µl of virus-free media added to each well to form a 
row of 10 control wells.  Media from the remaining wells was replaced with the 
Ad dilutions so that each dilution formed one row of the titre plate. The most 
concentrated virus (1X10-4) formed the top row and the most dilute virus (1X10-
11) formed the row directly above the control row.  Cells were maintained at 
37ºC in 5% CO2.  Media was replaced after 18-24 h and then every second day 
until the end of the assay. At day 8 titre plates were analysed under a 10X 
microscope for a cytopathic effect and positive wells containing viral plaques 
(holes in the cell layer surrounded by cells which are ‘rounded up’) were noted. 
PFU titre was determined by the following calculation (Lowenstein, 1996):     
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Proportionate Distance= (% positive wells above 50%- 50%) / (% positive wells 
above 50% - % positive wells below 50%)  
 
Log ID50 (infectivity dose) = log dilution above 50% + (proportionate distance X 
dilution factor) = -X 
ID50 = 10
-X 
TCID50  (Tissue culture infectivity dose 50) =1/10
-X 
TCID50/100 μl = 10
X 
TCID50/ml = 10
X X dilution factor [10] 
1 TCID50 = 0.7 PFU 
PFU/ml = TCID50/ml X 0.7 
In order to ensure no replication competent Ad was contaminating the AdmiR-
143 and AdmiR-145 stocks the end-point dilution assay was also carried out in 
HeLa cells. HeLa cells are an immortalised cell line derived from human cervical 
cancer cells which do not contain regions of the Ad5 genome, they are therefore 
non-permissive to viral replication using replication-incompetent Ads. If no 
cytopathic effect was found at the end of the end point dilution assay in HeLa 
cells it was assumed that the Ads were essentially replication incompetent.  
2.3.5 Viral particle titre 
The viral particle (VP) titre of AdmiR-143 and AdmiR-145 was calculated using 
the MicroBCA Protein Assay Kit (Thermo Scientific). Briefly, albumin stardards 
from 0.5 µg/ml to 200 µg/ml were prepared in accordance with the 
manufacturer’s instructions. Viral stocks were diluted 1:30, 1:50 and 1:150 in 
PBS and standards and samples were added in duplicate to a clear, flat-
bottomed 96-well plate. 150 μl of BCA working reagent was added to the 
standards and samples and the plate was incubated for 2 h at 37ºC. Absorbance 
was read at 570 nm using the Wallac VICTOR2 plate reader (Wallac, Turku, 
Finland).  Background absorbance was subtracted from the samples and 
standards and the total amount of protein contained within each virus was 
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calculated from the standard curve. VP titre was determined using the formula 
described by Von Seggern and colleagues (Von Seggern et al., 1998) whereby 1 
µg of protein is equal to 1X109 VP. 
2.4 Primary cell culture 
Excess human saphenous vein from patients undergoing CABG procedures was 
obtained with ethical approval and patient consent by the surgical team at the 
Golden Jubilee Hospital Clydebank and stored in sterile saline for collection. 
Non-varicosed portions of saphenous vein from patients undergoing varicose vein 
removal were isolated by the surgical team at New Stobhill Hospital Glasgow and 
stored in sterile saline. All primary cell isolations were performed in class II 
biological safety cabinets under sterile conditions.  
2.4.1 Isolation of primary vascular endothelial cells from the 
human saphenous vein 
Primary human saphenous vein endothelial cells (HSV ECs) were isolated on the 
day of surgery by collagenase digestion, based on the method previously 
described by Jaffe and colleagues (Jaffe et al., 1973). Briefly, the lumen was 
flushed with wash medium [Dulbecco’s Modified Eagle’s Medium (DMEM), 
supplemented with 100 IU/ml penicillin, 100 µg/ml streptomycin and 2 mM L-
glutamine]. The lumen was filled with 2 µg/ml collagenase solution diluted in 
wash medium and incubated at 37ºC in 5% CO2 for 15 min. The lumen was then 
flushed with wash medium to obtain HSV ECs in suspension. This process was 
repeated with collagenase digestion time reduced to 10 min. The wash 
medium/HSV EC suspension was centrifuged at 2000 x g for 15 min and pelleted 
HSV ECs were resuspended in EC growth medium [Large Vessel Endothelial Basal 
Cell Medium (TCS Cellworks Ltd, Bucks, UK), supplemented with 20% (v/v) FCS, 
100 IU/ml penicillin, 100 µg/ml streptomycin and 2 mM L-glutamine]. Cells were 
plated in 25 cm2 vented cap cell culture flasks and maintained in a 37ºC, 5% CO2 
incubator for 24 h to ensure cell adhesion before media was refreshed.  
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2.4.2 Isolation of primary vascular smooth muscle cells from the 
human saphenous vein  
Primary human saphenous vein smooth muscle cells (HSV SMCs) were isolated 
within 48 h of surgery by an explant technique originally described by Southgate 
and Newby (Southgate and Newby, 1990). Briefly, the lumen was flushed with 
wash medium before the vein was cut longitudinally and the 4 corners pinned 
out with the lumen en face. HSV ECs cells were removed by gently running a 
rubber policeman over the lumen surface. Vessels were scored with a scalpel 
blade and the SMC layer peeled back from the adventitia with forceps. The SMC 
tissue was cut into small pieces (~1 mm2) using the McIlwain tissue chopper. SMC 
tissue was washed twice with wash medium and once in SMC growth medium 
[Smooth Muscle Cell Growth Medium 2 (Contains: 0.5 ng/ml epidermal growth 
factor, 2 ng/ml basic fibroblast growth factor and 5 µg/ml insulin) (PromoCell, 
Heidelberg, Germany) supplemented with 15% FCS, 100 IU/ml penicillin and 100 
µg/ml streptomycin]. SMC tissue was plated in 25 cm2 vented cap cell culture 
flasks and maintained in a 37ºC 5% CO2 incubator. All excess SMC growth medium 
was removed to allow HSV SMCs to adhere to the flask before SMC growth 
medium was replaced 24 h later.   
2.5 Adenoviral transduction of cultured cells 
2.5.1.1 HeLa cells 
HeLa cells were plated in 6 well cell culture plates at a seeding density of 3X105 
cells/well in normal growth medium and incubated overnight at 37ºC in 5% CO2. 
AdmiR-143 and AdmiR-145 were diluted in normal growth medium to a final PFU 
of 10, 50 or 100 PFU/Cell. RAd60, a replication incompetent Ad5 based vector, 
was used as a control Ad. RAd60 contains no transgene and is thus thought of as 
an ‘empty’ vector (George et al., 2011). Cells were incubated with AdmiR-143, 
AdmiR-145, Rad60 or medium only (control) for 24 h at 37ºC at 5% CO2 before 
medium was replaced with virus-free normal growth medium and incubated for a 
further 24 h. Cells were lysed for RNA extraction and qRT-PCR analysis as 
described in sections 2.7 - 2.9.  
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2.5.1.2 Human primary cells  
HSV ECs and HSV SMCs were seeded at 3X105 cells/well in 6 well plates in the 
appropriate growth medium and incubated overnight at 37ºC in 5% CO2. Cells 
were then incubated for 24 h in growth medium alone or containing AdmiR-143 
or AdmiR-145 diluted to a final VP of 5000 - 50,000 VP/Cell. Ad5CMVlacZ, an Ad5 
vector made in-house using the pAdEasy-1 system and containing the lacZ 
transgene, was used as a control. The following day medium was replaced with 
0.1% (v/v) FCS EC growth medium or 0.1%, 2% or 15% (v/v) SMC growth medium 
and cells were incubated for a further 24 h (HSV EC) or 48h (HSV SMC). Cells 
were then used for migration assays, lysed for RNA extraction and qRT-PCR 
analysis or fixed and stained for X-gal expression.  
2.6 Transfections with premiRs and antimiRs 
Modulation of endogenous miR-143 and miR-145 expression in human primary 
cells was achieved by use of miRNA mimics and AntimiRs. Ambion Pre-miR miRNA 
precursor molecules (Life Technologies, Paisley, UK) premiR-143, premiR-145, 
premiR-negative control (will be referred to as premiR-scr) are double-stranded 
RNA molecules which mimic the mature form of the miRNA. These premiRs are 
chemically modified to ensure the correct strand is incorporated into the RISC 
complex and are used to increase mature miRNA expression levels within cells. 
AntimiR-143, antimiR-145 and antimiR-ctl were provided by MiRagen 
Therapeutics (Colorado, USA). AntimiRs are 16 nt in length with 
phosphorothioate backbones and consist of a mixture of LNA and DNA bases 
complimentary to the 5’ end of mature miR-143 (antimiR-143) or miR-145 
(antimiR-145) respectively. An antimiR which was targeted against a C. elegans 
specific miRNA (antimiR-ctl) was used as a control. AntimiRs bind tightly to 
mature miRNA to prevent the miRNA from binding to its mRNA targets. AntimiRs 
can therefore be used to investigate effects of reducing endogenous miRNA 
expression. 
HSV EC and HSV SMC transfection with premiRs (premiR-143, premiR-145 and 
premiR-scr) or antimiRs (antimiR-143, antimiR-145 and antimiR-ctl) was 
performed using siPORT NeoFX Transfection Agent (Life Technologies) in 
accordance with the manufacturer’s instructions. Briefly, Siport NeoFX 
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Transfection Agent was diluted in Opti-MEM® reduced serum medium 
(Invitrogen) at a ratio of 1 µl to 24 µl for 24 well plates or 5 µl to 95 µl for 6 well 
plates and incubated at room temperature (RT) for 10 min. PremiRs and 
antimiRs were diluted in a total volume of 25 µl (24 well plate) or 100 µl (6 well 
plate) Opti-MEM® medium to a final concentration of 10 nM, 25 nM or 50 nM. 
Siport NeoFX/OptiMEM® and diluted premiRs/antimiRs were combined and 
incubated for a further 10 min to allow transfection complexes to form before 
being dispensed into cell culture plates. HSV ECs or HSV SMCs were seeded in the 
appropriate growth medium at density of 4X104 or 3X105 cells/well for 24 well 
and 6 well plates, respectively. The final volumes were 500 µl for 24 well plates 
and 2.5 ml for 6 well plates. A ‘Mock’ control containing cells incubated with 
Siport NeoFX/Opti-MEM® and medium alone, and a control of cells incubated 
with Opti-MEM® and medium alone was included in each experiment. Cells were 
incubated with transfection complexes overnight. The following day media was 
removed and cells were incubated in 0.1% (v/v) FCS EC or SMC medium for a 
further 24 h (HSV EC) or 48 h (HSV SMC) to achieve cell quiescence. Cells were 
then lysed for RNA analysis or used in migration or proliferation experiments. 
Transfection efficiency was initially investigated in HSV SMCs using an AntimiR 
labelled with the fluorophore Cy3 (AntimiR-Cy3). Cy3 acts as a fluorescent 
reporter allowing visualisation of cells which have been transfected with the 
AntimiR. Transfections were carried out in 8 well chamber slides following the 
instructions for 24 well plates described above.  Cells were washed in PBS and 
fixed in 2% (w/v) paraformaldehyde (PFA) for 10 min before mounted with 
coverslips using Prolong Gold Antifade Reagent with DAPI (Life Technologies). 
Slides were kept in the dark overnight and photographed at 40X using Olympus 
IX70 fluorescent microscope. 
2.7 Extraction of RNA from cells and tissues 
Isolation of cells for RNA extraction was performed as described. Culture 
medium was removed and cells washed twice with PBS prior to the addition of 
700 µl QIAzol® Lysis Reagent (Qiagen, Crawley, UK) to each well. Cells were 
homogenised by pipetting up and down and transferred to 1.5 ml 
microcentrifuge tubes for storage at -80ºC until processing.   
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Tissues were snap frozen in liquid nitrogen at sacrifice and stored at -80ºC until 
processing. Tissue disruption was achieved as follows. A stainless-steel bead (5 
mm) and 700 µl QIAzol® were added to each sample and tissue disrupted using 
the TissueLyser System (Qiagen) at 25 Hz for 1-2 min until full tissue disruption 
occurred.  
Total RNA including miRNA was extracted from isolated cells and tissues using 
the miRNeasy Mini Kit (Qiagen) in accordance with the manufacturer’s 
instructions. Briefly, the cell/tissue homogenate was mixed thoroughly with 140 
µl chloroform and incubated for 3 min at RT. Samples were centrifuged at 
12,000 x g for 15 min at 4ºC to separate the sample into 3 distinct layers, a top 
aqueous phase containing the RNA and miRNA, an interphase containing DNA and 
proteins and an organic phase containing proteins. The aqueous phase was 
collected, added to 1.5 volumes of 100% ethanol and mixed thoroughly. Samples 
(700 µl) were transferred into RNeasy mini spin columns and centrifuged at 8000 
x g for 15 seconds (sec) at RT to allow binding of RNA to the spin column 
membrane, flow-through was discarded. Buffer RWT (350 µl) was added spin 
columns and centrifuged at 8000 x g for 15 sec. 
At this stage on-column DNase digestion was performed in order to remove 
contaminating genomic DNA from the samples. Briefly, DNase was prepared by 
according to the RNase-Free DNase Set (Qiagen) and diluted 1:8 (v/v) in buffer 
RDD. The DNase/RDD mixture (80 µl) was added to the spin columns and 
incubated for 15 min at RT.  
Spin columns were then washed with the following: 350 µl buffer RWT, 8000 x g 
for 15 sec; 500µl buffer RPE, 8000 x g for 15 sec and 500µl buffer RPE, 8000 x g 
for 2 min. Spin columns were placed in a fresh collection tubes and centrifuged 
at 12,000 x g for 1 min to remove any remaining buffer RPE contaminants. Spin 
columns were transferred into 1.5 ml microcentrifuge tubes and 30-50 µl RNase-
free H2O added to each tube. RNA was eluted by centrifugation at 8000 x g for 1 
min. The eluted RNA was collected and re-eluted through the spin column to 
increase RNA yield.  
The quantity of RNA in each sample was determined using the NanoDrop 1000 
Spectrophotometer (Thermo Scientific). This method determines the 
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concentration of nucleic acid in sample by determining its absorbance at 260 
nm.  A 260 nm / 280 nm ratio of ~2.0 is generally considered to denote RNA free 
from protein or phenol contaminants which absorb nearer 280 nm.   
2.8 Reverse transcription polymerase chain reaction (RT-
PCR) 
Reverse transcription complementary DNA (cDNA) synthesis of miRNAs was 
performed using the Taqman® MicroRNA Reverse Transcription Kit (Applied 
Biosystems, Warrington, UK) according to the manufacturer’s instructions. 
Reactions contained 2.5 µl of 2 ng/µl sample RNA, 0.25 mM of each dNTP, 3.33 
U/µl Multiscribe reverse transcriptase, 1X reverse transcriptase buffer, 0.25 U/µl 
RNAse inhibitor and 2.08 µl RNase-free water. Reaction mixtures also contain 1X 
vol. of Taqman® miRNA Reverse Transcription Primers (Applied Biosystems) for 
the mature sequence of the miRNA of interest, shown in Table 2.1. Reverse 
transcription of an endogenous control (Table 2.1) was also performed for each 
sample in order to normalise changes in miRNA expression. 
Table 2.1. MiRNA reverse transcription primers. 
miRNA/Control Sequence Species 
hsa-miR-143 3p 5’ UGAGAUGAAGCACUGUAGCUC 3’ Human/mouse 
hsa-miR-145 5p 5’ GUCCAGUUUUCCCAGGAAUCCCU 3’ Human/mouse 
RNU48 5’GATGACCCCAGGTAACTCTGAGTGTGTCGCTGATGCCA
TCA CCGCAGCGCTCTGACC 3’                                                  
Human 
U6  5’GTGCTCGCTTCGGCAGCACATATACTAAAATTGGAACG
ATACAGAGAAGATTAGCATGGCCCCTGCGCAAGGATGA
CACGCAAA TTCGTGAAGCGTTCCATATTTT 3’ 
 
 
Mouse  
 
Synthesis of cDNA was performed by incubating at 16ºC for 30 min to facilitate 
primer binding, 42ºC for 30 min for reverse transcription to take place and 
finally 85ºC for 5 min to inactivate the reverse transcriptase enzyme.  
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Reverse transcription of RNA was performed using Taqman® Reverse 
Transcription Reagents (Applied Biosystems). Each reaction contained 200-1000 
ng RNA, (concentration consistent within experiments) and the following 
reagents: 1X reverse transcriptase buffer, 5.5 mM MgCl2, 0.5 mM of each dNTP, 
2.5 µM random hexamers, 0.4 U/µl RNase inhibitor and 1.25 U/µl Multiscribe 
reverse transcriptase. RNase-free water was added to give a final reaction 
volume of 20 µl per well.  
Synthesis of cDNA for RNA samples was performed by incubating at 25ºC for 10 
min to allow annealing of primers, 48ºC for 30 min for reverse transcription and 
95ºC for 5 min to inactivate reverse transcriptase.  
A non-template control, where RNA was replaced with H2O was included in each 
experiment. Samples were then stored at 4ºC for short term or -20ºC for longer 
term storage. 
2.9 Taqman quantitative real-time PCR (qRT-PCR) 
QRT-PCR is a method of quantifying the abundance of an RNA within a sample. 
Taqman® qRT-PCR Assays are 5’ labelled with a fluorescent reporter dye e.g. 
FAM and 3’ labelled with a quencher dye that inhibits the 5’ dye fluorescence by 
fluorescence resonance energy transfer (FRET). When the probe anneals to its 
target it is cleaved by Taq DNA polymerase and the fluorescent reporter signal is 
emitted proportional to the amount of RNA product present within each cycle 
and can be measured and quantified. The number of cycles a product takes to 
reach a fixed threshold is known as the threshold cycle (CT), with lower CT values 
indicating higher expression and higher CT values indicating lower expression of 
the product respectively. A housekeeping gene, which is stably expressed, is 
used as an endogenous control to allow corrections due to RNA concentration to 
be made. CT values were normalised to the appropriate endogenous control and 
fold changes calculated by the 2-ΔΔCT method (Schmittgen and Livak, 2008). 
MiRNA qRT-PCR was performed using Taqman® miRNA Assay RT-PCR Probes and 
Taqman® Universal Mastermix II (Applied Biosystems) in accordance with the 
manufacturer’s instructions. Briefly, mastermixes were set up to contain 1X 
(v/v) Taqman® Mastermix, 1X (v/v) Taqman® miRNA Assay of interest and H2O 
Chapter 2 – Materials and Methods  80 
 
 
to a total volume of 9.33 µl per sample.  CDNA was pipetted in duplex into a 384 
well plate 0.67 µl per well and the mastermix added to each well to give a total 
reaction volume of 10 µl. Human RNU48 or mouse U6 were used as an 
endogenous control. 
QRT-PCR for RNA samples was performed using Taqman® Gene Expression Assays 
(Applied Biosystems) and Taqman® Universal Mastermix II in accordance with the 
manufacturer’s instructions. Mastermixes contained 1X (v/v) Taqman® 
Mastermix, 1X (v/v) Taqman® gene expression probe and H2O to a total volume 
of 8.5 µl were added to a 384 well plate.  CDNA was added in duplex to the 384 
well plate (1.5 µl/well) to give a total reaction volume of 10 µl. The endogenous 
control human 18s or mouse GAPDH was probed for in each sample in order to 
normalise changes in gene expression.  
MiRNA and RNA expression was measured using the ABI Prism Applied Biosystems 
7900HT sequence detection system. Cycling conditions for miRNA and RNA qRT-
PCR where: denaturing at 95ºC for 10 min, followed by 40 cycles of denaturing 
at 95ºC for 15 sec and primer and probe binding and primer extension at 60ºC for 
60 sec.  
2.10 X-gal staining 
Ad5CMVlacz expresses a lacZ transgene which encodes β-galactosidase (β-gal), 
an enzyme which hydrolyses β-galactoside bonds within its substrates to yield 
monosaccharides. X-gal (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside) is 
cleaved by β-gal to form galactose and 5-bromo-4-chloro-3-hydroxyindole, which 
dimerises and is oxidised into 5,5'-dibromo-4,4'-dichloro-indigo, which is seen by 
its intense blue colour.  
HSV SMCs were incubated with Ads as described in section 2.5.1.2. After 24 h in 
Ad containing medium cells were incubated in in 0.1%, 2% or 15% (v/v) FCS SMC 
growth medium for a further 48 h. Cells were washed twice in PBS and fixed for 
10 min in 2% PFA and washed a further 2 times in PBS. X-gal stain [100 mM 
sodium phosphate, pH 7.3, 1.3 mM magnesium chloride, 3 mM potassium 
ferricyanide, 3 mM potassium ferrocyanide, 1 mg/ml X-gal] was applied onto 
fixed cells and incubated at 37ºC overnight. Cells were imaged the following day 
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using a Nikon Eclipse TS1000 microscope and QICAM Fast1394 camera (QImaging, 
Maidenhead, UK) and the percentage of cells expressing X-gal was determined by 
cell counting. 
2.11 Northern blotting  
Northern blotting was performed to probe for mature miR-143 and miR-145. All 
solutions used in this process were made using dH20 which had been treated with 
0.1% diethylpyrocarbonate (DEPC), which inactivates RNase enzymes, for 24 h 
before autoclaving for 30 min/L to remove traces of DEPC. All equipment and 
surfaces used were treated with RNAseZap® (Life Technologies) to inhibit RNase 
enzymes. Briefly, 3-5 µg of RNA was mixed with RNA sample loading buffer 
(without ethidium bromide) (Sigma) and denatured at 95°C for 5 min along with 
RNA Marker Low Easy (Abnova, Heidelberg, Germany) then placed on ice. RNA 
samples were loaded into Novex® 15% TBE-Urea gels (Invitrogen) and ran at 150 
V in 1X Tris-EDTA until the dyefront reached the bottom of the gel. Gels were 
stained in ethidium bromide in Tris-EDTA for 5 min and imaged under ultraviolet 
light using the Molecular Imager Chemidoc XRS+ System to visualise RNA bands. 
Gels were transferred onto Amersham Hybond-NX Membranes (GE Life sciences, 
Buckinghamshire, UK) by blotting at 20 V for 1.5 h using the Trans-Blot Semi-Dry 
Transfer System (Biorad, Hertfordshire, UK). Gels were re-imaged under UV light 
to ensure RNA transfer to the membranes had been successful.  
Membranes were transferred to N-Ethyl-N′-(3-dimethylaminopropyl)carbodiimide 
hydrochloride (EDC) cross-linking solution [2 mM EDC, 1% (v/v) 1-
Methylimidazole] in order to crosslink RNA molecules to the nylon membrane. 
Cross-linking was carried out for 1 h at 60ºC before membranes were washed 
twice in DEPC H20.  
Membranes were pre-hybridised in hybridisation buffer [ 50% (v/v) formamide, 
5X SSPE Buffer, 5X Denharts solution, 0.02 mg/ml boiled herring sperm DNA, 
0.5% (v/v) sodium dodecyl sulphate (SDS), made to a final volume with DEPC 
H2O]. Pre-hybridisation was carried out at hybridisation temperature: 55ºC miR-
143, 45ºC miR-145 for 1 h. MiRCURY LNA miRNA 5’ DIG labelled detection probes 
(Exiqon, Vedbaek, Denmark) hsa-miR-143 (GAGCTACAGTGCTTCATCTCA), hsa-
miR-145 (AGGGATTCCTGGGAAAACTGGAC) were diluted 1:10,000 in hybridisation 
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buffer and hybridisation carried out overnight at hybridisation temperature. 
Hybridisation temperature was initially tested based on RNA melting 
temperature (Tm) (hsa-miR-143, RNA-Tm 85ºC; hsa-miR-145, RNA-Tm 84ºC) 
minus 30ºC. The hybridisation temperatures used in all experiments were then 
determined by a number of experiments where the temperature was altered 
slightly each time in order to reduce background staining while still effectively 
labelling the miRNA. 
Membranes were washed for at 50ºC in NorthernMax® Low Stringency and High 
Stringency Buffer (Life Technologies) each for 30 min then transferred to wash 
buffer [0.1 M Maleic acid, 0.15 M NaCl, 0.3% (v/v) Tween-20, pH 7.5] for a 
further 10 min. Membranes were then incubated in Anti-Digoxigenin-alkaline 
phosphatase (AP), Fab fragments (Roche Diagnostics Ltd, Burgess Hill, UK), 
which bind DIG-labelled probes with high affinity, diluted 1:10,000 in 1X 
Blocking Reagent (Roche Diagnostics Ltd) for 1 h at RT on a shaker. 
Membranes were washed twice in wash buffer for 15 min and then incubated 
with detection buffer [0.1M Tris-HCL, pH 7.5] for 5 min. CDP-Star® 
Chemiluminescent Substrate was applied to membranes for 5 min. Films were 
exposed to membranes for varying lengths of time (usually between 1-5 min) and 
films developed using the Kodak X-Omat developer. 
In order to reprobe for the U6 loading control, membranes were stripped in 1% 
(v/v) SDS by boiling in the microwave for 6-8 min and left to cool for 15 min. 
Membranes were rinsed in DEPC H2O before being probed overnight at 60ºC with 
control U6 miRCURY LNA™ miRNA 5’ DIG labelled detection probe 
(CACGAATTTGCGTGTCATCCTT) (Exiqon) diluted 1:10,000 in hybridisation buffer. 
The original protocol was then followed from this point forward. 
Intensity of miRNA bands was measured by densitometry on the Molecular Imager 
Chemidoc XRS+ System using Quantity One software. Bands were normalised to 
U6 loading control. 
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2.12 Protein isolation and western blotting 
2.12.1 Protein isolation  
Protein lysis buffer was prepared on ice containing the following reagents: 20 
mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM Ethylene glycol tetra-acetic 
acid (EGTA), 2.5 mM Na pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na3VO4, 
0.5% (w/v) sodium deoxycholate, 1 mM phenylmethylsulfonylfluoride (PMSF), 2 
mM NaF, 1 µg/ml leupeptin, 1X Roche Complete Mini Protease Inhibitor cocktail 
tablets (made up in H20) (Roche Diagnostics). Protein lysis was performed on 
snap frozen tissues. Briefly, 200 µl ice cold protein lysis buffer was added to 
eppendorfs containing 25 mg frozen tissue and tissue was disrupted using the 
Qiagen TissueLyser System as described in section 2.7. The eppendorfs 
containing the tissue/lysis buffer were shaken on a shaker for 1 h at 4ºC and 
then centrifuged at 12,000 rpm at 4ºC for 40 min. The protein supernatant was 
removed and stored at -80ºC. Protein concentration was determined using the 
Pierce BCA Protein Assay Kit (Thermo Scientific) in accordance with the 
manufacturer’s instructions and read at 570 nm using the Wallac VICTOR2 plate 
reader (Wallac). Protein concentrations were worked out from the standard 
curve produced by the protein standards.  
2.12.2 Western blots 
Protein samples were diluted to equal concentrations (10-20 µg) in PBS, mixed 
with NUPAGE® 4X LDS Sample Buffer (Life Technologies) and denatured by 
heating at 95ºC for 10 min. Samples were loaded in Mini-Protean® TGX 10% 
polyacrylamide  gels (Biorad) along with the reference ladder Full-Range 
Rainbow Molecular Weight Ladder  (GE Life sciences). Electrophoresis was 
performed at 80-120 V in running buffer [25mM Tris, 0.2M glycine, 1% (w/v) SDS] 
until the dye reached the bottom of the gel.  
Gels were transferred onto Amersham Hybond P nitrocellulose membranes (GE 
Life Sciences) in transfer buffer [Running buffer plus 20% (v/v) methanol]. 
Membranes were blocked for 1 h at RT on a shaker in 10% (w/v) fat-free milk 
power in Tris buffered saline plus tween (TBS-T) [150 mM NaCl, 2 mM KCl, 25 mM 
Tris and 1% (v/v) Tween-20]. Membranes were incubated with rabbit polyclonal 
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anti-KLF5 (ab137676; Abcam, Cambridge, UK) diluted 1:1000 in 5% milk in TBS-T 
overnight at 4ºC on shaker.  
The following day membranes were washed in 3 X 10 min changes of 10% milk 
TBS-T before being incubated with the secondary antibody: polyclonal swine 
anti-rabbit immunoglobulins/horseradish peroxidase (HRP) (P0217, Dako, 
Cambridgeshire, UK), diluted 1:1000 in 5% milk TBS-T for 1 h at RT. Membranes 
were washed in 4 changes of 5% milk TBS-T and 4 changes of TBS-T each for 15 
min on shaker.  
Proteins were visualised using Amersham Enhanced Chemiluminescence (ECL) 
Prime Western Detection Reagent (GE Life Sciences) according to the 
manufacturer’s instructions. Films were exposed for varying lengths of time and 
developed using the Kodak X-Omat developer.  
Membranes were stripped in 3 X 10 min washes in stripping buffer [0.2M glycine, 
0.1% (w/v) SDS, 1% (v/v) Tween-20] followed by 3 X 10 min washes in TBS-T. 
Membranes were then blocked in 10% milk TBS-T and protocol repeated to probe 
for rabbit monoclonal GAPDH (14C10, Cell signalling Technology, Hertfordshire, 
UK) diluted 1:1000 in 5% milk-TBS-T, for protein normalisation.  
Intensity of protein bands was measured by densitometry on the Molecular 
Imager Chemidoc XRS+ System using Quantity One software. Bands were 
normalised to GAPDH loading control.  
2.13 Migration assays  
Cell migration was assessed using a scratch wound assay previously described by 
Liang and colleagues (Liang et al., 2007). Briefly, cells were seeded at a density 
of 3X105 cells/well in 6 well plates and incubated with AdmiR-143, AdmiR-145 or 
Ad5CVlacZ as described in section 2.5 or transfected with premiRs or antimiRs as 
described in section 2.6. A horizontal line was drawn on the underside of each 
well to act as a reference. A 200 μl pipette tip was used to produce 3 vertical 
scratches per well and dead cells removed by gently washing with PBS. Media 
was replaced with 0.1% or 5% (v/v) FCS containing EC or SMC medium and the 
scratches were photographed immediately above the reference line under a 10X 
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lens using the Nikon Eclipse TS1000 microscope and QICAM Fast1394 camera 
(QImaging) to give the 0 h images. Cells were maintained at 37ºC at 5% CO2 
throughout the assay and photographed at further time points between 0 and 24 
h. The scratch in the cell monolayer produces a wound which the bordering cells 
migrate into, giving an in vitro model of wound healing. Migration of cells into 
the scratch was determined by measuring the scratch width using Image J 
software. To ensure measurements were unbiased a grid of 12 horizontal lines 
was overlaid on each image and measurement lines were drawn directly on these 
guidelines. Results are displayed as the distance migrated in 24 h.  
2.14 Cell proliferation assays 
Cell proliferation was assessed using the CellTiter96® Aqueous One Solution Cell 
Proliferation Assay (Promega, Southampton, UK). The assay consists of a solution 
containing both MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium] and the electron coupling reagent phenazine 
ethosulfate (PES). The MTS solution is bioreduced by living cells to form a 
soluble formazan product of which absorbance at 490 nm is directly proportional 
to the number of viable cells. 
HSV ECs or HSV SMCs were transfected, plated and serum starved in 24 well cell 
culture plates as described in section 2.6. Following serum starving for 24 h (HSV 
ECs) or 48 h (HSV SMC) proliferation was induced by incubating cells for 72 h 
with culture medium containing 0.1-5% (v/v) FCS. Cells were incubated with 
MTS/PES solution at a ratio of 100 µl culture medium to 20 µl MTS/PES solution 
for 3 h at 37ºC. Absorbance was read at 490 nm on the Wallac 1420 Victor2 plate 
reader (Wallac). 
2.15 Exosome isolation 
Exosomes are small vesicles released by cells which contain RNA and protein 
which allow paracrine communication to occur between different cell types. It 
has been shown that ECs are capable of producing exosomes enriched in miRNAs.  
In order to assess whether increased expression of miRNAs within HSV ECs results 
in transfer to exosomes HSV ECs were transfected in suspension with 10 nM 
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premiR-scr, premiR-143 or premiR-145 using SiPORT NeoFX Transfection Reagent 
(Invitrogen) and seeded at 3X105 cells/well in 6 well cell culture plates. Culture 
medium was replaced with 0.1% (v/v) FCS EC medium and cells were incubated 
at 37ºC for 96 h. HSV ECs were incubated in 0.1% FCS due to the naturally high 
levels of exosomes within FCS which would interfere with the results.  
Cell culture medium was collected for each sample and centrifuged at 2000 x g 
for 30 min in order to pellet any cell debris. The supernatant containing the 
exosomes was transferred to a fresh falcon tube. Exosome isolation was then 
performed using the Total Exosome Isolation (from cell culture media) Reagent 
(Invitrogen) according to the manufacturer’s instructions. Briefly, 0.5 vol. of 
Total Exosome Isolation Reagent was added to the medium and mixed by 
vortexing before being incubated at 4ºC overnight. The following day samples 
were centrifuged at 10, 000 x g at 4ºC for 1 h. The supernatant was discarded 
and the pelleted exosomes were resuspended with 1 ml PBS. RNA was then 
extracted from exosomes by following the protocol for RNA extraction from cells 
described in section 2.7.  
2.16 In vivo models  
All in vivo experiments were performed in accordance with the United Kingdom 
Animals Scientific Procedures Act of 1986 under the project license 60/4429 held 
by Professor Andrew Baker. C57BL/6 mice were purchased from Charles River 
(Kent, UK). Mice were maintained on a 12 h cycles of light and dark at ambient 
temperature and fed a normal chow diet with free access to food and water. 
Mice were aged to 18 weeks prior to surgery. 
2.16.1 MicroRNA knockout mice 
MiR-143, miR-145 and WT mice were kindly gifted by Professor Eric Olson of the 
University of Texas SouthWestern and bred in-house. MiRNA KO mice were 
generated by Professor Olson’s groups as described by Xin and colleagues (Xin et 
al., 2009).  
Briefly, targeting vectors were generated using the pGKNEO-F2DTA vector, 
which contains a neomycin resistance gene driven by the pGK promoter, flanked 
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by loxP sites, and a diphtheria toxin gene cassette. Targeting vectors for the 
pre-miR-143 or pre-miR-145 sequence were generated using 3.5 kb fragment 
upstream and a 4.5 - 5 kb fragment downstream of the respective pre-miRNA 
sequence to form the 5’ and 3’ targeting arms respectively. These targeting 
vectors were designed to replace the entire pre-miRNA sequence of miR-143 or 
miR-145 with the neomycin resistance cassette flanked by loxP sites. 
Following linearization and electroporation of the targeting vectors into 
129SvEv-derived ESCs, southern blotting was performed to identify cell clones 
which were positive for homologous recombination. Positive clones were 
injected into E3.5 C57BL/6 blastocysts and male chimeric offspring bred with 
female C57BL/6 mice.   This cross produced a number of heterozygous offspring 
that contained 1 allele for the neomycin resistance cassette flanked by loxP sites 
and 1 allele for the normal pre-miRNA. Cre recombinase is an enzyme which 
catalyses recombination events between loxP sites and results in deletion of DNA 
when loxP sites are located in the same direction on a chromosome (Sauer, 
1998). In order to remove the neomycin resistance cassette heterozygous mice 
were bred with Cre-transgenic mice producing mice heterozygous for miR-143 
KO or miR-145 KO.  Finally, miRNA homozygous KO mice were produced by 
breeding heterozygous KO mice.  
2.16.2 AntimiR dosing schedule 
AntimiR-ctl and antimiR-143 for were kindly provided by MiRagen Therapeutics 
(see section 2.6 for details). AntimiRs were reconstituted in sterile PBS and 
filter-sterilsed before being aliquoted and frozen at -20ºC for storage until use. 
AntimiRs were administered at 10 mg/kg by subcutaneous (SC) injection to donor 
and recipient 15 week old C57BL/6 mice at 1 week intervals for a total of 3 
doses for donor mice and 7 doses for recipient mice. AntimiRs were administered 
between 21 days prior to the stent surgery and 21 days post-operative.  
2.16.3 Mouse model of in-stent stenosis 
A mouse model of in-stent stenosis was used incorporating the technique 
developed by Ali and colleagues (Ali et al., 2007). An overview of the surgical 
technique is shown in Figure 2.2. Briefly, a 2.5 X 0.6 mm stainless-steel stent 
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(Cambus Medical, Galway, Ireland) was hand crimped onto a 1.2 X 8 mm 
coronary dilatation catheter (Abbott, Berkshire, UK) by applying equal pressure 
to all surfaces of the stent with the fore finger and thumb. The stent and 
catheter were then sterilised in Actril® cold sterilant (Guardline Technologies 
ltd, Norfolk, UK) followed by 2 washes in sterile saline. The donor (female) 
mouse was euthanized by intraperitoneal (IP) injection with 150 mg/kg sodium 
pentobarbital and the abdomen opened and rib cage deflected. A small incision 
was made in the right atrium and the vessels perfused with 100 IU/ml heparin in 
saline via cardiac puncture of the left ventricle. This process was continued 
periodically throughout the procedure to ensure vessels remained moist. The 
thoracic aorta was isolated from the aortic arch to the diaphragm and the layer 
of fat lining the anterior aorta was removed by dissection along the connecting 
fascia. A small incision was made at the distal end of the thoracic aorta close to 
the diaphragmatic outlet. The balloon catheter was inserted and positioned in 
the descending aorta. The stent was deployed by inflating the balloon catheter 
to 10 atmospheres pressure for 30 sec, to produce a final stent diameter of 1.25 
mm and a stent to vessel ratio of 1.5:1. The stented aorta was isolated by 
cauterisation of the intercostal vessels and stored in heparinised saline. 
Recipient (male) mice of identical genotype were anaesthetised using 1-3% 
vaporised Isoflurane (Abbott) and under a dissection microscope the right 
common carotid artery was isolated and ligated with 2, 7-0 sutures (Ethicon, 
Edinburgh, UK) distal to the bifurcation. The carotid was dissected between the 
sutures and each end was passed through a 0.65 mm outer diameter nylon cuff 
(Smiths Medical, Kent, UK) and secured with a microhemostatic clamp. Sutures 
were removed and each free end of the carotid was everted over its 
corresponding cuff and secured with an 8-0 silk suture (Ethicon). The donor 
stented aorta was then sleeved over the everted ends of the carotid and secured 
in place with sutures. Microhemostatic clamps were removed to restore blood 
flow and the skin closed with a continuous 5-0 suture. An overview of the 
surgery is shown in Figure 2.2. 
Recipient mice received approximately 10 mg/kg/day aspirin in their drinking 
water, 7 days pre- and 28 days post-surgery to help prevent in-stent thrombosis. 
Peri-operatively recipient mice received 0.5 ml SC saline to prevent dehydration 
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and 0.05 mg/kg of the analgesic, Buprenorphine. Following surgery mice were 
transferred to a 37ºC heated chamber for recovery.  
1!
Donor Aorta
A B C D E F
Recipient Carotid
 
Figure 2.2. Overview of surgery to produce mouse model of in-stent stenosis. 
The thoracic aorta of the donor mouse was isolated and a 2.5 X 0.6 mm stainless-steel stent hand-
crimped onto a 1.20 mm balloon angioplasty catheter was advanced into the aorta and deployed by 
inflating to 10 atmospheres pressure (A and B) to give a final internal diameter of 1.25 mm. The 
right common carotid was isolated in the genetically identical recipient mouse and ligated with 2 
sutures distal to the bifurcation (C). The carotid was dissected between the sutures and each end 
was passed through a plastic cuff and secured with microhemostatic clamps (D). The sutures were 
removed and each free end of the carotid was everted over its corresponding cuff and secured with 
a suture (E). The donor stented aorta was then sleeved over the everted ends of the carotid and 
secured in place with sutures (F). Microhemostatic clamps were removed to restore blood flow. 
2.16.4 Tissue harvesting 
Mice were euthanized 28 days post-operative by anaesthetic overdose followed 
by excision of the heart. Tissues were perfused with saline prior to fixation in 
10% (v/v) formalin for 24 h followed by transfer to 70% (v/v) ethanol for storage.  
2.16.5 Resin embedding 
Formalin fixed vessels were embedded in Technovit 8100 resin (TAAB, Berkshire, 
UK), a methyl methacrylate resin, in accordance with the manufacturer’s 
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instructions. Vessels were placed in 0.5 ml embedding capsules (Electron 
Microscopy Sciences, Hatfield, UK) and dehydrated in 100% acetone for 1 h at 
4ºC. Dehydrated vessels were then placed in infiltration solution [0.6% (w/v) 
Hardener 1 in Basic Solution] overnight at 4ºC. Finally, vessels were positioned in 
the correct orientation and covered in polymerisation solution [0.5 ml Hardener 
2 in 15 ml infiltration solution] and left to set overnight at 4ºC.  
2.16.6 Sectioning of resin embedded vessels 
Resin embedded vessels were glued to microscope slides and sectioned using the 
Isomet 1000® precision saw (Buehler, Düsseldorf, Germany). Sections were 
ground to approximately 7-10 µm using the Metaserv® 2000 Grinder Polisher 
(Buehler) using P1200 grit paper (Buehler) and placing the sample on the paper 
intermittently at 1 sec intervals for approximately 30-40 sec. Slides were then 
polished using P2500 grit paper holding the sample against the paper for 10 sec.  
2.16.7 Electrolysis 
Electrolysis was performed in order to remove the stent from the vessel prior to 
paraffin embedding. This process was developed from a method previously 
described by Bradshaw and colleagues (Bradshaw et al., 2009) based on the 
theory that if two metal objects are placed in a weak acid/salt solution and a 
differential voltage applied, then the object attached to the positive voltage 
will form complexes in solution i.e. dissolve.  Briefly, under a dissection 
microscope a small incision was made in the stented vessel to expose the top of 
a stent strut. The stent strut was hooked onto a stainless-steel expansion spring 
attached to a stainless-steel wire and positioned in a 5 ml universal tube. 
Through a small hole in the lid of the universal, a solution containing 5% (w/v) 
citric acid and 5% (w/v) NaCl was added to the tube until the distal stent struts 
were touching the liquid. An electrode connected to the positive terminal of a 
power supply was attached to stainless-steel wire. The negative electrode was 
connected to a copper wire which was submerged in the citric acid/NaCl solution 
at the distal end of the universal. The power supply was turned on to 5 V and 
small bubbles could be seen rising from the copper electrode. Stent struts began 
to dissolve after around 3-5 min. This process was repeated until all stent struts 
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were dissolved. A diagrammatic overview of the experimental setup is shown in 
Figure 2.3.  
+ 5.00V+-
5% citric acid 
5% NaCl
Copper wire
Stented graft 
 
Figure 2.3. Overview of equipment used in stent electrolysis.  
 
 
2.16.8 Histology 
Vessel samples to be embedded in paraffin wax were first dehydrated through an 
ethanol gradient to xylene and finally to 62ºC paraffin wax using the Shandon 
Excelsior tissue processor (Thermo Scientific) an overview of this process in 
shown in Table 2.2.  
Chapter 2 – Materials and Methods  92 
 
 
Table 2.2. Tissue processing for paraffin embedding. 
Solution Incubation Period 
70% Ethanol 30 min
95% Ethanol 30 min
100% Ethanol 30 min
100% Ethanol 30 min 
100% Ethanol 45 min
100% Ethanol 45 min
100% Ethanol 60 min
Xylene 30 min
Xylene 30 min
Xylene 30min
Paraffin wax 30 min
Paraffin wax 45 min
Paraffin wax 45 min 
 
 
Following the tissue processing sequence, vessels were held in the correct 
orientation in biopsy cassettes and embedded in paraffin wax using the Shandon 
Histocenter 3 (ThermoFisher Scientific). Vessels were sectioned at 3-5 µm using 
the Leica microtome and transferred to a 45ºC water bath where they were 
mounted onto slides and then baked overnight at 60ºC in a histology oven.  
2.16.9 Haematoxylin and eosin staining  
Haematoxylin and eosin (H&E) staining was performed to visualise neointimal 
formation in stented vessels.  Sections were rehydrated by placing in 2 changes 
of Histo-Clear® (Fisher Scientific Ltd, Leicestershire, UK) followed by 100%, 95%, 
70% ethanol and distilled water (dH2O) each for 7 min. Nuclei were stained with 
Harris modified haematoxylin (Cell Pathology Ltd, Newtown Powys, UK) before 
being washed in running tap water for 5 min and transferred to 70% (v/v) 
ethanol for 1 min. Sections were incubated in eosin Y solution for 2 min to stain 
cytoplasmic structures before being dehydrated in 2 changes of each of the 
following: 95% (v/v) ethanol, 100% ethanol and Histo-Clear® each for 5 min. 
Slides were mounted with glass coverslips using DPX non-aqueous mounting 
medium (Merck Millipore, Damstadt, Germany). 
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2.16.10 Elastin staining 
Elastin van gieson (EVG) staining was performed in order to visualise the internal 
and external elastic lamina in stented vessels.  Briefly, sections were rehydrated 
through the gradient described in 2.15.9. Sections were oxidised by incubating in 
0.5% (w/v) potassium permanganate for 10 min, washed in running tap water for 
3 min and rinsed in dH2O for 30 sec. Decolourising of sections was achieved by 
placing in 1% (w/v) oxalic acid for 10 min, running tap water for 3 min and dH2O 
for 30 sec. Sections were incubated overnight with Miller’s elastin stain (VWR 
Chemicals, Leicestershire, UK) which stains elastin fibres black. The following 
day sections were washed by dipping the slides 7 times in 70% (v/v) ethanol 
followed by distilled water for 5 min. Sections were counterstained with Van 
Gieson solution (contains picric acid and 1% acid fuchsin), which stains collagen 
red.   Slides were dried in a histology oven at 60ºC for 30 min and then rinsed in 
2 changes of 100% ethanol and transferred to 2 changes of Histo-Clear® before 
being mounted with glass slides using DPX non-aqueous mounting medium. 
2.16.11 Immunohistochemistry  
10X PBS [80g/L NaCl, 2g/L KCl, 14.4g/L Na2HPO4  and 2.4g/L KH2PO4  pH 7.4] was 
diluted to 1X PBS in dH2O for all washes. Following rehydration of sections (as 
described in 2.15.9) heat induced antigen retrieval was performed by heating 10 
mM citric acid (pH 6.0) to 95-100ºC at 5 min intervals for a total of 20 min 
before allowing sections to cool for 30 min followed by 2 X 5 min washes in PBS. 
In order to block endogenous peroxidase activity sections were incubated in 3-
20% (v/v) H2O2 in methanol for 30 min prior to 2 X 5 min washes in PBS. Blocking 
of tissue sections was performed by incubation with 20% (v/v) of the appropriate 
serum (Table 2.3), diluted in PBS, for 1 h at RT.  Sections were incubated in a 
humidified chamber with the primary antibody or control IgG antibody, diluted 
in 2% (v/v) blocking serum for 1 h at RT or 4ºC overnight. Details of the primary 
antibodies used are shown in Table 2.3. Control IgG antibodies were diluted to 
at equal concentration as that of the primary antibody against the protein of 
interest. Sections were washed 3 X 5 min in PBS prior to incubation with the 
biotinylated secondary antibody in PBS for 1 h at RT. A list of the secondary 
antibodies used in immunohistochemistry experiments is shown in Table 2.4. 
Sections were washed in 3 X 5 min in PBS prior to incubation with 1:200 (v/v) 
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ExtrAvidin®-peroxidise (Sigma). ExtrAvidin-peroxidase contains avidin, which 
contains 4 biotin biding sites and binds to biotin with high affinity. The resultant 
avidin-biotin peroxidase cleaves its substrate DAB (3, 3’-diaminobenzidine) 
(Vector Laboratories, Peterborough, UK) to reveal the antigen by producing a 
dark brown colour. This was perfomed as described. Sections were washed 3 X 5 
min in PBS prior to incubation with DAB peroxidase substrate for 2-5 min or until 
the dark brown staining was visualised. Sections were washed in H2O for 5 min 
prior to dehydration through dH2O, 70%, 95%, 100% ethanol and 2 changes of 
Histo-Clear® each for 7 min. Sections were mounted with glass coverslips using 
DPX non-aqueous mounting medium. 
α-SMA staining was performed using the VECTASTAIN® Elite ABC kit (Universal) 
(Vector Laboratories) in accordance with the manufacturer’s instructions. 
Briefly, following dehydration through the alcohol gradient (see 2.15.9) sections 
were blocked for 1 h at RT with 1% (v/v) blocking serum (normal horse serum) in 
PBS. The sections were incubated with primary antibody or primary control IgG 
antibody (described in Table 2.3) diluted in PBS 2% normal horse serum, for 1 h 
at RT and washed for 3 X 5 min in PBS. Biotinylated secondary antibody (Table 
2.4) diluted in 2% blocking serum was incubated with sections for 30 min at RT. 
VECTASTAIN® Elite avidin biotinylated enzyme complex (ABC) reagent was 
prepared by adding 2 drops reagent A and 2 drops reagent B to 5ml PBS prior to 
incubation for 30 min. Following 3 X 5 min washes in PBS sections were 
incubated with the ABC reagent for 30 min at RT. The ABC complex binds to the 
biotin of the secondary antibody, when incubated with DAB peroxidase substrate 
dark brown staining occurs to reveal the antigenic site. DAB staining was 
performed as described above. 
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Table 2.3. Primary antibodies used in immunohistochemistry. 
Primary 
antibody
Conc. Dilution IgG Control
antibody
Blocking Serum 
Rabbit polyclonal
anti-α-SMA (Abcam :
ab5694)
0.2mg/ml 1:75 Normal rabbit 
IgG
(Invitrogen: 
10500C)
Normal horse
(Vector)
Rat monoclonal anti-
CD31 (Dianova: DIA-
310)
0.2mg/ml 1:20 Normal rat IgG
(Invitrogen: 
10700)
Normal rabbit
(Vector)
Rat monoclonal
anti-MAC-2 
(Cedarlane:
CL8942AP)
1mg/ml 1:5000 Normal rat IgG
(Invitrogen: 
10700)
Normal rabbit
(Vector)
Rabbit polyclonal 
anti- PCNA (Abcam: 
ab2426)
0.2mg/ml 1:200 Normal rabbit 
IgG
(Invitrogen: 
10500C)
Normal goat
(Vector)
 
 
Table 2.4. Secondary antibodies used in immunohistochemistry. 
Primary antibody
used
Secondary
antibody
Conc. Dilution 
Rabbit polyclonal
anti-α-SMA 
(Abcam: ab5694)
Biotinylated
Universal antibody 
horse anti-rabbit 
IgG (Vector:  BA-
1400)
1.05mg/ml 1: 50
Rat monoclonal 
anti-CD31 
(Dianova: DIA-310)
Biotinylated rabbit 
anti-rat IgG (Vector: 
BA-4000)
1.5mg/ml 1:200
Rat monoclonal
anti-MAC-2 
(Cedarlane: 
CL8942AP)
Biotinylated rabbit 
anti-rat IgG (Vector: 
BA-4000)
1.5mg/ml 1:200
Rabbit polyclonal 
anti- PCNA (Abcam: 
ab2426)
Biotinylated goat 
anti-rabbit IgG
(Vector: BA-1000)
1.5mg/ml 1:250
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2.16.12 Morphometric analysis and injury scoring  
In order to assess the morphometry of stented sections, photographs of stained 
sections were taken using QCapture Pro 6.0 and a series of measurements were 
performed using Image-Pro® Analyzer 7.0 software (Media Cybernetics, Marlow, 
UK). Analysis was performed on at least 3 sections/animal, descriptions of each 
measurement performed are shown in Table 2.5 and a diagrammatic overview is 
shown in Figure 2.4. 
Table 2.5. Definition of morphometric measurements. 
Measurement Definition
Neointimal Thickness Perpendicular distance between internal 
elastic lamina and lumen measured 
between stent struts 
Strut Depth Perpendicular distance between stent 
struts and lumen
Neointimal Area Area inside internal elastic lamina minus 
lumen minus stent struts 
Total Vessel Area Area inside external elastic lamina
Medial Area Area inside external elastic lamina minus 
area inside internal elastic lamina
% Stenosis Neointimal area divided by area inside 
internal elastic lamina multiplied by 100 
Stent Expansion Area inside polygon connecting the centre 
of each stent strut
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Medial Thickness
Strut Depth
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External Elastic Lamina
Internal Elastic Lamina
 
Figure 2.4. Diagram of morphometric measurements. 
 
In order to assess whether the stenting procedure produced a consistent and 
reproducible injury to the vessel wall between animals, stented sections were 
given an injury score based on a modified version of the Schwartz method. For 
each stented section, each individual stent strut (n=10) was given a numeric 
injury score based on the criteria described in Table 2.6, this process was then 
repeated for a n=3 sections/animal.  
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Table 2.6. Definition of injury scores. 
Injury Score Definition 
0 Stent struts against internal elastic lamina
1 Perforation of internal elastic lamina
2 Perforation of media
3 Perforation of the external elastic lamina 
 
2.16.13 Measurement of heart weights 
Heart weight measurements were performed on formalin fixed hearts. The 
whole heart, left ventricle plus septum and right ventricle were weighed and 
weight displayed as a percentage of the body weight at the time of sacrifice.  
2.17 Statistical analysis 
All results are displayed as mean ± standard error of the mean (SEM). In vitro 
experiments were performed in biological triplicates and repeated on 3 separate 
occasions. In vivo experiments were performed on n = 7-13 animals per 
experiment group.  
Statistical analysis was performed using Graphpad Prism 4 Software (California, 
USA) by unpaired Student’s t-test when 2 groups were present or by one-way 
analysis of variance (ANOVA) when more than 2 groups were present. Tukey’s 
post hoc test, which corrects for multiple comparisons, was applied when using 
ANOVA in order to compare all groups. Significance was determined as a P value 
of P<0.05.  
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3  The role of miR-143 and miR-145 in human 
primary vascular cells 
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3.1 Introduction 
Neointimal formation is a pathological process that occurs following vascular 
injury and can lead to narrowing of the lumen. A key component of neointimal 
formation is activation of VSMCs which proliferate and migrate from the media 
to form the neointima (Schwartz et al., 1992). VSMCs are highly plastic and can 
modulate their phenotype in response to environmental cues. In normal adult 
vessels, VSMCs display a differentiated, contractile phenotype with expression of 
contractile proteins and minimal migration or proliferation (Owens et al., 2004, 
Shanahan and Weissberg, 1998). In contrast, during development and following 
vascular injury VSMCs display a synthetic phenotype characterised by lower 
contractile and higher synthetic protein expression, proliferation and migration 
(Kuro-o et al., 1991, Kocher et al., 1991).  
MiRNAs, miR-143 and miR-145 have been identified as regulators of VSMC 
contractile phenotype. In vitro studies have shown that transcription of miR-
143/miR-145 is activated at a CArG box in its regulatory region by SRF and its 
cofactors myocardin and MRTF (Cordes et al., 2009, Xin et al., 2009). MiR-145 is 
decreased in cells exposed to PDGF and overexpression of miR-145 prevents 
PDGF-induced VSMC proliferation and downregulation of contractile genes, 
including SM-MHC and α-SMA (Cordes et al., 2009, Cheng et al., 2009). 
Furthermore, identified miR-143 and miR-145 targets include several 
transcription factors that have been shown to promote a synthetic VSMC 
phenotype. These include KLF5 (Xin et al., 2009), which promotes cell 
proliferation and expression of synthetic proteins (Watanabe et al., 1999, Suzuki 
et al., 2009). Elk-1, a miR-143 target (Cordes et al., 2009), has been shown to 
competitively inhibit the interaction between SRF and its cofactor myocardin at 
CArG box binding sites in the promoter regions of contractile genes (Wang et al., 
2004). Another identified miR-143/miR-145 target is KLF4 (Xin et al., 2009) 
which has been shown to inhibit SRF-myocardin interaction at the α-SMA 
promoter and repress activation of α-SMA (Liu et al., 2005). Together this 
evidence suggests that expression of miR-143 and miR-145 promotes a 
contractile VSMC phenotype. Although detectable at low levels in other cell 
types miR-143 and miR-145 are particularly enriched in SMCs (Cheng et al., 
2009). This relatively specific expression of miR-143 and miR-145 in SMCs is 
potentially beneficial as it may allow a means of targeting VSMC proliferation 
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and migration whilst having minimal effects on other cell types.  One of the 
main issues associated with DES is delayed re-endothelialisation of the vessel 
due to inhibition of EC proliferation (Joner et al., 2006). This increases risk of in-
stent thrombosis and there is a need to develop more selective therapies to 
target VSMC without effecting EC proliferation and migration.  
The saphenous vein is an extensively used vessel in CABG procedures but is 
associated with around 40% failure by 10 years, due to vessel remodelling and 
superimposed atherosclerosis (Goldman et al., 2004). Initial stages of 
remodelling involve activation of VSMC proliferation and migration following the 
shift to the high pressure arterial circulation and is eventually followed by the 
development of atherosclerotic plaques (Cox et al., 1991). In the present study 
SMCs and ECs isolated from the saphenous vein were used for in vitro studies to 
test the effects of miR-143 and miR-145 modulation, due to their clinical 
relevance and ability to exhibit proliferative and migratory properties in vivo.  
Modulation of miRNA levels can be achieved by several different means including 
transfection with miRNA mimics or inhibitors or vector-mediated delivery (van 
Rooij, 2011) . PremiRs are double-stranded mature miRNA mimics which can be 
transfected directly into the cell where strand selection and incorporation into 
the RISC can take place. AntimiRs are complementary to the mature miRNA 
sequence and contain a mix of DNA and LNA bases. AntimiRs act as miRNA 
inhibitors by binding tightly to the miRNA and preventing its interaction with 
targets. Vectors such as Ads and lentiviruses are useful molecular tools as they 
facilitate transgene delivery to cells both in vitro and in vivo, without the need 
for transfection.  Ads are 90-100 nm non-enveloped DNA viruses, which comprise 
of at least 55 known species subdivided into groups A-G (Coughlan et al., 2010). 
Subgroup C Ads, particularly Ad5 and Ad2, are the most extensively studied 
serotypes for use as gene therapy vectors and enter cells through binding to the 
coxsackievirus and adenovirus receptor (CAR) present on the cell membrane 
(Bergelson et al., 1997). The Ads used in the present study are Ad5 vectors that 
have their E1 and E3 genes deleted in order to render them replication 
incompetent and to accommodate transgene insertion, so called “1st generation” 
Ads. Following cellular transduction via CAR, transgene expression is driven by 
the CMV promoter which acts as a potent transcriptional enhancer (Boshart et 
al., 1985).     
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This chapter was designed to study the effects of modulating miR-143 and miR-
145 expression in human primary cells with respect to proliferation, migration 
and target gene expression in order to investigate the importance of these 
miRNA in influencing VSMC phenotype in vitro. 
3.1.1 Aims 
 To successfully modulate miR-143 and miR-145 expression within HSV SMC 
and HSV ECs. 
 To carry out functional studies to investigate whether modulation of miR-
143 or miR-145 expression effects migration and proliferation of HSV SMCs 
or HSV ECs.  
 To investigate changes in miRNA target expression that could be linked to 
any detected changes in proliferation and migration.  
 
 
 
 
 
 
 
 
 
 
Chapter 3 – MiRNAs in primary vascular cells  103 
 
 
3.2 Results 
3.2.1 Adenovirus-mediated modulation of miRNA expression 
AdmiR-143 and AdmiR-145 were produced by cloning the human pre-miR-143 or 
pre-miR-145 sequence into the replication incompetent Ad5 based vector 
pAdEasy-1. AdmiR-143 and AdmiR-145 were designed to allow the effect of 
increased miR-143 or miR-145 expression to be studied. The ability of AdmiR-143 
and AdmiR-145 to increase miR-143 and miR-145 expression was first tested in 
the HeLa cell line. HeLa cells were incubated with media alone (control), or 
AdmiR-143, AdmiR-145 or RAd-60 at 10-100 PFU/cell for 24 h before being 
incubated for a further 24 h in normal growth medium. MiRNA analysis was 
performed on isolated RNA by Taqman® qRT-PCR and northern blotting (Figure 
3.1).  Incubation of HeLa cells with AdmiR-143 or AdmiR-145 resulted in a 
significant increase in miR-143 and miR-145 expression seen by qRT-PCR (Figure 
3.1). Bands for mature miR-143 and miR-145 were not detectable by northern 
blotting in control or RAd60 transduced HeLa cells but prominent bands were 
detected following transduction with the AdmiR-143 and AdmiR-145 (Figure 3.1).  
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Figure 3.1. MiRNA expression in HeLa cells transduced with AdmiR-143 and AdmiR-145. 
HeLa cells were exposed to growth medium alone (control) or containing AdmiR-143,  AdmiR-145 
or RAd60 at concentrations of 10, 50 and 100 PFU/cell for 24 h. Media was replaced with fresh 
growth medium and incubated for a further 24 h. A-B. MiRNA expression determined by Taqman® 
qRT-PCR for miR-143 and miR-145. C-D. Northern blots performed on 3 µg RNA for miR-143, 
miR-145 and U6. *P<0.05, **P<0.01 vs. RAd60. n = 3. 
In contrast to HeLa cells which readily express CAR (Bergelson et al., 1997), HSV 
SMCs are relatively non-permissive to Ad5 due to their low CAR expression 
(Havenga et al., 2001) and thus require a higher number of infectious particles 
per cell in order for adequate transduction to occur. Transduction of HSV SMCs 
was first tested using Ad5CMVlacZ which expresses the lacZ transgene and 
produces a blue product when in the presence of its substrate X-gal. VP titre was 
used for primary cell experiments due to toxicity seen after using PFU/cell in 
preliminary experiments, presumably due to high VP to PFU ratios and thus an 
abundance of non-infectious viral particles.  HSV SMCs were incubated with 
10,000-50,000 VP/cell Ad5CMVlacZ for 24 h before media was replaced with 0.1% 
FCS medium for 48 h to induce quiescence. Cells were fixed and stained with X-
gal and blue staining visualised (Figure 3.2A). Transgene expression could be 
seen in a small number of cells with the most prominent staining seen in cells 
treated with 50,000 VP/cell Ad5CMVlacZ (16.51 ± 3.63%)(Figure 3.2A).  
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Transgene expression driven by the CMV promoter has previously been shown to 
be responsive to changes in cell cycle and serum concentrations (Brightwell et 
al., 1997). In order to determine whether transgene expression was improved in 
the presence of serum the experiment was repeated with cells being transferred 
to 2% FCS or maintained in 15% FCS SMC growth medium following 24 h 
incubation with Ad5CMVlacZ. Transgene expression was greatest in cells treated 
with 50,000 VP/Cell Ad5CMVlacZ and maintained in 15% FCS (78.97 ± 
2.40%)(Figure 3.2A). Transfer of cells into low serum medium (2% FCS) improved 
transgene staining seen following transduction with 50,000 VP/Cell (39.36 ± 
9.15%) compared with serum starvation (Figure 3.2A).  
Serum starvation was included in the protocol when testing Ad-mediated gene 
expression in HSV SMCs as it is required to induce quiescence for migration and 
proliferation assays. In order to determine the proliferative response of HSV 
SMCs to FCS, HSV SMCs were exposed to different concentrations of FCS-
containing SMC growth medium for 48 h and cell proliferation determined by MTS 
assay (Figure 3.2B).  Maintenance of cells in 2% FCS medium did not significantly 
evoke cell proliferation compared to cells maintained in 0.1% FCS medium 
(Figure 3.2B). Therefore it was determined that HSV SMCs treated with Ads could 
be transferred to low serum (2% FCS) medium to reduce cell proliferation prior 
to functional assays.  
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Figure 3.2. X-gal expression in HSV SMCs transduced with Ad5CMVlacZ. 
A. X-gal staining of HSV SMCs transduced with 10,000 - 50,000 VP/cell Ad5CMVlacZ prior to 48 h 
incubation in 0.1%-15% FCS containing media. B. Proliferation of quiescent HSV SMCs exposed to 
0.1%-15% serum for 48 h. Proliferation was measured by MTS assay read at 490 nm. 10X 
magnification. Scale bar = 100 µm. P<0.05, ** P<0.01 vs. 0.1% FCS. n = 3. 
In order to confirm the results of our X-gal assay miRNA expression was 
measured by Taqman® qRT-PCR analysis in HSV SMCs after transduction with 
AdmiR-143 or AdmiR-145. Results showed a dose dependent increase in miR-143 
and miR-145 expression in HSV SMCs maintained in 2% or 15% FCS medium with 3-
4-fold increased expression seen in cells transduced with 50,000 VP/cell (Figure 
3.3B-C). Conversely, cells maintained in 0.1% FCS medium showed only non-
specific changes in miRNA expression (Figure 3.3A).  
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Figure 3.3. MiRNA expression in Ad-miR-143 and AdmiR-145 transduced HSV SMCs. 
HSV SMCs cells were incubated for 24 h in normal growth medium alone (control) or containing 
10,000-50,000 VP/cell AdmiR-143, AdmiR-145 or Ad5CMVlacZ. Cells were incubated in medium 
containing 0.1%, 2% or 15% FCS for a further 48 h before being lysed for RNA extraction and 
analysis. Taqman® qRT-PCR analysis of miR-143 and miR-145 levels in Ad transduced cells 
incubated in 0.1% (A) 2% (B) or 15% (C) FCS. *P<0.05, **P<0.01, ***P<0.001 vs. Ad5CMVlacZ. n 
= 3. 
The effect of increased miR-143 and miR-145 expression on migration was 
investigated by a scratch assay. Following transduction with 50,000 VP/cell 
AdmiR-143, AdmiR-145 or Ad5CMVlacZ and maintenance in low serum (2%) 
medium for 48 h, scratches were made in the cell monolayer using a 200 µl 
pipette tip and medium replaced with fresh 2% FCS medium. Migration into the 
wound was assessed over 24 h. Migration of HSV SMCs did not significantly differ 
following transduction with AdmiR-143, AdmiR-145 or Ad5CMVlacZ (Figure 3.4). 
However, control HSV SMCs migrated significantly further than those transduced 
with Ad5CMVlacZ (Figure 3.4), indicating that transduction with Ads in general 
decreased cell migration.  The high doses of Ads needed to modulate miRNA 
expression in HSV SMCs may therefore hinder the ability to detect any effect of 
miR-143 or miR-145 on migration.  
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Figure 3.4. Migration of HSV SMCs transduced with AdmiR-143 and AdmiR-145. 
HSV SMCs were seeded at 3X10
5
 cells/well in 6 well plates and incubated with control (media 
alone) or 50,000 VP/cell AdmiR-143, AdmiR-145 or Ad5CMVlacZ for 24 h prior to 48 h incubation 
in 2% FCS media. Vertical scratches were made in the cell monolayer with a 200 µl pipette tip and 
photographed  at 0 h, 12 h and 24 h post scratch to monitor migration into the wound (A). Images 
were analysed using image J software and distance migration determined over 24h (B). 10X 
magnification. Scale bar = 100 µm. **P<0.01 vs. Ad5CMVlacZ. n = 3. 
HSV ECs display greater expression of CAR than HSV SMCs making them more 
readily transduced with Ad5 vectors (Havenga et al., 2001). HSV ECs were 
incubated with 5000-20,000 VP/cell AdmiR-143, AdmiR-145 or Ad5CMVlacZ for 24 
h before being serum starved in 0.1% FCS medium for 24 h. MiR-143 and miR-145 
expression, determined by Taqman® qRT-PCR, was significantly increased in a 
dose dependent manner reaching approximately 20-fold and 7-fold respectively 
at 20,000 VP/cell (Figure 3.5).  
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Figure 3.5. MiRNA expression in AdmiR-143 and AdmiR-145 transduced HSV ECs. 
HSV ECs cells were incubated for 24 h in normal growth medium alone (control) or containing 
5000-20,000 VP/cell AdmiR-143, AdmiR-145 or Ad5CMVlacZ. Cells were incubated in medium 
containing 0.1% FCS for a further 24 h before being lysed for RNA extraction and analysis. 
Taqman® qRT-PCR analysis of miR-143 (A) and miR-145 (B) levels in Ad transduced cells 
incubated in 0.1% FCS.  **P<0.01, ***P<0.001 vs. Ad5CMVlacZ. n = 3. 
Following a number of optimisation experiments HSV ECs incubated with 20,000 
VP/cell Ads displayed significant toxicity during migration assays. This is thought 
to be due to the combination of high viral transduction and serum starvation. 
Migration was therefore assessed in HSV ECs transduced with 10,000 VP/cell Ads, 
which also produced significant increases in miR-143 and miR-145 expression 
(Figure 3.5) but was not associated with toxicity. Assessment of HSV EC 
migration over 24 h revealed that transduction with AdmiR-145 produced a 
significant reduction in migration (Figure 3.6).  
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Figure 3.6. Migration of HSV ECs transduced with AdmiR-143 and AdmiR-145. 
HSV SMCs were seeded at 3X10
5
 cells/well in 6 well plates and incubated with control (media 
alone) or 10,000 VP/cell AdmiR-143, AdmiR-145 or Ad5CMVlacZ for 24 h prior to 24 h incubation 
in 0.1% FCS media. Vertical scratches were made in the cell monolayer with a 200 µl pipette tip 
and photographed at 0 h, 12 h and 24 h post scratch to monitor migration into the wound (A). 
Images were analysed using image J software and distance migration determined over 24h (B). 
10X magnification. Scale bar = 100 µm. **P<0.01 vs. Ad5CMVlacZ. n = 3. 
Analysis of expression of miR-143 and miR-145 targets KLF4 and KLF5 in HSV 
SMCs by Taqman® qRT-PCR did not reveal any significant changes in mRNA 
expression following transduction with AdmiR-143 or AdmiR-145 (Figure 3.7).  
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Figure 3.7. Gene expression in HSV SMCs transduced with AdmiR-143 and AdmiR-145. 
HSV SMCs were isolated 48 h after incubation with media alone (control) or containing 10,000-
50,000 VP/cell AdmiR-143, AdmiR-145 or Ad5CMVlacZ. Taqman® qRT-PCR analysis of KLF4 (A) 
and KLF5 (B) expression.  *P<0.05 vs. Ad5CMVlacZ. n = 3. 
Whilst optimising Ads as modulators of miRNA expression for functional assays 
many problems arose including the need to use high VP/cell in order to achieve 
adequate overexpression, lack of transgene expression following serum 
starvation, non-specific effects of Ads on cell migration and toxicity. These 
effects together with the variability in VP to PFU ratios between different Ads 
(80 and 46 for AdmiR-143 and AdmiR-145, respectively) made their use in 
functional assays unreliable and as a result a different direction of modulating 
miRNA expression was pursued through transfection of small molecule mimics 
and inhibitors.   
3.2.2 PremiR and antimiR modulation of miRNA expression 
Transfections carried out using SiPORT NeoFX were initially optimised in HSV 
SMCs using non-targeting antimiR tagged with Cy3 fluorescent reporter. HSV 
SMCs were plated with antimiR-Cy3 transfection complexes and media changed 
to 0.1% SMC medium the following day. Cy3 expression was photographed under 
fluorescent microscope 48 h later. Cy3 was detectable in all cells transfected 
with 10 nM, 25 nM and 50 nM antimiR-Cy3 (Figure 3.8). 
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Figure 3.8. Cy3 fluorescence in HSV SMCs transfected with antimiR-Cy3.      
HSV SMCs were transfected with 10 nM - 50 nM antimiR-Cy3 using SiPORT-NeoFX and seeded 
at 4X10
4
 cells/well in chamber slides. Cells were fixed 48 h later and mounted with Prolong Gold 
Antifade Reagent with DAPI. Top panel shows blue DAPI nuclear stain. Middle panel shows red 
Cy3 fluorescence. A merger of both images is shown in the bottom panel. 40X magnification. Scale 
bar = 20 µm. n = 3. 
Analysis of miRNA expression in HSV SMCs following transfection with premiRs or 
antimiRs was carried by Taqman® qRT-PCR and northern blotting. Transfection 
with premiR-143 and premiR-145 produced significant increases in miR-143 and 
miR-145 expression compared to premiR-scr with more than 100-fold increases in 
expression detected at the 10 nM concentration for both miRNA (Figure 3.9A and 
3.10A). Northern blots confirmed overexpression with large bands of the 
respective miRNA detected in RNA isolated from HSV SMCs transfected with 
premiR-143 and premiR-145 (Figures 3.9C and 3.10C). AntimiR-143 and antimiR-
145 decreased miR-143 and miR-145 expression by approximately 0.5-0.7-fold 
detected by qRT-PCR (Figure 3.9B and 3.10B) and expression was undetectable 
by northern blot compared to antimiR-ctl (Figure 3.9D and 3.10D). MiR-145 
expression was greater in control HSV SMCs when compared to mock and 
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antimiR-ctl transfected cells suggesting that the transfection process itself may 
reduce miR-145 levels (Figure 3.10B).  
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Figure 3.9. MiR-143 expression in transfected HSV SMCs. 
HSV SMCs were incubated overnight in medium alone (control), medium + SiPORT NeoFX alone 
(Mock) or transfected with 10 nM - 50 nM premiR or antimiR. Cells were quiesced in 0.1% FCS for 
48 h. MiR-143 expression was analysed by Taqman® qRT-PCR in HSV SMCs transfected with 
premiRs (A) and antimiRs (B).  Northern blots of miR-143 and U6 expression in premiR (C) and 
antimiR (D) transfected cells. *P<0.05, **P<0.01, ***P<0.001 vs. premiR-scr or antimiR-ctl. n = 3. 
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Figure 3.10. MiR-145 expression in transfected HSV SMCs. 
HSV SMCs were incubated overnight in medium alone (control), medium + SiPORT NeoFX alone 
(Mock) or transfected with 10 nM - 50 nM  PremiR or antimiR. Cells were then quiesced in 0.1% 
FCS for 48 h. MiR-145 expression was analysed by Taqman® qRT-PCR in HSV SMCs transfected 
with premiRs (A) and antimiRs (B).  Northern blots of miR-145 and U6 expression in premiR (C) 
and antimiR (D) transfected cells. *P<0.05, **P<0.01, ***P<0.001 vs. premiR-scr or antimiR-ctl. n = 
3. 
MiR-143 and miR-145 expression is relatively restricted to SMCs however it is 
detectable at low levels in other tissues including HSV ECs. Transfection of 
premiR-145 and premiR-143 into HSV ECs increased miRNA expression, detected 
by Taqman® qRT-PCR by more than 5000–fold and 10,000-fold for miR-145 and 
miR-143 respectively (Figure 3.11 A-B). Bands for miR-143 expression were 
undetectable by northern blot in premiR-scr treated HSV ECs but large bands 
were present following transfection with premiR-143 (Figure 3.11C). Similarly, 
northern blots showed that miR-145 bands were considerably larger in HSV ECs 
transfected with premiR-145 when compared to transfection with premiR-scr at 
the same concentration (Figure 3.11D).  
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Figure 3.11. MiR-143 and miR-145 expression in premiR transfected HSV ECs. 
HSV ECs were incubated overnight with media alone (control) or transfected with medium + 
SiPORT NeoFX alone (Mock), or 10 nM - 50 nM premiR-143, premiR-145 or premiR-scr. Cells 
were quiesced in 0.1% FCS for 24 h and isolated for RNA analysis. A-B. Taqman® qRT-PCR of 
miR-143 and miR-145 expression following transfection with premiRs. C-D. Northern blot analysis 
of miR-143, miR-145 and U6 expression. ***P<0.001 vs. premiR-scr. n = 3. 
 
3.2.3 Functional studies in human primary cells with modulated 
miRNA expression  
In order to ascertain whether modulation of miR-143 or miR-145 expression 
effects migration of HSV EC or HSV SMCs, scratch assays were performed. Cells 
were seeded in 6 wells plates and transfected in suspension with SiPORT NeoFX 
before being serum starved in 0.1% FCS medium for 24h (HSV ECs) or 48 h (HSV 
SMCs). Vertical scratches were made in the cell monolayer and medium was 
replaced with either fresh 0.1% FCS or 5% FCS, to determine whether modulation 
of miR-143 or miR-145 promotes migration in quiescent cells, or alternatively has 
an inhibitory effect on serum evoked migration. Analysis of migration over 24 h 
revealed that HSV SMCs maintained in 5% FCS medium migrated approximately 
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100-150 µm more than those maintained in 0.1% FCS medium (Figure 3.12) 
However, no significant difference in migration was detectable in HSV SMCs 
transfected with premiR-143, premiR-145 when compared to premiR-scr (Figure 
3.12). Similarly migration of HSV SMCs transfected with antimiR-143 or antimiR-
145 was not significantly different from those treated with antimiR-ctl (Figure 
3.13). Control HSV SMCs maintained in 5% FCS migrated significantly further than 
those treated with antimiR-ctl indicating that transfection process may affect 
migration (Figure 3.13). Increases in miR-143 and miR-145 expression following 
transfection with premiR-143 and premiR-145 did not result in any significant 
changes in HSV EC migration (Figure 3.14).  
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Figure 3.12. Migration of HSV SMCs transfected with premiRs. 
HSV SMCs were transfected in 6 well plates at 3X10
5
 cells/well with 10 nM PremiRs, medium + 
SiPORT NeoFX alone (Mock) or medium alone (control) and incubated overnight. Medium was 
replaced with 0.1% FCS medium and cells were incubated for a further 48 h to promote cell 
quiescence. Vertical scratches were made in the cell monolayer with a 200 µl pipette tip and media 
changed to either 0.1% or 5% FCS medium. A. Images taken 0 h and 24 h post scratch to monitor 
migration into the wound. B. Analysis of Images using ImageJ software showing distance migration 
over 24h. 10X magnification. Scale bar = 100 µm. n = 3. 
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Figure 3.13. Migration of HSV SMCs transfected with antimiRs. 
HSV SMCs were transfected in 6 well plates at 3X10
5
 cells/well with 10 nM  antimiRs, medium + 
SiPORT NeoFX alone (Mock) or media alone (control) and incubated overnight. Cells were 
quiesced for 48 h in 0.1% FCS medium. Vertical scratches were made in the cell monolayer and 
medium replaced with 0.1% or 5% FCS medium. A. Images of migration into the wound at 0 h and 
24 h post scratch. B.  Analysis of Images showing distance migration over 24h. 10X magnification. 
Scale bar = 100 µm. **P<0.01 vs. antimiR-ctl. n = 3. 
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Figure 3.14. Migration of HSV ECs transfected with premiRs. 
HSV ECs were transfected in 6 well plates at 3X10
5
 cells/well with 10 nM premiRs, medium + 
SiPORT NeoFX alone (Mock) or medium alone (control) and incubated overnight. Cells were 
quiesced for 24 h in 0.1% FCS medium before vertical scratches were made in the cell monolayer 
and media replaced with 0.1% or 5% FCS medium. A. Images of migration into the wound at 0 h 
and 24 h post scratch. B.  Analysis of Images showing distance migration over 24h. 10X 
magnification. Scale bar = 100 µm. n = 3. 
We next assessed the proliferation rates of HSV SMCs and HSV ECs with 
modulated miR-143 or miR-145 expression. Following transfection with premiRs 
or antimiRs and serum starvation, cells were immersed in 0.1% or 5% FCS 
medium for 72 h for proliferation to occur before MTS solution was added and 
absorbance read at 490 nm. Incubation in 5% medium caused a significant 
increase in cell proliferation compared to 0.1% medium in both HSV SMCs and 
HSV ECs (Figure 3.15).   No significant difference in proliferation was detectable 
between HSV SMCs transfected with premiR-143 or premiR-145 compared with 
premiR-scr (Figure 3.15A). Similarly HSV SMCs transfected with antimiR-143 or 
antimiR-145 did not show any significant differences in proliferation compared 
to antimiR-ctl (Figure 3.15B).   
Chapter 3 – MiRNAs in primary vascular cells  119 
 
 
Increased cell proliferation was detectable in control (0.1% and 5% FCS) and 
mock transfected (5% FCS) HSV ECs when compared to premiR-scr (Figure 3.15C). 
Proliferation of cells transfected with premiR-145 was decreased in cells 
maintained in 5% but not 0.1% medium (Figure 3.15C).  
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Figure 3.15. Proliferation in primary cells with modulated miR-143 and miR-145 levels. 
Cells were transfected in 24 well plates at 4X10
4
 cells/well with 10 nM premiRs, medium + SiPORT 
NeoFX Transfection Agent alone (Mock) or medium alone (control) and incubated overnight. Cells 
were quiesced for 24 h (HSV ECs) or 48 h (HSV SMCs) in 0.1% FCS medium before transfer to 
0.1% or 5% FCS medium for 72 h. Proliferation was measured by MTS assay read at 490 nm. 
Proliferation of HSV SMCs transfected with premiRs (A) or antimiRs (B). Proliferation of HSV ECs 
transfected with premiRs (C). +++ P<0.001 vs.  0.1% FCS. * P<0.05, ***P<0.001 vs. premiR-scr. n 
= 3. 
To determine whether increasing cellular levels of miR-143 or miR-145 results in 
increased transfer to exosomes, exosomal RNA was isolated from the media of 
HSV ECs that had been transfected with premiR-143 or premiR-145 then 
maintained for 96 h in 0.1% FCS medium. MiR-143 and miR-145 expression in HSV 
ECs was more than 1000-fold 5 days post-transfection with premiRs (Figure 3.16 
A-B). Despite a trend for increased miR-143 and miR-145 expression in exosomes 
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treated with premiR-143 or premiR-145 this did not reach significance (Figure 
3.16 C-D). 
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Figure 3.16. MiR-143 and miR-145 expression in HSV EC exosomes. 
HSV ECs were transfected in suspension with SiPORT NeoFX with 10 nM premiR-143, premiR-
145 or premiR-scr and seeded at 3X10
5
 cells/well in 6 well plates. The following day cells were 
transferred to 0.1% FCS medium and incubated for 96 h. Exosomes were isolated from the cell 
medium and subjected to Taqman® qRT-PCR analysis. A-B. MiR-143 and miR-145 expression in 
HSV ECs. C-D. miR-143 and miR-145 expression in HSV EC exosomes. n = 3. 
 
3.2.4 Analysis of miR-143 and miR-145 target expression 
MiRNAs act by negatively regulating the expression of target genes by binding to 
mRNA sequences and preventing translation either through miRNA degradation or 
inhibition. Decreased expression of a miRNA may therefore lead to increased 
levels of target mRNA. Likewise, increasing the expression of a miRNA may 
decrease levels of its target mRNA.  Expression of miR-143 and miR-145 targets 
was analysed in HSV SMCs following transfection with 10 nM premiRs and 
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antimiRs by Taqman® qRT-PCR. Expression of KLF4 and KLF5 was significantly 
upregulated by antimiR-143 compared with antimiR-ctl (Figure 3.17A-B). 
However, expression of ACE, ELK-1, ITGBL1 or FSCN1 was not significantly 
altered (Figure 3.17C-F). In cells transfected with premiRs no significant changes 
in target mRNA expression were detectable for KLF4, KLF5, ELK-1, ACE, ITGBL1, 
or TGFβ2 (Figure 3.18).  
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Figure 3.17. Target mRNA expression in HSV SMCs transfected with antimiRs. 
Expression of miR-143 or miR-145 targets KLF4 (A), KLF5 (B) ELK-1 (C) ACE (D) ITGBL1 (E) and 
FSCN1 (F) was analysed by qRT-PCR in HSV SMCs 48 h post transfection with 10 nM antimiR-
143, antimiR-145 or antimiR-ctl.  **P<0.01 vs. antimiR-ctl. n = 3. 
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Figure 3.18. Target mRNA expression in HSV SMCs transfected with premiRs 
Expression of miR-143 and miR-145 targets KLF4 (A) KLF5 (B) ELK-1 (C) ACE (D) ITGBL1 (E) 
and TGFβ2 (F) in HSV SMCs 48 h post transfection with premiR-143, premiR-145 or premiR-scr. n 
= 3. 
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3.3 Discussion 
In summary, it was shown that transduction of human primary cells with Ads that 
express pre-miR-143 or pre-miR-145 resulted in increased expression of the 
mature miRNA but was associated with toxicity issues. Modulation of mature 
miR-143 or miR-145 expression levels using premiR miRNA mimics and antimiR 
miRNA inhibitors was found to have no effect on HSV SMC proliferation or 
migration. Migration of HSV ECs was not affected by premiR overexpression of 
miRNAs but results of proliferation assays were inconclusive and require further 
investigation. KLF4 and KLF5 expression levels increased following antimiR-143 
delivery suggesting that target de-repression had occurred. However, the 
expression of other previously identified targets remained unchanged in 
response to modulation of miR-143 or miR-145 levels.  
AdmiR-143 and AdmiR-145 encode pre-miR-143 and pre-miR-145 which require 
processing in the cell by Dicer and its cofactors into mature miRNA 
(Chendrimada et al., 2005). Successful processing on the pre-miRNA transgenes 
was confirmed by increased expression of mature miR-143 and miR-145 in cells 
following transduction by AdmiR-143 and AdmiR-145. The degree of miRNA 
overexpression following incubation with AdmiR-143 or AdmiR-145 was greatest 
in HeLa cells, which readily express CAR (Bergelson et al., 1997) and lower in 
HSV ECs and HSV SMCs which have little to no detectable CAR expression 
respectively (Havenga et al., 2001). CAR is the primary attachment receptor 
utilised by Ad5 (Bergelson et al., 1997) to enter the cell and thus it is probable 
that the availability of CAR acted as a rate-limiting step for viral transduction. 
This was overcome by use of high doses of Ad in primary cells in order to 
increase transduction.  
A previous study showed that activity of the CMV promoter is significantly 
reduced in cells maintained in the G0/G1 versus the S phase of cell cycle and 
leads to lower transgene expression (Brightwell et al., 1997). Furthermore, the 
addition of serum to cells maintained in G0/G1 promotes accelerated 
transcription and transgene expression by the CMV promoter, which importantly 
is not associated with any change in the number of cells in the S phase 
(Brightwell et al., 1997). This serum responsive aspect of CMV activity was 
evident in AdmiR-143 and AdmiR-145 transduced HSV SMCs, in which increases in 
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miRNA expression were absent in serum-starved cells but evident in cells 
maintained in the presence of FCS. Conversely, detectable increases in miR-143 
and miR-145 expression were apparent in serum-starved HSV ECs transduced 
with AdmiR-143 and AdmiR-145. We hypothesise that this superior transduction 
of HSV ECs by Ads is due to their greater expression of CAR, which would result 
in a greater fold increase in transgene expression. Reduction in CMV activity by 
serum starvation would therefore still result in detectable transgene expression 
in HSV ECs. Other contributing factors may have included the shorter period of 
serum starvation (24 h vs. 48 h) and lower basal expression of miR-143 and miR-
145 in HSV ECs when compared to HSV SMCs.    
Ad transduction of HSV SMCs had a negative effect on overall cell migration 
which was significantly reduced compare to control cells. This was most likely 
due to toxicity caused by the high doses of Ads required to obtain adequate 
transduction and miR-143 and miR-145 overexpression. Migration of HSV ECs was 
significantly reduced following transduction with AdmiR-145 but conversely 
transfection with premiR-145 was found not to significantly alter HSV EC 
migration. This may be due to each Ad having a different VP:PFU ratio, which 
results in variation in the PFU/cell between Ads at a defined VP. Therefore a 
higher PFU/cell may have resulted in toxicity and reduced migration in HSV ECs 
transduced with AdmiR-145. Thus Ad5-based vectors were not optimal for 
functional studies in primary cells. 
One method to overcome poor transduction of HSV SMCs by AdmiR-143 and 
AdmiR-145 would be retargeting the vectors to utilise a receptor more readily 
expressed on vascular cells.  Subgroup B Ads enter cells through a CAR-
independent mechanism by binding to the CD46 cellular receptor which is readily 
expressed on VSMCs (Gaggar et al., 2003, Parker et al., 2013).  Transduction of 
HSV SMCs with Ad35, a subgroup B Ad, is significantly greater than that which 
occurs with an equivalent dose of Ad5 (Parker et al., 2013). Modification of the 
Ad5 to contain targeting components of subgroup B Ads, termed ‘pseudotyping’ 
is another method being extensively studied to enhance Ad5 transduction of cells 
with low CAR expression. Transduction of HSV SMCs and vascular ECs is 
significantly improved when the fiber region of Ad5, which mediates cell 
binding, is replaced with that of subgroup B Ad16 (Havenga et al., 2001). 
Delivery of pre-miR-143 and pre-miR-145 to vascular cells using a subgroup B Ad 
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vector would allow transduction to occur at lower doses and thus potentially 
avoid toxicity issues associated with the high doses of Ad5 needed to transduce 
these cells.  
Transfection of primary cells with premiRs and antimiRs offered an alternative 
mechanism of modulating miRNA expression without the need for Ads. PremiRs 
produced a greater fold increase in miRNA levels when compared with Ads as 
they were transfected directly into cells and were not limited by CAR expression 
or activity of the CMV promoter. PremiRs also require less processing within the 
cell as they exist as mature duplexes.  
Previous reports have indicated that miR-143 and miR-145 expression is 
associated with a non-proliferative phenotype in vitro (Cheng et al., 2009, 
Cordes et al., 2009). Knockdown of miR-143 expression using an antimiR has 
been shown to double the proliferation rate in the rat A10 VSMC line (Cordes et 
al., 2009). Furthermore, miR-145 overexpression reduced PDGF-induced 
proliferation in A10 cells and primary rat VSMCs (Cordes et al., 2009, Cheng et 
al., 2009).  Our study found that proliferation of HSV SMCs was not affected by 
premiR mediated overexpression or antimiR mediated knockdown of miR-143 or 
miR-145 levels. These different observations may be due to species differences 
with the importance of modulating these miRNAs less significant in human VSMCs 
than rat VSMCs. It also may be indicative of the need for a specific proliferative 
stimulant such as PDGF in order for the anti-proliferative effects of miR-143 or 
miR-145 to be observed. PDGF is a potent regulator of VSMC gene expression and 
proliferation, and has been previously shown to decrease miR-143 and miR-145 
expression in cells (Cheng et al., 2009, Quintavalle et al., 2010). FCS also 
promotes cell proliferation but contains an array of growth factors which are 
likely to affect cells through a number of signalling pathways, thus modulation 
of miR-143 or miR-145 alone may be insufficient to affect cell proliferation. 
Migration of medial VSMCs to the intima occurs following injury to the vessel 
wall and is a major contributing factor to neointimal formation (Clowes and 
Schwartz, 1985). Migration was measured by scratch assay which is a model of 
wound healing where cells migrate to replace injured or denuded cells (Liang et 
al., 2007). Neither premiR-mediated increase nor antimiR-mediated decrease in 
miR-143 or miR-145 expression affected VSMC migration in the presence or 
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absence of FCS which was used as a non-specific promoter of cell migration. 
These results indicate that modulation of miR-143 or miR-145 alone is not 
sufficient to affect HSV SMC migration.  
A reduction in HSV ECs proliferation was seen following transfection with 
premiR-145 which indicates that miR-145 can have functional effects on cell 
types other than SMCs. However, proliferation of transfected HSV ECs was often 
less than control or mock transfected HSV ECs. MTS assays are an indirect 
measure of cell proliferation that measure the bioreduction of MTS by living 
cells, the absorbance of the product is directly proportional to cell number. This 
does not take cell viability into account and the transfection process may have 
reduced viability of HSV ECs which would result in lower absorbance. As such, 
further studies are now required to ascertain whether premiR-145 affects HSV EC 
proliferation. One way of doing this would be to perform a 5-bromo-2-
deoxyuridine (BrdU) assay. BrdU is a thymidine analogue which is incorporated 
into DNA in place of thymidine during synthesis in proliferating cells (Porstmann 
et al., 1985).  Incorporated BrdU can then be detected using an immunoassay 
which produces a colourmetric change that can be detected by 
spectrophotometer to give an absorbance directly related to cell proliferation. 
BrdU may be preferable over MTS assays as it is a measure of DNA synthesis and 
is not affected by cell viability.  
KLF4 and KLF5 are previously identified targets of miR-143 and miR-145 (Cordes 
et al., 2009, Cheng et al., 2009, Xin et al., 2009). HSV SMCs transfected with 
antimiR-143 had increased mRNA levels of KLF4 and KLF5 suggesting that target 
de-repression occurs following knockdown of miR-143 expression. Conversely, 
premiR-143 did not alter KLF4 or KLF5 mRNA levels. One reason for this may be 
that KLF5 is maintained at a baseline level by miR-143 in HSV SMCs which cannot 
be further lowered by increasing miR-143 levels, perhaps due to greater 
availability of other targets under these conditions. Another reason for this could 
be that despite the large increases in miRNA expression following transfection 
with premiRs, incorporation of the guide strand into the RISC may be rate 
limited and therefore the actual increase in functioning mature miR-143 or miR-
145 may be much lower. One way of assessing this would be to use a ‘pull-down’ 
assay where a transfected biotinylated miRNA mimic is isolated from cell 
lysates, first by using an antibody against Ago proteins and then by streptavidin 
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bead isolation of the bound biotinylated miRNA mimic (Nonne et al., 2010, 
Beitzinger et al., 2007). This would allow a measure of the amount of functional 
miRNA mimic following transfection. MiR-145 is a more potent repressor of KLF4 
and KLF5 than miR-143 in COS cells and human pulmonary artery SMCs (Xin et 
al., 2009, Davis-Dusenbery et al., 2011). However, neither premiR-145 nor 
antimiR-145 significantly altered KLF4 or KLF5 mRNA levels in HSV SMCs, 
suggesting that these targets may be preferentially regulated by miR-143 in 
these cells.  
No other previously identified targets investigated in this study were 
significantly altered by miR-143 or miR-145 knockdown or overexpression in HSV 
SMCs. We hypothesise that this is due to a number of reasons. Firstly, several of 
the miR-143 and miR-145 targets investigated in this study were identified as 
targets by luciferase assays in cells (Xin et al., 2009, Cordes et al., 2009, Cheng 
et al., 2009). One issue with this is that it involves overexpression of both the 
miRNA and the 3’ UTR target within the cell and therefore it is perhaps 
unsurprising that target regulation at the complementary site would occur under 
these circumstances. Although beneficial in identifying whether target 
regulation can occur, luciferase assays do not necessarily reflect endogenous 
target regulation, where one target is unlikely to be over-represented at such a 
level.  
Another possible reason why target regulation is not apparent in premiR and 
antimiR treated cells may be that target mRNA is being repressed rather than 
degraded. As a result, target regulation may only be seen at the protein level. 
This has been observed for ELK-1 and KLF4 following treatment with antimiR-143 
or antimiR-145 in A10 cells (Cordes et al., 2009). However, others have detected 
regulation of ELK-1 and KLF4 at the mRNA level following increasing levels of 
miR-143 and miR-145 in human aortic and pulmonary artery SMCs (Davis-
Dusenbery et al., 2011, Hergenreider et al., 2012). Further studies could be 
carried out to investigate this by performing western blots to look at protein 
expression of targets following transfection with premiRs and antimiRs.  
Furthermore, modulating miR-143 and miR-145 expression alone may not be 
sufficient to alter target expression without the influence of certain signalling 
pathways. MiR-143/miR-145 expression is transcriptionally activated by signalling 
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molecules including SRF-myocardin/MRTF, TGF-β and BMP4 whereas their 
expression is repressed by PDGF (Cheng et al., 2009, Cordes et al., 2009, Xin et 
al., 2009, Davis-Dusenbery et al., 2011, Long and Miano, 2011). MiR-145 
expression is essential for downregulation of KLF4 by TGF-β and BMP4 in human 
pulmonary artery SMCs (Davis-Dusenbery et al., 2011). PDGF-induced increases 
in KLF5 expression are inhibited by premiR-145 and enhanced by miR-145 
inhibition (Cheng et al., 2009). Increased expression of contractile genes, 
including α-SMA, SM22α and calponin, by TGF-β, BMP4 and Notch signalling is 
reduced by miR-145 inhibition (Davis-Dusenbery et al., 2011, Boucher et al., 
2011) whereas PDGF-induced downregulation of contractile gene expression is 
partially rescued by premiR-145 (Cheng et al., 2009). This evidence together 
suggests that miR-143 and miR-145 are important downstream regulators of 
several signalling molecules which regulate VSMC phenotype. However, these 
signalling pathways are likely to affect a whole host of other genes and miRNAs 
which combine to produce a phenotype. Thus modulation of miR-143 and miR-
145 levels alone may not be sufficient to significantly alter target expression. 
It has been reported that KLF2 activates transcription of miR-143/145 in 
HUVECs, resulting in increased expression levels of miR-143 and miR-145 in 
exosomes (Hergenreider et al., 2012). These exosomes where shown in a co-
culture system to mediate functional miR-143 and miR-145 transfer from HUVECs 
to humans aortic SMCs. This paracrine transfer of miRNAs from ECs to SMCs is 
potentially very significant as it could allow SMC miRNA levels to be altered by 
delivery of miRNAs to the overlying EC layer of the vessel wall. In our study, 
treatment with premiR-143 and premiR-145 produced non-significant increases 
in miR-143 and miR-145 expression in HSV EC exosomes. Interestingly, KLF2 was 
previously reported to enrich miR-143 and miR-145 in exosomes by around 30-
fold compared with around 10-fold increase in HUVECs (Hergenreider et al., 
2012). In contrast to this our study found that premiRs increased miR-143 and 
miR-145 expression in HSV ECs by more than 1000-fold but did not significantly 
increase expression in exosomes. The discrepancy may be due to the direct 
increase in mature miRNA with premiRs versus the transcriptional activation of 
miR-143 and miR-145 by KLF2. KLF2 expression is induced in ECs by sheer stress 
and has important roles in managing vessel tone through regulation of a host of 
genes (Dekker et al., 2005). Enrichment of miR-143/145 in exosomes may 
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require additional signalling which is not activated by premiR transfection. 
Interestingly transfection of cel-miR-39, a C. elegans miRNA which is not 
expressed in human cells, did result in transfer to vesicles (Hergenreider et al., 
2012), suggesting that endogenous miRNA may be under more rigorous 
regulation.  
In summary, it was shown that miR-143 and miR-145 expression can be 
successfully modulated in human primary cells using Ad5 vectors that express 
pre-miRNA sequences but that other methods are preferable due to toxicity 
issues.  It was shown that modulation of miR-143 and miR-145 expression is not 
sufficient to significantly effect in vitro migration or proliferation of HSV SMCs 
and results in altered expression of only a small number of target mRNA. 
Additional studies or new methods to confirm results were suggested but could 
not be further investigated due to time constraints.  
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4 Analysis of neointimal formation in a mouse 
model of in-stent stenosis  
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4.1 Introduction 
Atherosclerotic plaques that impinge on the lumen can reduce blood and oxygen 
flow to the heart, causing the symptoms of angina. PCI is the most common 
procedure carried out to treat this severe narrowing of the arteries (British 
Heart Foundation, 2012). During the procedure the lumen is re-opened by 
inflation of a balloon angioplasty catheter which compresses the atherosclerotic 
plaque against the vessel wall. The most common PCI’s performed today involve 
deployment of a metal stent at the time of inflation, which acts as a scaffold to 
help maintain the resultant increase in lumen size (Serruys et al., 1994, Sigwart 
et al., 1987, Fischman et al., 1994).  
During deployment, stent expansion causes denudation of the endothelium and 
stretch and injury to the vessel wall. This triggers a signalling cascade involving 
the release of cytokines and growth factors from inflammatory cells, injured 
ECs, VSMCs and platelets which drives inflammation and promotes activation of 
VSMCs which migrate and proliferate from the media to form the neointima 
(Libby et al., 1992, Schwartz et al., 2004). Proliferation, migration and ECM 
production by VSMCs is the major cause of neointimal formation after vascular 
injury (Clowes and Schwartz, 1985, Clowes and Clowes, 1985).  
DES were developed to circumvent the issue of in-stent restenosis. DES are 
coated with polymers which elute cell cycle inhibitory drugs, for example 
sirolimus or paclitaxel, over a 4-6 week period to lessen the initial proliferative 
response to injury following stent deployment (Htay and Liu, 2005). DES have 
been highly successful at reducing restenosis rates when compared to first 
generation BMS, confirming that the inhibition of proliferation produces a 
substantial clinical benefit following stenting (Schampaert et al., 2006, Stone et 
al., 2009).  
However, several studies have reported that DES are associated with an 
increased risk of late in-stent thrombosis (Bavry et al., 2006, Joner et al., 2006, 
Luscher et al., 2007), although there are conflicting arguments about the risk 
(Moreno et al., 2005, Schampaert et al., 2006, Caixeta et al., 2009). DES inhibit 
not only VSMC but also EC proliferation, which is detrimental as denudation of 
the EC lining of the artery following stent deployment exposes the blood to a 
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thrombogenic surface (Joner et al., 2006). DES delay healing of the artery by 
reducing EC repopulation following stent deployment (Finn et al., 2007). This 
process has been shown to occur through direct inhibition of EC proliferation by 
DES and not as a consequence of uncovered stent struts due to reduced VSMC 
proliferation and migration (Douglas et al., 2012). Therefore new therapies are 
needed to prevent VSMC proliferation and migration without affecting ECs.  
Porcine models of stenting are the gold standard for preclinical studies as the 
overall action of different therapies in this model have correlated well with 
human clinical studies (Schwartz et al., 2004). The procedure commonly involves 
accessing the circulation via cutdown of an artery such as the femoral artery and 
guiding the catheter through the circulation to one of the coronary arteries 
where the stent is then deployed (Lowe et al., 2003). This results in the 
development of a defined neointima over 28 days which is proportional to the 
degree of damage to the vessel wall (Schwartz et al., 1992). Porcine models of 
stenting share many of the major characteristics of clinical in-stent restenosis 
including early mural thrombus formation at the stent struts, inflammation, 
VSMC proliferation and migration and re-endothelialisation (Schwartz et al., 
2004, Lowe et al., 2003). However, large animal models are expensive and not 
ideal for early investigative studies.  
Several small animal models of stenting have now been developed including 
mouse models, which provide the advantage of being able to utilise genetically 
altered strains (Rodriguez-Menocal et al., 2010, Chamberlain et al., 2010, Ali et 
al., 2007). In situ stenting of the abdominal aorta has been described by several 
different methods (Rodriguez-Menocal et al., 2010, Chamberlain et al., 2010).  
One technique involves feeding a catheter with a spring loaded metal wire 
through the femoral artery to the aorta where wire deploys to form a spring 
(Chamberlain et al., 2010). A drawback of this technique is that the coiled shape 
of the spring means that this model is unlikely to mimic the medial angulation 
and stretch that occurs clinically following stent deployment and is associated 
with degree of injury (Schwartz et al., 1992). Direct stenting of the abdominal 
aorta has also been performed via insertion of a catheter through a direct access 
point made in the aorta which is then resealed (Rodriguez-Menocal et al., 2010). 
This produced a modest neointima in ApoE KO mice but very little neointimal 
formation in C57BL/6 mice (Rodriguez-Menocal et al., 2010) suggesting that this 
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model would not be ideal to study neointima formation in mice without 
underlying inflammation or hypercholesterolemia. Furthermore both models 
were associated with incidence of hind limb paralysis due to damage to the 
femoral artery and/or thrombosis (Chamberlain et al., 2010, Rodriguez-Menocal 
et al., 2010).   
The mouse model of stenting developed by Ali and colleagues (Ali et al., 2007) 
involves stenting of the thoracic aorta of a ‘donor’ mouse which is then isolated 
and interposition grafted into the carotid artery of a recipient mouse. The model 
utilises a 2.5 X 0.6 mm stainless steel stent which is expanded to a final 
diameter of 1.25 mm. The stent was designed to produce comparable vessel 
stretch, medial angulation, distance between struts and strut coverage to what 
occurs clinically (Ali et al., 2007). This model was shown to produce a defined 
neointima over 28 days in C57BL/6 mice indicating that it is a suitable model to 
investigate the influence of miRNA expression on in-stent stenosis.   
Processing of stented tissue for histology is challenging as the presence of a 
metal stent prohibits traditional paraffin embedding and sectioning. Stented 
vessels are commonly processed by embedding in a plastic resin which exhibits 
considerably more durability than paraffin to allow sectioning with a rotary saw. 
Several drawbacks are associated with resin embedding as sectioning of resin 
produces sections that are thicker and as a result less numerous than paraffin 
and the resin itself hinders the use of many immunohistochemical stains 
(Rippstein et al., 2006, Malik et al., 1998). A study by Bradshaw and colleagues 
(Bradshaw et al., 2009) described a method of dissolving human stents by 
applying a differential voltage across the stented vessel in a weak acid/salt 
solution which resulted in the metal stent forming ions in solution and thus being 
removed. Electrolysis is therefore a potential method to circumvent the issues 
associated with processing stented vessels. 
This chapter describes a small pilot study designed to reproduce a mouse model 
of in-stent stenosis which can then be utilised for further in vivo experiments to 
investigate the role of miRNAs in neointimal formation. The potential of using 
electrolysis as a means of processing stented vessels is also investigated. 
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4.2 Aims   
 To reproduce a mouse model of in-stent stenosis that can be used for 
future in vivo studies. 
 To determine whether electrolysis of stents from mouse vessels is a 
practical method of processing stented tissue. 
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4.3 Results 
4.3.1 Vessel morphology following stent electrolysis  
The stented vessels of C57BL/6 mice were isolated 28 days post-surgery and 
fixed in 10% formalin. Stents were electrolysed from the surrounding tissue by 
electrolysis prior to embedding in paraffin. H&E staining was performed on 5 µm 
sections to assess vessel morphology. A defined neointima that surrounded the 
stent struts was seen in all vessels that underwent successful electrolysis (~60%) 
(Figure 4.1). Electrolysis where all stent struts successfully dissolved permitted 
sectioning by microtome. However, some damage did occur to vessels due to the 
nature of the electrolysis technique (Figure 4.1). Frequently, stent electrolysis 
was non-uniform with the outer edge of a stent strut dissolving and leaving the 
remainder of the strut intact.  When this occurred in each strut of a vessel the 
stent could no longer be hooked on to the expansion spring to continue 
electrolysis. In these cases loosely attached struts were manually removed with 
forceps prior to being sectioned.  
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Figure 4.1. Morphology of electrolysed vessels from C57BL/6 mice stained with H&E. 
Stented vessels were isolated 28 days post-operative and fixed in 10% formalin. Electrolysis was 
performed to remove the stent from the surrounding vessel prior to embedding in paraffin and 
sectioning using a microtome.  Sections were stained with H&E to visualise vessel morphology. 
Representative images are shown at 10X (A-B), 20X (C) and 40X magnification (D). n = 6.  Scale 
bar = 100 µm (A-C) and 50 µm (D). 
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4.3.2 Neointimal formation in C57BL/6 mice 28 day post-stenting  
Morphometric measurements were performed on electrolysed sections to 
quantify the degree of neointimal formation 28 days post-stenting (Table 4.1). 
Stented sections displayed a defined neointima layer which surrounded the stent 
struts, with an average neointimal thickness of 96.29 µm and strut depth of 
55.98 µm. Neointimal area was approximately 0.19 mm2 with a lumen area of 
0.24 mm2 and an average percentage stenosis of 37.66%. Injury score was 
consistent between animals.  
Table 4.1. Neointimal measurements from 28 day stented C57BL/6 mice. 
Measurement C57BL/6 mice day 28
Neointimal thickness µm 96.29 ± 6.08
Strut depth µm 55.98 ± 6.97
Neointimal area mm2 0.19 ± 0.03
Total vessel area mm2 0.54 ± 0.02
Medial area mm2 0.08 ± 0.01
Lumen area mm2 0.24 ± 0.03
Neointimal:medial 1.87 ± 0.04
% stenosis 37.66 ± 0.98
Injury Score 0.05± 0.03
Measurements were performed using Image-Pro® Analyzer 7.0 software. n = 6.  
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4.3.3 Composition of neointima in 28 day stented C57BL/6 mice 
In order to determine the cell types comprising the neointima a variety of 
histological stains for common neointimal components were performed. EVG 
staining revealed that the neointima of 28 day stented vessels contained a high 
proportion of collagen and elastin indicating an abundance of ECM (Figure 4.2).   
VSMCs migration and proliferation to the intima and ECM production is a major 
contributor to neointimal formation and in-stent restenosis in humans. 
Therefore, to determine whether VSMCs were present in the neointima in the 
mouse stent model immunohistochemistry was performed for α-SMA, a marker of 
SMCs. DAB staining for α-SMA was seen within the neointima of 28 day stented  
C57BL/6 mice and was absent in the IgG control sections indicating the presence 
of VSMCs within the neointima (Figure 4.3). Immunohistochemistry for 
proliferating cell nuclear antigen (PCNA) which identifies proliferating cells 
revealed a small number of proliferating cells were present within the neointima 
of 28 day stented vessels (Figure 4.4 C-D).  To gain insight of the inflammatory 
cell presence in the neointima immunohistochemistry for macrophage marker 
MAC-2 was performed which detected the presence of macrophages in the 
neointima of stented vessels (Figure 4.4 A-B).  
Immunohistochemistry for CD31, a marker of ECs, was performed to assess 
whether re-endothelialisation occurred by day 28 following stenting (Figure 4.5). 
In all sections a thin layer of CD31 staining was that surrounded the lumen was 
observed indicating an intact EC layer was present.  
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Figure 4.2. EVG staining of electrolysed vessels from C57BL/6 mice. 
EVG staining was performed to visualise the elastic lamina and determine the composition of the 
neointimal layer. Staining revealed a high proportion of elastin (black/purple) and collagen (pink) 
staining within the neointima. Representative images of control unstented (A) and stented (B-D) 
aorta. Magnification 40X. n = 6. Scale bar = 50 µm. 
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Figure 4.3. α-SMA expression in electrolysed vessels from 28 day stented C57BL/6 mice. 
Immunohistochemistry for α-SMA was performed to investigate whether VSMCs formed part of the 
neointima. α-SMA positive cells are visualised by brown DAB staining. Representative images are 
shown for IgG control (A and C) and α-SMA (B and D) at 20X and 40X magnification. n = 6. Scale 
bar = 100 µm (A-B) and 50 µm (C-D).  
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Figure 4.4. MAC-2 and PCNA expression in vessels from 28 day stented C57BL/6 mice 
Immunohistochemistry was performed on electrolysed sections for macrophage marker MAC-2 (B) 
and proliferating cell marker PCNA (arrowheads) (D) and an IgG control (A and C). Positive cells 
are identified by brown DAB stain. Magnification 40X. n = 6. Scale bar = 50 µm.  
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Figure 4.5. CD31 expression in vessels from 28 day stented C57BL/6 mice. 
Immunohistochemistry for the EC marker CD31 shown in non-stented control aorta (B) and 28 day 
stented aorta (D), IgG control (A and C). CD31 staining is visualised by brown DAB (brown) 
staining. Magnification 40X. n = 6.  Scale bar = 50 µm.  
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4.4 Discussion 
To summarise, this study showed the reproduction of a complex mouse model of 
in-stent stenosis using the technique originally developed by Ali and colleagues 
(Ali et al., 2007). BMS were delivered to the thoracic aorta of donor mice and 
the stented vessels were isolated and interposition grafted into the carotid 
artery of recipient mice. Stented vessels isolated 28 day post-surgery had a 
defined neointima surrounding the stent struts which was largely comprised of 
collagen, elastin and VSMCs. A small number of proliferating cells and 
macrophages were evident and re-endothelialisation was complete 28 days post- 
stenting.  
Porcine models have been traditionally used to investigate vessel remodelling 
following stenting as they share structural similarity with the human heart and 
develop comparable neointimal formation (Schwartz et al., 1992, Miller et al., 
1996, Taylor et al., 2001). However, the mouse model of stenting utilised in the 
present study is advantageous over porcine models, particularly for explorative 
studies, due to the small size of the animals which enables high throughput and 
use of genetically modified strains.  
Although technically challenging, the model proved highly reproducible and a 
defined neointimal layer which surrounded the stent struts was observed in all 
vessels 28 day post stenting. Injury scores were consistent between animals 
indicating that the degree of injury was comparable between vessels. Stent 
deployment in the porcine model often leads to fracturing of the internal elastic 
lamina or medial layers (Schwartz et al., 1992). However, puncture of the 
internal elastic lamina was rare in the mouse stent model which is most likely 
due to the elasticity of the mouse aorta versus the muscular coronary arteries of 
the pig (Lowe et al., 2003).  
Proliferation and migration of VSMCs is a pivotal component of neointimal 
formation (Clowes and Schwartz, 1985, Clowes and Clowes, 1985, Hanke et al., 
1990). In the present study α-SMA staining revealed the presence of numerous 
VSMCs within the neointima of 28 day stented C57BL/6 mice.  Furthermore, an 
abundance of the ECM components collagen and elastin, which are produced by 
VSMCs (Nikkari et al., 1994, Amento et al., 1991), was also seen within the 
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neointima, indicating that the mouse model produces a neointima which has a 
similar composition to that found in porcine models and in clinical restenosis 
(Lowe et al., 2003). The degree of neointimal formation seen in this study was 
also comparable with what has been previously reported (Ali et al., 2007), 
indicating that the model had been successfully reproduced.  
Drugs released from DES can result in significant delays and incomplete healing 
of the endothelium which can lead to late onset in-stent thrombosis (Bavry et 
al., 2006, Luscher et al., 2007). Re-endothelialisation after injury also appears 
important in reducing neointimal response with several studies reporting that 
reduced EC migration and endothelial progenitor cell (EPC) attachment and 
differentiation is correlated with a greater degree of neointimal formation (Bai 
et al., 2010, Mayr et al., 2006). It is therefore desirable that any treatment to 
prevent in-stent restenosis does not delay the re-endothelialisation of vessels. 
The presence of a defined layer of CD31 positive ECs surrounding the lumen in 28 
day stented vessels indicated that re-endothelialisation had occurred by day 28 
post-stenting in our model. This is consistent with other models of stenting 
where re-endothelialisation occurs by day 28 (Joner et al., 2008, Schwartz et 
al., 2004). EC repopulation in the mouse stent model has been previously shown 
to occur primarily by proliferation and migration of ECs from the adjacent 
vasculature and to a lesser extent via EPCs from the bone marrow (Douglas et 
al., 2012). Our results are in contrast with studies in ApoE KO mice which display 
impaired re-endothelialisation which is incomplete even at 56 days post-stenting 
(Douglas et al., 2012), this may be due in part to the reduced number of 
circulating EPCs in these mice (Xu et al., 2003). 
A small number of proliferating cells were detected in the neointima of 28 day 
stented C57BL/6 mice. This is consistent with previous studies of vascular injury 
which have detected a high proportion of proliferating cells 7 days after vascular 
injury which thereafter declines with proliferating cells comprising only around 
2% of the neointima by day 28 (Ali et al., 2007, Lindner et al., 1993).  
Macrophages play an important role in atherosclerotic plaque formation and 
progression through the uptake of LDL to form foam cells (Ross, 1993). They also 
influence plaque remodelling through release of cytokines and growth factors 
which promote VSMC proliferation and migration (Libby et al., 1992, Assoian et 
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al., 1987).   Furthermore, macrophage presence after vascular injury has been 
shown to correlate with neointimal lesion size and macrophage inhibition using 
clondronate liposomes significantly reduces neointimal formation in animal 
models (Moreno et al., 1996, Danenberg et al., 2002). Consistent with previous 
reports a small number of inflammatory macrophages were detected in the 
neointima of 28 day stented mice and tended to be concentrated near the stent 
struts.  
Electrolysis of stents proved challenging due to the small size of the vessels and 
stent struts often dissolving unevenly. As a result, around 40% of vessels were 
unusable for morphological analysis. Bradshaw and colleagues (Bradshaw et al., 
2009) described similar issues in their study while developing this method. 
However, the use of human stented vessels in their study meant that undissolved 
stent struts could be removed manually without causing as much damage as was 
seen in the delicate mouse vessels. Morphology was more readily conserved in 
stents that dissolved evenly and these could be embedded in paraffin and cut 
into thin sections for immunohistochemistry. Further development of this 
method would be beneficial to optimise the technique and produce more even 
electrolysis of the stent and negate the need for manual removal of undissolved 
struts.  
Several differences exist between the clinical practice of stenting the mouse 
model, which are important to consider when interpreting results. Similar to the 
porcine model the mouse stent model does not involve direct stenting of an 
atherosclerotic plaque nor does it share the underlying inflammation seen in 
human atherosclerosis (Ross, 1999). However, potential therapies could be 
tested in a mouse model of atherosclerosis, such as the ApoE KO mouse (Plump 
et al., 1992, Piedrahita et al., 1992). ApoE KO mice have elevated blood very-
low density lipoprotein (VLDL) and inflammation and start to develop 
spontaneous atherosclerosis around 6 weeks of age, which can be further 
exacerbated by high fat feeding (Piedrahita et al., 1992, Plump et al., 1992, 
Nakashima et al., 1994). These mice have been shown to develop greater 
neointimal formation than WT mice following stenting without direct stenting of 
an atherosclerotic plaque (Ali et al., 2007). Another notable difference is that 
stents are used clinically to press atherosclerotic plaques against the artery wall 
and therefore restore the lumen to its original diameter. Conversely, the mouse 
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model involves stretching the vessel wall to a diameter greater than its original 
size.  
The use of donor vessel raises questions about whether engraftment itself may 
promote neointimal formation to a greater degree than in situ stenting. The 
lumen of a mouse carotid artery is approximately 3-fold smaller than that of the 
aorta and around 5-fold smaller than the stented aorta (Ali et al., 2007). 
Therefore blood flow and shear stress may be altered in the model due to the 
flow of blood from the carotid to the engrafted aorta. This is potentially 
significant as alterations in shear stress are known to influence atherosclerotic 
plaque and neointimal formation (Ku et al., 1985, Papafaklis et al., 2009, 
Sanmartin et al., 2006). Furthermore, an in situ model of aortic stenting 
reported significantly less neointimal formation than what was observed in the 
present study suggesting that the engraftment process may contribute to 
neointimal formation (Rodriguez-Menocal et al., 2010).  However, engraftment 
of the uninjured or balloon-catheter injured aorta into the carotid of C57BL/6 
mice did not result in any significant neointima formation when compared with 
control non-engrafted aortas (Ali et al., 2007). This suggests that that majority 
of neointimal formation seen in our study is due to the mechanical injury of the 
vessel and presence of the stent. 
Despite the differences there are several similarities between the mouse model 
of in-stent stenosis and the clinical condition in-stent restenosis. Most notably, 
the mechanical injury to the vessel wall leads formation of a defined neointima 
comprised largely of VSMCs and ECM (Carter et al., 1994, Ali et al., 2007). This 
makes the model relevant to investigate the therapeutic benefit of molecules 
which influence VSMC phenotype.  
In summary, 28 day stented C57BL/6 mice had a defined neointimal layer that 
contained a high proportion of VSMCs and ECM components collagen and elastin. 
Re-endothelialisation of the vessel had occurred by day 28 which will be 
important for future studies when determining whether alteration of miRNA 
levels have a detrimental effect on re-endothelialisation. Finally, electrolysis of 
stented vessels was a beneficial method as it permitted paraffin embedding and 
thin sectioning of stented tissue for immunohistochemistry. However the process 
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was highly variable and refinement of the technique will be required to prevent 
vessel damage before this method can be used routinely.  
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5 Analysis of neointimal formation following 
stenting in miR-143 and miR-145 knockout mice  
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5.1 Introduction 
In vivo studies have shown that expression levels of miR-143 and miR-145 are 
reduced at sites of vascular injury including mouse models of transverse aortic 
constriction and carotid artery ligation as well as balloon catheter injury in the 
rat (Cordes et al., 2009, Elia et al., 2009, Cheng et al., 2009).  Furthermore, 
miR-143 and miR-145 expression levels are also decreased in the vessels of ApoE 
KO mice, a model of hyperlipidaemia (Elia et al., 2009). Expression levels of 
these miRNA are further decreased within the vessels of ApoE KO mice following 
a period of fat feeding, which is known to promote atherosclerotic lesion 
formation (Piedrahita et al., 1992, Plump et al., 1992). Previous studies have 
demonstrated that adenovirus-mediated over-expression of miR-143 or miR-145 
is sufficient to reduce neointimal formation in the rat carotid balloon-injury 
model (Elia et al., 2009, Cheng et al., 2009), indicating that loss of miR-143 and 
miR-145 expression is a contributing factor in neointimal formation. 
Mice which are genetically ablated of both miR-143 and miR-145 (miR-143/145 
KO) have reduced numbers of contractile and greater number of synthetic VSMCs 
within their vessels walls (Boettger et al., 2009). In vitro, VSMCs isolated from 
miR-143/145 KO mice show increased migration towards PDGF (Elia et al., 2009). 
It was also shown that miR-143/145 KO VSMCs have increased propensity to form 
podosomes, actin rich structures important in cell migration, in response to 
PDGF (Quintavalle et al., 2010). Furthermore, in vivo, accumulations of 
synthetic VSMCs have been found in the intima of vessels isolated from miR-
143/145 KO mice (Elia et al., 2009, Boettger et al., 2009). Neointimal lesions 
have been identified in the femoral arteries of aged (18 month) miR-143/145 KO 
mice (Boettger et al., 2009). These lesions contained large amounts of VSMCs, as 
well as macrophages and collagen I, with the media of the vessel showing 
thinning (Boettger et al., 2009).   
Interestingly, despite the increase in synthetic VSMCs found in miR-143/145 KO 
mice, virtually no neointimal formation occurred in miR-145 and miR-143/145 KO 
mice following carotid artery ligation, whilst neointimal formation was 
significantly reduced in miR-143 KO mice (Xin et al., 2009). This result strongly 
suggests that miR-143 and miR-145 are important in the triggering or guiding 
neointimal formation following injury. In the present study miR-143 or miR-145 
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homozygous KO mice were used to study the individual importance of these 
miRNA in the context of stenting. 
5.2 Aims 
 To determine the effect of genetic ablation of miR-143 or miR-145 
expression on neointimal formation following stenting. 
 To investigate whether miR-143 and miR-145 gene target expression levels 
are altered in miR-143 or miR-145 KO mice. 
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5.3 Results 
5.3.1 MiRNA expression in miR-143 and miR-145 KO mice  
In order to confirm that miR-143 KO and miR-145 KO mice did not express the 
respective miRNA, RNA was isolated from snap frozen aortas and miRNA 
expression analysed by Taqman® qRT-PCR. Loss of miR-143 and miR-145 
expression was detected in miR-143 KO and miR-145 KO mice respectively, when 
compared to WT mice (Figure 5.1 A-B). Northern blotting confirmed this result 
revealing large bands for mature miR-143 and miR-145 in WT mice which were 
absent in miR-143 and miR-145 KO mice (Figure 5.1 C-D).  
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Figure 5.1. MiR-143 and miR-145 expression in mouse aortas. 
Aortas were collected at sacrifice from miR-143 KO, miR-145 KO and WT mice and immediately 
transferred to liquid nitrogen. RNA was isolated and miRNA expression analysed by Taqman® 
qRT-PCR or northern blotting. Taqman analysis of miR-143 (A) or miR-145 (B). Northern blotting 
performed using 5 µg RNA to probe for miR-143, miR-145 or U6 (C) and analysed by densitometry 
(D). ***P<0.001 vs. WT. n = 6/group.   
In order to assess neointimal formation in mice ablated of miR-143 or miR-145 
expression, stent surgery was performed on 18 week old miR-143 KO, miR-145 
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KO and WT mice. Stents were delivered to the thoracic aorta of age matched 
donor mice and then isolated before being interposition grafted into the carotid 
artery of recipient mice. Mice were sacrificed 28 day post-operative. Despite the 
greater body weight seen in miR-143 KO mice at day 0 of the study, body weight 
was comparable between groups by day 28 (Table 5.1).  Formalin fixed stented 
grafts were embedded in Technovit 8100 resin, sectioned and ground to 
approximately 7-10 µm and morphometric measurements performed.  No 
significant differences in stent expansion or injury score were present between 
groups indicating that stent deployment resulted in a consistent injury to the 
aortic wall (Table 5.1).  
Table 5.1. Body weights and injury scores of miRNA KO and WT mice. 
WT MiR-143 KO MiR-145 KO
Weight day 0 (g) 25.64 ±0.57 28.06±0.64* 26.62±0.84
Weight day 28 (g) 27.52±0.58 28.69±0.68 28.00±0.64
Stent Expansion 
(mm2)
0.67 ± 0.01 0.66 ± 0.03 0.68 ± 0.03
Injury Score 0.06±0.05 0.03±0.03 0.05±0.03
 
5.3.2 Neointimal formation in miRNA KO mice 
H&E staining was performed on resin embedded stented sections to visualise 
vessel morphology (Figure 5.2). Morphometric analysis revealed that stented 
miR-143 KO and miR-145 KO mice displayed significantly less neointimal 
thickness when compared to WT mice with a mean of 83.09 ± 10.08, 90.81 ± 7.14 
and 121.65 ± 6.64 µm for miR-143 KO, miR-145 KO and WT mice respectively 
(Figure 5.2 and 5.3A).  Strut depth did not significantly differ between groups 
(Figure 5.3B) however neointimal area was significantly reduced in miR-143 KO 
when compared to WT mice (0.22 ± 0.03 vs. 0.31 ± 0.01 mm2) (Figure 5.3C). 
Overall percentage stenosis was significantly reduced in both miR-143 KO and 
miR-145 KO when compared to WT mice (Figure 5.2 and 5.3D). Lumen area was 
found to be significantly greater in 28 day miR-145 KO mice when compared to 
WT mice (Figure 5.3E). Total vessel area was reduced in 28 day stented miR-143 
KO mice when compared to WT mice (Figure 5.3F) despite no difference in stent 
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expansion between these groups (Table 5.1). The reduced stenosis seen in miR-
143 KO and miR-143 KO mice was not reflected in any change in the neointimal 
to medial ratio (Figure 5.3G). This was found to be due to reduced medial area 
in miR-143 KO and miR-145 KO compared with WT mice (Figure 5.3H).  
WT miR-143 KO miR-145 KO
10X
40X
 
Figure 5.2. H&E staining of 28 day stented vessels from miRNA KO and WT mice.  
Representative H&E staining performed on resin embedded sections from stented vessels isolated 
28 day post-operative shown at 10X and 40X magnification.  Scale bar = 100 µm. 
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Figure 5.3. Analysis of neointimal formation in 28 day stented miRNA KO and WT mice. 
Morphometric analysis was performed on resin embedded sections from 28 day stented mice using 
Image-Pro® Analyzer 7.0 software. A. Neointimal thickness, B. Strut depth, C. Neointimal area, E. 
Percentage stenosis, E. Lumen area, F. Total vessel area, G. Neointimal:medial ratio, H. Medial 
area. *P<0.05, **P<0.01 vs. WT. n = 9-13/group.  
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Mice genetically ablated of both miR-143 and miR-145, or miR-145 alone have 
been previously reported to have thinner walled aortas than WT mice measured 
at 8 weeks of age (Xin et al., 2009). In order to assess whether differences in 
medial wall thickness are observed in 18 week miR-143 KO, miR-145 KO and WT 
mice prior to stenting, morphometric measurements were performed on thoracic 
aortas (Figure 5.4). No significant differences in medial thickness or area were 
detected between groups (Figure 5.4), suggesting that the reduced medial 
thickness seen in miR-143 KO and miR-145 KO mice following stenting may be 
due to reduced medial remodelling. 
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Figure 5.4. Analysis of medial morphometry in control miRNA KO and WT mice. 
EVG staining was performed to visualise the elastic lamina of aortas isolated from 18 week old 
miR-143 KO, miR-145 KO and WT mice. A. Images of EVG stained miR-143 KO, miR-145 KO and 
WT mice displayed at 10X magnification.  B. Mean medial thickness of day 0 aortas. C. Mean 
medial area of day 0 aortas. Scale bar = 100 µm. n = 6/group. 
MiR-143 and miR-145 are the most highly expressed miRNA in the artery wall and 
have been shown to promote a contractile VSMC phenotype (Ji et al., 2007, 
Cheng et al., 2009). In order to assess whether genetic ablation of miR-145 or 
miR-145 alters the presence of VSMCs in the neointima, immunohistochemistry 
Chapter 5 – Neointimal formation in miRNA KO mice  156 
 
 
for SMC marker α-SMA was performed (Figure 5.5). Staining revealed comparable 
α-SMA expression in the media and neointima of vessels from each group which 
was not present in the IgG control (Figure 5.5). 
IgG
miR-143 KOWT
miR-145 KO
 
Figure 5.5. α-SMA expression in stented vessels from miRNA KO and WT mice. 
Immunohistochemistry probing for α-SMA or control IgG performed on resin embedded sections 
from 28 day stented miR-143 KO, miR-145 KO and WT mice. Expression is shown by brown DAB 
staining. 40X magnification. Scale bar = 50 µm.   
5.3.3 MiR-143 and miR-145 target expression in miRNA KO mice 
Next the expression of previously identified miR-143 and miR-145 targets KLF4, 
KLF5 and ELK-1 (Cheng et al., 2009, Xin et al., 2009, Cordes et al., 2009) was 
analysed in tissue isolated from miR-143 KO, miR-145 KO and WT mice. Taqman® 
qRT-PCR analysis for target expression in the aorta revealed no significant 
difference in the expression of KLF4 or ELK-1 between groups (Figure 5.6). KLF5 
expression was significantly reduced in miR-143 KO mice compared with control 
mice (Figure 5.6B).  
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Figure 5.6. MiRNA target expression in the aorta of miR-143 KO, miR-145 KO and WT mice. 
Taqman® qRT-PCR analysis performed on RNA isolated from snap frozen aortas of miR-143 KO, 
miR-145 KO and WT mice for KLF4 (A), KLF5 (B) and ELK-1 (C). **P<0.01 vs. WT. n = 6/group. 
To determine whether changes in target expression occurred in other tissues 
target analysis was also performed on RNA isolated from the heart. MiR-143 and 
miR-145 expression was, as expected; significantly lower in the hearts of miR-
143 KO and miR-145 KO mice when compared to WT mice (Figure 5.7 A-B). 
However, expression of KLF4, KLF5 or ELK-1, determined by Taqman® qRT-PCR, 
did not differ significantly between groups (Figure 5.7 C-E). Analysis of KLF5 
protein expression, determined by western blot was not significantly different 
between groups (Figure 5.7F).  
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Figure 5.7. MiRNA target expression in the heart of miR-143 KO, miR-145 KO and WT mice.  
Taqman® qRT-PCR analysis performed on RNA isolated from snap frozen hearts of miR-143 KO, 
miR-145 KO and WT mice for miRNAs miR-143 (A) and miR-145 (B) and target genes KLF4 (C) 
KLF5 (D) and ELK-1 (E). (F) Western blot probing for KLF5 or GAPDH (left) and densitometry 
analysis of western blot (right). ***P<0.001 vs. WT. n = 6/group. 
MiR-145 KO mice have been previously shown to have a reduced heart weight 
and left ventricular mass when compared to WT mice (Xin et al., 2009). To 
investigate whether this was apparent in our stented mice we measured heart 
weight following sacrifice at 22 weeks. Neither total heart weight nor right 
ventricle weight differed significantly between groups (Figure 5.8 A and C) 
however left ventricle plu0073 septum weight was significantly lower in miR-145 
KO mice compared with WT mice (Figure 5.8B). 
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Figure 5.8. Analysis of heart weight indices in miRNA KO and WT mice. 
Hearts were perfused at sacrifice with PBS and fixed in 10% formalin overnight before being 
analysed and displayed as a percentage of bodyweight at sacrifice for A. Whole heart, B. Left 
ventricle plus septum, C. Right ventricle. n = 12/group. 
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5.4 Discussion 
In this chapter it has been shown that vessel remodelling in response to stenting 
is reduced by genetic ablation of miR-143 or miR-145. Neointimal thickness and 
percentage stenosis were significantly less in miR-143 KO and miR-145 KO 
compared with WT mice. Neointimal area was also reduced in stented vessels 
from miR-143 KO mice. Furthermore, medial remodelling was reduced in miR-
143 KO and miR-145 KO mice. Genetic loss of miR-143 and miR-145 did not result 
in de-repression of previously identified targets indicating that alternative 
regulatory mechanisms may be implicated upon loss of miRNA expression. 
These results agree, in part, with a previous study where mice genetically 
ablated of miR-143, miR-145, or both miR-143/145, developed significantly less 
neointimal formation following carotid artery ligation than WT mice (Xin et al., 
2009). Interestingly, in contrast to our model where neointima formation 
occurred in all mice, miR-145 KO and miR-143/145 KO mice formed virtually no 
neointima in response to carotid artery ligation (Xin et al., 2009). This may be 
due to the use of a different vessel or differences in the models. The stent 
model is driven by EC denudation, mechanical injury to the vessel wall and the 
presence of a stent, whereas the carotid ligation model is driven by altered 
blood flow and haemodynamic changes and does not involve mechanical EC 
denudation (Ali et al., 2007, Kumar and Lindner, 1997). MiR-143/145 KO mice 
and miR-145 KO mice have been previously shown to have reduced blood 
pressure as a result of both reduced vascular tone and receptor mediated 
constriction (Boettger et al., 2009, Xin et al., 2009, Elia et al., 2009). This 
decrease in blood pressure is likely to have contributed to the altered 
remodelling in these mice following carotid artery ligation.  
MiR-143 and miR-145 expression is not essential for VSMC development per se, 
however a body of evidence exists to suggest that that are required for the 
normal VSMC biology.  VSMCs isolated from miR-143/145 KO mice show increased 
proliferative and migratory properties in vitro (Elia et al., 2009, Quintavalle et 
al., 2010). The vessels of miR-143/145 KO mice contain a greater number of 
synthetic SMCs identified by their increased circularity, reduced numbers of 
contractile machinery, dense bodies and focal adhesions, and increased numbers 
of rough E.R, typical of synthetic SMCs (Boettger et al., 2009, Elia et al., 2009). 
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Furthermore, stress fibers in the aorta of both miR-143/145 KO mice and miR-
145 KO mice are less prominent and are disorganised compared with WT mice 
(Xin et al., 2009). Interestingly, in vivo the presence of higher numbers of 
synthetic and less contractile VSMCs in the vessels of miR-143/145 KO mice is 
not accompanied by any basal increases in proliferation (Boettger et al., 2009). 
These studies, together with evidence from the present study that miR-143 or 
miR-145 ablation reduces neointima formation in mice, suggest the regulatory 
pathways in VSMCs are likely to be significantly altered by genetic loss of these 
miRNA. This is perhaps unsurprising when it is considered that a number of 
signalling molecules are known to utilise miR-143 and miR-145 in their signalling 
pathways by transcriptional activation (Davis-Dusenbery et al., 2011, Long and 
Miano, 2011, Xin et al., 2009, Cordes et al., 2009). Loss of endogenous miR-143 
and miR-145 expression occurs following vascular injury (Cordes et al., 2009, Elia 
et al., 2009) and may act as a trigger to promote VSMC proliferation and 
migration. Genetic KO of these miRNA, could potentially affect the ability of 
VSMC phenotypic switching to occur which may explain why miR-143 KO and 
miR-145 KO mice have less neointimal formation.  
The present study revealed that medial area of 28 day stented miR-143 KO and 
miR-145 KO mice was decreased when compared to WT mice. Previous studies 
have indicated that mice genetically ablated of both miR-143 and miR-145 have 
thinner walled femoral arteries and to a lesser extent aortas (Boettger et al., 
2009, Xin et al., 2009, Elia et al., 2009). This was found to be due to a reduced 
number of larger, contractile VSMCs and increased numbers of smaller, synthetic 
VSMCs within the vessel walls of miR-143/145 KO mice, which are attributed to 
the reduction in wall thickness (Elia et al., 2009, Boettger et al., 2009). Xin and 
colleagues went on to show that genetic loss of miR-145 alone, but not miR-143 
alone led to a reduction in aortic wall thickness (Xin et al., 2009). No 
quantification was shown in the study to indicate whether miR-145 KO vessels 
have as great a reduction in wall thickness as miR-143/145 KO mice however we 
would speculate that miR-143/145 KO mice may display a more severe 
phenotype due to accumulative effects of loss of both miRNA. Morphometric 
analysis of non-stented miR-143 KO, miR-145 KO and WT aortas found no 
difference in basal aortic medial thickness or medial area between the groups. 
The mice used in our study were however considerably older at the time of 
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measurements (18 weeks vs. 8 weeks). One explanation for this disparity could 
be that mice which lack only one of these miRNA and maintain expression of the 
other may develop compensatory mechanisms to regulate VSMC phenotype by 
which the reduction in aortic medial thickness in miR-145 KO mice is no longer 
present by 18 weeks. As basal aortic wall thickness of miR-143 KO mice did not 
differ from WT mice (Xin et al., 2009) we deduce that the reduced medial area 
seen in 28 day stented miR-143 and miR-145 KO mice is due to a reduced 
propensity for medial remodelling following stenting. This observation has also 
been noted in the carotid artery following ligation (Xin et al., 2009). 
Resin embedding of stented grafts was challenging due to the small size of the 
grafts and their buoyancy within the resin which despite anchorage often 
resulted in the stent moving from the optimum positioning for sectioning during 
resin setting. Sectioning of resin embedded sections in itself was also challenging 
due to the small size of the stent in comparison to the sectioning saw which 
resulted in only a few sections per stent.   Performing immunohistochemistry on 
resin embedded sections proved problematic and despite several optimisation 
experiments only proved successful for α-SMA.  
Staining for α-SMA was present in sections from all groups indicating the 
presence of VSMCs within the neointima. α-SMA is a marker protein for SMCs 
however it is not SMC-specific and is also expressed by myofibroblasts, which can 
derive from resident cells or the bone marrow following vascular injury (Forte et 
al., 2010).  Studies have indicated that myofibroblasts derived from the 
adventitia can contribute to neointimal formation following severe vascular 
injury with dissection of the media (Shi et al., 1996). Myofibroblasts have also 
been shown to significantly contribute to neointimal formation in the balloon-
catheter injured rat carotid without disruption of the media (Siow et al., 2003). 
However, others disagree with this and state that myofibroblasts contribute only 
minimally to neointimal formation (De Leon et al., 2001, Maeng et al., 2003). 
VSMCs have previously been identified as the main cell type present in the 
neointima following vascular injury and derive from migration and proliferation 
of activated medial VSMCs (Clowes and Schwartz, 1985, Clowes and Clowes, 
1985). However, this does not rule out the possibility that myofibroblasts may 
contribute to neointimal formation. SM-MHC and smoothelin are not expressed 
on myofibroblasts and smoothelin expression is thought to be SMC-specific (Forte 
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et al., 2010) therefore these markers could be utilised in future studies to 
ensure correct identification of VSMCs in the neointima.  
MiR-145 KO mice were found to have reduced left ventricular mass compared 
with miR-143 KO and WT mice but total heart weight was not decreased as 
previously reported (Xin et al., 2009). This difference is likely accountable to 
the difference between methods of measuring heart weight, as a percentage of 
the total body weight or normalised to tibial length.  Although final body weight 
did not vary significantly between groups fluctuations in body weight in 
individual mice may have decreased the accuracy of the measurements. Tibial 
length is constant after maturity and may therefore be preferable to produce 
more accurate results (Yin et al., 1982).  
A previous study showed the upregulation of KLF4 and to a lesser extent KLF5 
mRNA in the carotid arteries of miR-143/145 KO mice (Xin et al., 2009). 
Similarly, in the lung KLF4 expression is increased in miR-145 KO when compared 
to WT mice (Caruso et al., 2012). The expression of miR-143 and miR-145 targets 
KLF4, KLF5 and ELK-1 was measured at the mRNA level in both the aorta and 
heart. Expression of KLF5 was significantly decreased in the aorta of miR-143 KO 
mice but was not significantly altered within the heart either at the mRNA or 
protein level. The decrease in KLF5 expression following miR-143 KO is 
unexpected and may be due to altered regulation of KLF5 expression by other 
means upon loss of miR-143, possibly by more pronounced negative regulation of 
KLF5 by miR-145. The unaltered expression of the other targets may be due to 
compensatory regulation of these targets following loss of miR-143 or miR-145. 
Changes in target regulation induced by miR-143 or miR-145 KO may however 
become evident in tissues that are undergoing remodelling, such as the stented 
vessel itself. One example of this is that miR-145 targets ACE, FSCN1, CTGF and 
ITGBL1 are expressed at similar levels in the WT and miR-145 KO pulmonary 
artery at normoxic conditions but are upregulated in the miR-145 KO in hypoxic 
conditions (Caruso et al., 2012). It is also possible that changes in target 
expression may be occurring at the protein level and it would be important to 
assess this in future studies by western blots. 
In conclusion, it has been shown that genetic ablation of miR-143 or miR-145 
reduces vessel remodelling following stent-induced vascular injury. Further 
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studies are now needed to define the mechanism and to establish whether this is 
a result of genetic KO or whether pharmacological knockdown of these miRNA 
produces similar results.   
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6 Neointimal formation following AntimiR-
mediated knockdown of miR-143 in mice 
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6.1 Introduction 
Loss of local miR-143 and miR-145 expression is often reported following 
vascular injury and exogenous delivery of these miRNA has been shown to reduce 
vascular remodelling (Cheng et al., 2009, Elia et al., 2009, Cordes et al., 2009). 
The results of the study outlined in chapter 5 revealed that genetic KO of miR-
143 or miR-145 reduced neointimal formation following stenting in mice. This 
prompted an investigation into whether pharmacological knockdown of these 
miRNA produces similar results to genetic KO.  
Several methods can be used to decrease miRNA expression in vivo including 
knockdown by antagomiRs or antimiRs or scavenging by miRNA sponges (Ebert 
and Sharp, 2010, Krutzfeldt et al., 2005, Montgomery et al., 2011). MiRNA 
sponges are RNAs encoded by transgenes that can be delivered in vivo via viruses 
such as Ads or lentiviruses (Ebert and Sharp, 2010). They encode tandem binding 
sites for a single or multiple miRNA in their 3’ UTR which are bulged at certain 
sites (usually nucleotides 9-12) to prevent endonucleolytic cleavage by Ago 
proteins. MiRNA regulation of endogenous targets is competitively inhibited by 
miRNA binding to complementary regions in sponges thereby resulting in target 
de-repression (Ebert et al., 2007). AntagomiRs are complementary to the mature 
miRNA sequence, contain phosphorothioate moieties for enhanced stability and 
are conjugated to cholesterol by a 2’-O-methyl bond to enhance uptake into 
tissues, particularly the liver (Krutzfeldt et al., 2005). Use of antagomiRs is 
gradually being replaced by unconjugated antimiRs, which contain chemical 
modifications to reduce nuclease degradation and increase melting temperature 
of the bound duplex thus increasing antimiR stability, these include 2’-O-
methoxyethyl and 2’-fluoro modifications (van Rooij and Olson, 2012).  
In order to achieve pharmacological knockdown of miR-143 we utilised an 
unconjugated antimiR that contains a mixture of DNA and LNA bases. LNA bases 
are structurally based on RNA with the addition of a methylene bridge between 
the 2’ oxygen and the 4’ carbon of the ribose ring, which locks the nucleic acid 
in the 3’ endo conformation. This acts to enhance organisation of the backbone 
and base stacking which increases melting temperature, stability and binding 
affinity (Braasch and Corey, 2001). AntimiRs also contain phosphorophioate 
backbone linkages which further stabilise the antimiR by reducing degradation 
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by nucleases and promote cellular uptake due to their lipophilicity (van Rooij 
and Olson, 2012, Krutzfeldt et al., 2007). AntimiRs are highly water soluble and 
delivery by intravenous (IV), SC, or IP routes has been shown to result in 
comparable knockdown in miRNA expression (Montgomery et al., 2011). 
Furthermore, antimiRs show enhanced stability and long half-lives within tissues 
which can lead to robust miRNA inhibition for several weeks after administration 
(Montgomery et al., 2011). Evidence has suggested that antimiRs containing LNA 
bases work by forming a high affinity duplex with the miRNA, inhibiting its 
ability to interact with target mRNA by sequestering rather than degrading the 
miRNA (Figure 6.1) (Elmen et al., 2008b, Elmen et al., 2008a, Torres et al., 
2011). AntimiRs have been shown to effectively inhibit miRNA expression and 
provide a therapeutic benefit in a number of models including non-human 
primates (Lanford et al., 2010, Rayner et al., 2011).  Delivery of three 10 mg/kg 
doses of antimiR-122 led to sustained antagonism of miR-122 expression in the 
liver of African green monkeys and resulted in a dose dependent decrease in 
serum cholesterol for at least 7 weeks following antimiR-122 delivery (Elmen et 
al., 2008a). MiR-122 promotes hepatitis C infection in the liver by upregulating 
the expression of hepatitis C RNA by binding to its 5’ non coding region (Lanford 
et al., 2010). AntimiR-122 has been shown to de-repress a number of miR-122 
mRNA targets and significantly reduce viremia in hepatitis infected chimpanzees 
(Lanford et al., 2010). An antimiR against miR-122 has now been taken forward 
to clinical trials for treatment of hepatitis C infection (Lindow and Kauppinen, 
2012). Target de-repression following delivery of antimiR-33A/33B led to 
increased expression of target mRNA involved in high density lipoprotein (HDL) 
biogenesis and fatty acid oxidation resulting in an increase in plasma HDL and 
decrease in VLDL in African green monkeys (Rayner et al., 2011).  
It has been reported that the phenotypic consequence of miRNA knockdown may 
not become apparent until several weeks following antimiR delivery. For 
example delivery of antimiR-208a to mice led to rapid knockdown of miR-208a 
and de-repression of direct target mRNA, however downregulation of indirect 
targets miR-499 and Myh7, of which miR-208a promotes expression, did not 
occur until several weeks following antimiR-208a delivery (Montgomery et al., 
2011). Therefore in the present study mice were pre-dosed with antimiRs to 
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theoretically allow sufficient time for target modulation/de-repression to occur. 
The dosing schedule is shown in Figure 6.2. 
Translational repression mRNA degradation
3’
miR-143
RISC
5’
mRNA 3’
RISC
5’ 3’5’
RISC
3’ 5’
3’
miR-143
RISC
5’
AntimiR
 
Figure 6.1. AntimiR mediated inhibition of miRNA. 
AntimiR-143 contains LNA and DNA bases and is complimentary to the reverse sequence of miR-
143. Following subcutaneous delivery antimiR-143 is absorbed by cells and binds miR-143 with 
high affinity. This reduces the proportion of miR-143 within the cell that is bioavailable and thus 
reduces its ability to bind to target mRNA. As a result de-repression of target mRNA may occur.  
 
-21 d -7 d-14 d 0 d +7 d +14 d +28 d
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SC SC SC SC SC SC SC Sacrifice 
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Figure 6.2. AntimiR study dosing schedule. 
C57BL/6 donor and recipient mice received 10 mg/kg SC antimiR-ctl or antimiR-143 at 1 week 
intervals commencing 21 days prior to the surgery and continuing until 1 week prior to sacrifice.  
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6.2 Aim 
 To determine whether antimiR-mediated reduction in miR-143 expression 
levels leads to altered neointimal formation in mice. 
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6.3 Results 
6.3.1 MiRNA expression levels in tissues of antimiR treated mice 
Results described in chapter 5 revealed that both miR-143 KO and miR-145 KO 
mice displayed significantly less neointimal formation than WT mice in response 
to stenting, with miR-143 KO mice showing a reduction in the greatest number of 
measurements. Therefore, in the present study the neointimal formation 
following antimiR-mediated knockdown of miR-143 was investigated. Both donor 
and recipient mice were dosed with 10 mg/kg antimiR-143 or antimiR-ctl 
administered by a once-weekly SC injection on days -21, -14 and -7 in order to 
establish knockdown of miR-143 within the tissues prior to surgery. Recipient 
mice received 4 additional 10 mg/kg SC doses of antimiR on day 0, 7, 14 and 21 
post-surgery (Figure 6.2). 
MiR-143 expression following SC delivery of antimiR-143 was analysed in hearts 
isolated from donor mice on the day of stent surgery to confirm that miR-143 
knockdown had occurred successfully prior to stenting. Due to its use as the 
donor vessel miR-143 expression could not be measured in the thoracic aorta of 
donor mice. However, miR-143 expression was analysed in the thoracic aorta of 
recipient mice at sacrifice to confirm miR-143 knockdown within this tissue. 
Taqman® qRT-PCR analysis revealed significant loss of miR-143 expression in the 
heart and aorta following treatment with antimiR-143 but not antimiR-ctl (Figure 
6.3 A-B). Northern blotting showed that expression of miR-143 was greater in the 
aorta than the heart in antimiR-ctl treated mice and that expression was 
significantly reduced in both tissues by antimiR-143 (Figure 6.3 C-D).  
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Figure 6.3. Tissue expression of miR-143 following dosing with antimiRs. 
Donor C57BL/6 mice received 3 SC 10 mg/kg doses of antimiR-143 or antimiR-ctl at 1 week 
intervals from – 21 d until – 7 d and hearts were isolated at sacrifice on the day of surgery (0 d). 
Recipient mice received 7 SC 10 mg/kg doses of antimiR-143 or antimiR-ctl at 1 week intervals 
beginning at - 21 d until + 21 d and aortas were isolated at sacrifice at + 28 d. MiRNA was isolated 
and miR-143 expression analysed by Taqman® qRT-PCR in donor hearts (A) or recipient aortas 
(B) or by northern blotting (C) and densitometry analysis (D). *P<0.05, ***P<0.001 vs. antimiR-ctl. 
+++P<0.001 vs. antimiR-ctl heart. n = 8-12/group. 
MiR-143 and miR-145 are produced from a bicistronic precursor and are 
predicted to share a number of common targets despite differences in their seed 
sequences. They are also known to target different mRNA which are involved in 
common pathways such as cytoskeletal arrangement (Xin et al., 2009) suggesting 
that miR-143 and miR-145 may work in unison to contribute to a desired 
phenotype. We investigated whether knockdown of miR-143 expression by 
antimiR-143 leads to altered miR-145 expression.  Taqman® qRT-PCR analysis 
revealed that treatment with antimiR-143 significantly reduced miR-145 
expression in the heart of donor mice and the aorta of recipient mice when 
compared to antimiR-ctl (Figure 6.4 A-B). Following treatment with antimiR-143, 
Taqman® qRT-PCR CT for miR-145 expression in both the heart and aorta was 
found to be around 1 CT higher in mice treated with antimiR-143 compared with 
antimiR-ctl. In comparison, antimiR-143 increased CT for miR-143 in the heart 
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and aorta by 6 CT and 8 CT respectively, indicating that antimiR-143 had a much 
more potent effect on reducing miR-143 expression than miR-145 expression 
levels.  Northern blotting showed that as with miR-143, miR-145 expression was 
also significantly greater in the aorta than the heart of antimiR-ctl treated mice 
(Figure 6.4 C-D). However, northern blotting did not reveal any significant 
decrease in miR-145 expression following treatment with antimiR-143 when 
compared to antimiR-ctl (Figure 6.4 C-D).   
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Figure 6.4. Tissue expression of miR-145 following dosing with antimiRs. 
Donor C57BL/6 mice received 3 SC 10 mg/kg doses of antimiR-143 or antimiR-ctl at 1 week 
intervals from – 21 d until – 7 d and hearts were isolated at sacrifice on the day of surgery (0 d). 
Recipient mice received 7 SC 10 mg/kg doses of antimiR-143 or antimiR-ctl at 1 week intervals 
beginning at -21 d until +21 d and aortas were isolated at sacrifice at + 28 d. MiRNA was isolated 
and miR-145 expression analysed by Taqman® qRT-PCR in donor hearts (A) or recipient aortas 
(B) or by northern blotting (C) and densitometry analysis (D). *P<0.05, **P<0.01 vs. antimiR-ctl. 
+P<0.05, ++P<0.01 vs. heart. n = 8-12/group. 
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Neither body weight nor injury score varied significantly between antimiR-ctl 
and antimiR-145 treated mice over the course of the experiment (Table 6.1).  
Table 6.1. Body weights and injury scores of antimiR treated mice. 
AntimiR-ctl AntimiR-143
Weight (g) 0d 28.92 ± 0.34 29.58 ± 0.36
Weight (g) +7d 28.5 ± 0.22 27.55 ± 0.52
Weight (g) +14d 28.00 ± 0.38 28.75 ± 0.53
Weight (g)  +21d 28.13 ± 0.20 29.18 ± 0.56
Weight (g) +28d 28.75 ± 0.37 29.09 ± 0.52
Injury Score 0.05 ± 0.03 0.03 ± 0.02
 
6.3.2 Analysis of neointimal formation in antimiR treated mice 
H&E staining was performed to visualise the stented vessels and morphometric 
analysis was performed. No significant difference in neointimal thickness, 
neointimal area, strut depth or percentage stenosis was found in mice treated 
with antimiR-143 compared with those treated with antimiR-ctl (Figures 6.5 and 
6.6) indicating that knockdown of miR-143 expression did not promote 
neointimal formation in response to stenting. Likewise, no significant differences 
were found in vessel, medial or lumen area or neointimal to medial ratio 
between antimiR-143 and antimiR-ctl treated mice (Figure 6.5 and 6.6).  
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Figure 6.5. H&E staining of stented vessels from antimiR treated mice.  
Stented grafts were isolated 28 day post-operative and fixed in 10% formalin before stents were 
electrolysed and tissue embedded in paraffin wax. H&E staining performed on paraffin embedded 
sections at 10X and 40X magnification.  Scale bar = 100 µm (top) and 50 µm (bottom). 
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Figure 6.6. Quantification of vessel morphometry in 28 day stented antimiR treated mice. 
Morphometric analysis was performed on paraffin embedded sections from 28 day stented mice 
treated with antimiR-ctl or antimiR-143 using Image-Pro® Analyzer 7.0 software. Quantification is 
shown for A. Neointimal thickness, B. Strut depth, C. Neointimal area, D. Percentage stenosis, E. 
Lumen area, F. Total vessel area, G. Neointimal:medial ratio, H. Medial area. n = 6-8/group. 
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6.3.3 Composition of the 28 day neointima in antimiR treated mice  
Histological analysis was performed to investigate the composition of the 
neointima of antimiR-143 and antimiR-ctl treated mice. EVG analysis revealed a 
large proportion of elastin and was present in the neointimal of both antimiR-ctl 
and antimiR-143 treated mice (Figure 6.7).   Immunohistochemistry for CD31, a 
marker of ECs showed a complete layer of CD31 positive cells at the luminal 
edge of the neointima in all sections indicating that re-endothelialisation had 
occurred by day 28 post-stenting in both antimiR-ctl and antimiR-143 treated 
mice (Figure 6.8). Similar staining patterns for α-SMA were present in sections 
from vessels isolated from both antimiR-143 and antimiR-ctl treated mice 
indicating that treatment with antimiR-143 does not appear to alter the 
presence of VSMCs within the neointima (Figure 6.9). Both antimiR-ctl and 
antimiR-143 treated mice contained small numbers of proliferating cells within 
their neointima 28 day post stenting revealed by staining for PCNA (Figure 6.10). 
A small number of MAC-2 positive cells were detected in the neointima of 
approximately 20% of all vessels and did not vary significantly between antimiR-
ctl and antimiR-143 treated mice.  
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Figure 6.7. EVG staining of 28 day stented vessels from antimiR treated mice.  
EVG staining was performed on the electrolysed vessels of antimiR-143 or antimiR-ctl treated 
C57BL/6 mice 28 d post-stenting to visualise the elastic lamina and determine the composition of 
the neointimal layer. Representative images showing staining reveal the presence of collagen 
(pink) and a large proportion of elastin (purple) within the neointima of both antimiR-143 and 
antimiR-ctl treated mice. Scale bar = 100 µm (top) 50 µm (bottom). 
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Figure 6.8. CD31 expression in 28 day stented vessels from antimiR treated mice. 
Representative images of immunohistochemistry shown by DAB (brown) staining for CD31 or IgG 
control in vessels isolated from antimiR-ctl and antimiR-143 treated mice. Scale bar = 50 µm 
Magnification 40X. 
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Figure 6.9. α-SMA expression in 28 day stented vessels from antimiR treated mice. 
Immunohistochemistry for VSMC marker α-SMA revealed high proportion of α-SMA positive cells in 
the neointima of 28 day stented antimiR-ctl and antimiR-143 treated mice shown by brown DAB 
staining which was absent from the IgG control. 40X magnification. Scale bar = 50 µm. 
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Figure 6.10. PCNA expression in 28 day stented vessels from antimiR treated mice. 
PCNA staining for proliferating cells revealed that a small number of proliferating cells were present 
in the neointima of both antimiR-143 and antimiR-ctl treated mice as shown by DAB staining 
(arrowheads) for PCNA or (top panel) IgG control (bottom panel). 40X magnification, scale bar = 50 
µm  
6.3.4 Target gene expression in tissues from antimiR treated mice  
Following treatment with antimiR-143 mRNA target expression did not 
significantly change within the hearts of donors mice (Figure 6.11 A-C). KLF4 
expression was significantly decreased in the aorta of recipient mice following 
treatment with antimiR-143 however both KLF5 and ELK-1 mRNA expression 
remained unchanged (Figure 6.11 D-F). To identify whether prolonged treatment 
(7 doses vs. 3 doses) with antimiR-143 resulted in altered in target mRNA 
expression, mRNA levels were measured in the hearts of recipient mice, however 
no significant changes were detected (Figure 6.12 C-E).  Interestingly, treatment 
with antimiR-143 resulted in a significant increase in miR-145 expression within 
the heart of recipient mice (Figure 6.12 B). This increase in miR-145 expression 
within the heart was not present in donor mice which showed reduced miR-145 
levels following treatment with antimiR-143 (Figure 6.4 A).  
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KLF5 expression was also analysed in the hearts of both donor and recipient mice 
by western blot to determine whether antimiR-143 affected target expression at 
the protein level. No significant difference in KLF5 expression levels were 
detected western blotting (Figure 6.13). 
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Figure 6.11. Expression of miR-143 target mRNA in the tissues of antimiR treated mice. 
Tissues were isolated on the day of stent surgery (donor hearts) or at sacrifice (recipient aortas) 
and RNA extracted and expression of target mRNA KLF4, KLF5 or ELK-1 was analysed by 
Taqman® qRT-PCR in the donor heart (A-C) and the recipient aorta (D-F). *P<0.05 vs. antimiR-ctl. 
n = 8-12/group. 
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Figure 6.12. Analysis of miRNA and target mRNA expression in the recipient heart.  
MiRNA expression was analysed by Taqman® qRT-PCR in the hearts of recipient mice isolated at 
sacrifice following treatment with 7 doses of 10 mg/kg antimiR-143 or antimiR-ctl delivered at 1 
week intervals. Analysis is shown for miR-143 (A) and miR-145 (B). MRNA expression for targets 
KLF4 (C), KLF5 (D) and ELK-1 (E). ***P<0.001 vs. antimiR-ctl. n = 8-12/group. 
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Figure 6.13. Western blot of KLF5 expression in hearts of antimiR treated mice. 
Western blots were performed on RNA from the hearts of donor mice or recipient mice isolated at 
sacrifice following 3 or 7 weekly doses of 10mg/kg antimiR-143 or antimiR-ctl respectively. Blots 
were probed for KLF5 or GAPDH (A) and analysed by densitometry (B). n = 3/group. 
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6.4 Discussion 
In summary, results from this study revealed that SC delivery of antimiR-143, but 
not antimiR-ctl resulted in potent knockdown in miR-143 expression within the 
tissues. Neointimal formation 28 days post-stenting was comparable in mice that 
received antimiR-ctl and antimiR-143, indicating that pharmacological 
knockdown of miR-143 expression does not alter neointimal formation in 
response to aortic stenting in mice. 
MiR-143 promotes a contractile VSMC phenotype by repressing mRNA targets 
which promote proliferation and migration (Cordes et al., 2009, Xin et al., 
2009). It has previously been reported that following vascular injury local 
expression of miR-143 is reduced (Cordes et al., 2009, Elia et al., 2009). 
Furthermore, adenovirus-mediated delivery of miR-143 to the balloon-injured 
rat carotid artery results in a significant reduction in neointimal formation (Elia 
et al., 2009). This indicates that loss of miR-143 expression following vascular 
injury is a contributing factor in the development of neointima. Additionally, our 
results detailed in chapter 5 revealed that miR-143 KO mice form less neointima 
in response to stenting than WT mice. When considered together, these studies 
suggest that endogenous knockdown of miR-143 levels following vascular injury 
is necessary for the shift towards a more synthetic VSMC phenotype and that this 
action is potentially hindered by genetic ablation of miR-143 expression. In the 
present study, analysis of miRNA expression revealed that antimiR-143 treatment 
produced a significant knockdown of miR-143 expression levels within the aorta 
and heart but had no effect on neointimal formation in response to stenting.  
Mice treated with antimiR-143, had significantly reduced miR-143 tissue 
expression levels prior to stenting, whereas mice dosed with antimiR-ctl 
displayed normal vessel levels of miR-143 expression which, if consistent with 
previous studies (Cordes et al., 2009, Elia et al., 2009), may have been lost upon 
vascular injury. AntimiR-mediated knockdown of miR-143 prior to stenting may 
have mirrored the endogenous process of miR-143 knockdown that occurs 
following vascular injury (Cordes et al., 2009, Elia et al., 2009). Target de-
repression following endogenous or pharmacological knockdown of miR-143 
expression levels may be comparable and accordingly the degree of neointimal 
formation unaffected by antimiR-143.  
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The possibility of systemic delivery of antimiRs leading to sequestration in 
cellular compartments such as endosomes has been suggested (van Rooij, 2011), 
which could lead to reduced bioavailability of antimiRs within cells and hinder 
their ability to bind miRNA. Addition of LNA/DNA antimiRs to cell lysates has 
been shown to significantly hinder miRNA detection by northern blot (Torres et 
al., 2011) which raises the possibility that antimiRs stored in endosomes could 
be released upon tissue lysis and bind to the target miRNA. Therefore, the 
genuine degree of miR-143 knockdown induced by antimiR-143 delivery in vivo 
could be less than that detected by methods employed following tissue 
disruption, including Taqman® qRT-PCR and northern blotting. No consistent 
upregulation in miR-143 target gene expression was detected in the heart or 
aorta following antimiR-143 delivery. This may be indicative of antimiR-143 not 
sufficiently inhibiting miR-143 within the tissues to result in target de-repression 
and is another potential reason why no difference in the neointimal formation 
was detected. However, several studies have reported target de-repression 
following antimiR delivery in vivo which have resulted in functional effects 
(Elmen et al., 2008b, Elmen et al., 2008a) providing evidence that antimiRs do in 
fact inhibit miRNA expression in vivo. For example, antimiR-29b was shown to 
upregulate the expression of several miR-29b target genes including col1a1 and 
elastin which resulted in increased fibrosis and reduced abdominal aortic 
aneurysm progression in 2 different mouse models (Maegdefessel et al., 2012).  
The decreased KLF4 expression detected in the aortas of antimiR-143 recipient 
mice may be due to compensatory increased regulation of this mRNA by miR-145 
upon knockdown of miR-143 expression. A number of other possibilities exist as 
to why target de-repression was not detected following antimiR-143 delivery. 
MiRNAs have previously been shown to alter mRNA expression for the vast 
majority of targets (Baek et al., 2008) however this does not rule out that some 
targets may be regulated at the protein level and western blots could be 
performed to rule this out. As discussed in chapter 5, de-repression of KLF4, 
KLF5 or ELK-1 was not detected in miR-143 KO mice and therefore expression of 
these genes may not be regulated by miR-143 in the tissues analysed. However, 
it is also possible that de-repression of these targets was not apparent as 
expression levels were analysed in non-stressed tissues. It has previously been 
shown that target de-repression may only become apparent following stress such 
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as hypoxia induced remodelling in the pulmonary artery (Caruso et al., 2012). A 
drawback of this study was that target expression could not be measured in the 
stented vessels due to their small size and the demands of histology. AntimiR-
29b-dependent increases in target mRNA col1a1, col3a1 and elastin were 
detected at day 14 but not day 7 or 28 following abdominal aortic aneurysm 
induction by Ang II infusion in ApoE KO mice (Maegdefessel et al., 2012).  This 
indicates that influence of miRNA modulation on a target gene expression can be 
temporal and is likely to be dependent upon the abundance of the mRNA target 
during the stage of the remodelling process. It would be important for future 
studies that target expression is measured in the stented vessel at an 
appropriate time point during which VSMC proliferation and migration is at a 
peak. Confirming that target gene de-repression does occur is important to 
ascertain that antimiR-143 functioned efficiently to inhibit miR-143 expression 
within the stented aorta and that the detected knockdown in expression is not a 
processing artefact.   
Changes in miRNA and mRNA expression after injury can be both spatial and 
temporal (Port et al., 2011). Balloon injury to the rat carotid artery induces loss 
of miR-133 expression by day 2 post-injury when VSMC proliferation is 
pronounced , however by day 14 post-injury miR-133 levels significantly recover 
towards levels seen in control animals (Torella et al., 2011).  Similar results 
were seen in the mouse left ventricle following MI where changes in miRNA 
expression tended to normalise by day 14 post injury (Port et al., 2011). 
Unpublished findings from our own group have found recovery of miR-143 
expression levels towards control levels in the stented porcine coronary artery 
by day 28 post-injury. It is unknown whether this also occurs in the mouse stent 
model, however loss of miR-145 expression following balloon injury of the rat 
carotid is followed by a time dependent recovery of expression (Cheng et al., 
2009). Prolonged knockdown of miR-143 over the 28 day post-stenting period did 
not result in any increase in neointimal formation compared with control mice. 
This suggests that reduced miR-143 expression is most important in the early 
stages of vascular injury, possibly by allowing VSMC switching, but is not 
sufficient to prolong the neointimal formation in itself. Proliferation is greatest 
7 days following stenting in the mouse stent model but is minimal by 28 day (Ali 
et al., 2007). Both antimiR-143 and antimiR-ctl treated mice showed similar 
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expression of PCNA and α-SMA at day 28 indicating that antimiR-143 treatment 
did not result in a prolonged increase in proliferation or increased presence of 
VSMCs within the neointima.  
Our results described in chapter 5 showed that genetic KO of miR-143 expression 
resulted in a significant reduction in neointimal formation compared with WT 
mice in response to stenting. We hypothesise that the disparity between the 
results of our genetic KO versus antimiR knockdown of miR-143 is due to altered 
VSMC signalling following genetic KO. MiR-143 KO mice are viable and display 
less severe differences in VSMC structure and function than miR-145 KO and miR-
143/145 KO mice (Xin et al., 2009, Boettger et al., 2009, Elia et al., 2009). As 
miR-143 is not essential for VSMC development a large proportion of miR-143 
gene regulation may be compensated for by the action of other miRNAs or 
signalling molecules in its absence. In comparison to miR-143 KO mice antimiR-
143 treated mice were fully developed by the time miR-143 loss was induced and 
as such target de-repression and signalling may be significantly different. MiR-
143 and miR-145 are predicted to target a range of genes involved in 
cytoskeletal arrangement and SRF signalling, and it has been suggested that 
genetic KO of these miRNA may hinder the ability of VSMCs to alter their 
phenotype in response to stress (Xin et al., 2009). This is a possible reason for 
the differences in neointimal formation observed between miR-143 KO and 
antimiR-143 treated mice. 
MiR-145 expression was reduced in both the aorta and heart of recipient mice 
treated with antimiR-143. This was detectable by Taqman® qRT-PCR but not 
northern blotting, most probably due to the increased sensitivity of qRT-PCR in 
detecting small changes in miRNA expression. AntimiR-143 is complimentary to 
the reverse sequence of miR-143 which shares very little homology with miR-145 
and it is therefore unlikely that the decrease in miR-145 expression is due to 
unspecific binding of antimiR-143. MiR-143 and miR-145 are co-transcribed from 
a common bicistronic precursor and are transcriptionally activated by signalling 
molecules including SRF, TGF-β and BMP4 (Cordes et al., 2009, Davis-Dusenbery 
et al., 2011, Xin et al., 2009). One reason for reduced miR-145 expression could 
be that loss of miR-143 expression triggers a feedback mechanism whereby 
transcription of miR-143/145 is reduced. SRF in combination with its cofactor 
myocardin or MRTF promotes transcription of miR-143/145 by binding to the 
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CArG box in its regulatory region (Cordes et al., 2009, Xin et al., 2009). Targets 
of miR-143 and miR-145, ELK-1 and KLF4, have been shown to act as competitive 
inhibitors of myocardin and MRTF binding to SRF at the CArG box region in 
contractile genes, significantly reducing transcriptional activation by SRF (Wang 
et al., 2004, Liu et al., 2005). In the present study ELK-1 expression was not 
altered at the mRNA level in the heart or aorta of antimiR-143 treated mice 
however it may only be altered at the protein level as previously reported 
(Cordes et al., 2009). It is also possible that other targets of miR-143 may act in 
a similar way as to reduce gene activation by SRF or other signalling molecules 
which promote miR-143/145 transcription. 
Interestingly, in comparison to reduced miR-145 expression seen in donor 
antimiR-143 treated mice, prolonged miR-143 inhibition in the heart but not the 
aorta of recipient mice resulted in upregulation in miR-145 expression. MiR-143 
and miR-145 are known to regulate gene expression within common pathways 
and also share a number of targets despite differences in seed sequence (Xin et 
al., 2009). It is plausible that prolonged loss of miR-143 and target dysregulation 
could result in a compensatory increase in miR-145 expression within the heart.  
As referred to in chapter 5, several issues arose during resin embedding of 
stented vessels and immunohistochemistry proved challenging. Following several 
optimisation experiments the success rate of stent electrolysis was improved 
upon by small adjustments in the technique. In the present study it was decided 
that electrolysis of stents and paraffin embedding offered more advantages than 
resin embedding with regards to the number of sections and ability to perform 
immunohistochemistry. Electrolysis of the stent strut removes the scaffold 
holding the vessel in position and as such the vessel collapses inward slightly 
hence the reduced vessel area seen in this study when compared to that of 
chapter 5.  
In the present study the degree of neointimal formation in response to stenting 
in antimiR-ctl treated mice was found to be considerably less than that of WT 
mice described in chapter 5. Neointimal formation after vascular injury has been 
shown to vary significantly between mice of different genetic background, with 
C57BL/6 mice relatively resistant to neointima formation (Harmon et al., 2000, 
Kuhel et al., 2002). The transgenic mice used in chapter 5 have a mixed genetic 
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background (Xin et al., 2009) and thus direct comparisons in neointima 
formation between these two studies cannot be made and they must be 
considered separately and compared to their own experimental controls. It was 
shown in chapter 5 that deployment of the stent by inflation of the balloon 
catheter to 10 atmospheres pressure resulted in a highly consistent stent 
expansion. Furthermore injury scores are comparable between the present study 
and those shown in chapters 4 and 5 indicating that all mice received an 
equivalent vascular injury. It has previously been shown that C57BL/6J mice 
develop only a modest neointimal layer following in situ stenting of the 
abdominal aorta with a percentage stenosis of around 20% (Rodriguez-Menocal et 
al., 2010) which is similar to the present study. Also consistent with the present 
study was the low presence of macrophages in the model (Rodriguez-Menocal et 
al., 2010). In contrast, macrophages were detected in all vessels examined in 
the preliminary study in chapter 4, indicating that these mice had a greater 
degree of inflammation which may have in turn contributed to development of a 
more pronounced neointima. Refinement of the procedure may have reduced 
vessel damage during handling and this together with optimisation of the 
surgical technique e.g. graft size and position, most likely accounts for the 
difference in neointima seen between the present study and that described in 
chapter 4.  
To conclude, SC delivery of antimiR-143 resulted in a detectable knockdown of 
miR-143 expression in both donor and recipient mice. Reduction of miR-143 
expression levels by antimiR-143 did not result in any alterations in neointimal 
formation or composition in response to stenting. This suggests that antimiR-143 
may have mimicked the endogenous loss of miR-143 that occurs following 
vascular injury (Cordes et al., 2009, Elia et al., 2009). Despite reduced miR-143 
expression within the tissues no de-repression of miR-143 targets ELK-1, KLF4 or 
KLF5 was detected. Further studies are required to confirm that target 
regulation occurs following antimiR-143 treatment to ascertain that miR-143 
knockdown did occur in vivo and was not detected due to any processing 
artefacts.   
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7.1 General discussion 
This thesis contains research outputs that increase current understanding of the 
role of miR-143 and miR-145 with respect to their regulation of VSMC phenotype. 
Further we identify for the first time the influence of these miRNA on restenosis 
following stenting. Using a mouse model we investigated the effect of 
modulating miR-143 and miR-145 levels on in-stent stenosis and uncovered 
differences between the effect of genetic and pharmacological knockdown of 
these miRNA. Genetic KO of miR-143 and miR-145 reduced stenosis following 
deployment of a metal stent, highlighting the fundamental importance of these 
miRNA in vessel response to injury.  
A common consequence of injury to the vascular wall is activation of VSMCs 
which causes a shift from a contractile to a synthetic phenotype (Kocher et al., 
1991, Orlandi et al., 1994). Synthetic VSMCs show enhanced proliferation and 
migration which results in vessel remodelling and neointimal formation and is a 
key component in the development of vascular injury associated diseases 
including in-stent restenosis and vein graft disease (Schwartz et al., 1992, Cox et 
al., 1991). DES are currently used to prevent in-stent restenosis, however they 
are associated with an increased risk of thrombosis due to delayed re-
endothelialisation (Joner et al., 2006, Finn et al., 2007). Therefore the 
development of cell selective therapies is desirable. MiR-143 and miR-145 are 
enriched in VSMCs and have been shown to regulate VSMC phenotype (Cordes et 
al., 2009, Elia et al., 2009, Cheng et al., 2009).  
Previous reports have indicated that miRNAs can act as a phenotypic switch in 
VSMCs in vitro, for example loss of miR-21 by antagomiR delivery leads to a dose 
dependent decrease in VSMC proliferation and increase in apoptosis (Ji et al., 
2007). Similarly miR-133 overexpression decreases VSMC proliferation whereas 
knockdown of miR-133 leads to an increased proliferative response (Torella et 
al., 2011). The studies described in chapter 3 were carried out using primary 
cells isolated from the human saphenous vein, a vessel often used for CABG 
(Goldman et al., 2004). These experiments were designed to gain insight into 
the level of influence miR-143 and miR-145 can exert on VSMC phenotype.  
Chapter 7 – General Discussion  192 
 
 
MiRNA mimics and antimiRs were used successfully to increase and knockdown 
miR-143 and miR-145 expression levels in HSV SMCs and HSV ECs. Modulation of 
miR-143 or miR-145 alone was insufficient to significantly alter proliferation of 
HSV SMCs in response to serum. This is in contrast to a study in rat A10 SMC line 
where an antagomiR against miR-143, but not miR-145, was capable of 
significantly inducing proliferation (Cordes et al., 2009). MTS proliferation assays 
were found to be unreliable when used with HSV ECs due to the sensitivity of 
these cells to transfection and the inability of the assay to account for cell 
death, thus effect of these miRNA on EC proliferation were inconclusive. Further 
investigation could not be undertaken due to time constraints however 
thymidine incorporation experiments such as BrdU assays are a more direct 
measure of proliferation (Porstmann et al., 1985) and could be performed in 
future studies to clarify this result. Both miR-143 and miR-145 levels are reduced 
by PDGF (Quintavalle et al., 2010) and overexpression of these miRNA reduces 
PDGF induced proliferation and migration in VSMCs (Cordes et al., 2009, Cheng 
et al., 2009). This would suggest that these miRNAs act as downstream effectors 
of PDGF-induced but not serum-induced VSMC proliferation. Furthermore 
knockdown of miR-143 or miR-145 levels alone did not induce VSMC proliferation 
indicating that additional signalling by PDGF is required to promote proliferation 
though downregulation of these miRNA. 
MiR-143 and miR-145 expression is often downregulated in cancer cells and is 
associated with reduced migration and metastasis (Lee et al., 2013, Xu et al., 
2011). Less is known about the role of miR-143 and miR-145 with regards to SMC 
migration. VSMCs isolated from miR-143/145 KO mice show increased migration 
and formation of podosomes, actin rich protrusions involved in cell migration, in 
response to PDGF (Quintavalle et al., 2010). Several miR-143 and miR-145 target 
proteins have been identified as regulators of migration including FSCN1 and 
KLF5 (Quintavalle et al., 2010). To assess whether alteration of miR-143 or miR-
145 expression alone is capable of influencing VSMC migration we investigated 
the response of HSV SMCs and HSV ECs to a well establish scratch assay 
technique where cells migrate into a wound to replace denuded cells (Liang et 
al., 2007). PremiRs and antimiRs were used to modulate miRNA levels in these 
studies as they did not exhibit the toxicity seen with Ads as described in chapter 
3. Migration was not affected by overexpression or knockdown of miR-143 or 
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miR-145 levels in either cell type.  As overexpression of miR-143 or miR-145 has 
been shown to reduce podosome formation induced by PDGF (Quintavalle et al., 
2010) it is possible that altered migration could be seen by modulation of miR-
143 or miR-145 in a chemotaxis experiment with PDGF such as a boyden chamber 
assay.  
The majority of miRNA targets are regulated at both the mRNA and protein level 
(Guo et al., 2010). KLF4 and KLF5 have been previously identified as targets of 
both miR-143 and miR-145 (Cordes et al., 2009, Xin et al., 2009, Cheng et al., 
2009, Davis-Dusenbery et al., 2011). Analysis of mRNA in our study supported 
these findings with KLF4 and KLF5 expression upregulated following delivery of 
antimiR-143 to HSV SMCs suggesting that target de-repression had occurred. 
Following delivery of miR-143 or miR-145 mimics to cells miR-145 was found to 
exert a more pronounced repression of these mRNA in pulmonary artery SMCs 
and luciferase vectors that express their 3’ UTR (Davis-Dusenbery et al., 2011, 
Xin et al., 2009). Conversely, our studies in HSV SMCs found that antimiR-145 
delivery did not lead to altered KLF4 or KLF5 expression, indicating that the 
importance of each miRNA in regulating common targets may vary according to 
cell type. It is also possible that additional signalling must be activated in order 
for miR-145 targeting of these mRNA to be seen. AntagomiRs against miR-143 
and miR-145 both exert an inhibitory effect on BMP4- or TGF-β-mediated down-
regulation of KLF4 expression in pulmonary artery SMCs (Davis-Dusenbery et al., 
2011). Furthermore, downregulation of miR-145 levels by PDGF has been shown 
to lead to de-repression of KLF5 (Cheng et al., 2009).  Regulation of KLF4, KLF5 
and ELK-1 (Cheng et al., 2009, Cordes et al., 2009) has been reported to only be 
detectable at protein level however others disagree and have detected changes 
in mRNA level (Hergenreider et al., 2012, Davis-Dusenbery et al., 2011). Western 
blots could be carried out in future studies to investigate this.  
In contrast to antimiR-143, delivery of premiR-143 did not alter KLF4 or KLF5 
expression. The de-repression of KLF4 and KLF5 evoked by loss of miR-143 
expression suggests that under basal conditions miR-143 actively represses these 
mRNA in HSV SMCs. It is possible that increasing miR-143 levels may result in 
preferential repression of more highly expressed mRNA targets with greater 
bioavailability for binding.  One study revealed that the availability of miRNA for 
target binding following delivery of a miRNA mimic is subject to saturation 
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(Mukherji et al., 2011). This indicates that large increases in miRNA expression 
seen by qRT-PCR following mimic delivery may not be reflective of the actual 
amount of miRNA which is incorporated into the RISC and is biologically active.  
Significantly, repression or de-repression of mRNA target levels in HSV SMCs by 
premiRs or antimiRs was not detected for any other previously identified targets 
tested in the study. Many of these targets were identified in other cell types or 
by luciferase assay and as such may not be valid targets of miR-143 and miR-145 
in HSV SMCs. The development of biotinylated miRNA mimics, offers one 
approach to identify miR-143 and miR-145 targets in HSV SMCs (Orom and Lund, 
2007). These mimics exist as duplexes, structurally similar to the premiR mimics 
used in chapter 3, but contain a biotin group attached to the 3’ sense strand 
which is selectively chosen for incorporation into the RISC. Following cell lysis 
miRNAs and bound mRNAs are captured by affinity purification by streptavidin 
beads and mRNA purified and identified by qRT-PCR or microarray (Orom and 
Lund, 2007). This method was previously successful in identifying both validated 
and novel miR-21 targets (Kang et al., 2012). Tandem affinity precipitation 
target identification (TAP-Tar) increases the specificity of mRNA target 
purification by using stable cell lines which express tagged AGO proteins (Nonne 
et al., 2010). Targets are identified from cell lysates first by pulldown of AGO 
proteins followed by streptavidin bead isolation as described above. This allows 
identification of biotinylated miRNA in association with the RISC and helps 
eliminate binding of non-incorporated biotinylated miRNA (Nonne et al., 2010). 
Genetic KO studies are often beneficial in identifying the essential roles which a 
miRNA plays in a biological system. The study described in chapter 5 found that 
mice genetically ablated of miR-143 or miR-145 develop significantly less 
neointimal formation in response to stenting than WT mice indicating that these 
miRNA are essential for normal VSMC response to injury. Similar results were 
shown in the carotid artery following ligation however, in contrast to our stent 
model where neointima did form in miR-145 KO mice, ligated mice were shown 
to develop virtually no neointima (Xin et al., 2009).  This is surprising as carotid 
artery ligation in WT mice produces a substantial neointimal formation far 
greater than that which develops in WT stented mice (Xin et al., 2009, Ali et al., 
2007). The disparities between these two studies are probably due to the 
underlying differences between these models. Carotid ligation causes cessation 
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of blood flow through the vessel resulting in reduced vessel diameter a shift in 
haemodynamic forces that drives neointimal formation (Kumar and Lindner, 
1997). MiR-145 KO mice have been reported to have low blood pressure which 
may have contributed to the lack of neointima seen in the carotid artery ligation 
model (Xin et al., 2009). This reduction in blood pressure may account for the 
reduced left ventricular mass index seen in miR-145 KO mice by ourselves and 
others (Xin et al., 2009). In contrast to the ligation model the stent model is 
driven by endothelial denudation, vessel stretch and presence of a metal stent 
(Ali et al., 2007).  
Medial remodelling was also reduced following stenting in miR-143 KO and miR-
145 KO mice, this was also noted in the carotid artery ligation model (Xin et al., 
2009). Several studies have reported reduced medial vessel thickness in miR-
143/145 double KO mice (Boettger et al., 2009, Elia et al., 2009) and one report 
stated that this was also apparent in the aorta of miR-145 but not miR-143 KO 
mice (Xin et al., 2009). Our own study revealed that aortic wall thickness was 
comparable between miR-143 KO, miR-145 KO and WT mice. As no quantification 
was shown in the previous study it is unclear the extent of this vessel reduction 
in miR-145 KO mice although we would predict it would be less than that seen in 
miR-143/145 KO (Boettger et al., 2009, Elia et al., 2009) as loss of both miRNA 
may have accumulative effects. The disparity between our results may be due to 
our mice being older at the time of measurements, 18 weeks vs. 8 weeks by 
which point compensatory VSMC regulation, possibly by miR-143 may have led to 
differences in vessel thickness being rectified. 
The results found in chapter 5 added to the body of knowledge on the role of 
miR-143 and miR-145 by showing how genetic loss of these miRNA affects vessel 
remodelling in a clinically relevant model which shares many pathological 
features with human disease (Ali et al., 2007, Carter et al., 1994). Previous 
studies have shown that restoration of miR-143 or miR-145 expression reduces 
neointimal formation after injury (Elia et al., 2009, Cheng et al., 2009). MiR-143 
and miR-145 are expressed during development and KO mice have been shown to 
have differences in VSMC phenotype such as disturbed stress fiber formation and 
increased expression of synthetic machinery (Xin et al., 2009, Cordes et al., 
2009). MiR-143 and miR-145 have many predicted targets which are involved in 
cytoskeletal maintenance and it has been suggested that genetic loss of these 
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miRNA may affect the ability of VSMC phenotypic switching to occur (Xin et al., 
2009).  Compensatory regulation of the targets of these miRNA is likely to 
develop upon genetic loss resulting in altered VSMC signalling which may explain 
the differences seen between our genetic KO study and previous overexpression 
studies.  
The study performed in chapter 6 is the first carried out, to our knowledge, 
which assesses the effect of pharmacological-induced loss of miR-143 expression 
in a vascular injury model. It was shown that SC delivery of an antimiR-143 leads 
to a potent knockdown of miR-143 expression. Contrary to the results of our 
genetic KO study which showed reduced neointimal formation in response to loss 
of miR-143, no significant difference in neointimal formation was detected 
following antimiR knockdown of miR-143 in mice. There are several possible 
reasons for this result which suggest the need for further studies. AntimiR-143 
treatment may have mimicked the endogenous loss of miR-143 seen after 
vascular injury (Cordes et al., 2009, Elia et al., 2009, Cheng et al., 2009) and 
thus may have added no additional affect. Knockdown of miR-145 expression 
following ligation of the carotid in the rat has been shown to be followed by a 
time-dependent recover towards control levels (Cheng et al., 2009). As miR-143 
is cotranscribed with miR-145 it is probable that miR-143 expression also 
recovers over time following vascular injury. Pre-treatment of mice resulted in 
miR-143 loss occurring prior to vascular injury and being sustained throughout 
the entire study period, indicating that sustained knockdown of this miRNA is not 
sufficient to further promote neointimal formation. Taken together with 
overexpression studies this would suggest that low expression of miR-143 is most 
important during the early stages of vascular injury, perhaps by facilitating the 
initial highly proliferative and migratory stage.  
Another possibility as to why antimiR-143 treatment did not alter neointimal 
formation in response to stenting is that the antimiRs may not have been 
processed correctly in the target tissue. It has been shown that antimiRs 
interfere with miRNA detection methods by binding to miRNAs following cell lysis 
(Torres et al., 2011). AntimiR-143 could be compartmentalised within cells 
separate from miR-143 and be release upon tissue lysis, this potential artefact 
could result in the actual in vivo knockdown of the miR-143 being 
overrepresented.  However, several studies using antimiRs of similar structure to 
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those used in chapter 6 have shown that functional effects occur upon antimiR 
delivery in vivo providing evidence that true miRNA inhibition does occur (Elmen 
et al., 2008b, Montgomery et al., 2011, Maegdefessel et al., 2012). Inhibiting 
endogenous miR-143 bioavailability using a different approach, such as miRNA 
sponges, is one option to confirm the effect of miR-143 knockdown on 
neointimal formation. MiRNA sponges encode miRNA target RNA sequences which 
act to competitively inhibit miRNA repression of endogenous targets (Ebert et 
al., 2007).  
In the simplest model, knockdown of a miRNA would result in an increase in the 
expression of its target genes. However, as described in chapters 5 and 6, target 
de-repression was not detectable following genetic KO or antimiR delivery in 
mice. Previous studies have revealed that most mRNAs contain multiple binding 
sites for several different miRNAs within their 3’ UTR and thus expression of a 
given target may be under regulation from multiple miRNAs (Friedman et al., 
2009). Fluctuations in target expression that may be induced by modulation of 
miR-143 or miR-145 expression could potentially be rectified by compensatory 
increased or decreased repression by other miRNAs. 
Under basal conditions miRNAs appear to act to fine-tune target gene expression 
and single cell studies have indicated that target regulation by miRNAs is both is 
non-linear and subject to thresholds (Mukherji et al., 2011). MiRNAs were shown 
to only modestly modulate target protein expression when expression of the 
target mRNA remains above a certain threshold level. However, if target mRNA 
expression is below the threshold the miRNA will strongly repress the target 
protein. Increasing the number of complementary binding sites or increasing 
miRNA expression raises the threshold so that a greater number of target mRNA 
are required to meet the threshold (Mukherji et al., 2011). The lack of target 
de-repression seen following antimiR-143 delivery could be due to the expression 
of these target mRNA being above the threshold and hence subject to only mild 
regulation by the miR-143. If this were the case then antimiR knockdown may 
result in only modest change in target expression, which could be obscured by 
other compensatory regulation.  
It is possible that a tissue may need to be stressed in order for altered target 
regulation to become apparent. A limitation of the study was that qRT-PCR 
Chapter 7 – General Discussion  198 
 
 
analysis of target expression could not be performed on the stented tissue due 
to the small size and the requirements for histology. It has been previously 
shown that de-repression may only become apparent following vascular stress 
such hypoxia, which induces upregulation of miR-145 targets in the lung and 
pulmonary artery of miR-145 KO mice (Caruso et al., 2012). This could be due to 
induction of miRNA targets through stress signalling activated upon vascular 
injury. AntimiR knockdown of miRNA expression in stressed tissue may lead to an 
exacerbated increase in target expression due to the lack of availability of the 
miRNA for regulation and the increasing levels of mRNA. Other studies have 
shown that during vessel remodelling target de-repression by antimiRs occurs in 
only at certain time points (Maegdefessel et al., 2012) indicating that regulation 
by antimiRs can be temporal rather than constant. This type of regulation 
probably depends on the relative abundance of the mRNA target at a specific 
stage of the remodelling process.  It would be important for future studies to 
assess target de-repression within the stented aorta and at an appropriate time 
when proliferation and migration are at their peak.  Bioinformatics programs 
offer ways to identify potential miRNA targets by identifying complementary 
binding sites in the 3’ UTR of mRNA. Potential targets could then be confirmed 
by qRT-PCR. Performing a microarray or proteomic analysis on tissues from 
antimiR-143 treated mice, in combination with bioinformatics studies is another 
option to identify targets (Lim et al., 2005, Baek et al., 2008). This would be 
particularly important as detectable target de-repression is needed to confirm 
that miR-143 knockdown by antimiR-143 occurs in vivo and that the decrease in 
miR-143 expression detected following tissue lysis is not due to processing 
artefacts.  
Clinically, stenting and CABG are performed in patients that have pre-existing 
atherosclerosis and thus the effects of hyperlipidaemia and increased 
inflammation must be considered. To increase the clinical relevance of future 
studies stenting could be performed in ApoE KO mice (Piedrahita et al., 1992, 
Plump et al., 1992). These mice have elevated levels of VLDL and increased 
inflammation and display significantly more neointimal formation than WT mice 
following stenting (Ali et al., 2007). It would be important to assess whether the 
therapeutic effect of increased miR-143 and miR-145 expression levels on 
reducing neointimal formation (Elia et al., 2009) extends to models with 
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increased pro-inflammatory signalling.  Furthermore, delayed EC repopulation is 
seen in ApoE KO mice (Xu et al., 2003, Douglas et al., 2012) and it would be 
important to ascertain that overexpression of miR-143 or miR-145 does not have 
a detrimental effect on EC repopulation as this could have implications for 
thrombosis.  
Results from our genetic KO study support the view that miR-143 and miR-145 
expression are essential for normal vessel response to injury.  Others have 
identified that overexpression of these miRNA can reduce remodelling after 
vascular injury in mouse models (Cheng et al., 2009, Elia et al., 2009, Cordes et 
al., 2009). Future studies could involve analysis of overexpression of these 
miRNA in the vessel wall using the adenoviral vectors developed in chapter 3. 
Further, miRNA transgenes could be re-cloned into a different Ad vector, such as 
a subgroup B Ad, to improve transgene delivery to the vessel wall (Havenga et 
al., 2001). Delivery of Ads which express miR-143 or miR-145 has been shown to 
reduce neointimal formation after balloon-injury to the rat carotid artery (Elia 
et al., 2009, Cheng et al., 2009). In terms of clinical relevance local delivery of 
miR-143 or miR-145 to the vessel wall is a preferable therapeutic option as 
systemic delivery may lead to target repression in non-target tissues which could 
have functional consequences. Several studies have reported the use of 
chemistries to attach viruses to metal stents which permit local release to the 
vessel wall (Johnson et al., 2005, Sharif et al., 2008) providing a possible means 
of direct miRNA delivery to the site of vascular injury.  
In summary, this thesis has presented studies which extend current knowledge of 
the influence of miR-143 and miR-145 on VSMC phenotype following injury. 
Modulation of miR-143 or miR-145 levels alone was shown to be insufficient to 
modify proliferation or migration of human VSMCs. A previous study identified 
that endogenous loss of miR-143 after injury is important in promoting 
neointimal formation (Elia et al., 2009). Conversely, we have demonstrated that 
genetic loss of miR-143 or miR-145 results in reduced neointimal formation in 
response to stenting, confirming that these miRNA play a fundamental role in 
modulating VSMC phenotype in response to injury. Further, we have shown that 
systemic delivery of an antimiR inhibitor of miR-143 had no effect on neointimal 
formation despite detecting a sustained reduction in miR-143 expression levels 
throughout the study duration. This compliments current knowledge of these 
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miRNA and demonstrates that antimiR-mediated inhibition of miR-143 does not 
mimic the effects of genetic KO of miR-143 on neointimal formation in response 
to stenting.   
  201 
 
 
List of References 
 
ADAM, P. J., REGAN, C. P., HAUTMANN, M. B. & OWENS, G. K. 2000. Positive- 
and negative-acting Kruppel-like transcription factors bind a transforming 
growth factor beta control element required for expression of the smooth 
muscle cell differentiation marker SM22alpha in vivo. J Biol Chem, 275, 
37798-806. 
ALBINSSON, S., SKOURA, A., YU, J., DILORENZO, A., FERNANDEZ-HERNANDO, C., 
OFFERMANNS, S., MIANO, J. M. & SESSA, W. C. 2011. Smooth muscle 
miRNAs are critical for post-natal regulation of blood pressure and 
vascular function. PLoS One, 6, e18869. 
ALBINSSON, S., SUAREZ, Y., SKOURA, A., OFFERMANNS, S., MIANO, J. M. & 
SESSA, W. C. 2010. MicroRNAs are necessary for vascular smooth muscle 
growth, differentiation, and function. Arterioscler Thromb Vasc Biol, 30, 
1118-26. 
ALI, Z. A., ALP, N. J., LUPTON, H., ARNOLD, N., BANNISTER, T., HU, Y., MUSSA, 
S., WHEATCROFT, M., GREAVES, D. R., GUNN, J. & CHANNON, K. M. 2007. 
Increased in-stent stenosis in ApoE knockout mice: insights from a novel 
mouse model of balloon angioplasty and stenting. Arterioscler Thromb 
Vasc Biol, 27, 833-40. 
AMBROS, V. & HORVITZ, H. R. 1987. The lin-14 locus of Caenorhabditis elegans 
controls the time of expression of specific postembryonic developmental 
events. Genes Dev, 1, 398-414. 
AMENTO, E. P., EHSANI, N., PALMER, H. & LIBBY, P. 1991. Cytokines and growth 
factors positively and negatively regulate interstitial collagen gene 
expression in human vascular smooth muscle cells. Arterioscler Thromb, 
11, 1223-30. 
ARBUSTINI, E., DE SERVI, S., BRAMUCCI, E., PORCU, E., COSTANTE, A. M., 
GRASSO, M., DIEGOLI, M., FASANI, R., MORBINI, P., ANGOLI, L., 
BOSCARINI, M., REPETTO, S., DANZI, G., NICCOLI, L., CAMPOLO, L., 
LUCREZIOTTI, S. & SPECCHIA, G. 1995. Comparison of coronary lesions 
obtained by directional coronary atherectomy in unstable angina, stable 
angina, and restenosis after either atherectomy or angioplasty. Am J 
Cardiol, 75, 675-82. 
ASSOIAN, R. K., FLEURDELYS, B. E., STEVENSON, H. C., MILLER, P. J., MADTES, 
D. K., RAINES, E. W., ROSS, R. & SPORN, M. B. 1987. Expression and 
secretion of type beta transforming growth factor by activated human 
macrophages. Proc Natl Acad Sci U S A, 84, 6020-4. 
AUERBACH, W. & AUERBACH, R. 1994. Angiogenesis inhibition: a review. 
Pharmacol Ther, 63, 265-311. 
BAEK, D., VILLEN, J., SHIN, C., CAMARGO, F. D., GYGI, S. P. & BARTEL, D. P. 
2008. The impact of microRNAs on protein output. Nature, 455, 64-71. 
BAI, X., MARGARITI, A., HU, Y. H., SATO, Y., ZENG, L. F., IVETIC, A., HABI, O., 
MASON, J. C., WANG, X. & XU, Q. B. 2010. Protein Kinase C delta 
Deficiency Accelerates Neointimal Lesions of Mouse Injured Artery 
Involving Delayed Reendothelialization and Vasohibin-1 Accumulation. 
Arteriosclerosis Thrombosis and Vascular Biology, 30, 2467-2474. 
BARTEL, D. P. 2009. MicroRNAs: target recognition and regulatory functions. 
Cell, 136, 215-33. 
  202 
 
 
BASKERVILLE, S. & BARTEL, D. P. 2005. Microarray profiling of microRNAs reveals 
frequent coexpression with neighboring miRNAs and host genes. RNA, 11, 
241-7. 
BATTEGAY, E. J., RAINES, E. W., SEIFERT, R. A., BOWEN-POPE, D. F. & ROSS, R. 
1990. TGF-beta induces bimodal proliferation of connective tissue cells 
via complex control of an autocrine PDGF loop. Cell, 63, 515-24. 
BAVRY, A. A., KUMBHANI, D. J., HELTON, T. J., BOREK, P. P., MOOD, G. R. & 
BHATT, D. L. 2006. Late thrombosis of drug-eluting stents: a meta-
analysis of randomized clinical trials. Am J Med, 119, 1056-61. 
BEITZINGER, M., PETERS, L., ZHU, J. Y., KREMMER, E. & MEISTER, G. 2007. 
Identification of human microRNA targets from isolated argonaute protein 
complexes. RNA Biol, 4, 76-84. 
BENNETT, M. R., EVAN, G. I. & SCHWARTZ, S. M. 1995. Apoptosis of human 
vascular smooth muscle cells derived from normal vessels and coronary 
atherosclerotic plaques. J Clin Invest, 95, 2266-74. 
BERGELSON, J. M., CUNNINGHAM, J. A., DROGUETT, G., KURT-JONES, E. A., 
KRITHIVAS, A., HONG, J. S., HORWITZ, M. S., CROWELL, R. L. & FINBERG, 
R. W. 1997. Isolation of a common receptor for Coxsackie B viruses and 
adenoviruses 2 and 5. Science, 275, 1320-3. 
BERNSTEIN, E., KIM, S. Y., CARMELL, M. A., MURCHISON, E. P., ALCORN, H., LI, 
M. Z., MILLS, A. A., ELLEDGE, S. J., ANDERSON, K. V. & HANNON, G. J. 
2003. Dicer is essential for mouse development. Nat Genet, 35, 215-7. 
BLANK, R. S. & OWENS, G. K. 1990. Platelet-derived growth factor regulates 
actin isoform expression and growth state in cultured rat aortic smooth 
muscle cells. J Cell Physiol, 142, 635-42. 
BLENKIRON, C., GOLDSTEIN, L. D., THORNE, N. P., SPITERI, I., CHIN, S. F., 
DUNNING, M. J., BARBOSA-MORAIS, N. L., TESCHENDORFF, A. E., GREEN, 
A. R., ELLIS, I. O., TAVARE, S., CALDAS, C. & MISKA, E. A. 2007. MicroRNA 
expression profiling of human breast cancer identifies new markers of 
tumor subtype. Genome Biol, 8, R214. 
BOETTGER, T., BEETZ, N., KOSTIN, S., SCHNEIDER, J., KRUGER, M., HEIN, L. & 
BRAUN, T. 2009. Acquisition of the contractile phenotype by murine 
arterial smooth muscle cells depends on the Mir143/145 gene cluster. J 
Clin Invest, 119, 2634-47. 
BOHNSACK, M. T., CZAPLINSKI, K. & GORLICH, D. 2004. Exportin 5 is a RanGTP-
dependent dsRNA-binding protein that mediates nuclear export of pre-
miRNAs. RNA, 10, 185-91. 
BONAUER, A., CARMONA, G., IWASAKI, M., MIONE, M., KOYANAGI, M., FISCHER, 
A., BURCHFIELD, J., FOX, H., DOEBELE, C., OHTANI, K., CHAVAKIS, E., 
POTENTE, M., TJWA, M., URBICH, C., ZEIHER, A. M. & DIMMELER, S. 2009. 
MicroRNA-92a controls angiogenesis and functional recovery of ischemic 
tissues in mice. Science, 324, 1710-3. 
BORCHERT, G. M., LANIER, W. & DAVIDSON, B. L. 2006. RNA polymerase III 
transcribes human microRNAs. Nat Struct Mol Biol, 13, 1097-101. 
BOSHART, M., WEBER, F., JAHN, G., DORSCH-HASLER, K., FLECKENSTEIN, B. & 
SCHAFFNER, W. 1985. A very strong enhancer is located upstream of an 
immediate early gene of human cytomegalovirus. Cell, 41, 521-30. 
BOUCHER, J. M., PETERSON, S. M., URS, S., ZHANG, C. & LIAW, L. 2011. The 
miR-143/145 cluster is a novel transcriptional target of Jagged-1/Notch 
signaling in vascular smooth muscle cells. J Biol Chem, 286, 28312-21. 
BRAASCH, D. A. & COREY, D. R. 2001. Locked nucleic acid (LNA): fine-tuning the 
recognition of DNA and RNA. Chem Biol, 8, 1-7. 
  203 
 
 
BRADSHAW, S. H., KENNEDY, L., DEXTER, D. F. & VEINOT, J. P. 2009. A practical 
method to rapidly dissolve metallic stents. Cardiovasc Pathol, 18, 127-33. 
BRIGHTWELL, G., POIRIER, V., COLE, E., IVINS, S. & BROWN, K. W. 1997. Serum-
dependent and cell cycle-dependent expression from a cytomegalovirus-
based mammalian expression vector. Gene, 194, 115-23. 
BRITISH HEART FOUNDATION. 2012. Coronary heart disease statistics. A 
compendium of health statistics.  [Online]. Available: 
http://www.bhf.org.uk/publications/view-publication.aspx?ps=1002097 
[Accessed 30.09.13. 
BURKE, A. P., KOLODGIE, F. D., FARB, A., WEBER, D. K., MALCOM, G. T., 
SMIALEK, J. & VIRMANI, R. 2001. Healed plaque ruptures and sudden 
coronary death: evidence that subclinical rupture has a role in plaque 
progression. Circulation, 103, 934-40. 
CAI, X., HAGEDORN, C. H. & CULLEN, B. R. 2004. Human microRNAs are 
processed from capped, polyadenylated transcripts that can also function 
as mRNAs. RNA, 10, 1957-66. 
CAIXETA, A., LEON, M. B., LANSKY, A. J., NIKOLSKY, E., AOKI, J., MOSES, J. W., 
SCHOFER, J., MORICE, M. C., SCHAMPAERT, E., KIRTANE, A. J., POPMA, J. 
J., PARISE, H., FAHY, M. & MEHRAN, R. 2009. 5-year clinical outcomes 
after sirolimus-eluting stent implantation insights from a patient-level 
pooled analysis of 4 randomized trials comparing sirolimus-eluting stents 
with bare-metal stents. J Am Coll Cardiol, 54, 894-902. 
CAO, L., KONG, L. P., YU, Z. B., HAN, S. P., BAI, Y. F., ZHU, J., HU, X., ZHU, C., 
ZHU, S. & GUO, X. R. 2012. microRNA expression profiling of the 
developing mouse heart. Int J Mol Med, 30, 1095-104. 
CAPLICE, N. M., ARONEY, C. N., BETT, J. H., CAMERON, J., CAMPBELL, J. H., 
HOFFMANN, N., MCENIERY, P. T. & WEST, M. J. 1997. Growth factors 
released into the coronary circulation after vascular injury promote 
proliferation of human vascular smooth muscle cells in culture. J Am Coll 
Cardiol, 29, 1536-41. 
CARTER, A. J., LAIRD, J. R., FARB, A., KUFS, W., WORTHAM, D. C. & VIRMANI, R. 
1994. Morphologic characteristics of lesion formation and time course of 
smooth muscle cell proliferation in a porcine proliferative restenosis 
model. J Am Coll Cardiol, 24, 1398-405. 
CARUSO, P., DEMPSIE, Y., STEVENS, H. C., MCDONALD, R. A., LONG, L., LU, R., 
WHITE, K., MAIR, K. M., MCCLURE, J. D., SOUTHWOOD, M., UPTON, P., 
XIN, M., VAN ROOIJ, E., OLSON, E. N., MORRELL, N. W., MACLEAN, M. R. & 
BAKER, A. H. 2012. A role for miR-145 in pulmonary arterial hypertension: 
evidence from mouse models and patient samples. Circ Res, 111, 290-300. 
CHAMBERLAIN, J., WHEATCROFT, M., ARNOLD, N., LUPTON, H., CROSSMAN, D. 
C., GUNN, J. & FRANCIS, S. 2010. A novel mouse model of in situ stenting. 
Cardiovasc Res, 85, 38-44. 
CHAMLEY-CAMPBELL, J., CAMPBELL, G. R. & ROSS, R. 1979. The smooth muscle 
cell in culture. Physiol Rev, 59, 1-61. 
CHEN, J., KITCHEN, C. M., STREB, J. W. & MIANO, J. M. 2002. Myocardin: a 
component of a molecular switch for smooth muscle differentiation. J Mol 
Cell Cardiol, 34, 1345-56. 
CHEN, J. F., MURCHISON, E. P., TANG, R., CALLIS, T. E., TATSUGUCHI, M., 
DENG, Z., ROJAS, M., HAMMOND, S. M., SCHNEIDER, M. D., SELZMAN, C. 
H., MEISSNER, G., PATTERSON, C., HANNON, G. J. & WANG, D. Z. 2008. 
Targeted deletion of Dicer in the heart leads to dilated cardiomyopathy 
and heart failure. Proc Natl Acad Sci U S A, 105, 2111-6. 
  204 
 
 
CHENDRIMADA, T. P., GREGORY, R. I., KUMARASWAMY, E., NORMAN, J., COOCH, 
N., NISHIKURA, K. & SHIEKHATTAR, R. 2005. TRBP recruits the Dicer 
complex to Ago2 for microRNA processing and gene silencing. Nature, 436, 
740-4. 
CHENG, Y., LIU, X., YANG, J., LIN, Y., XU, D. Z., LU, Q., DEITCH, E. A., HUO, Y., 
DELPHIN, E. S. & ZHANG, C. 2009. MicroRNA-145, a novel smooth muscle 
cell phenotypic marker and modulator, controls vascular neointimal lesion 
formation. Circ Res, 105, 158-66. 
CHIYOMARU, T., ENOKIDA, H., TATARANO, S., KAWAHARA, K., UCHIDA, Y., 
NISHIYAMA, K., FUJIMURA, L., KIKKAWA, N., SEKI, N. & NAKAGAWA, M. 
2010. miR-145 and miR-133a function as tumour suppressors and directly 
regulate FSCN1 expression in bladder cancer. Br J Cancer, 102, 883-91. 
CIFUENTES, D., XUE, H., TAYLOR, D. W., PATNODE, H., MISHIMA, Y., CHELOUFI, 
S., MA, E., MANE, S., HANNON, G. J., LAWSON, N. D., WOLFE, S. A. & 
GIRALDEZ, A. J. 2010. A novel miRNA processing pathway independent of 
Dicer requires Argonaute2 catalytic activity. Science, 328, 1694-8. 
CLARKE, M. C., FIGG, N., MAGUIRE, J. J., DAVENPORT, A. P., GODDARD, M., 
LITTLEWOOD, T. D. & BENNETT, M. R. 2006. Apoptosis of vascular smooth 
muscle cells induces features of plaque vulnerability in atherosclerosis. 
Nat Med, 12, 1075-80. 
CLOWES, A. W. & CLOWES, M. M. 1985. Kinetics of cellular proliferation after 
arterial injury. II. Inhibition of smooth muscle growth by heparin. Lab 
Invest, 52, 611-6. 
CLOWES, A. W. & SCHWARTZ, S. M. 1985. Significance of quiescent smooth 
muscle migration in the injured rat carotid artery. Circulation Research, 
56, 139-45. 
CORDES, K. R., SHEEHY, N. T., WHITE, M. P., BERRY, E. C., MORTON, S. U., 
MUTH, A. N., LEE, T. H., MIANO, J. M., IVEY, K. N. & SRIVASTAVA, D. 
2009. miR-145 and miR-143 regulate smooth muscle cell fate and 
plasticity. Nature, 460, 705-10. 
COUGHLAN, L., ALBA, R., PARKER, A. L., BRADSHAW, A. C., MCNEISH, I. A., 
NICKLIN, S. A. & BAKER, A. H. 2010. Tropism-modification strategies for 
targeted gene delivery using adenoviral vectors. Viruses, 2, 2290-355. 
COX, J. L., CHIASSON, D. A. & GOTLIEB, A. I. 1991. Stranger in a strange land: 
the pathogenesis of saphenous vein graft stenosis with emphasis on 
structural and functional differences between veins and arteries. Prog 
Cardiovasc Dis, 34, 45-68. 
CUNNINGHAM, K. S. & GOTLIEB, A. I. 2005. The role of shear stress in the 
pathogenesis of atherosclerosis. Lab Invest, 85, 9-23. 
DAEMEN, M. J., LOMBARDI, D. M., BOSMAN, F. T. & SCHWARTZ, S. M. 1991. 
Angiotensin II induces smooth muscle cell proliferation in the normal and 
injured rat arterial wall. Circ Res, 68, 450-6. 
DANENBERG, H. D., FISHBEIN, I., GAO, J., MONKKONEN, J., REICH, R., GATI, I., 
MOERMAN, E. & GOLOMB, G. 2002. Macrophage depletion by clodronate-
containing liposomes reduces neointimal formation after balloon injury in 
rats and rabbits. Circulation, 106, 599-605. 
DAVIES, M. J., RICHARDSON, P. D., WOOLF, N., KATZ, D. R. & MANN, J. 1993. 
Risk of thrombosis in human atherosclerotic plaques: role of extracellular 
lipid, macrophage, and smooth muscle cell content. Br Heart J, 69, 377-
81. 
DAVIES, M. J. & THOMAS, A. C. 1985. Plaque fissuring--the cause of acute 
myocardial infarction, sudden ischaemic death, and crescendo angina. Br 
Heart J, 53, 363-73. 
  205 
 
 
DAVIGNON, J. & GANZ, P. 2004. Role of endothelial dysfunction in 
atherosclerosis. Circulation, 109, III27-32. 
DAVIS-DUSENBERY, B. N., CHAN, M. C., RENO, K. E., WEISMAN, A. S., LAYNE, M. 
D., LAGNA, G. & HATA, A. 2011. down-regulation of Kruppel-like factor-4 
(KLF4) by microRNA-143/145 is critical for modulation of vascular smooth 
muscle cell phenotype by transforming growth factor-beta and bone 
morphogenetic protein 4. J Biol Chem, 286, 28097-110. 
DAVIS, E., CAIMENT, F., TORDOIR, X., CAVAILLE, J., FERGUSON-SMITH, A., 
COCKETT, N., GEORGES, M. & CHARLIER, C. 2005. RNAi-mediated allelic 
trans-interaction at the imprinted Rtl1/Peg11 locus. Curr Biol, 15, 743-9. 
DE LEON, H., OLLERENSHAW, J. D., GRIENDLING, K. K. & WILCOX, J. N. 2001. 
Adventitial cells do not contribute to neointimal mass after balloon 
angioplasty of the rat common carotid artery. Circulation, 104, 1591-3. 
DEANFIELD, J. E., HALCOX, J. P. & RABELINK, T. J. 2007. Endothelial function 
and dysfunction: testing and clinical relevance. Circulation, 115, 1285-95. 
DEATON, R. A., GAN, Q. & OWENS, G. K. 2009. Sp1-dependent activation of KLF4 
is required for PDGF-BB-induced phenotypic modulation of smooth 
muscle. Am J Physiol Heart Circ Physiol, 296, H1027-37. 
DEGUCHI, J., NAMBA, T., HAMADA, H., NAKAOKA, T., ABE, J., SATO, O., MIYATA, 
T., MAKUUCHI, M., KUROKAWA, K. & TAKUWA, Y. 1999. Targeting 
endogenous platelet-derived growth factor B-chain by adenovirus-
mediated gene transfer potently inhibits in vivo smooth muscle 
proliferation after arterial injury. Gene Ther, 6, 956-65. 
DEKKER, R. J., VAN THIENEN, J. V., ROHLENA, J., DE JAGER, S. C., ELDERKAMP, 
Y. W., SEPPEN, J., DE VRIES, C. J., BIESSEN, E. A., VAN BERKEL, T. J., 
PANNEKOEK, H. & HORREVOETS, A. J. 2005. Endothelial KLF2 links local 
arterial shear stress levels to the expression of vascular tone-regulating 
genes. Am J Pathol, 167, 609-18. 
DENLI, A. M., TOPS, B. B., PLASTERK, R. H., KETTING, R. F. & HANNON, G. J. 
2004. Processing of primary microRNAs by the Microprocessor complex. 
Nature, 432, 231-5. 
DEWS, M., HOMAYOUNI, A., YU, D., MURPHY, D., SEVIGNANI, C., WENTZEL, E., 
FURTH, E. E., LEE, W. M., ENDERS, G. H., MENDELL, J. T. & THOMAS-
TIKHONENKO, A. 2006. Augmentation of tumor angiogenesis by a Myc-
activated microRNA cluster. Nat Genet, 38, 1060-5. 
DJEBALI, S., DAVIS, C. A., MERKEL, A., DOBIN, A., LASSMANN, T., MORTAZAVI, 
A., TANZER, A., LAGARDE, J., LIN, W., SCHLESINGER, F., XUE, C., 
MARINOV, G. K., KHATUN, J., WILLIAMS, B. A., ZALESKI, C., ROZOWSKY, 
J., RODER, M., KOKOCINSKI, F., ABDELHAMID, R. F., ALIOTO, T., 
ANTOSHECHKIN, I., BAER, M. T., BAR, N. S., BATUT, P., BELL, K., BELL, I., 
CHAKRABORTTY, S., CHEN, X., CHRAST, J., CURADO, J., DERRIEN, T., 
DRENKOW, J., DUMAIS, E., DUMAIS, J., DUTTAGUPTA, R., FALCONNET, E., 
FASTUCA, M., FEJES-TOTH, K., FERREIRA, P., FOISSAC, S., FULLWOOD, M. 
J., GAO, H., GONZALEZ, D., GORDON, A., GUNAWARDENA, H., HOWALD, 
C., JHA, S., JOHNSON, R., KAPRANOV, P., KING, B., KINGSWOOD, C., LUO, 
O. J., PARK, E., PERSAUD, K., PREALL, J. B., RIBECA, P., RISK, B., ROBYR, 
D., SAMMETH, M., SCHAFFER, L., SEE, L. H., SHAHAB, A., SKANCKE, J., 
SUZUKI, A. M., TAKAHASHI, H., TILGNER, H., TROUT, D., WALTERS, N., 
WANG, H., WROBEL, J., YU, Y., RUAN, X., HAYASHIZAKI, Y., HARROW, J., 
GERSTEIN, M., HUBBARD, T., REYMOND, A., ANTONARAKIS, S. E., 
HANNON, G., GIDDINGS, M. C., RUAN, Y., WOLD, B., CARNINCI, P., GUIGO, 
R. & GINGERAS, T. R. 2012. Landscape of transcription in human cells. 
Nature, 489, 101-8. 
  206 
 
 
DOEBELE, C., BONAUER, A., FISCHER, A., SCHOLZ, A., REISS, Y., URBICH, C., 
HOFMANN, W. K., ZEIHER, A. M. & DIMMELER, S. 2010. Members of the 
microRNA-17-92 cluster exhibit a cell-intrinsic antiangiogenic function in 
endothelial cells. Blood, 115, 4944-50. 
DOUGLAS, G., VAN KAMPEN, E., HALE, A. B., MCNEILL, E., PATEL, J., CRABTREE, 
M. J., ALI, Z., HOERR, R. A., ALP, N. J. & CHANNON, K. M. 2012. 
Endothelial cell repopulation after stenting determines in-stent neointima 
formation: effects of bare-metal vs. drug-eluting stents and genetic 
endothelial cell modification. European Heart Journal. 
DU, K. L., IP, H. S., LI, J., CHEN, M., DANDRE, F., YU, W., LU, M. M., OWENS, G. 
K. & PARMACEK, M. S. 2003. Myocardin is a critical serum response factor 
cofactor in the transcriptional program regulating smooth muscle cell 
differentiation. Mol Cell Biol, 23, 2425-37. 
EBERT, M. S., NEILSON, J. R. & SHARP, P. A. 2007. MicroRNA sponges: 
competitive inhibitors of small RNAs in mammalian cells. Nat Methods, 4, 
721-6. 
EBERT, M. S. & SHARP, P. A. 2010. MicroRNA sponges: progress and possibilities. 
RNA, 16, 2043-50. 
ELIA, L., QUINTAVALLE, M., ZHANG, J., CONTU, R., COSSU, L., LATRONICO, M. 
V., PETERSON, K. L., INDOLFI, C., CATALUCCI, D., CHEN, J., 
COURTNEIDGE, S. A. & CONDORELLI, G. 2009. The knockout of miR-143 
and -145 alters smooth muscle cell maintenance and vascular homeostasis 
in mice: correlates with human disease. Cell Death Differ, 16, 1590-8. 
ELMEN, J., LINDOW, M., SCHUTZ, S., LAWRENCE, M., PETRI, A., OBAD, S., 
LINDHOLM, M., HEDTJARN, M., HANSEN, H. F., BERGER, U., GULLANS, S., 
KEARNEY, P., SARNOW, P., STRAARUP, E. M. & KAUPPINEN, S. 2008a. LNA-
mediated microRNA silencing in non-human primates. Nature, 452, 896-9. 
ELMEN, J., LINDOW, M., SILAHTAROGLU, A., BAK, M., CHRISTENSEN, M., LIND-
THOMSEN, A., HEDTJARN, M., HANSEN, J. B., HANSEN, H. F., STRAARUP, 
E. M., MCCULLAGH, K., KEARNEY, P. & KAUPPINEN, S. 2008b. Antagonism 
of microRNA-122 in mice by systemically administered LNA-antimiR leads 
to up-regulation of a large set of predicted target mRNAs in the liver. 
Nucleic Acids Res, 36, 1153-62. 
EULALIO, A., HUNTZINGER, E., NISHIHARA, T., REHWINKEL, J., FAUSER, M. & 
IZAURRALDE, E. 2009. Deadenylation is a widespread effect of miRNA 
regulation. RNA, 15, 21-32. 
EVANS, M. J. & KAUFMAN, M. H. 1981. Establishment in culture of pluripotential 
cells from mouse embryos. Nature, 292, 154-6. 
FALK, E. 1989. Morphologic features of unstable atherothrombotic plaques 
underlying acute coronary syndromes. Am J Cardiol, 63, 114E-120E. 
FALK, E. 1991. Coronary thrombosis: pathogenesis and clinical manifestations. 
Am J Cardiol, 68, 28B-35B. 
FATIGATI, V. & MURPHY, R. A. 1984. Actin and tropomyosin variants in smooth 
muscles. Dependence on tissue type. J Biol Chem, 259, 14383-8. 
FERNS, G. A., RAINES, E. W., SPRUGEL, K. H., MOTANI, A. S., REIDY, M. A. & 
ROSS, R. 1991. Inhibition of neointimal smooth muscle accumulation after 
angioplasty by an antibody to PDGF. Science, 253, 1129-32. 
FIEDLER, J., JAZBUTYTE, V., KIRCHMAIER, B. C., GUPTA, S. K., LORENZEN, J., 
HARTMANN, D., GALUPPO, P., KNEITZ, S., PENA, J. T., SOHN-LEE, C., 
LOYER, X., SOUTSCHEK, J., BRAND, T., TUSCHL, T., HEINEKE, J., MARTIN, 
U., SCHULTE-MERKER, S., ERTL, G., ENGELHARDT, S., BAUERSACHS, J. & 
THUM, T. 2011. MicroRNA-24 regulates vascularity after myocardial 
infarction. Circulation, 124, 720-30. 
  207 
 
 
FINN, A. V., JONER, M., NAKAZAWA, G., KOLODGIE, F., NEWELL, J., JOHN, M. 
C., GOLD, H. K. & VIRMANI, R. 2007. Pathological correlates of late drug-
eluting stent thrombosis: strut coverage as a marker of endothelialization. 
Circulation, 115, 2435-41. 
FISCHMAN, D. L., LEON, M. B., BAIM, D. S., SCHATZ, R. A., SAVAGE, M. P., PENN, 
I., DETRE, K., VELTRI, L., RICCI, D., NOBUYOSHI, M. & ET AL. 1994. A 
randomized comparison of coronary-stent placement and balloon 
angioplasty in the treatment of coronary artery disease. Stent Restenosis 
Study Investigators. N Engl J Med, 331, 496-501. 
FORTE, A., DELLA CORTE, A., DE FEO, M., CERASUOLO, F. & CIPOLLARO, M. 
2010. Role of myofibroblasts in vascular remodelling: focus on restenosis 
and aneurysm. Cardiovasc Res, 88, 395-405. 
FRANK, F., SONENBERG, N. & NAGAR, B. 2010. Structural basis for 5'-nucleotide 
base-specific recognition of guide RNA by human AGO2. Nature, 465, 818-
22. 
FRIEDMAN, R. C., FARH, K. K. H., BURGE, C. B. & BARTEL, D. P. 2009. Most 
mammalian mRNAs are conserved targets of microRNAs. Genome 
Research, 19, 92-105. 
FURCHGOTT, R. F. & ZAWADZKI, J. V. 1980. The obligatory role of endothelial 
cells in the relaxation of arterial smooth muscle by acetylcholine. Nature, 
288, 373-6. 
GAGGAR, A., SHAYAKHMETOV, D. M. & LIEBER, A. 2003. CD46 is a cellular 
receptor for group B adenoviruses. Nat Med, 9, 1408-12. 
GALIS, Z. S., SUKHOVA, G. K., LARK, M. W. & LIBBY, P. 1994. Increased 
expression of matrix metalloproteinases and matrix degrading activity in 
vulnerable regions of human atherosclerotic plaques. J Clin Invest, 94, 
2493-503. 
GENG, Y. J. & LIBBY, P. 1995. Evidence for apoptosis in advanced human 
atheroma. Colocalization with interleukin-1 beta-converting enzyme. Am 
J Pathol, 147, 251-66. 
GENG, Y. J., WU, Q., MUSZYNSKI, M., HANSSON, G. K. & LIBBY, P. 1996. 
Apoptosis of vascular smooth muscle cells induced by in vitro stimulation 
with interferon-gamma, tumor necrosis factor-alpha, and interleukin-1 
beta. Arterioscler Thromb Vasc Biol, 16, 19-27. 
GEORGE, S. J., WAN, S., HU, J., MACDONALD, R., JOHNSON, J. L. & BAKER, A. H. 
2011. Sustained reduction of vein graft neointima formation by ex vivo 
TIMP-3 gene therapy. Circulation, 124, S135-42. 
GIMONA, M., KAVERINA, I., RESCH, G. P., VIGNAL, E. & BURGSTALLER, G. 2003. 
Calponin repeats regulate actin filament stability and formation of 
podosomes in smooth muscle cells. Mol Biol Cell, 14, 2482-91. 
GIRALDEZ, A. J., MISHIMA, Y., RIHEL, J., GROCOCK, R. J., VAN DONGEN, S., 
INOUE, K., ENRIGHT, A. J. & SCHIER, A. F. 2006. Zebrafish MiR-430 
promotes deadenylation and clearance of maternal mRNAs. Science, 312, 
75-9. 
GO, A. S., MOZAFFARIAN, D., ROGER, V. L., BENJAMIN, E. J., BERRY, J. D., 
BORDEN, W. B., BRAVATA, D. M., DAI, S., FORD, E. S., FOX, C. S., 
FRANCO, S., FULLERTON, H. J., GILLESPIE, C., HAILPERN, S. M., HEIT, J. 
A., HOWARD, V. J., HUFFMAN, M. D., KISSELA, B. M., KITTNER, S. J., 
LACKLAND, D. T., LICHTMAN, J. H., LISABETH, L. D., MAGID, D., MARCUS, 
G. M., MARELLI, A., MATCHAR, D. B., MCGUIRE, D. K., MOHLER, E. R., 
MOY, C. S., MUSSOLINO, M. E., NICHOL, G., PAYNTER, N. P., SCHREINER, 
P. J., SORLIE, P. D., STEIN, J., TURAN, T. N., VIRANI, S. S., WONG, N. D., 
WOO, D. & TURNER, M. B. 2013. Heart disease and stroke statistics--2013 
  208 
 
 
update: a report from the American Heart Association. Circulation, 127, 
e6-e245. 
GOLDMAN, S., ZADINA, K., MORITZ, T., OVITT, T., SETHI, G., COPELAND, J. G., 
THOTTAPURATHU, L., KRASNICKA, B., ELLIS, N., ANDERSON, R. J. & 
HENDERSON, W. 2004. Long-term patency of saphenous vein and left 
internal mammary artery grafts after coronary artery bypass surgery: 
results from a Department of Veterans Affairs Cooperative Study. J Am 
Coll Cardiol, 44, 2149-56. 
GREGORY, P. A., BERT, A. G., PATERSON, E. L., BARRY, S. C., TSYKIN, A., 
FARSHID, G., VADAS, M. A., KHEW-GOODALL, Y. & GOODALL, G. J. 2008. 
The miR-200 family and miR-205 regulate epithelial to mesenchymal 
transition by targeting ZEB1 and SIP1. Nat Cell Biol, 10, 593-601. 
GREGORY, R. I., YAN, K. P., AMUTHAN, G., CHENDRIMADA, T., DORATOTAJ, B., 
COOCH, N. & SHIEKHATTAR, R. 2004. The Microprocessor complex 
mediates the genesis of microRNAs. Nature, 432, 235-40. 
GRIMSON, A., FARH, K. K., JOHNSTON, W. K., GARRETT-ENGELE, P., LIM, L. P. & 
BARTEL, D. P. 2007. MicroRNA targeting specificity in mammals: 
determinants beyond seed pairing. Mol Cell, 27, 91-105. 
GUO, H., INGOLIA, N. T., WEISSMAN, J. S. & BARTEL, D. P. 2010. Mammalian 
microRNAs predominantly act to decrease target mRNA levels. Nature, 
466, 835-40. 
HAASE, A. D., JASKIEWICZ, L., ZHANG, H., LAINE, S., SACK, R., GATIGNOL, A. & 
FILIPOWICZ, W. 2005. TRBP, a regulator of cellular PKR and HIV-1 virus 
expression, interacts with Dicer and functions in RNA silencing. EMBO 
Rep, 6, 961-7. 
HAN, C. I., CAMPBELL, G. R. & CAMPBELL, J. H. 2001. Circulating bone marrow 
cells can contribute to neointimal formation. J Vasc Res, 38, 113-9. 
HAN, J., LEE, Y., YEOM, K. H., KIM, Y. K., JIN, H. & KIM, V. N. 2004. The Drosha-
DGCR8 complex in primary microRNA processing. Genes Dev, 18, 3016-27. 
HAN, J., LEE, Y., YEOM, K. H., NAM, J. W., HEO, I., RHEE, J. K., SOHN, S. Y., 
CHO, Y., ZHANG, B. T. & KIM, V. N. 2006. Molecular basis for the 
recognition of primary microRNAs by the Drosha-DGCR8 complex. Cell, 
125, 887-901. 
HANKE, H., STROHSCHNEIDER, T., OBERHOFF, M., BETZ, E. & KARSCH, K. R. 
1990. Time course of smooth muscle cell proliferation in the intima and 
media of arteries following experimental angioplasty. Circulation 
Research, 67, 651-9. 
HARMON, K. J., COUPER, L. L. & LINDNER, V. 2000. Strain-dependent vascular 
remodeling phenotypes in inbred mice. Am J Pathol, 156, 1741-8. 
HARRIS, T. A., YAMAKUCHI, M., FERLITO, M., MENDELL, J. T. & LOWENSTEIN, C. 
J. 2008. MicroRNA-126 regulates endothelial expression of vascular cell 
adhesion molecule 1. Proc Natl Acad Sci U S A, 105, 1516-21. 
HAUTMANN, M. B., MADSEN, C. S. & OWENS, G. K. 1997. A transforming growth 
factor beta (TGFbeta) control element drives TGFbeta-induced 
stimulation of smooth muscle alpha-actin gene expression in concert with 
two CArG elements. J Biol Chem, 272, 10948-56. 
HAVENGA, M. J., LEMCKERT, A. A., GRIMBERGEN, J. M., VOGELS, R., HUISMAN, 
L. G., VALERIO, D., BOUT, A. & QUAX, P. H. 2001. Improved adenovirus 
vectors for infection of cardiovascular tissues. J Virol, 75, 3335-42. 
HENDRICKSON, D. G., HOGAN, D. J., MCCULLOUGH, H. L., MYERS, J. W., 
HERSCHLAG, D., FERRELL, J. E. & BROWN, P. O. 2009. Concordant 
regulation of translation and mRNA abundance for hundreds of targets of 
a human microRNA. PLoS Biol, 7, e1000238. 
  209 
 
 
HENDRIX, J. A., WAMHOFF, B. R., MCDONALD, O. G., SINHA, S., YOSHIDA, T. & 
OWENS, G. K. 2005. 5' CArG degeneracy in smooth muscle alpha-actin is 
required for injury-induced gene suppression in vivo. J Clin Invest, 115, 
418-27. 
HERGENREIDER, E., HEYDT, S., TREGUER, K., BOETTGER, T., HORREVOETS, A. J., 
ZEIHER, A. M., SCHEFFER, M. P., FRANGAKIS, A. S., YIN, X., MAYR, M., 
BRAUN, T., URBICH, C., BOON, R. A. & DIMMELER, S. 2012. 
Atheroprotective communication between endothelial cells and smooth 
muscle cells through miRNAs. Nat Cell Biol, 14, 249-56. 
HERMILLER, J. B., TENAGLIA, A. N., KISSLO, K. B., PHILLIPS, H. R., BASHORE, T. 
M., STACK, R. S. & DAVIDSON, C. J. 1993. In vivo validation of 
compensatory enlargement of atherosclerotic coronary arteries. Am J 
Cardiol, 71, 665-8. 
HOLYCROSS, B. J., BLANK, R. S., THOMPSON, M. M., PEACH, M. J. & OWENS, G. 
K. 1992. Platelet-derived growth factor-BB-induced suppression of smooth 
muscle cell differentiation. Circ Res, 71, 1525-32. 
HOSHINO, Y., KURABAYASHI, M., KANDA, T., HASEGAWA, A., SAKAMOTO, H., 
OKAMOTO, E., KOWASE, K., WATANABE, N., MANABE, I., SUZUKI, T., 
NAKANO, A., TAKASE, S., WILCOX, J. N. & NAGAI, R. 2000. Regulated 
expression of the BTEB2 transcription factor in vascular smooth muscle 
cells: analysis of developmental and pathological expression profiles 
shows implications as a predictive factor for restenosis. Circulation, 102, 
2528-34. 
HOUBAVIY, H. B., MURRAY, M. F. & SHARP, P. A. 2003. Embryonic stem cell-
specific MicroRNAs. Dev Cell, 5, 351-8. 
HOUSE, S. J. & SINGER, H. A. 2008. CaMKII-delta isoform regulation of neointima 
formation after vascular injury. Arterioscler Thromb Vasc Biol, 28, 441-7. 
HTAY, T. & LIU, M. W. 2005. Drug-eluting stent: a review and update. Vasc 
Health Risk Manag, 1, 263-76. 
HUGHES, S. E., CROSSMAN, D. & HALL, P. A. 1993. Expression of basic and acidic 
fibroblast growth factors and their receptor in normal and atherosclerotic 
human arteries. Cardiovasc Res, 27, 1214-9. 
HUMPHREYS, D. T., WESTMAN, B. J., MARTIN, D. I. & PREISS, T. 2005. MicroRNAs 
control translation initiation by inhibiting eukaryotic initiation factor 
4E/cap and poly(A) tail function. Proc Natl Acad Sci U S A, 102, 16961-6. 
HUTVAGNER, G., MCLACHLAN, J., PASQUINELLI, A. E., BALINT, E., TUSCHL, T. & 
ZAMORE, P. D. 2001. A cellular function for the RNA-interference enzyme 
Dicer in the maturation of the let-7 small temporal RNA. Science, 293, 
834-8. 
IGNARRO, L. J., BUGA, G. M., WOOD, K. S., BYRNS, R. E. & CHAUDHURI, G. 1987. 
Endothelium-derived relaxing factor produced and released from artery 
and vein is nitric oxide. Proc Natl Acad Sci U S A, 84, 9265-9. 
IHGSC 2004. Finishing the euchromatic sequence of the human genome. Nature, 
431, 931-45. 
ISNER, J. M., KEARNEY, M., BORTMAN, S. & PASSERI, J. 1995. Apoptosis in human 
atherosclerosis and restenosis. Circulation, 91, 2703-11. 
JAFFE, E. A., NACHMAN, R. L., BECKER, C. G. & MINICK, C. R. 1973. Culture of 
human endothelial cells derived from umbilical veins. Identification by 
morphologic and immunologic criteria. J Clin Invest, 52, 2745-56. 
JAWIEN, A., BOWEN-POPE, D. F., LINDNER, V., SCHWARTZ, S. M. & CLOWES, A. 
W. 1992. Platelet-derived growth factor promotes smooth muscle 
migration and intimal thickening in a rat model of balloon angioplasty. J 
Clin Invest, 89, 507-11. 
  210 
 
 
JI, R., CHENG, Y., YUE, J., YANG, J., LIU, X., CHEN, H., DEAN, D. B. & ZHANG, 
C. 2007. MicroRNA expression signature and antisense-mediated depletion 
reveal an essential role of MicroRNA in vascular neointimal lesion 
formation. Circ Res, 100, 1579-88. 
JOHNSON, T. W., WU, Y. X., HERDEG, C., BAUMBACH, A., NEWBY, A. C., 
KARSCH, K. R. & OBERHOFF, M. 2005. Stent-based delivery of tissue 
inhibitor of metalloproteinase-3 adenovirus inhibits neointimal formation 
in porcine coronary arteries. Arterioscler Thromb Vasc Biol, 25, 754-9. 
JONER, M., FINN, A. V., FARB, A., MONT, E. K., KOLODGIE, F. D., LADICH, E., 
KUTYS, R., SKORIJA, K., GOLD, H. K. & VIRMANI, R. 2006. Pathology of 
drug-eluting stents in humans: delayed healing and late thrombotic risk. J 
Am Coll Cardiol, 48, 193-202. 
JONER, M., NAKAZAWA, G., FINN, A. V., QUEE, S. C., COLEMAN, L., ACAMPADO, 
E., WILSON, P. S., SKORIJA, K., CHENG, Q., XU, X., GOLD, H. K., 
KOLODGIE, F. D. & VIRMANI, R. 2008. Endothelial cell recovery between 
comparator polymer-based drug-eluting stents. Journal of the American 
College of Cardiology, 52, 333-42. 
JOPLING, C. L., YI, M., LANCASTER, A. M., LEMON, S. M. & SARNOW, P. 2005. 
Modulation of hepatitis C virus RNA abundance by a liver-specific 
MicroRNA. Science, 309, 1577-81. 
KANELLOPOULOU, C., MULJO, S. A., KUNG, A. L., GANESAN, S., DRAPKIN, R., 
JENUWEIN, T., LIVINGSTON, D. M. & RAJEWSKY, K. 2005. Dicer-deficient 
mouse embryonic stem cells are defective in differentiation and 
centromeric silencing. Genes Dev, 19, 489-501. 
KANG, H., DAVIS-DUSENBERY, B. N., NGUYEN, P. H., LAL, A., LIEBERMAN, J., 
VAN AELST, L., LAGNA, G. & HATA, A. 2012. Bone morphogenetic protein 
4 promotes vascular smooth muscle contractility by activating microRNA-
21 (miR-21), which down-regulates expression of family of dedicator of 
cytokinesis (DOCK) proteins. J Biol Chem, 287, 3976-86. 
KANO, M., SEKI, N., KIKKAWA, N., FUJIMURA, L., HOSHINO, I., AKUTSU, Y., 
CHIYOMARU, T., ENOKIDA, H., NAKAGAWA, M. & MATSUBARA, H. 2010. 
miR-145, miR-133a and miR-133b: Tumor-suppressive miRNAs target 
FSCN1 in esophageal squamous cell carcinoma. Int J Cancer, 127, 2804-14. 
KHVOROVA, A., REYNOLDS, A. & JAYASENA, S. D. 2003. Functional siRNAs and 
miRNAs exhibit strand bias. Cell, 115, 209-16. 
KIEMENEIJ, F., SERRUYS, P. W., MACAYA, C., RUTSCH, W., HEYNDRICKX, G., 
ALBERTSSON, P., FAJADET, J., LEGRAND, V., MATERNE, P., BELARDI, J., 
SIGWART, U., COLOMBO, A., GOY, J. J., DISCO, C. M. & MOREL, M. A. 
2001. Continued benefit of coronary stenting versus balloon angioplasty: 
five-year clinical follow-up of Benestent-I trial. J Am Coll Cardiol, 37, 
1598-603. 
KIM, Y. K. & KIM, V. N. 2007. Processing of intronic microRNAs. EMBO J, 26, 775-
83. 
KOCHER, O., GABBIANI, F., GABBIANI, G., REIDY, M. A., COKAY, M. S., PETERS, 
H. & HUTTNER, I. 1991. Phenotypic features of smooth muscle cells during 
the evolution of experimental carotid artery intimal thickening. 
Biochemical and morphologic studies. Lab Invest, 65, 459-70. 
KOCHER, O., SKALLI, O., BLOOM, W. S. & GABBIANI, G. 1984. Cytoskeleton of rat 
aortic smooth muscle cells. Normal conditions and experimental intimal 
thickening. Lab Invest, 50, 645-52. 
KOTANI, M., FUKUDA, N., ANDO, H., HU, W. Y., KUNIMOTO, S., SAITO, S. & 
KANMATSUSE, K. 2003. Chimeric DNA-RNA hammerhead ribozyme 
  211 
 
 
targeting PDGF A-chain mRNA specifically inhibits neointima formation in 
rat carotid artery after balloon injury. Cardiovasc Res, 57, 265-76. 
KOVANEN, P. T., KAARTINEN, M. & PAAVONEN, T. 1995. Infiltrates of activated 
mast cells at the site of coronary atheromatous erosion or rupture in 
myocardial infarction. Circulation, 92, 1084-8. 
KOYAMA, N., KOSHIKAWA, T., MORISAKI, N., SAITO, Y. & YOSHIDA, S. 1990. 
Bifunctional effects of transforming growth factor-beta on migration of 
cultured rat aortic smooth muscle cells. Biochem Biophys Res Commun, 
169, 725-9. 
KRICHEVSKY, A. M., KING, K. S., DONAHUE, C. P., KHRAPKO, K. & KOSIK, K. S. 
2003. A microRNA array reveals extensive regulation of microRNAs during 
brain development. RNA, 9, 1274-81. 
KRUTZFELDT, J., KUWAJIMA, S., BRAICH, R., RAJEEV, K. G., PENA, J., TUSCHL, 
T., MANOHARAN, M. & STOFFEL, M. 2007. Specificity, duplex degradation 
and subcellular localization of antagomirs. Nucleic Acids Res, 35, 2885-92. 
KRUTZFELDT, J., RAJEWSKY, N., BRAICH, R., RAJEEV, K. G., TUSCHL, T., 
MANOHARAN, M. & STOFFEL, M. 2005. Silencing of microRNAs in vivo with 
'antagomirs'. Nature, 438, 685-9. 
KU, D. N., GIDDENS, D. P., ZARINS, C. K. & GLAGOV, S. 1985. Pulsatile flow and 
atherosclerosis in the human carotid bifurcation. Positive correlation 
between plaque location and low oscillating shear stress. Arteriosclerosis, 
5, 293-302. 
KUEHBACHER, A., URBICH, C., ZEIHER, A. M. & DIMMELER, S. 2007. Role of Dicer 
and Drosha for endothelial microRNA expression and angiogenesis. Circ 
Res, 101, 59-68. 
KUHEL, D. G., ZHU, B., WITTE, D. P. & HUI, D. Y. 2002. Distinction in genetic 
determinants for injury-induced neointimal hyperplasia and diet-induced 
atherosclerosis in inbred mice. Arterioscler Thromb Vasc Biol, 22, 955-60. 
KUMAR, A. & LINDNER, V. 1997. Remodeling with neointima formation in the 
mouse carotid artery after cessation of blood flow. Arterioscler Thromb 
Vasc Biol, 17, 2238-44. 
KUMAR, M. S., ERKELAND, S. J., PESTER, R. E., CHEN, C. Y., EBERT, M. S., 
SHARP, P. A. & JACKS, T. 2008. Suppression of non-small cell lung tumor 
development by the let-7 microRNA family. Proc Natl Acad Sci U S A, 105, 
3903-8. 
KUMARSWAMY, R., VOLKMANN, I., JAZBUTYTE, V., DANGWAL, S., PARK, D. H. & 
THUM, T. 2012. Transforming growth factor-beta-induced endothelial-to-
mesenchymal transition is partly mediated by microRNA-21. Arterioscler 
Thromb Vasc Biol, 32, 361-9. 
KURO-O, M., NAGAI, R., NAKAHARA, K., KATOH, H., TSAI, R. C., TSUCHIMOCHI, 
H., YAZAKI, Y., OHKUBO, A. & TAKAKU, F. 1991. cDNA cloning of a myosin 
heavy chain isoform in embryonic smooth muscle and its expression during 
vascular development and in arteriosclerosis. J Biol Chem, 266, 3768-73. 
KWAK, P. B. & TOMARI, Y. 2012. The N domain of Argonaute drives duplex 
unwinding during RISC assembly. Nat Struct Mol Biol, 19, 145-51. 
LAGOS-QUINTANA, M., RAUHUT, R., LENDECKEL, W. & TUSCHL, T. 2001. 
Identification of novel genes coding for small expressed RNAs. Science, 
294, 853-8. 
LANDTHALER, M., YALCIN, A. & TUSCHL, T. 2004. The human DiGeorge syndrome 
critical region gene 8 and Its D. melanogaster homolog are required for 
miRNA biogenesis. Curr Biol, 14, 2162-7. 
LANFORD, R. E., HILDEBRANDT-ERIKSEN, E. S., PETRI, A., PERSSON, R., LINDOW, 
M., MUNK, M. E., KAUPPINEN, S. & ORUM, H. 2010. Therapeutic silencing 
  212 
 
 
of microRNA-122 in primates with chronic hepatitis C virus infection. 
Science, 327, 198-201. 
LAU, N. C., LIM, L. P., WEINSTEIN, E. G. & BARTEL, D. P. 2001. An abundant 
class of tiny RNAs with probable regulatory roles in Caenorhabditis 
elegans. Science, 294, 858-62. 
LEE, H. K., BIER, A., CAZACU, S., FINNISS, S., XIANG, C., TWITO, H., POISSON, L. 
M., MIKKELSEN, T., SLAVIN, S., JACOBY, E., YALON, M., TOREN, A., 
REMPEL, S. A. & BRODIE, C. 2013. MicroRNA-145 is downregulated in glial 
tumors and regulates glioma cell migration by targeting connective tissue 
growth factor. PLoS One, 8, e54652. 
LEE, R. C., FEINBAUM, R. L. & AMBROS, V. 1993. The C. elegans heterochronic 
gene lin-4 encodes small RNAs with antisense complementarity to lin-14. 
Cell, 75, 843-54. 
LEE, Y., AHN, C., HAN, J., CHOI, H., KIM, J., YIM, J., LEE, J., PROVOST, P., 
RADMARK, O., KIM, S. & KIM, V. N. 2003. The nuclear RNase III Drosha 
initiates microRNA processing. Nature, 425, 415-9. 
LEE, Y., HUR, I., PARK, S. Y., KIM, Y. K., SUH, M. R. & KIM, V. N. 2006. The role 
of PACT in the RNA silencing pathway. EMBO J, 25, 522-32. 
LEE, Y., JEON, K., LEE, J. T., KIM, S. & KIM, V. N. 2002. MicroRNA maturation: 
stepwise processing and subcellular localization. EMBO J, 21, 4663-70. 
LEE, Y., KIM, M., HAN, J., YEOM, K. H., LEE, S., BAEK, S. H. & KIM, V. N. 2004. 
MicroRNA genes are transcribed by RNA polymerase II. EMBO J, 23, 4051-
60. 
LENDON, C. L., DAVIES, M. J., BORN, G. V. & RICHARDSON, P. D. 1991. 
Atherosclerotic plaque caps are locally weakened when macrophages 
density is increased. Atherosclerosis, 87, 87-90. 
LEWIS, B. P., SHIH, I. H., JONES-RHOADES, M. W., BARTEL, D. P. & BURGE, C. B. 
2003. Prediction of mammalian microRNA targets. Cell, 115, 787-98. 
LI, L., LIU, Z., MERCER, B., OVERBEEK, P. & OLSON, E. N. 1997. Evidence for 
serum response factor-mediated regulatory networks governing SM22alpha 
transcription in smooth, skeletal, and cardiac muscle cells. Dev Biol, 187, 
311-21. 
LI, S., WANG, D. Z., WANG, Z., RICHARDSON, J. A. & OLSON, E. N. 2003. The 
serum response factor coactivator myocardin is required for vascular 
smooth muscle development. Proc Natl Acad Sci U S A, 100, 9366-70. 
LIANG, C. C., PARK, A. Y. & GUAN, J. L. 2007. In vitro scratch assay: a 
convenient and inexpensive method for analysis of cell migration in vitro. 
Nat Protoc, 2, 329-33. 
LIBBY, P., SCHWARTZ, D., BROGI, E., TANAKA, H. & CLINTON, S. K. 1992. A 
cascade model for restenosis. A special case of atherosclerosis 
progression. Circulation, 86, III47-52. 
LIM, L. P., LAU, N. C., GARRETT-ENGELE, P., GRIMSON, A., SCHELTER, J. M., 
CASTLE, J., BARTEL, D. P., LINSLEY, P. S. & JOHNSON, J. M. 2005. 
Microarray analysis shows that some microRNAs downregulate large 
numbers of target mRNAs. Nature, 433, 769-73. 
LINDER, S. & AEPFELBACHER, M. 2003. Podosomes: adhesion hot-spots of 
invasive cells. Trends Cell Biol, 13, 376-85. 
LINDNER, V., FINGERLE, J. & REIDY, M. A. 1993. Mouse model of arterial injury. 
Circ Res, 73, 792-6. 
LINDNER, V. & REIDY, M. A. 1991. Proliferation of smooth muscle cells after 
vascular injury is inhibited by an antibody against basic fibroblast growth 
factor. Proc Natl Acad Sci U S A, 88, 3739-43. 
  213 
 
 
LINDOW, M. & KAUPPINEN, S. 2012. Discovering the first microRNA-targeted 
drug. J Cell Biol, 199, 407-12. 
LIU, J., CARMELL, M. A., RIVAS, F. V., MARSDEN, C. G., THOMSON, J. M., SONG, 
J. J., HAMMOND, S. M., JOSHUA-TOR, L. & HANNON, G. J. 2004. 
Argonaute2 is the catalytic engine of mammalian RNAi. Science, 305, 
1437-41. 
LIU, N., BEZPROZVANNAYA, S., WILLIAMS, A. H., QI, X., RICHARDSON, J. A., 
BASSEL-DUBY, R. & OLSON, E. N. 2008. microRNA-133a regulates 
cardiomyocyte proliferation and suppresses smooth muscle gene 
expression in the heart. Genes Dev, 22, 3242-54. 
LIU, X., CHENG, Y., ZHANG, S., LIN, Y., YANG, J. & ZHANG, C. 2009. A necessary 
role of miR-221 and miR-222 in vascular smooth muscle cell proliferation 
and neointimal hyperplasia. Circ Res, 104, 476-87. 
LIU, Y., SINHA, S., MCDONALD, O. G., SHANG, Y., HOOFNAGLE, M. H. & OWENS, 
G. K. 2005. Kruppel-like factor 4 abrogates myocardin-induced activation 
of smooth muscle gene expression. J Biol Chem, 280, 9719-27. 
LONG, X., BELL, R. D., GERTHOFFER, W. T., ZLOKOVIC, B. V. & MIANO, J. M. 
2008. Myocardin is sufficient for a smooth muscle-like contractile 
phenotype. Arterioscler Thromb Vasc Biol, 28, 1505-10. 
LONG, X. & MIANO, J. M. 2011. Transforming growth factor-beta1 (TGF-beta1) 
utilizes distinct pathways for the transcriptional activation of microRNA 
143/145 in human coronary artery smooth muscle cells. J Biol Chem, 286, 
30119-29. 
LOVREN, F., PAN, Y., QUAN, A., SINGH, K. K., SHUKLA, P. C., GUPTA, N., STEER, 
B. M., INGRAM, A. J., GUPTA, M., AL-OMRAN, M., TEOH, H., MARSDEN, P. 
A. & VERMA, S. 2012. MicroRNA-145 targeted therapy reduces 
atherosclerosis. Circulation, 126, S81-90. 
LOWE, H. C., SCHWARTZ, R. S., MAC NEILL, B. D., JANG, I. K., HAYASE, M., 
ROGERS, C. & OESTERLE, S. N. 2003. The porcine coronary model of in-
stent restenosis: current status in the era of drug-eluting stents. Catheter 
Cardiovasc Interv, 60, 515-23. 
LOWENSTEIN, P. R., SHERING, I. A. F., BAIN, D., CASTRO, M. G., AND WILKINSON, 
G. W. G. 1996. How to examine the interactions between adenoviral 
mediated gene transfer and different indentified target brain cell types 
in vitro, In Towards Gene Therapy for Neurological Disorders  Chichester, 
UK. 
LU, J., GETZ, G., MISKA, E. A., ALVAREZ-SAAVEDRA, E., LAMB, J., PECK, D., 
SWEET-CORDERO, A., EBERT, B. L., MAK, R. H., FERRANDO, A. A., 
DOWNING, J. R., JACKS, T., HORVITZ, H. R. & GOLUB, T. R. 2005. 
MicroRNA expression profiles classify human cancers. Nature, 435, 834-8. 
LUCIANO, D. J., MIRSKY, H., VENDETTI, N. J. & MAAS, S. 2004. RNA editing of a 
miRNA precursor. RNA, 10, 1174-7. 
LUDMER, P. L., SELWYN, A. P., SHOOK, T. L., WAYNE, R. R., MUDGE, G. H., 
ALEXANDER, R. W. & GANZ, P. 1986. Paradoxical vasoconstriction induced 
by acetylcholine in atherosclerotic coronary arteries. N Engl J Med, 315, 
1046-51. 
LUND, E., LIU, M., HARTLEY, R. S., SHEETS, M. D. & DAHLBERG, J. E. 2009. 
Deadenylation of maternal mRNAs mediated by miR-427 in Xenopus laevis 
embryos. RNA, 15, 2351-63. 
LUSCHER, T. F., STEFFEL, J., EBERLI, F. R., JONER, M., NAKAZAWA, G., TANNER, 
F. C. & VIRMANI, R. 2007. Drug-eluting stent and coronary thrombosis - 
Biological mechanisms and clinical implications. Circulation, 115, 1051-
1058. 
  214 
 
 
MA, J. B., YE, K. & PATEL, D. J. 2004. Structural basis for overhang-specific 
small interfering RNA recognition by the PAZ domain. Nature, 429, 318-
22. 
MACHLIN, E. S., SARNOW, P. & SAGAN, S. M. 2011. Masking the 5' terminal 
nucleotides of the hepatitis C virus genome by an unconventional 
microRNA-target RNA complex. Proc Natl Acad Sci U S A, 108, 3193-8. 
MACK, C. P. & OWENS, G. K. 1999. Regulation of smooth muscle alpha-actin 
expression in vivo is dependent on CArG elements within the 5' and first 
intron promoter regions. Circ Res, 84, 852-61. 
MACRAE, I. J., MA, E., ZHOU, M., ROBINSON, C. V. & DOUDNA, J. A. 2008. In 
vitro reconstitution of the human RISC-loading complex. Proc Natl Acad 
Sci U S A, 105, 512-7. 
MACRAE, I. J., ZHOU, K., LI, F., REPIC, A., BROOKS, A. N., CANDE, W. Z., 
ADAMS, P. D. & DOUDNA, J. A. 2006. Structural basis for double-stranded 
RNA processing by Dicer. Science, 311, 195-8. 
MAEGDEFESSEL, L., AZUMA, J., TOH, R., MERK, D. R., DENG, A., CHIN, J. T., 
RAAZ, U., SCHOELMERICH, A. M., RAIESDANA, A., LEEPER, N. J., 
MCCONNELL, M. V., DALMAN, R. L., SPIN, J. M. & TSAO, P. S. 2012. 
Inhibition of microRNA-29b reduces murine abdominal aortic aneurysm 
development. J Clin Invest, 122, 497-506. 
MAENG, M., MERTZ, H., NIELSEN, S., VAN EYS, G. J., RASMUSSEN, K. & 
ESPERSEN, G. T. 2003. Adventitial myofibroblasts play no major role in 
neointima formation after angioplasty. Scand Cardiovasc J, 37, 34-42. 
MAJESKY, M. W., LINDNER, V., TWARDZIK, D. R., SCHWARTZ, S. M. & REIDY, M. 
A. 1991. Production of transforming growth factor beta 1 during repair of 
arterial injury. J Clin Invest, 88, 904-10. 
MALIK, N., GUNN, J., HOLT, C. M., SHEPHERD, L., FRANCIS, S. E., NEWMAN, C. 
M., CROSSMAN, D. C. & CUMBERLAND, D. C. 1998. Intravascular stents: a 
new technique for tissue processing for histology, immunohistochemistry, 
and transmission electron microscopy. Heart, 80, 509-16. 
MANABE, I. & OWENS, G. K. 2001. CArG elements control smooth muscle 
subtype-specific expression of smooth muscle myosin in vivo. J Clin 
Invest, 107, 823-34. 
MANDERSON, J. A., MOSSE, P. R., SAFSTROM, J. A., YOUNG, S. B. & CAMPBELL, 
G. R. 1989. Balloon catheter injury to rabbit carotid artery. I. Changes in 
smooth muscle phenotype. Arteriosclerosis, 9, 289-98. 
MANN, J. & DAVIES, M. J. 1999. Mechanisms of progression in native coronary 
artery disease: role of healed plaque disruption. Heart, 82, 265-8. 
MARON, D. J., FAZIO, S. & LINTON, M. F. 2000. Current perspectives on statins. 
Circulation, 101, 207-13. 
MARTIN, G. R. 1981. Isolation of a pluripotent cell line from early mouse 
embryos cultured in medium conditioned by teratocarcinoma stem cells. 
Proc Natl Acad Sci U S A, 78, 7634-8. 
MAYORGA, M. E. & PENN, M. S. 2012. miR-145 is differentially regulated by TGF-
beta1 and ischaemia and targets Disabled-2 expression and wnt/beta-
catenin activity. J Cell Mol Med, 16, 1106-13. 
MAYR, U., ZOU, Y. P., ZHANG, Z. Y., DIETRICH, H., HU, Y. H. & XU, Q. B. 2006. 
Accelerated arteriosclerosis of vein grafts in inducible NO synthase(-/-) 
mice is related to decreased endothelial progenitor cell repair. 
Circulation Research, 98, 412-420. 
MCCAFFREY, T. A., CONSIGLI, S., DU, B., FALCONE, D. J., SANBORN, T. A., 
SPOKOJNY, A. M. & BUSH, H. L., JR. 1995. Decreased type II/type I TGF-
beta receptor ratio in cells derived from human atherosclerotic lesions. 
  215 
 
 
Conversion from an antiproliferative to profibrotic response to TGF-beta1. 
J Clin Invest, 96, 2667-75. 
MCFADDEN, E. P., STABILE, E., REGAR, E., CHENEAU, E., ONG, A. T., KINNAIRD, 
T., SUDDATH, W. O., WEISSMAN, N. J., TORGUSON, R., KENT, K. M., 
PICHARD, A. D., SATLER, L. F., WAKSMAN, R. & SERRUYS, P. W. 2004. Late 
thrombosis in drug-eluting coronary stents after discontinuation of 
antiplatelet therapy. Lancet, 364, 1519-21. 
MEISTER, G., LANDTHALER, M., PATKANIOWSKA, A., DORSETT, Y., TENG, G. & 
TUSCHL, T. 2004. Human Argonaute2 mediates RNA cleavage targeted by 
miRNAs and siRNAs. Mol Cell, 15, 185-97. 
MERCER, T. R., DINGER, M. E. & MATTICK, J. S. 2009. Long non-coding RNAs: 
insights into functions. Nat Rev Genet, 10, 155-9. 
MIANO, J. M., LONG, X. & FUJIWARA, K. 2007. Serum response factor: master 
regulator of the actin cytoskeleton and contractile apparatus. Am J 
Physiol Cell Physiol, 292, C70-81. 
MII, S., WARE, J. A. & KENT, K. C. 1993. Transforming growth factor-beta 
inhibits human vascular smooth muscle cell growth and migration. 
Surgery, 114, 464-70. 
MILLER, D. D., KARIM, M. A., EDWARDS, W. D. & SCHWARTZ, R. S. 1996. 
Relationship of vascular thrombosis and inflammatory leukocyte 
infiltration to neointimal growth following porcine coronary artery stent 
placement. Atherosclerosis, 124, 145-55. 
MINENO, J., OKAMOTO, S., ANDO, T., SATO, M., CHONO, H., IZU, H., TAKAYAMA, 
M., ASADA, K., MIROCHNITCHENKO, O., INOUYE, M. & KATO, I. 2006. The 
expression profile of microRNAs in mouse embryos. Nucleic Acids Res, 34, 
1765-71. 
MOHR, F. W., MORICE, M. C., KAPPETEIN, A. P., FELDMAN, T. E., STAHLE, E., 
COLOMBO, A., MACK, M. J., HOLMES, D. R., JR., MOREL, M. A., VAN DYCK, 
N., HOULE, V. M., DAWKINS, K. D. & SERRUYS, P. W. 2013. Coronary 
artery bypass graft surgery versus percutaneous coronary intervention in 
patients with three-vessel disease and left main coronary disease: 5-year 
follow-up of the randomised, clinical SYNTAX trial. Lancet, 381, 629-38. 
MONTEYS, A. M., SPENGLER, R. M., WAN, J., TECEDOR, L., LENNOX, K. A., XING, 
Y. & DAVIDSON, B. L. 2010. Structure and activity of putative intronic 
miRNA promoters. RNA, 16, 495-505. 
MONTGOMERY, R. L., HULLINGER, T. G., SEMUS, H. M., DICKINSON, B. A., SETO, 
A. G., LYNCH, J. M., STACK, C., LATIMER, P. A., OLSON, E. N. & VAN 
ROOIJ, E. 2011. Therapeutic inhibition of miR-208a improves cardiac 
function and survival during heart failure. Circulation, 124, 1537-47. 
MORENO, P. R., BERNARDI, V. H., LOPEZ-CUELLAR, J., NEWELL, J. B., 
MCMELLON, C., GOLD, H. K., PALACIOS, I. F., FUSTER, V. & FALLON, J. T. 
1996. Macrophage infiltration predicts restenosis after coronary 
intervention in patients with unstable angina. Circulation, 94, 3098-102. 
MORENO, R., FERNANDEZ, C., HERNANDEZ, R., ALFONSO, F., ANGIOLILLO, D. J., 
SABATE, M., ESCANED, J., BANUELOS, C., FERNANDEZ-ORTIZ, A. & 
MACAYA, C. 2005. Drug-eluting stent thrombosis - Results from a pooled 
analysis including 10 randomized studies. Journal of the American College 
of Cardiology, 45, 954-959. 
MUKHERJI, S., EBERT, M. S., ZHENG, G. X., TSANG, J. S., SHARP, P. A. & VAN 
OUDENAARDEN, A. 2011. MicroRNAs can generate thresholds in target 
gene expression. Nat Genet, 43, 854-9. 
  216 
 
 
MURCHISON, E. P., PARTRIDGE, J. F., TAM, O. H., CHELOUFI, S. & HANNON, G. 
J. 2005. Characterization of Dicer-deficient murine embryonic stem cells. 
Proc Natl Acad Sci U S A, 102, 12135-40. 
NABEL, E. G., SHUM, L., POMPILI, V. J., YANG, Z. Y., SAN, H., SHU, H. B., 
LIPTAY, S., GOLD, L., GORDON, D., DERYNCK, R. & ET AL. 1993. Direct 
transfer of transforming growth factor beta 1 gene into arteries stimulates 
fibrocellular hyperplasia. Proc Natl Acad Sci U S A, 90, 10759-63. 
NAGA PRASAD, S. V., DUAN, Z. H., GUPTA, M. K., SURAMPUDI, V. S., VOLINIA, S., 
CALIN, G. A., LIU, C. G., KOTWAL, A., MORAVEC, C. S., STARLING, R. C., 
PEREZ, D. M., SEN, S., WU, Q., PLOW, E. F., CROCE, C. M. & KARNIK, S. 
2009. Unique microRNA profile in end-stage heart failure indicates 
alterations in specific cardiovascular signaling networks. J Biol Chem, 
284, 27487-99. 
NAKASHIMA, Y., PLUMP, A. S., RAINES, E. W., BRESLOW, J. L. & ROSS, R. 1994. 
ApoE-deficient mice develop lesions of all phases of atherosclerosis 
throughout the arterial tree. Arterioscler Thromb, 14, 133-40. 
NEMENOFF, R. A., HORITA, H., OSTRIKER, A. C., FURGESON, S. B., SIMPSON, P. 
A., VANPUTTEN, V., CROSSNO, J., OFFERMANNS, S. & WEISER-EVANS, M. 
C. 2011. SDF-1alpha induction in mature smooth muscle cells by 
inactivation of PTEN is a critical mediator of exacerbated injury-induced 
neointima formation. Arterioscler Thromb Vasc Biol, 31, 1300-8. 
NIKKARI, S. T., JARVELAINEN, H. T., WIGHT, T. N., FERGUSON, M. & CLOWES, A. 
W. 1994. Smooth muscle cell expression of extracellular matrix genes 
after arterial injury. Am J Pathol, 144, 1348-56. 
NIKOL, S., ISNER, J. M., PICKERING, J. G., KEARNEY, M., LECLERC, G. & WEIR, L. 
1992. Expression of transforming growth factor-beta 1 is increased in 
human vascular restenosis lesions. J Clin Invest, 90, 1582-92. 
NISHIOKA, T., LUO, H., EIGLER, N. L., BERGLUND, H., KIM, C. J. & SIEGEL, R. J. 
1996. Contribution of inadequate compensatory enlargement to 
development of human coronary artery stenosis: an in vivo intravascular 
ultrasound study. J Am Coll Cardiol, 27, 1571-6. 
NONNE, N., AMEYAR-ZAZOUA, M., SOUIDI, M. & HAREL-BELLAN, A. 2010. Tandem 
affinity purification of miRNA target mRNAs (TAP-Tar). Nucleic Acids Res, 
38, e20. 
NOTTROTT, S., SIMARD, M. J. & RICHTER, J. D. 2006. Human let-7a miRNA blocks 
protein production on actively translating polyribosomes. Nat Struct Mol 
Biol, 13, 1108-14. 
OLSEN, P. H. & AMBROS, V. 1999. The lin-4 regulatory RNA controls 
developmental timing in Caenorhabditis elegans by blocking LIN-14 
protein synthesis after the initiation of translation. Dev Biol, 216, 671-80. 
OLSON, N. E., CHAO, S., LINDNER, V. & REIDY, M. A. 1992. Intimal smooth 
muscle cell proliferation after balloon catheter injury. The role of basic 
fibroblast growth factor. Am J Pathol, 140, 1017-23. 
ORLANDI, A., EHRLICH, H. P., ROPRAZ, P., SPAGNOLI, L. G. & GABBIANI, G. 
1994. Rat aortic smooth muscle cells isolated from different layers and at 
different times after endothelial denudation show distinct biological 
features in vitro. Arterioscler Thromb, 14, 982-9. 
OROM, U. A. & LUND, A. H. 2007. Isolation of microRNA targets using 
biotinylated synthetic microRNAs. Methods, 43, 162-5. 
OWENS, G. K., KUMAR, M. S. & WAMHOFF, B. R. 2004. Molecular regulation of 
vascular smooth muscle cell differentiation in development and disease. 
Physiol Rev, 84, 767-801. 
  217 
 
 
PALMER, R. M., FERRIGE, A. G. & MONCADA, S. 1987. Nitric oxide release 
accounts for the biological activity of endothelium-derived relaxing 
factor. Nature, 327, 524-6. 
PAPAFAKLIS, M. I., BOURANTAS, C. V., THEODORAKIS, P. E., KATSOURAS, C. S., 
FOTIADIS, D. I. & MICHALIS, L. K. 2009. Relationship of shear stress with 
in-stent restenosis: bare metal stenting and the effect of brachytherapy. 
Int J Cardiol, 134, 25-32. 
PARKER, A. L., WHITE, K. M., LAVERY, C. A., CUSTERS, J., WADDINGTON, S. N. & 
BAKER, A. H. 2013. Pseudotyping the adenovirus serotype 5 capsid with 
both the fibre and penton of serotype 35 enhances vascular smooth 
muscle cell transduction. Gene Ther. 
PASTERKAMP, G., WENSING, P. J., POST, M. J., HILLEN, B., MALI, W. P. & 
BORST, C. 1995. Paradoxical arterial wall shrinkage may contribute to 
luminal narrowing of human atherosclerotic femoral arteries. Circulation, 
91, 1444-9. 
PETERSEN, C. P., BORDELEAU, M. E., PELLETIER, J. & SHARP, P. A. 2006. Short 
RNAs repress translation after initiation in mammalian cells. Mol Cell, 21, 
533-42. 
PFISTERER, M., BRUNNER-LA ROCCA, H. P., BUSER, P. T., RICKENBACHER, P., 
HUNZIKER, P., MUELLER, C., JEGER, R., BADER, F., OSSWALD, S. & 
KAISER, C. 2006. Late clinical events after clopidogrel discontinuation 
may limit the benefit of drug-eluting stents: an observational study of 
drug-eluting versus bare-metal stents. J Am Coll Cardiol, 48, 2584-91. 
PIAO, X., ZHANG, X., WU, L. & BELASCO, J. G. 2010. CCR4-NOT deadenylates 
mRNA associated with RNA-induced silencing complexes in human cells. 
Mol Cell Biol, 30, 1486-94. 
PIEDRAHITA, J. A., ZHANG, S. H., HAGAMAN, J. R., OLIVER, P. M. & MAEDA, N. 
1992. Generation of mice carrying a mutant apolipoprotein E gene 
inactivated by gene targeting in embryonic stem cells. Proc Natl Acad Sci 
U S A, 89, 4471-5. 
PILLAI, R. S., BHATTACHARYYA, S. N., ARTUS, C. G., ZOLLER, T., COUGOT, N., 
BASYUK, E., BERTRAND, E. & FILIPOWICZ, W. 2005. Inhibition of 
translational initiation by Let-7 MicroRNA in human cells. Science, 309, 
1573-6. 
PLUMP, A. S., SMITH, J. D., HAYEK, T., AALTO-SETALA, K., WALSH, A., 
VERSTUYFT, J. G., RUBIN, E. M. & BRESLOW, J. L. 1992. Severe 
hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient 
mice created by homologous recombination in ES cells. Cell, 71, 343-53. 
POLISENO, L., TUCCOLI, A., MARIANI, L., EVANGELISTA, M., CITTI, L., WOODS, 
K., MERCATANTI, A., HAMMOND, S. & RAINALDI, G. 2006. MicroRNAs 
modulate the angiogenic properties of HUVECs. Blood, 108, 3068-71. 
PORSTMANN, T., TERNYNCK, T. & AVRAMEAS, S. 1985. Quantitation of 5-bromo-
2-deoxyuridine incorporation into DNA: an enzyme immunoassay for the 
assessment of the lymphoid cell proliferative response. J Immunol 
Methods, 82, 169-79. 
PORT, J. D., WALKER, L. A., POLK, J., NUNLEY, K., BUTTRICK, P. M. & 
SUCHAROV, C. C. 2011. Temporal expression of miRNAs and mRNAs in a 
mouse model of myocardial infarction. Physiol Genomics, 43, 1087-95. 
QUINTAVALLE, M., ELIA, L., CONDORELLI, G. & COURTNEIDGE, S. A. 2010. 
MicroRNA control of podosome formation in vascular smooth muscle cells 
in vivo and in vitro. J Cell Biol, 189, 13-22. 
RAINES, E. W. & ROSS, R. 1993. Smooth muscle cells and the pathogenesis of the 
lesions of atherosclerosis. Br Heart J, 69, S30-7. 
  218 
 
 
RAMALINGAM, P., PALANICHAMY, J. K., SINGH, A., DAS, P., BHAGAT, M., KASSAB, 
M. A., SINHA, S. & CHATTOPADHYAY, P. 2014. Biogenesis of intronic 
miRNAs located in clusters by independent transcription and alternative 
splicing. RNA, 20, 76-87. 
RAO, P. K., TOYAMA, Y., CHIANG, H. R., GUPTA, S., BAUER, M., MEDVID, R., 
REINHARDT, F., LIAO, R., KRIEGER, M., JAENISCH, R., LODISH, H. F. & 
BLELLOCH, R. 2009. Loss of cardiac microRNA-mediated regulation leads 
to dilated cardiomyopathy and heart failure. Circ Res, 105, 585-94. 
RAPPOLEE, D. A., MARK, D., BANDA, M. J. & WERB, Z. 1988. Wound macrophages 
express TGF-alpha and other growth factors in vivo: analysis by mRNA 
phenotyping. Science, 241, 708-12. 
RAYNER, K. J., ESAU, C. C., HUSSAIN, F. N., MCDANIEL, A. L., MARSHALL, S. M., 
VAN GILS, J. M., RAY, T. D., SHEEDY, F. J., GOEDEKE, L., LIU, X., 
KHATSENKO, O. G., KAIMAL, V., LEES, C. J., FERNANDEZ-HERNANDO, C., 
FISHER, E. A., TEMEL, R. E. & MOORE, K. J. 2011. Inhibition of miR-33a/b 
in non-human primates raises plasma HDL and lowers VLDL triglycerides. 
Nature, 478, 404-7. 
REDDY, K. B. & HOWE, P. H. 1993. Transforming growth factor beta 1-mediated 
inhibition of smooth muscle cell proliferation is associated with a late G1 
cell cycle arrest. J Cell Physiol, 156, 48-55. 
REHWINKEL, J., BEHM-ANSMANT, I., GATFIELD, D. & IZAURRALDE, E. 2005. A 
crucial role for GW182 and the DCP1:DCP2 decapping complex in miRNA-
mediated gene silencing. RNA, 11, 1640-7. 
RHOADES, M. W., REINHART, B. J., LIM, L. P., BURGE, C. B., BARTEL, B. & 
BARTEL, D. P. 2002. Prediction of plant microRNA targets. Cell, 110, 513-
20. 
RIPPSTEIN, P., BLACK, M. K., BOIVIN, M., VEINOT, J. P., MA, X., CHEN, Y. X., 
HUMAN, P., ZILLA, P. & O'BRIEN, E. R. 2006. Comparison of processing and 
sectioning methodologies for arteries containing metallic stents. J 
Histochem Cytochem, 54, 673-81. 
RO, S., PARK, C., YOUNG, D., SANDERS, K. M. & YAN, W. 2007. Tissue-dependent 
paired expression of miRNAs. Nucleic Acids Res, 35, 5944-53. 
RODRIGUEZ-MENOCAL, L., WEI, Y., PHAM, S. M., ST-PIERRE, M., LI, S., WEBSTER, 
K., GOLDSCHMIDT-CLERMONT, P. & VAZQUEZ-PADRON, R. I. 2010. A novel 
mouse model of in-stent restenosis. Atherosclerosis, 209, 359-66. 
ROSS, R. 1993. The pathogenesis of atherosclerosis: a perspective for the 1990s. 
Nature, 362, 801-9. 
ROSS, R. 1999. Atherosclerosis--an inflammatory disease. N Engl J Med, 340, 
115-26. 
ROSS, R., MASUDA, J., RAINES, E. W., GOWN, A. M., KATSUDA, S., SASAHARA, 
M., MALDEN, L. T., MASUKO, H. & SATO, H. 1990. Localization of PDGF-B 
protein in macrophages in all phases of atherogenesis. Science, 248, 1009-
12. 
RUBARTELLI, P., VERNA, E., NICCOLI, L., GIACHERO, C., ZIMARINO, M., 
BERNARDI, G., VASSANELLI, C., CAMPOLO, L. & MARTUSCELLI, E. 2003. 
Coronary stent implantation is superior to balloon angioplasty for chronic 
coronary occlusions: six-year clinical follow-up of the GISSOC trial. J Am 
Coll Cardiol, 41, 1488-92. 
RUVKUN, G. & GIUSTO, J. 1989. The Caenorhabditis elegans heterochronic gene 
lin-14 encodes a nuclear protein that forms a temporal developmental 
switch. Nature, 338, 313-9. 
SABATEL, C., MALVAUX, L., BOVY, N., DEROANNE, C., LAMBERT, V., GONZALEZ, 
M. L., COLIGE, A., RAKIC, J. M., NOEL, A., MARTIAL, J. A. & STRUMAN, I. 
  219 
 
 
2011. MicroRNA-21 exhibits antiangiogenic function by targeting RhoB 
expression in endothelial cells. PLoS One, 6, e16979. 
SAINI, H. K., GRIFFITHS-JONES, S. & ENRIGHT, A. J. 2007. Genomic analysis of 
human microRNA transcripts. Proc Natl Acad Sci U S A, 104, 17719-24. 
SAKAMOTO, H., SAKAMAKI, T., KANDA, T., HOSHINO, Y., SAWADA, Y., SATO, M., 
SATO, H., OYAMA, Y., NAKANO, A., TAKASE, S., HASEGAWA, A., NAGAI, R. 
& KURABAYASHI, M. 2003. Smooth muscle cell outgrowth from coronary 
atherectomy specimens in vitro is associated with less time to restenosis 
and expression of a key Transcription factor KLF5/BTEB2. Cardiology, 100, 
80-5. 
SANMARTIN, M., GOICOLEA, J., GARCIA, C., GARCIA, J., CRESPO, A., RODRIGUEZ, 
J. & GOICOLEA, J. M. 2006. [Influence of shear stress on in-stent 
restenosis: in vivo study using 3D reconstruction and computational fluid 
dynamics]. Rev Esp Cardiol, 59, 20-7. 
SATA, M., SAIURA, A., KUNISATO, A., TOJO, A., OKADA, S., TOKUHISA, T., HIRAI, 
H., MAKUUCHI, M., HIRATA, Y. & NAGAI, R. 2002. Hematopoietic stem 
cells differentiate into vascular cells that participate in the pathogenesis 
of atherosclerosis. Nat Med, 8, 403-9. 
SAUER, B. 1998. Inducible gene targeting in mice using the Cre/lox system. 
Methods, 14, 381-92. 
SCHAMPAERT, E., MOSES, J. W., SCHOFER, J., SCHLUTER, M., GERSHLICK, A. H., 
COHEN, E. A., PALISAITIS, D. A., BREITHARDT, G., DONOHOE, D. J., 
WANG, H., POPMA, J. J., KUNTZ, R. E., LEON, M. B. & INVESTIGATORS, S. 
E.-C.-S. 2006. Sirolimus-eluting stents at two years: A pooled analysis of 
SIRIUS, E-SIRIUS, and C-SIRIUS with emphasis on late revascularizations 
and stent thromboses. American Journal of Cardiology, 98, 36-41. 
SCHMITTGEN, T. D. & LIVAK, K. J. 2008. Analyzing real-time PCR data by the 
comparative C(T) method. Nat Protoc, 3, 1101-8. 
SCHOENHAGEN, P., ZIADA, K. M., KAPADIA, S. R., CROWE, T. D., NISSEN, S. E. & 
TUZCU, E. M. 2000. Extent and direction of arterial remodeling in stable 
versus unstable coronary syndromes : an intravascular ultrasound study. 
Circulation, 101, 598-603. 
SCHWARTZ, R. S., CHRONOS, N. A. & VIRMANI, R. 2004. Preclinical restenosis 
models and drug-eluting stents: still important, still much to learn. 
Journal of the American College of Cardiology, 44, 1373-85. 
SCHWARTZ, R. S., HUBER, K. C., MURPHY, J. G., EDWARDS, W. D., CAMRUD, A. 
R., VLIETSTRA, R. E. & HOLMES, D. R. 1992. Restenosis and the 
proportional neointimal response to coronary artery injury: results in a 
porcine model. J Am Coll Cardiol, 19, 267-74. 
SCHWARTZ, S. M., STEMERMAN, M. B. & BENDITT, E. P. 1975. The aortic intima. 
II. Repair of the aortic lining after mechanical denudation. Am J Pathol, 
81, 15-42. 
SCHWARZ, D. S., HUTVAGNER, G., DU, T., XU, Z., ARONIN, N. & ZAMORE, P. D. 
2003. Asymmetry in the assembly of the RNAi enzyme complex. Cell, 115, 
199-208. 
SEIFERT, R. A., SCHWARTZ, S. M. & BOWEN-POPE, D. F. 1984. Developmentally 
regulated production of platelet-derived growth factor-like molecules. 
Nature, 311, 669-71. 
SELBACH, M., SCHWANHAUSSER, B., THIERFELDER, N., FANG, Z., KHANIN, R. & 
RAJEWSKY, N. 2008. Widespread changes in protein synthesis induced by 
microRNAs. Nature, 455, 58-63. 
SERRUYS, P. W., DE JAEGERE, P., KIEMENEIJ, F., MACAYA, C., RUTSCH, W., 
HEYNDRICKX, G., EMANUELSSON, H., MARCO, J., LEGRAND, V., MATERNE, 
  220 
 
 
P. & ET AL. 1994. A comparison of balloon-expandable-stent implantation 
with balloon angioplasty in patients with coronary artery disease. 
Benestent Study Group. N Engl J Med, 331, 489-95. 
SERRUYS, P. W., MORICE, M. C., KAPPETEIN, A. P., COLOMBO, A., HOLMES, D. 
R., MACK, M. J., STAHLE, E., FELDMAN, T. E., VAN DEN BRAND, M., BASS, 
E. J., VAN DYCK, N., LEADLEY, K., DAWKINS, K. D. & MOHR, F. W. 2009. 
Percutaneous coronary intervention versus coronary-artery bypass grafting 
for severe coronary artery disease. N Engl J Med, 360, 961-72. 
SHAH, P. K., FALK, E., BADIMON, J. J., FERNANDEZ-ORTIZ, A., MAILHAC, A., 
VILLAREAL-LEVY, G., FALLON, J. T., REGNSTROM, J. & FUSTER, V. 1995. 
Human monocyte-derived macrophages induce collagen breakdown in 
fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading 
metalloproteinases and implications for plaque rupture. Circulation, 92, 
1565-9. 
SHANAHAN, C. M. & WEISSBERG, P. L. 1998. Smooth muscle cell heterogeneity: 
patterns of gene expression in vascular smooth muscle cells in vitro and in 
vivo. Arterioscler Thromb Vasc Biol, 18, 333-8. 
SHARIF, F., HYNES, S. O., COONEY, R., HOWARD, L., MCMAHON, J., DALY, K., 
CROWLEY, J., BARRY, F. & O'BRIEN, T. 2008. Gene-eluting stents: 
adenovirus-mediated delivery of eNOS to the blood vessel wall accelerates 
re-endothelialization and inhibits restenosis. Mol Ther, 16, 1674-80. 
SHI, Y., O'BRIEN, J. E., FARD, A., MANNION, J. D., WANG, D. & ZALEWSKI, A. 
1996. Adventitial myofibroblasts contribute to neointimal formation in 
injured porcine coronary arteries. Circulation, 94, 1655-64. 
SHINDO, T., MANABE, I., FUKUSHIMA, Y., TOBE, K., AIZAWA, K., MIYAMOTO, S., 
KAWAI-KOWASE, K., MORIYAMA, N., IMAI, Y., KAWAKAMI, H., NISHIMATSU, 
H., ISHIKAWA, T., SUZUKI, T., MORITA, H., MAEMURA, K., SATA, M., 
HIRATA, Y., KOMUKAI, M., KAGECHIKA, H., KADOWAKI, T., KURABAYASHI, 
M. & NAGAI, R. 2002. Kruppel-like zinc-finger transcription factor 
KLF5/BTEB2 is a target for angiotensin II signaling and an essential 
regulator of cardiovascular remodeling. Nat Med, 8, 856-63. 
SIGWART, U., PUEL, J., MIRKOVITCH, V., JOFFRE, F. & KAPPENBERGER, L. 1987. 
Intravascular stents to prevent occlusion and restenosis after transluminal 
angioplasty. N Engl J Med, 316, 701-6. 
SIOW, R. C., MALLAWAARACHCHI, C. M. & WEISSBERG, P. L. 2003. Migration of 
adventitial myofibroblasts following vascular balloon injury: insights from 
in vivo gene transfer to rat carotid arteries. Cardiovasc Res, 59, 212-21. 
SMITH, J. D., BRYANT, S. R., COUPER, L. L., VARY, C. P., GOTWALS, P. J., 
KOTELIANSKY, V. E. & LINDNER, V. 1999. Soluble transforming growth 
factor-beta type II receptor inhibits negative remodeling, fibroblast 
transdifferentiation, and intimal lesion formation but not endothelial 
growth. Circ Res, 84, 1212-22. 
SONG, J. J., LIU, J., TOLIA, N. H., SCHNEIDERMAN, J., SMITH, S. K., 
MARTIENSSEN, R. A., HANNON, G. J. & JOSHUA-TOR, L. 2003. The crystal 
structure of the Argonaute2 PAZ domain reveals an RNA binding motif in 
RNAi effector complexes. Nat Struct Biol, 10, 1026-32. 
SONG, J. J., SMITH, S. K., HANNON, G. J. & JOSHUA-TOR, L. 2004. Crystal 
structure of Argonaute and its implications for RISC slicer activity. 
Science, 305, 1434-7. 
SOUTHGATE, K. & NEWBY, A. C. 1990. Serum-induced proliferation of rabbit 
aortic smooth muscle cells from the contractile state is inhibited by 8-Br-
cAMP but not 8-Br-cGMP. Atherosclerosis, 82, 113-23. 
  221 
 
 
STEINBERG, D. 1997. Low density lipoprotein oxidation and its pathobiological 
significance. J Biol Chem, 272, 20963-6. 
STONE, G. W., LANSKY, A. J., POCOCK, S. J., GERSH, B. J., DANGAS, G., WONG, 
S. C., WITZENBICHLER, B., GUAGLIUMI, G., PERUGA, J. Z., BRODIE, B. R., 
DUDEK, D., MOCKEL, M., OCHALA, A., KELLOCK, A., PARISE, H. & MEHRAN, 
R. 2009. Paclitaxel-eluting stents versus bare-metal stents in acute 
myocardial infarction. N Engl J Med, 360, 1946-59. 
STOUFFER, G. A. & OWENS, G. K. 1994. TGF-beta promotes proliferation of 
cultured SMC via both PDGF-AA-dependent and PDGF-AA-independent 
mechanisms. J Clin Invest, 93, 2048-55. 
SUAREZ, Y., FERNANDEZ-HERNANDO, C., POBER, J. S. & SESSA, W. C. 2007. Dicer 
dependent microRNAs regulate gene expression and functions in human 
endothelial cells. Circ Res, 100, 1164-73. 
SUAREZ, Y., FERNANDEZ-HERNANDO, C., YU, J., GERBER, S. A., HARRISON, K. D., 
POBER, J. S., IRUELA-ARISPE, M. L., MERKENSCHLAGER, M. & SESSA, W. C. 
2008. Dicer-dependent endothelial microRNAs are necessary for postnatal 
angiogenesis. Proc Natl Acad Sci U S A, 105, 14082-7. 
SUCHAROV, C., BRISTOW, M. R. & PORT, J. D. 2008. miRNA expression in the 
failing human heart: functional correlates. J Mol Cell Cardiol, 45, 185-92. 
SUH, M. R., LEE, Y., KIM, J. Y., KIM, S. K., MOON, S. H., LEE, J. Y., CHA, K. Y., 
CHUNG, H. M., YOON, H. S., MOON, S. Y., KIM, V. N. & KIM, K. S. 2004. 
Human embryonic stem cells express a unique set of microRNAs. Dev Biol, 
270, 488-98. 
SUN, S. G., ZHENG, B., HAN, M., FANG, X. M., LI, H. X., MIAO, S. B., SU, M., 
HAN, Y., SHI, H. J. & WEN, J. K. 2011. miR-146a and Kruppel-like factor 4 
form a feedback loop to participate in vascular smooth muscle cell 
proliferation. EMBO Rep, 12, 56-62. 
SUZUKI, T., SAWAKI, D., AIZAWA, K., MUNEMASA, Y., MATSUMURA, T., ISHIDA, J. 
& NAGAI, R. 2009. Kruppel-like factor 5 shows proliferation-specific roles 
in vascular remodeling, direct stimulation of cell growth, and inhibition of 
apoptosis. J Biol Chem, 284, 9549-57. 
TAKAHASHI, K., TANABE, K., OHNUKI, M., NARITA, M., ICHISAKA, T., TOMODA, K. 
& YAMANAKA, S. 2007. Induction of pluripotent stem cells from adult 
human fibroblasts by defined factors. Cell, 131, 861-72. 
TANG, R. H., ZHENG, X. L., CALLIS, T. E., STANSFIELD, W. E., HE, J., BALDWIN, 
A. S., WANG, D. Z. & SELZMAN, C. H. 2008. Myocardin inhibits cellular 
proliferation by inhibiting NF-kappaB(p65)-dependent cell cycle 
progression. Proc Natl Acad Sci U S A, 105, 3362-7. 
TANG, Z., WANG, A., YUAN, F., YAN, Z., LIU, B., CHU, J. S., HELMS, J. A. & LI, 
S. 2012. Differentiation of multipotent vascular stem cells contributes to 
vascular diseases. Nat Commun, 3, 875. 
TAYLOR, A. J., GORMAN, P. D., KENWOOD, B., HUDAK, C., TASHKO, G. & 
VIRMANI, R. 2001. A comparison of four stent designs on arterial injury, 
cellular proliferation, neointima formation, and arterial dimensions in an 
experimental porcine model. Catheter Cardiovasc Interv, 53, 420-5. 
TORELLA, D., IACONETTI, C., CATALUCCI, D., ELLISON, G. M., LEONE, A., 
WARING, C. D., BOCHICCHIO, A., VICINANZA, C., AQUILA, I., CURCIO, A., 
CONDORELLI, G. & INDOLFI, C. 2011. MicroRNA-133 controls vascular 
smooth muscle cell phenotypic switch in vitro and vascular remodeling in 
vivo. Circ Res, 109, 880-93. 
TORRES, A. G., FABANI, M. M., VIGORITO, E. & GAIT, M. J. 2011. MicroRNA fate 
upon targeting with anti-miRNA oligonucleotides as revealed by an 
  222 
 
 
improved Northern-blot-based method for miRNA detection. RNA, 17, 933-
43. 
VAN DER WAL, A. C. & BECKER, A. E. 1999. Atherosclerotic plaque rupture--
pathologic basis of plaque stability and instability. Cardiovasc Res, 41, 
334-44. 
VAN DER WAL, A. C., BECKER, A. E., KOCH, K. T., PIEK, J. J., TEELING, P., VAN 
DER LOOS, C. M. & DAVID, G. K. 1996. Clinically stable angina pectoris is 
not necessarily associated with histologically stable atherosclerotic 
plaques. Heart, 76, 312-6. 
VAN DER WAL, A. C., BECKER, A. E., VAN DER LOOS, C. M. & DAS, P. K. 1994. 
Site of intimal rupture or erosion of thrombosed coronary atherosclerotic 
plaques is characterized by an inflammatory process irrespective of the 
dominant plaque morphology. Circulation, 89, 36-44. 
VAN ROOIJ, E. 2011. The art of microRNA research. Circ Res, 108, 219-34. 
VAN ROOIJ, E. & OLSON, E. N. 2012. MicroRNA therapeutics for cardiovascular 
disease: opportunities and obstacles. Nat Rev Drug Discov, 11, 860-72. 
VAN ROOIJ, E., SUTHERLAND, L. B., LIU, N., WILLIAMS, A. H., MCANALLY, J., 
GERARD, R. D., RICHARDSON, J. A. & OLSON, E. N. 2006. A signature 
pattern of stress-responsive microRNAs that can evoke cardiac 
hypertrophy and heart failure. Proc Natl Acad Sci U S A, 103, 18255-60. 
VARNAVA, A. M., MILLS, P. G. & DAVIES, M. J. 2002. Relationship between 
coronary artery remodeling and plaque vulnerability. Circulation, 105, 
939-43. 
VAUGHAN, C. J., GOTTO, A. M., JR. & BASSON, C. T. 2000. The evolving role of 
statins in the management of atherosclerosis. J Am Coll Cardiol, 35, 1-10. 
VON SEGGERN, D. J., KEHLER, J., ENDO, R. I. & NEMEROW, G. R. 1998. 
Complementation of a fibre mutant adenovirus by packaging cell lines 
stably expressing the adenovirus type 5 fibre protein. J Gen Virol, 79 ( Pt 
6), 1461-8. 
WALKER, L. N., BOWEN-POPE, D. F., ROSS, R. & REIDY, M. A. 1986. Production of 
platelet-derived growth factor-like molecules by cultured arterial smooth 
muscle cells accompanies proliferation after arterial injury. Proc Natl 
Acad Sci U S A, 83, 7311-5. 
WANG, C., HAN, M., ZHAO, X. M. & WEN, J. K. 2008a. Kruppel-like factor 4 is 
required for the expression of vascular smooth muscle cell differentiation 
marker genes induced by all-trans retinoic acid. J Biochem, 144, 313-21. 
WANG, D. Z., LI, S., HOCKEMEYER, D., SUTHERLAND, L., WANG, Z., SCHRATT, 
G., RICHARDSON, J. A., NORDHEIM, A. & OLSON, E. N. 2002. Potentiation 
of serum response factor activity by a family of myocardin-related 
transcription factors. Proc Natl Acad Sci U S A, 99, 14855-60. 
WANG, S., AURORA, A. B., JOHNSON, B. A., QI, X., MCANALLY, J., HILL, J. A., 
RICHARDSON, J. A., BASSEL-DUBY, R. & OLSON, E. N. 2008b. The 
endothelial-specific microRNA miR-126 governs vascular integrity and 
angiogenesis. Dev Cell, 15, 261-71. 
WANG, Z., WANG, D. Z., HOCKEMEYER, D., MCANALLY, J., NORDHEIM, A. & 
OLSON, E. N. 2004. Myocardin and ternary complex factors compete for 
SRF to control smooth muscle gene expression. Nature, 428, 185-9. 
WASSMANN, S., WASSMANN, K., JUNG, A., VELTEN, M., KNUEFERMANN, P., 
PETOUMENOS, V., BECHER, U., WERNER, C., MUELLER, C. & NICKENIG, G. 
2007. Induction of p53 by GKLF is essential for inhibition of proliferation 
of vascular smooth muscle cells. J Mol Cell Cardiol, 43, 301-7. 
WATANABE, N., KURABAYASHI, M., SHIMOMURA, Y., KAWAI-KOWASE, K., 
HOSHINO, Y., MANABE, I., WATANABE, M., AIKAWA, M., KURO-O, M., 
  223 
 
 
SUZUKI, T., YAZAKI, Y. & NAGAI, R. 1999. BTEB2, a Kruppel-like 
transcription factor, regulates expression of the SMemb/Nonmuscle 
myosin heavy chain B (SMemb/NMHC-B) gene. Circ Res, 85, 182-91. 
WIENHOLDS, E., KLOOSTERMAN, W. P., MISKA, E., ALVAREZ-SAAVEDRA, E., 
BEREZIKOV, E., DE BRUIJN, E., HORVITZ, H. R., KAUPPINEN, S. & 
PLASTERK, R. H. 2005. MicroRNA expression in zebrafish embryonic 
development. Science, 309, 310-1. 
WIGHTMAN, B., HA, I. & RUVKUN, G. 1993. Posttranscriptional regulation of the 
heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in 
C. elegans. Cell, 75, 855-62. 
WOLF, Y. G., RASMUSSEN, L. M. & RUOSLAHTI, E. 1994. Antibodies against 
transforming growth factor-beta 1 suppress intimal hyperplasia in a rat 
model. J Clin Invest, 93, 1172-8. 
WORLD HEALTH ORGANIZATION. 2013. Cardiovascular diseases (CVDs) Fact sheet 
No 317. [Online]. Available: 
http://www.who.int/mediacentre/factsheets/fs317/en/index.html 
[Accessed 30.09.13. 
WU, L., FAN, J. & BELASCO, J. G. 2006. MicroRNAs direct rapid deadenylation of 
mRNA. Proc Natl Acad Sci U S A, 103, 4034-9. 
XIN, M., SMALL, E. M., SUTHERLAND, L. B., QI, X., MCANALLY, J., PLATO, C. F., 
RICHARDSON, J. A., BASSEL-DUBY, R. & OLSON, E. N. 2009. MicroRNAs 
miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness 
of smooth muscle cells to injury. Genes Dev, 23, 2166-78. 
XU, B., NIU, X., ZHANG, X., TAO, J., WU, D., WANG, Z., LI, P., ZHANG, W., WU, 
H., FENG, N., HUA, L. & WANG, X. 2011. miR-143 decreases prostate 
cancer cells proliferation and migration and enhances their sensitivity to 
docetaxel through suppression of KRAS. Mol Cell Biochem, 350, 207-13. 
XU, Q., ZHANG, Z., DAVISON, F. & HU, Y. 2003. Circulating progenitor cells 
regenerate endothelium of vein graft atherosclerosis, which is diminished 
in ApoE-deficient mice. Circulation Research, 93, e76-86. 
YANG, J. S., MAURIN, T., ROBINE, N., RASMUSSEN, K. D., JEFFREY, K. L., 
CHANDWANI, R., PAPAPETROU, E. P., SADELAIN, M., O'CARROLL, D. & LAI, 
E. C. 2010. Conserved vertebrate mir-451 provides a platform for Dicer-
independent, Ago2-mediated microRNA biogenesis. Proc Natl Acad Sci U S 
A, 107, 15163-8. 
YANG, W., CHENDRIMADA, T. P., WANG, Q., HIGUCHI, M., SEEBURG, P. H., 
SHIEKHATTAR, R. & NISHIKURA, K. 2006. Modulation of microRNA 
processing and expression through RNA editing by ADAR deaminases. Nat 
Struct Mol Biol, 13, 13-21. 
YANG, X., DU, W. W., LI, H., LIU, F., KHORSHIDI, A., RUTNAM, Z. J. & YANG, B. 
B. 2013. Both mature miR-17-5p and passenger strand miR-17-3p target 
TIMP3 and induce prostate tumor growth and invasion. Nucleic Acids Res, 
41, 9688-704. 
YEKTA, S., SHIH, I. H. & BARTEL, D. P. 2004. MicroRNA-directed cleavage of 
HOXB8 mRNA. Science, 304, 594-6. 
YI, R., QIN, Y., MACARA, I. G. & CULLEN, B. R. 2003. Exportin-5 mediates the 
nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev, 17, 
3011-6. 
YIN, F. C., SPURGEON, H. A., RAKUSAN, K., WEISFELDT, M. L. & LAKATTA, E. G. 
1982. Use of tibial length to quantify cardiac hypertrophy: application in 
the aging rat. Am J Physiol, 243, H941-7. 
YOSHIDA, T., KAESTNER, K. H. & OWENS, G. K. 2008. Conditional deletion of 
Kruppel-like factor 4 delays downregulation of smooth muscle cell 
  224 
 
 
differentiation markers but accelerates neointimal formation following 
vascular injury. Circ Res, 102, 1548-57. 
YOSHIDA, T., SINHA, S., DANDRE, F., WAMHOFF, B. R., HOOFNAGLE, M. H., 
KREMER, B. E., WANG, D. Z., OLSON, E. N. & OWENS, G. K. 2003. 
Myocardin is a key regulator of CArG-dependent transcription of multiple 
smooth muscle marker genes. Circ Res, 92, 856-64. 
ZAMAN, A. G., HELFT, G., WORTHLEY, S. G. & BADIMON, J. J. 2000. The role of 
plaque rupture and thrombosis in coronary artery disease. 
Atherosclerosis, 149, 251-66. 
ZENG, Y., YI, R. & CULLEN, B. R. 2003. MicroRNAs and small interfering RNAs can 
inhibit mRNA expression by similar mechanisms. Proc Natl Acad Sci U S A, 
100, 9779-84. 
ZHANG, B., PAN, X., COBB, G. P. & ANDERSON, T. A. 2007. microRNAs as 
oncogenes and tumor suppressors. Dev Biol, 302, 1-12. 
ZHANG, H., KOLB, F. A., BRONDANI, V., BILLY, E. & FILIPOWICZ, W. 2002. 
Human Dicer preferentially cleaves dsRNAs at their termini without a 
requirement for ATP. EMBO J, 21, 5875-85. 
ZHANG, Y., YANG, P., SUN, T., LI, D., XU, X., RUI, Y., LI, C., CHONG, M., 
IBRAHIM, T., MERCATALI, L., AMADORI, D., LU, X., XIE, D., LI, Q. J. & 
WANG, X. F. 2013. miR-126 and miR-126* repress recruitment of 
mesenchymal stem cells and inflammatory monocytes to inhibit breast 
cancer metastasis. Nat Cell Biol, 15, 284-94. 
ZHAO, Y., RANSOM, J. F., LI, A., VEDANTHAM, V., VON DREHLE, M., MUTH, A. N., 
TSUCHIHASHI, T., MCMANUS, M. T., SCHWARTZ, R. J. & SRIVASTAVA, D. 
2007. Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in 
mice lacking miRNA-1-2. Cell, 129, 303-17. 
ZHAO, Y., SAMAL, E. & SRIVASTAVA, D. 2005. Serum response factor regulates a 
muscle-specific microRNA that targets Hand2 during cardiogenesis. 
Nature, 436, 214-20. 
ZHU, N., ZHANG, D., CHEN, S., LIU, X., LIN, L., HUANG, X., GUO, Z., LIU, J., 
WANG, Y., YUAN, W. & QIN, Y. 2011. Endothelial enriched microRNAs 
regulate angiotensin II-induced endothelial inflammation and migration. 
Atherosclerosis, 215, 286-93. 
 
 
